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Abstract.
The HSV-1 immediate early protein ICPO is a well-characterised regulator of gene 
expression, which enhances expression of all classes of genes throughout the viral 
genome. ICPO plays an important role in reactivation of HSV-1 from quiescent 
infection, and for efficient initiation of the lytic cycle. One way ICPO may favour the 
lytic cycle is by altering the intracellular environment by targeting cellular proteins for 
degradation through its RING finger mediated E3 ubiquitin ligase activity. Amongst the 
proteins that have been found to be degraded in cells expressing ICPO are certain 
components of cellular nuclear sub-structures known as ND10 or PML nuclear bodies. 
These proteins may be part of a cellular repression mechanism that inhibits viral gene 
expression and leads to the assembly of viral genomes into a quiescent chromatin 
structure. Alternatively, disruption of ND10 could release transcription factors that 
stimulate viral gene expression. All of the aforementioned activities have been shown to 
be dependent of ICPO having a functional RING finger domain, a cysteine-rich 
sequence that is situated near the N terminus of the protein and is structurally 
coordinated by the presence of two zinc atoms. ICPO and its isolated RING finger 
domain have been shown to act as E3 ubiquitin ligases in vitro and cause substrate 
independent polyubiquitin chain formation in the presence of the E2 ubiquitin 
conjugating enzymes UbcH5a and UbcH6.
The proteins of interest to this study are the homologues of ICPO that are expressed by 
other members of the alphaherpesvirus sub-family, including BICPO of BHV-1, Eg63 of 
EHV-1, EPO of PRV and Vg61 of VZV. The homology between these proteins is 
limited to the RING finger domain and indeed mainly to the zinc coordinating and 
certain other structurally important residues therein. Previously, it was shown that in a 
similar manner to that of ICPO, these related proteins to varying degrees cause the 
disruption of ND10 by affecting certain cellular proteins, and they induce the formation 
of colocalising conjugated ubiquitin. Together, this evidence suggested that these 
members of the ICPO family of proteins also act as E3 ubiquitin ligase enzymes.
Using the techniques of protein expression, purification and in vitro ubiquitin 
conjugation assays, the work described in this thesis demonstrates that the isolated 
RING finger domains of the ICPO related proteins, to varying degrees, act as E3 
ubiquitin ligase enzymes. In addition, they simulate the same E2 ubiquitin conjugating
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enzymes UbcH5a and UbcH6, in a manner similar to that previously shown for ICPO. It 
was also shown that the isolated RING finger domains of the ICPO family of proteins 
could form stable interactions with specific E2 partners in vitro. Transfection assays 
additionally demonstrated that the full-length versions of the ICPO related proteins 
formed foci that co-localised with certain E2 proteins in vivo. In addition, studies using 
truncated versions of the RING finger domains of Eg63 and BICPO identified 
differences between their activities in partnership with the E2 enzymes UbcH5a and 
UbcH6 that depended on residues on the C-terminal side of their core RING finger 
domains. Finally, using a transfection assay, it was shown that even though the 
homology of the ICPO family of protein is largely limited to their RING finger domains, 
to varying degrees they are able to complement ICPO-null mutant HSV-1.
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Abbreviations. DMSO.Dimethyl sulphoxide. 
DTT Dithiothreitol.
A.
A.A. Amino acid.
Ac. Autographa californica.
Amp. Ampicillin.
Ampr. Ampicillin resistance.
ATP. Adenosine triphosphate.
B
Bac. Baculovirus.
BAC. Bacterial artificial chromosome, 
b.p. Base pair.
BICPO. The BHV-1 homologue of ICPO. 
BHK. Baby hamster kidney 
BHV-1.Bovine herpes virus type 1.
BM. Boiling mix.
BSA. Bovine serum albumin.
C
C- Carboxy.
°C. Degrees Celsius.
CHV. Canine herpes virus.
Ci. Curie.
CEP. Calf intestinal phosphatase.
Cm. Chloramphenicol.
Cmr. Chloramphenicol resistance. 
CPE. Cytopathic effect.
CsCl. Caesium chloride.
D.
Da. Dalton.
(IH2O. Distilled water.
DNA. Deoxyribonucleic acid.
E.
E. Early.
EBV. Epstein Barr Virus.
E.coli. Escherichia coli.
EDR. Envelopment, deenvelopment, 
reenvelopment pathway.
Eg63. The EHV-1 homologue of ICPO 
EHV-l.Equine herpes virus type 1.
EM. Electron Microscope. 
ELISA.Enzyme linked
immunoabsorbent assay.
EPO. The PRV homologue of ICPO. 
EtBr Ethidium bromide.
ER. Endoplasmic Reticulum,
F.
FdA. Fold activation.
FHV. Feline herpes virus.
FITC Fluoroscein thiocynate.
FCS. Foetal calf serum
G.
GAGS. Glycosaminoglycans.
Gen. Gentamycin.
Genr. Gentamycin resistance.
GFP. Green fluorescent protein.
GHV. Gallid herpesvirus.
H.
HCMV. Human cytomegalovirus. 
6xHis. 6 histidine residues 
hr. Hour.
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HCF. Host cell factor. mA milliamps.
HVB. Herpes B virus. mAh Monoclonal antibody.
HHV. Human herpesvirus Mdm2.Mouse double mutant 2.
HSV. Herpes simplex virus. Min. Minute.
Hve. Herpesvirus mediator. M.O.I. Multiplicity of infection.
Min. Minute.
I. mg. Milligrams.
IE. Immediate-Early. ml. Millilitres.
ICP. Infected cell protein mM. Millimolar.
IE. Immediate early mRNA.Messenger ribonucleic acid.
Ig. Immunoglobulin MW. Molecular weight.
ERL. Internal repeat long
IRS. Internal repeat short N.
IPTG Isopropylthio-P-D-galactoside n Nano (10'9).
N- Amino.
K. NaCl Sodium chloride.
k. Kilo (103) NA. Not applicable.
Kan. Kanamycin. NP40 nonidet P40.
Kanr. Kanamycin resistance.
kbp Kilobase pair. O.
KSHV.Kaposi’s Sarcoma-Associated OBP. Origin binding protein.
Herpesvirus OD. Optical density.
o/n Overnight.
L. ORF. Open reading frame.
L. Late. Ori. Origin of replication.
1 Litre.
LAT. Latency associated transcript. P.
LB. Luria Broth. PAGE. Polyacrylamide gel
electrophoresis.
M. PBS-T. Phosphate buffered saline
P Micro (10'6). supplemented with 0.1%
Pg Microgram. Tween-20.
pi Microlitre. p.f.u. plaque-forming unit.
M Molar. PCR. Polymerase chain reaction.
m Milli (10‘3). Plq. Plaque
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PRV. Pseudorabies virus.
PS. Penicillin/streptomycin.
R.
RGB. Resolving gel buffer.
RNA. Ribonucleic acid.
I RnaseA. Ribonuclease A.
r.p.m. Revolutions per minute 
RT. Room temperature.
S.
Sec. Second.
35[S] Sulphur-35-radioisotope. 
SDS. Sodium dodecyl sulphate.
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T.
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tk. Thymidine kinase.
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US. Unique short.
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Amino acid abbreviations
Amino acid
Three letter 
code
One letter 
code
Properties
Alanine Ala A
Non-polar
(hydrophobic)
Arginine Arg R Basic
Asparagine Asn N Polar, uncharged
Aspartic acid Asp D Acidic
Cysteine Cys C Polar, uncharged
Glutamine Gin Q Polar, uncharged
Glutamic acid Glu E Acidic
Glycine Gly G Polar, uncharged
Histidine His H Basic
Isoleucine lie 1
Non-polar
(hydrophobic)
Leucine Leu L
Non-polar
(hydrophobic)
Lysine Lys K Basic
Methionine Met M
Non-polar
(hydrophobic)
Phenylalanine Phe F
Non-polar
(hydrophobic)
Proline Pro P
Non-polar
(hydrophobic)
Serine Ser S Polar, uncharged
Threonine Thr T Polar, uncharged
Tryptophan Trp W
Non-polar
(hydrophobic)
Tyrosine Tyr Y Polar, uncharged
Valine Val V
Non-polar
(hydrophobic)
DNA Abbreviations.
Base One letter code
Adenine (Purine) A
Cytosine (Pyrimidine) C
Guanine (Purine) G
Thymidine (Pyrimidine) T
Uracil (Pyrimidine) U
Chapter 1 -  Introduction - Part I -  Herpesviridae.
i
j
I 1.0. Herpesviruses.
i
Herpesviruses are members of the Herpesviridae, a large family of viruses containing 
over 120 known species (Roizman & Sears, 1996), infecting a wide spectrum of 
vertebrates and a least one invertebrate. Generally, at least one herpesvirus has been 
described in most animal species including fish, amphibians, reptiles, birds and 
especially mammals, including cattle, pigs, and man (Roizman, 2003). The occurrence 
of host specific herpesviruses is an indication they have evolved with their hosts over 
long periods of time and are exquisitely well adapted to them (Davison, 2002). 
Herpesviruses differ widely in their pathogenic potential, but share the ability, after 
primary infection, to remain latent throughout the lifetime of the host. To date eight 
distinct human herpesviruses have been identified causing various disease states; an 
overview of these viruses is shown in figure 1.0A.
1.0.1. Classification o f the herpesviruses.
Herpesviruses are amongst the largest and most complex of viruses and their 
classification is primarily based on the four conserved features of the virion (Roizman & 
Sears, 1996).
i) An electron opaque core that contains a single linear double stranded DNA molecule, 
typically 120-230 Kbp in length, with a varying G+C content of between 31 and 75%.
ii) An icosahedral capsid that is approximately 125 nm in diameter, which surrounds the 
nucleic acid.
iii) An amorphous tegument, a matrix that surrounds the capsid.
iv) The envelope, a lipid bilayer containing glycoprotein spikes.
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common
name
subfamily G + C 
(%)
DNA size 
(Kbp)
common disease / 
symptoms
HSV-1 a 68.3 152 cold sores + other
occasional
symptoms
HSV-2 a 69 152 genital lesions
VZV a 46 125 chicken pox / 
■shingles
EBV Y 60 172 infectious 
mononucleosis 
(glandular fever), 
Burkitt’s
lymphoma + other 
cancers
HCMV P 57 229 Cytomegalia
HHV-6 P 42 162 exanthum subitum 
or roseola 
infantum
HHV-7 P 45 145 none known
KSHV Y 53 140.5 Kaposi’s sarcoma, 
PEL, MCD
Figure 1.0A. The human herpesviruses.
Overview of the eight herpesviruses that have so far been identified to 
infect humans.
Abbreviations: Herpes Simplex Virus (HSV), Varicella-Zoster Virus 
(VZV), Epstein-Barr virus (EBV), Human Cytomegalovirus (HCMV), 
Human Herpesvirus (HHV), Kaposi’s Sarcoma-Associated
Herpesvirus (KSHV), Primary Effusion Lymphoma (PEL), 
Multicentric Castleman’s Disease (MCD).
Herpesviruses have been classified into three groups based upon tissue tropism, 
pathogenicity and behaviour under laboratory conditions and all share four significant 
properties:
; i) All herpesviruses specify enzymes and other factors involved in DNA synthesis, e.g.
DNA polymerase, helicase, primase, origin binding protein, and DNA metabolism e.g. 
thymidine kinase, thymidylate synthetase, dUTPase, ribonucleotide reductase. 
Herpesviruses specify at least one protease and a variable number of protein kinases.
ii) The synthesis of viral DNA and assembly of capsids occurs in the nucleus, with 
initial envelopment of the capsid happening as it migrates through the nuclear envelope.
iii) The production of infectious progeny virus is generally accompanied by the 
destruction of the infected cell.
iv) Herpesviruses have the ability to remain latent in their natural hosts.
Various additional criteria, such as antigenic properties, have been used for classifying 
herpesviruses into lower taxa of subfamily, genus and species. These criteria have been 
superseded by relationships based on comparisons of viral DNA or amino acid 
sequences (Davison, 2002). This is discussed in a later section.
1.0.2. Subfamily classification o f herpesviruses
The subfamilies of the herpesviridae are classified into three groups Alpha-, Beta-, and 
Gamma-herpesvirinae (Roizman et al., 1981), the division being based upon the 
biological properties of the viruses. Historically, subfamily classification was based on 
biological characteristics, such as host range, duration of reproductive cycle, 
j cytopathology and characteristics of latent infection, these are summarised below:
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A Iph ah erpesvirin ae.
Herpesviruses within this subfamily demonstrate a variable host range in vitro, a 
relatively short reproductive cycle (<24 hours), rapid spread within tissue culture that 
results in the efficient destruction of infected cells, and a capacity to establish a latent 
state of infection, predominantly within sensory ganglia. The subfamily of 
Alphaherpesvirinae has been further divided into two genera; Simplexviruses, which 
include herpes simplex virus type-1 and type-2 (HSV-1 and HSV-2), and 
Varicelloviruses, which includes varicella-zoster virus (VZV) (Roizman & Sears, 1996).
Betaherpesvirinae.
Herpesviruses within this subfamily demonstrate a restricted host range, a long 
reproductive cycle and slow growth in tissue culture. Infected cells frequently become 
enlarged in appearance (cytomegalia) and latency occurs in secretary glands, 
lymphoreticular cells, kidney and other tissues (Roizman & Sears, 1996). The subfamily 
of Betaherpesvirinae has been further divided into three genera; Cytomegalovirus, 
which includes the human cytomegalovirus (HCMV-1), Muromegalovirus, which 
includes murine cytomegalovirus, and Roseolovirus, which includes the human 
herpesvirus type-6 and type-7 (HHV-6 and HHV-7) (Roizman & Sears, 1996).
Gammaherpesvirinae.
Members of this subfamily typically demonstrate an in vitro host range restricted to the 
species of the natural host. In vitro, all members of this subfamily replicate in 
lymphoblastoid cells and some also cause lytic infection within epithelioid and 
fibroblastic cells. Within the natural host, viruses tend to be specific for either T or B- 
lymphocytes. Viruses within this subfamily frequently maintain a latent state of 
infection within lymphoid tissue. The subfamily of Gammaherpesvirinae has been 
further divided into two genera, Lymphocryptovirus, which includes the Epstein-Barr 
virus (EBV) and Rhadinovirus, which includes human herpes virus type-8 (HHV-8).
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1.0.3. Sequence-based classification o f the herpesviruses.
The traditional approach to classification of herpesviruses was based on the biological 
properties of the viruses. However, due to the advent of sequencing technology the 
classification was reanalysed based upon DNA sequence homology and genome 
organisation (Davison, 2002). Currently, more sequence information is available for 
herpesviruses than any other large DNA virus family; they are highly diverse, ranging in 
size from 125 to 230 kbp, with around 70 to 200 genes and they exhibit widely differing 
base composition and patterns of repeated sequences (McGeoch, 1989; Roizman et al., 
1992). Extensive sequencing of the genomes of several mammalian herpesviruses from 
all three subfamilies indicates they share around 40 genes, by the criteria of their 
genomic position and amino acid sequence (McGeoch et a l , 1995). The available data 
has helped reassess the subfamily classification, taking into consideration factors such 
as the arrangement of terminal sequences required for DNA packaging, the presence of 
nucleotides subject to methylation, conservation and positioning of genes and gene 
clusters. The classification of members of the herpesvirus family based on sequence 
data caused only a few alterations to the original classification system (Davison, 2002). 
In particular, HHV-6, HHV-7 and GHV-1 were originally classified as 
Gammaherpesvirinae as they exhibited lymphotropism. Following sequence analysis 
HHV-6, HHV-7 were reassigned to the Betaherpesvirinae and GHV-1 to 
Alphaherpesvirinae as their genomes more closely resembled other members of their 
‘new’ respective families (Buckmaster et a l , 1988; Roizman et a l, 1992). Furthermore, 
comparison of the vast array of sequence data has enabled the identification of a 
common ancestral origin of the herpesvirus family. It was estimated that the three 
subfamilies arose approximately 180 to 220 million years ago and the subsequent 
divisions within these families arose 80 to 60 million years ago (see figure 1.0.3A) 
(McGeoch et al, 1995).
1.1.0 HSV biology
The herpes simplex viruses consist of two serotypes HSV-1 and HSV-2, and were the 
first of the human herpesviruses to be discovered. Due to their biological properties and 
the relative facility with which they can be cultured in the laboratory, they are among 
the most intensely investigated of the herpesviruses (reviewed by Roizman & Sears,
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Figure. 1.0.3A. Evolutionary divergence o f the Herpesvirus 
family.
Horizontal lines of branches are proportional to their respective 
time of divergence. Subfamily groups (only key members are 
shown) are indicated by the presence of their appropriate Greek 
letter. The oldest parts of the tree are indicated by broken lines to 
represent the low confidence in the exact time scale of 
divergence. BP = Before present time. This figure was adapted 
from McGeoch et al., 1995.
1996). Furthermore, like other members of the herpesvirus family, the herpes simplex 
viruses are highly evolved and capable of establishing both persistent lytic and latent 
infection for the lifetime of the host, thus ensuring their ubiquity is maintained amongst 
the human population. HSV-1 is normally associated with orofacial infections and rare 
cases of encephalitis, whereas HSV-2 usually causes genital infections. However, both 
forms of HS V can enter the body at either site of infection owing to the presence of cell 
surface target receptor heparan sulphate proteoglycans (Whitley & Roizman, 2001).
1.1.1. Ubiquity and transmission in the population.
Although HSV is highly infectious, it is not transmitted casually from person to person. 
The enveloped virions are relatively unstable in atmospheric conditions and close 
interpersonal contact is usually required for their transmission. HSV is transmitted 
easily through body fluids and the direct contact of infected to uninfected mucous 
membranes. Transmission of the virus is enhanced if the uninfected membrane that is in 
contact with the infected membrane is damaged. Symptomatic infection by HSV is 
usually noted by the presence of a lesion, which occurs in conjunction with the period of 
highest viral shedding (Stanberry, 1986). Obvious measures can be taken to limit the 
spread of the virus from person to person or from one part of the body to another by 
simply limiting contact with the symptomatic area. These precautions are not fully 
effective when the ubiquity of the virus amongst the population is considered. It is likely 
that an individual may be unaware that asymptomatic shedding is occurring, as they 
appear to be symptom-free. Patients with recurrent genital disease have been 
documented to shed HSV-2 as often as 10% of the time that they appear to be lesion- 
free (Kohl, 1997). In fact, the majority of individuals throughout their life are unaware 
of encountering the virus or of becoming infected (Connelly & Stanberry, 1995). 
Symptomatic and asymptomatic shedding ensures the continued spread of HSV-1 and 
HSV-2, as it exploits its host’s need for social contact. Transmission and ubiquity in the 
population is reviewed in more detail elsewhere (Bernstein, 1991; Stanberry, 2000; 
Whitley, 2002; Whitley & Roizman, 2001).
1.1.2. Definition and serotypes o f the herpes simplex viruses.
The genome of HSV-1 and HSV-2 share 47-50% base sequence homology, and their 
genetic maps are largely co-linear (Roizman & Sears, 1996). They differ in restriction
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endonuclease (RE) cleavage sites and apparent size of viral proteins. Antigenic 
differences can be detected (Roizman et al., 1984) and distinctive biological markers 
include virus titres, plaque size and growth in cultured cells. Due to occasional base 
substitutions/deletions resulting in changes in restriction endonuclease sites or a.a. 
sequence, and because of the variability of certain repeated sequences, 
epidemiologically unrelated isolates of the same HSV serotype do not contain identical 
DNA sequences (Chou & Roizman, 1990).
1.1.3. HSV-1 virion structure.
HSV-1, like other members of the alphaherpesvirus family, has four distinct 
components that make up its particle: the DNA core, nucleocapsid, tegument, and 
envelope (Wildy et a l, 1960). A generalised structure is shown in figure 1.0.1 A, while a 
more detailed electron micrograph is shown in figure 1.1.3 A.
The HSV-1 virion consists of electron-opaque core, containing the viral genome, which 
is surrounded by an icosahedral capsid and an outer lipid envelope. The icosahedral 
capsid consists of 162 capsomers, of which 150 are hexameric and 12 are pentameric. 
The hexamers are located on the faces and edges of the capsid and the pentamers are on 
the vertices (Booy et al., 1991). More recent studies have used electron cryomicroscopy 
to produce a highly detailed structure of the HSV-1 capsid at a resolution of 8.5 
angstroms, providing a wealth information regarding the secondary folding of the capsid 
proteins (Zhou et al., 2000).
The amorphous tegument layer contains over 20 distinct structural proteins which are 
thought to influence the process of infection (Rixon, 1993). The outer surface of the 
tegument is enclosed by the envelope -  a trilaminar lipid membrane of host origin, 
containing a number of glycoproteins (named gB to gM), which are involved in 
attachment and penetration of the virus into the host cell (Schrag et a l, 1989). The 
specific roles of the virion proteins will be discussed in more detail later.
1.1.4 The viral genome.
The HSV-1 genome consists of a large single double stranded DNA molecule, encoding 
at least 84 different polypeptides (Ward & Roizman, 1994). It is at least 152 kbp in size
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Envelope
Tegument
Capsid
dsDNA core
Figure. 1.1.3A Electron micrograph o f a frozen 
hydrated HSV-1 virion.
The major structural features o f the virion, 
including envelope, tegument, capsid, and DNA 
core are indicate by the appropriate arrows. The 
diameter of capsid is approximately 125 nm and 
the whole virion is approximately 200 nm. This 
figure was reproduced with permission from Dr. 
Frazer Rixon, MRC Virology Unit, Glasgow.
Figure. 1.1.4A. Schematic illustration o f the structure o f the HSV-1 
genome.
The HSV-1 genome contains unique long (UL) and unique short (Us) 
sequences, the "a ” sequences, the terminal repeats (TRL and TRS) and 
internal repeats (IRL and IRS) are shown. (B) Schematic illustration of 
the four possible isomers of the UL and Us sequences: P (prototype), IL 
(inversion of L), IS (inversion of S), and ISL (inversion of both S and L).
with a high G + C content of around 68% (McGeoch et al., 1988) and consists of two 
covalently linked segments designated L (Long) and S (Short). Primarily, the variation 
in the size of the genome is due to the number of reiterations of a 400 bp repeat unit 
termed the ‘a’ sequence (Hayward et al., 1975; Wadsworth et al., 1976; Wadsworth et 
al., 1975), which is located at the termini of the genome and at the junction between the 
L and S segments (Whitley et al., 1998). Each of the long and short components is 
composed of unique sequences (U l  or Us respectively). The U l  region is 107.9 kbp and 
the unique short Us region is 13 kbp. The inverted repeat sequences flanking U l are 
known as b, whereas those flanking Us are known as c. Thus as shown in figure 1.1.4A, 
U l is flanked by the sequence a’b and its inversion b’a’ around 9.2 Kbp each, whereas 
Us is flanked by sequences a’c and its inversion c’a, each of 6.6 Kbp (McGeoch et al., 
1988). The two unique segments can invert relative to each other via the repeat 
sequences, such that a population of HSV DNA molecules consists of four equimolar 
isomers (see figure 1.1.4A).
More than 84 different genes are distributed throughout the genome (Ward & Roizman, 
1994), sixty-five mapping in U l, fourteen in Us and two copies of four genes (including 
the IE-1 gene that encodes ICPO) flanking Ul- In general, each gene has its own 
promoter to direct transcription, although some transcripts share 3' ends. Amongst the 
various naming terminologies that have been used, one is the naming of a viral gene 
according to the relative position within the genome e.g. Ul 1-56 and Us 1-11.
>
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1.2.0. Stages of productive infection of HSV-1.
Productive infection of a cell by HSV-1 involves the following steps (figure 1.2.0A): 
entry (viral attachment and adsorption), gene expression, DNA synthesis and 
assembly/egress of progeny virions (Roizman & Sears, 1996). From the initial infection 
of fully permissive tissue culture cells, to the final viral release takes approximately 18- 
20 hr.
1.2.1. Viral attachment to cell surface receptors.
Entry of HSV-1 into the host cell is mediated by the glycoproteins situated within the 
viral envelope and proceeds in a sequential manner. In HSV-1 and the rest of the 
alphaherpesvirus family 12 glycoproteins have been identified so far: glycoprotein B 
(gB), gC, gD, gE, gG, gH, gl, gJ, gK, gL, gM and gN (predicted) (Spear, 2004). 
However, only gB, gD, gH, and gL play an indispensable role in cell fusion and entry 
(Spear, 2004). Initially, the virus binds to heparin sulphate moieties on the host cell 
surface, via gB and gC (Herold et al., 1994). This initial step enhances infection, 
however gC (but not gB) has been shown to be dispensable for viral growth and 
replication in vitro, although infectivity of gC-negative virus is reduced by as much as 
10-fold (Herold et a l, 1991). However, it is thought that the degree of reduction in HSV 
infectivity as a result of gC deletion may be dependent on virus serotype and cell type 
(Cheshenko & Herold, 2002). Furthermore, the glycosaminoglycan (GAG) heparin 
sulphate is thought to be the primary receptor for HSV-1, as cell lines devoid of GAG 
have been shown to be 85% resistant to infection. Consequently, as cells remain 
partially susceptible to infection it indicates that heparin sulphate is the primary, but 
perhaps not the sole initial receptor for HSV-1 (Banfield et a l,  1995a; Gruenheid et a l, 
1993; Shieh et a l, 1992). Proposed candidates for secondary or co-receptors have 
included the fibroblast growth factor receptor (FGFR) (Baird et al., 1990) and 
chondroitin sulphate (Banfield et a l, 1995b).
Entry and  
uncoatfng
E replication 
proteins L structural 
proteins
Viral
DNA
aniRNA PmRNA
cytoplasm
DNA Replicationnucleus
I I T T I I I I I I I I I
Assembl
Virions exit cell
Figure 1.2.0A. Life cycle o f HSV-1.
The stages of HSV-1 infection are: 1) Receptor binding and membrane 
fusion. 2) Release of the viral nucleocapsid and tegument into the cell 
cytoplasm and transport of the nucleocapsid to the nuclear pore. 3) Release of 
viral DNA into the nucleus. 4) Transcription and translation of the viral 
immediate early and early genes. 5) Viral DNA synthesis. 6) Transcription 
and translation of the viral late genes 7) Capsid assembly and DNA 
packaging. 8) Egress of the progeny virus, a , (3 and y represent IE, Early and 
Late mRNA, respectively. Diagram adapted from Ackermann, et al. 1998.
1.2.2. Viral absorption into the cell.
The interaction of gB and gC with heparan sulphate alone is not sufficient for viral entry 
into the cell. Glycoprotein D is required to interact with one of several cellular 
receptors, termed herpes virus entry proteins (Hve) (Spear et a l , 2000), which trigger 
the fusion of the viral envelope with the cell membrane. The Hve proteins are composed 
of members of three families of receptor, the tumour necrosis factor (TNF) receptor 
family, including HveA (Montgomery et al., 1996; Whitbeck et al., 1997) and the 
immunoglobulin super family, including nectin-1 (HveB) (Warner et a l, 1998), nectin-2 
(HveC) (Geraghty et a l, 1998), and heparan sulphate receptors which have been 
modified by 3-O-sulphatotransferases (Shukla et a l, 1999). An overview of the binding 
and fusion process of the HSV-1 virion is shown in figure 1.2.2A. The fusion process 
also requires the action of other viral glycoproteins, gB and a heterodimer of gH-gL. 
The role of all the virus glycoproteins is reviewed in further detail elsewhere (Spear, 
2004; Spear & Longnecker, 2003).
Following viral penetration and internalisation into the cell, several of the tegument 
proteins play a crucial role. These include the virion host shut off protein (VHS), which 
degrades mRNA and causes an early shut down of host protein synthesis (Kwong & 
Frenkel, 1987). Virus capsids are transported to the nuclear membrane by a process 
mediated by microtubules, where the viral DNA and at least some tegument proteins 
(VP 16, VP1 and VP2) enter the nucleus via a nuclear pore by an unknown mechanism 
(Sodeik et a l, 1997). The viral DNA in the nucleus forms an episome and it is at this 
point, where the course of infection depends on whether the virus undergoes lytic or 
latent infection.
1.2.3. Viral gene expression.
Upon internalisation into the nucleus, HSV-1 exploits the host cell machinery to ensure 
expression of viral proteins necessary for replication and cell-to-cell spread. The viral 
DNA encodes proteins that are essential for viral DNA replication and structural 
proteins, which make up the virion envelope and are involved in viral DNA packaging. 
Like other members of the herpesvirus family, HSV-1 gene expression involves the 
sequential cascade of three sets of genes that are named immediate early (IE), early (E) 
and late (L), and which are classified according to their time of expression during the
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Figure 1.2.2A. Cell surface receptors and viral ligands that 
participate in IfSV entry.
Only five of the HSV-1 glycoproteins gB, gC, gD, gH and gL have 
been shown to participate in viral entry. Binding of virus to cells 
can be mediated by the binding of gB or gC to heparan sulphate 
(HS) chains on cell surface proteoglycans, which facilitates the 
binding of gD to one of its cell surface receptors. These include the 
herpesvirus entry proteins (Hve) nectin-1 and nectin-2, and 
specific sites in heparin sulphate generated by certain 3-O-sulphate 
transferases. Binding of gD to any one of these receptors triggers 
fusion of the viral envelope with the cell membrane. This 
membrane fusion requires the action of gB and gH-gL 
heterodimers as well as gD and a gD receptor. Diagram adapted 
from Spear, 2004.
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Figure 1.2.3A. The role o f  VP16-induced complex in the initiation o f  
viral gene expression.
Upon HSV infection the virus can enter a lytic or latent phase (i). In 
the lytic mode, VP 16 is delivered to the host cell, (ii) VP 16 then 
associates with HCF-1. (iii) This leads to VP16-induced complex 
assembly on HSV immediate-early (IE) promoters with Oct-1., which 
initiates a cascade of gene expression, (iv) Resulting in virus 
production and lysis of the host cell The diagram is adapted from 
Wysocka & Herr, 2003.
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Figure 1.2.3B. Schematic representation o f IE, E, and L HSV- 
l promoters.
The general arrangement and composition of cis-acting 
regulatory elements for generic IE, early and late promoters is 
shown. The actual number and arrangement of elements varies 
among promoters of each class.
(A) In addition to the TATA element, IE promoters have 
TAATGARAT elements in the upstream region through which 
the viral VP 16 protein mediates transcriptional activation. 
Binding sites for eukaryotic transcription factors such as SPl 
are also present upstream from the TATA element and in at 
least some IE promoters, binding sites for ICP4.
(B) Early promoters have binding sites for eukaryotic 
transcription factors upstream of the TATA element but no 
identified cis-acting regulatory elements further downstream.
(C) Late promoters have an initiator element (Inr) at the start 
of transcription, and in at least some late promoters, a 
downstream activation site. Diagram adapted from Weir,
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viral replication cycle (Clements et al., 1977; Honess & Roizman, 1974). Transcription 
of the viral DNA within the nucleus of host cells is carried out by host DNA-dependent 
RNA polymerase II, which is responsible for the synthesis of all viral mRNA (Alwine et 
al., 1974; Costanzo et al., 1977).
Figure 1.2.3 A shows an overview of the steps that initiate gene expression in the host 
cell nucleus. Following internalisation into the cell and the induction of the lytic 
infection cycle, the tegument protein VP 16 (a key activator of the lytic infection), forms 
a trimeric association with the cellular transcription factor Oct-1 (octamer DNA-binding 
protein) and the cell proliferation factor HCF-1. The interaction of HCF and VP 16, 
promotes stable interaction with Oct-1 and the association of VP 16 with Oct-1 enables 
the former to bind to DNA (Hughes et al., 1999). The sub-cellular distribution of HCF 
has been shown to be altered during HSV-1 infection and particularly during the early 
stages of infection, and it is thought to act as a nuclear import factor for VP 16 (La 
Boissiere et al., 1999; La Boissiere & O'Hare, 2000). Furthermore, during latency it has 
been shown that HCF remains in the cytoplasm of sensory neurons; however under 
experimental conditions that induce the initiation of the lytic infection, it is rapidly 
relocated into the nucleus. This indicates a possible role for HCF in the switch between 
latency and productive infection (Kristie et a l, 1999)
The Oct-l-VP16-HCF-l complex initiates immediate early gene expression by binding 
to the upstream consensus IE promoter element ‘TAATGARAT’ which is present in at 
least one copy in all HSV IE promoters (Gaffney et al., 1985). An overview of the 
composition of the different promoter types within the HSV-1 genome is shown in 
figure 1.2.3B. Oct-1 binds directly to the TAAT region of the motif and the recruitment 
of VP 16 is dependent on the presence of the GARAT half of the sequence (where R is a 
purine) (O'Hare et al., 1988). The availability of Oct-1 can influence the efficiency of 
initiation of the HSV lytic cycle as recently it was shown that at low M.O.I. the 
initiation of the lytic cycle is greatly impaired in Oct-1 deficient cells. However, Oct-1 
deficiency could be overcome at high M.O.I., suggesting that induction of transcription 
by VP 16 can occur through other IE regulatory elements (Nogueira et a l, 2004).
The IE genes are defined as those expressed in the absence of viral protein synthesis and 
are ICP0, ICP4, ICP22, ICP27 and ICP47, which will discussed in more detail in section
1.2.4. IE protein expression serves to transactivate early gene expression, which in turn
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produces proteins that are generally required for DNA replication, such as DNA 
polymerase, single-stranded DNA-binding protein (SSB or ICP8), the DNA helicase- 
primase complex, and the origin binding protein. Early genes also include enzymes that 
are required for nucleotide metabolism and DNA repair (Roizman & Sears, 1996).
The synthesis of E genes can be detected as early as 2 hours post infection and reaches a 
peak at 5 - 7 hours. Viral DNA synthesis commences shortly after the onset of early 
gene expression and continues up to 15 hours post-infection, with a peak between 7 - 1 0  
hours post-infection (Roizman & Sears, 1996). The regulated cascade of gene 
; expression ends with the expression of L genes that generally encode structural proteins
of the virion. Late genes can be subdivided into leaky late, such as VP5 encoded by 
UL19, and true late, such as VP 19c encoded by UL38. Expression of leaky late genes 
I can occur in the absence of DNA synthesis, although their expression is enhanced
I during DNA replication, the true late genes are only expressed after the onset of DNA
[ replication. Late gene expression peaks at 8-10 hours post-infection and persists for the
remainder of the lytic cycle (Harris-Hamilton & Bachenheimer, 1985). Further detailed 
[ review of HSV-1 gene expression can be found elsewhere (Preston, 2000; Roizman &
I Sears, 1996).
| 1.2.4. Proteins encoded by the immediate early genes o f HSV-1.
t The IE gene products play an essential role in the regulation of the viral gene expressionf
I (see figure 1.2.4A) and they control the host cell to create an environment conducive for!
1 viral replication. ICP4 and ICP27 are essential regulatory proteins in all experimental
r
f systems (in vitro and in vivo); ICP0 and ICP22 are dispensable in at least some systems,
but the evidence indicates that each plays an important regulatory role in viral gene
i
regulation. Furthermore, collectively the immediate early proteins have been implicated 
in being essential for the induction of apoptosis during the early stages of viral infection 
(Sanfilippo et al., 2004). Below is a brief review of the immediate early gene products, 
highlighting their key biological functions. As it is not possible to go into depth with all 
of the immediate early gene products, appropriate references are included in each 
section. However, a detailed review of ICP0 can be found in section 1.4.0.
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Figure 1.2.4A. Schematic diagram showing the location o f IE genes within the 
genome o f HSV-1 and the regulation HSV-1 gene expression by the IE proteins.
The immediate early gene are ICPO (IE1 or aO), ICP27 (IE2 or a l l ) ,  ICP4 (IE3 
or a4), ICP22 (IE4 or a22) and ICP47 (IE5 or a47). ICPO can transactivate all 
classes o f genes.) is essential for the activation of transcription of the early and 
late genes. It can also regulate expression of IE proteins including itself and 
ICPO. ICP27 is essential for the expression of late genes and several early 
genes. ICP22 also contributes to the efficient expression of L gene products. 
Further details can be found within the text. Diagram B, adapted from Everett, 
2000 .
The role ofICP27.
ICP27 is an essential regulatory IE gene encoding a 63 KDa nuclear phosphoprotein, 
being required for the expression of certain early genes and most late genes. ICP27 
functions at least in part at the transcriptional level (McCarthy et a l , 1989; McLauchlan 
et al., 1989). Furthermore, the protein associates with RNA polymerase II holoenzyme 
and the viral transcription factor ICP4, which is thought to reflect its role in stimulating 
early and late gene expression and/or its role in inhibiting host transcription (Zhou & 
Knipe, 2002). Furthermore, ICP27 can also function to repress expression from certain 
HSV-1 encoded promoters in the presence of ICP4 or ICPO (Sekulovich et al., 1988). 
Through stimulating the expression of the early genes that encode essential replication 
proteins ICP27 promotes viral DNA replication (McCarthy et al., 1989).
Despite evidence that ICP27 functions at the transcriptional level, recent evidence 
indicates that its major roles are at the post-transcriptional level. For example, ICP27 
stimulates the usage of certain polyadenylation signals and inhibits host gene expression 
by preventing splicing, which contributes to the shut-off of host protein synthesis seen 
during productive infection (Bryant et al., 2000; Hardwicke & Sandri-Goldin, 1994; 
Hardy & Sandri-Goldin, 1994). Furthermore, ICP27 has been shown to shuttle between 
the nucleus and cytoplasm, and additionally can cross link with viral RNA in the 
nucleus and cytoplasm, suggesting a role for it in the nuclear export of viral transcripts 
(Phelan et al., 1997; Sandri-Goldin, 1998; Soliman et a l, 1997). More recent studies 
have shown ICP27’s ability to export RNA is specific for intron-less viral mRNAs. 
Furthermore, ICP27 in vitro and in virally infected cells has been shown to bind to REF 
and TAP, factors involved in cellular mRNA export (Chen et a l, 2002a; Koffa et a l, 
2001). An ICP27 mutant that does not interact with REF was inactive in viral mRNA 
export (Koffa et a l, 2001). It was proposed that ICP27 associates with viral mRNAs 
and recruits TAP via its interaction with REF proteins, therefore enabling otherwise 
inefficiently exported viral mRNAs to access the TAP-mediated export pathway (Koffa 
et a l, 2001). Research has supported the role of TAP in ICP27-mediated export of viral 
mRNA (Chen et a l, 2002a) and additionally showed that over-expression of a TAP 
mutant that cannot bind to nucleoporins inhibits ICP27 translocation (Chen et a l, 
2002a). The ability of ICP27 to bind to RNA and shuttle between the nucleus and 
cytoplasm has been shown to be required for efficient cytoplasmic localisation of the 
long UL24 transcript (Pearson et a l, 2004), which encodes nuclear associated proteins
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that have a supposed role in inhibiting cell to cell fusion during infection (Sanders et a l, 
1982; Tognon et a l, 1991). Finally, in certain human cells, ICP27 prevents apoptotic 
cell death, which is otherwise induced by early events in viral infection (Aubert et al.,
1999).
The role o f ICP4.
ICP4 is a 175-kDa protein encoded by both copies of the RSI or IE3 gene within the 
repeats flanking the S segment of the viral genome. ICP4 acts as a transactivator of early 
and late gene expression and is essential for lytic infection to progress past expression of 
the immediate early genes alone (Preston, 1979; Watson & Clements, 1980). 
Furthermore, ICP4 acts to down regulate its own expression and that of other IE 
proteins such as ICPO (DeLuca et a l, 1985; Roberts et a l, 1988). As a transactivator, 
ICP4 serves to increase transcription by increasing the assembly of transcription 
complexes within promoter sequences (Grondin & DeLuca, 2000). ICP4 contains a 
DNA binding region that is essential for its transactivation function (DeLuca & 
Schaffer, 1988; Michael et a l, 1988; Paterson & Everett, 1988), however no specific 
ICP4 binding sites have yet been identified on more than a minority of the early and late 
promoters that ICP4 activates (Everett, 1984; Imbalzano et a l, 1990; Smiley et a l, 
1992). Mutational studies have shown that complete deletion of ICP4 severely impairs 
expression of early and late genes (DeLuca et a l, 1985).
Several lines of evidence have proposed that ICP4 transactivation occurs through 
interaction with TATA-binding protein (TBP) and general transcription factor TF11B 
(Gu et a l, 1995a; Kuddus et a l, 1995) and that these interactions are facilitated by the 
cellular high mobility group factor 1 (HMG1) protein and DNA (Carrozza & DeLuca, 
1998). Most recently in vitro studies have shown using the structurally distinct 
promoters, the early tk and the late gC promoter, that TFILA was necessary for ICP4- 
mediated activation of the latter. This suggests a mechanism of action by which ICP4 
regulates the early and late promoters (Zabierowski & DeLuca, 2004).
The role o f ICP47.
ICP47 is encoded by the US 12 gene and is non-essential for replication and doesn’t act 
as a regulatory protein in the same manner as ICPO, ICP4 and ICP27 (Mavromara-
34
Nazos et al., 1986). ICP47 is able to bind to the cytosolic face of TAP, a transporter 
which is associated with antigen processing (Tomazin et al., 1996), this process inhibits 
the translocation of peptides across the ER (Fruh et al., 1995; Hill et a l, 1995), which is 
thought to have an important function in inhibiting antigen presentation to CD8 T 
lymphocytes. Processing of viral proteins for recognition by the cytotoxic T 
lymphocytes normally involves degradation of the proteins in the cytosol of an infected 
cell followed by transport of the resulting peptides into the endoplasmic reticulum (ER) 
by TAP. Due to the lack of translocated peptides inside the ER, MHC class I molecules 
fail to assemble and therefore MHC peptide complexes do not reach the cell surface for 
immune recognition. Thus ICP47 may provide a mechanism by which HSV-1 escapes 
immune surveillance by the host (York & Rock, 1996)
The role ofICP22.
ICP22 is a 68 kDa protein expressed from the IE4 gene and is involved in gene 
regulation although its role is yet to be defined. ICP22 null mutants grow as well as wild 
type HSV-1 in many cell types (Post & Roizman, 1981), however they exhibit a reduced 
level of ICPO expression and a subset of late genes (Sears et al., 1985). The carboxyl 
terminus of ICP22 is also encoded by a second overlapping transcript that has been 
designated as US 1.5 (Carter & Roizman, 1996). Analysis of the ICP22 and US 1.5 
shared domain has shown that it is necessary for optimal expression of several L genes, 
and HSV-1 deletion mutants lacking these domains are avirulent in experimental animal 
systems (Ogle & Roizman, 1999).
ICP22 has also been implicated in the production of an aberrantly phosphorylated form 
of cellular RNA polymerase II, however the significance of this remains unclear (Rice et 
al., 1995). Interestingly, the role of ICP22/Usl.5 is tied to that of the UL13 protein 
kinase (Purves et al., 1987). The UL13 kinase, along with the US3 kinase, 
phosphorylates ICP22/US1.5, and HSV mutants lacking functional UL13 have similar 
phenotypes to those of ICP22 null mutants (Rice et al., 1995). Studies that are more 
recent have indicated that ICP22 and UL13 have an important relationship with cell 
cycle regulated protein cdc2, which is activated in HSV-1 infected cells. Specific 
inhibition of this cellular kinase results in inhibition of expression of the same set of late 
genes that are inhibited by inactivation of ICP22 or UL13 (Advani et al., 2000). How
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cdc2 actually regulates the expression of this subset of late genes remains to be 
elucidated.
1.2.5. The role o f HSV-1 early proteins.
The E gene products encode proteins involved in viral DNA synthesis, DNA binding 
proteins, thymidine kinase and other enzymes. The temporal regulation of the early class 
of genes is mediated by cis-acting elements in E promoters and by ICP4 and ICPO, 
which work synergistically with one another to stimulate expression of these genes (and 
late genes).
Studies to develop the understanding of temporal regulation of early genes in HSV-1 
were originally carried out using the gene encoding thymidine kinase (UL23). The 
studies showed the tk, like other early promoters contain regulatory elements similar to 
that of other eukaryote promoters, such as a TATA element linked to two upstream 
binding sites for the transcription factor Spl and a CAAT element. Both elements were 
required for efficient tk gene transcription during HSV infection (Everett, 1983, 1984). 
No additional cis-acting elements were necessary for expression during infection (Coen,
1986). Besides these elements, analysis of the gD gene expression revealed the cap-site 
region is necessary for E promoter activation; deletion of this region moderately 
decreased gD gene expression (Everett, 1983, 1984). An overview of the early promoter 
structure can be found in figure 1.2.3B.
These results were intriguing as a viral gene such as tk, which apparently contains all of 
the cis-acting regulatory elements that are sufficient for expression in the eukaryotic 
cell, is not expressed when present in the viral genome until HSV-1 IE proteins are 
synthesised (Coen et a l, 1986). Subsequent studies showed that ICP4 is necessary for 
expression of the tk gene in the viral genome, that transactivation is mediated through 
the TATA element of the tk promoter, and that expression is enhanced by the presence 
of the CAAT motif and Spl binding sites. Furthermore, the tk TATA element alone can 
direct modest transcription in the absence of the upstream regulatory elements, but only 
in the presence of functional ICP4 (Imbalzano et a l, 1991). It is thought that the TATA 
element appears to influence the strength of expression rather than the timing (Cook et 
a l, 1995).
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From the detailed analysis of the UL37 and UL50 early promoters, it has been shown 
that individual HSV early promoters contain a variety of cis-acting regulatory elements, 
commonly found in eukaryotic genes transcribed by RNA polymerase II (Pande et a l , 
1998). In conjunction with earlier studies carried out on the tk gene, the results 
demonstrate the composition and arrangement of these elements differ considerably 
among HSV early promoters, but all are found upstream from an essential TATA 
element (Weir, 2001). Therefore, unlike the IE promoters, the E promoters do not 
contain regulatory elements that are specific to viral genes, and instead the E promoters 
rely on cis-acting sequences that are in common with those of typical cellular genes 
(Everett, 1984). This is supported by research that showed the HSV-1 gD promoter 
transactivation does not require elements other than those involved in promoter function 
in the absence of the IE proteins (Everett, 1983, 1984). Indeed, HSV-1 is unable to 
differentiate between viral and cellular promoters when the latter are placed in the 
context of the viral genome (Smiley et al., 1987).
1.2.6. The role of the late gene products.
Expression of the L genes is activated by the IE genes, but only after viral DNA 
synthesis has occurred. Again, ICPO and ICP4 work synergistically with one another to 
stimulate their expression. In addition, ICP27 can further enhance the expression of 
certain L genes, beyond the levels achieved by the combination of ICP4 and ICPO 
(Everett, 1986; Sacks et al., 1985). Furthermore, ICP22 has been implicated in 
stimulating the expression of L genes in a cell type specific manner (Sears et a l, 1985).
Concurrently with DNA replication, viral late gene expression is initiated as early gene 
expression begins to decline. These processes are linked, since inhibition of DNA 
replication also inhibits late gene expression and prolongs the expression of early genes 
(Weir, 2001). The L genes encode the structural proteins of the capsid, tegument and 
envelope. Following the expression of the L genes, the viral DNA concatamers are 
cleaved into genome length units and packaged into the capsids. The cleavage and 
packaging signal derives from ‘a’ sequences that lie between the repeat regions of the 
DNA concatamer (see figure 1.1.4A) (Roizman & Sears, 1996).
A detailed analysis has been carried out on the composition of late gene promoters (see 
figure 1.2.3b). Like IE and E promoters, the L promoters require a TATA element and
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appear to be identical to other viral or eukaryotic TATA elements that account for 
temporal expression (Johnson et al., 1986). As mentioned previously, ICP4 is necessary 
for the activation of L gene expression and mediates its action through the TATA 
element, the same mechanism as used for early promoters. Late promoters are 
functionally silent before DNA replication even at a time when ICP4 is present. The IE 
and early promoters differ from the true late promoters, as the latter do not possess cis- 
acting regulatory elements upstream from the TATA element. Instead, L promoters 
contain other elements downstream from the TATA including an initiator element at the 
start of transcription (Guzowski & Wagner, 1993; Kibler et al., 1991; Mavromara- 
Nazos & Roizman, 1989). The regulatory elements so far identified as necessary for 
efficient late promoter activity also appear to be identical to the eukaryotic regulatory 
elements. The key feature that distinguishes E and L promoters from one another is the 
arrangement and composition of these regulatory elements suggesting a potential 
mechanism to how the transcriptional machinery distinguishes between the E and L 
promoter during the course of infection. (Weir, 2001)
There are two sets of L genes referred to as leaky-late or yl genes and the true HSV-1 
late genes referred to as y2 genes that require DNA replication for any appreciable 
accumulation of their mRNAs (Weir, 2001). The leaky-late genes are expressed to a 
degree in the absence of DNA replication, but require DNA synthesis for maximal 
expression (Weir, 2001). Expression is classed as leaky due to cis-acting regulatory 
sequences upstream of the TATA element similar to early promoters, as well as an 
initiator element at the start of transcription similar to strict late promoters (Huang et al., 
1993; Lieu & Wagner, 2000)
Further studies have proposed that ICP8 is required for late gene expression (Chen & 
Knipe, 1996; Gao & Knipe, 1991; McNamee et al., 2000). ICP8 mutants exhibit 
reduced levels of gene expression, possibly due to the reduced levels of DNA 
replication that results from defective ICP8. However, certain mutants of ICP8 inhibit 
late gene expression to a far greater extent than they inhibit viral DNA replication, 
suggesting a more direct role in late gene expression (Chen & Knipe, 1996; Gao & 
Knipe, 1991). Furthermore, it has been shown that the viral regulatory proteins ICP4 
and ICP22 co-localise with RNA polymerase II and viral DNA replication proteins late 
in infection (Leopardi et al., 1997). More recently, a study to further elucidate the role 
of ICP8 have shown that it coprecipitates with a vast array of proteins including proteins
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involved in DNA replication (Taylor & Knipe, 2004). Possibly further analysis of these 
proteins will give new insight into what part ICP8 plays in HSV-1 replication.
1.2.7 The role o f VHS in HSV host cell interactions and viral gene expression.
The uncoating of the virion following fusion of the viral envelope with the cell 
membrane results in the release of the tegument proteins into the cytoplasm of the host 
cell. Some of these proteins serve to stall host protein synthesis and accelerate the 
activation of viral gene transcription (reviewed by Roizman and Sears, 1996). The 
primary mechanism that initiates the shut-off of host protein synthesis during the initial 
stages of infection is regulated by the virion associated host shut-off (VHS) protein; 
classed as early (primary or virion associated) shut off. VHS instigates the shut-off of 
host cell protein production by globally increasing the rate of mRNA degradation in the 
cytoplasm (Kwong & Frenkel, 1987), resulting in a decrease in the levels of the 
corresponding proteins (Koppers-Lalic et al., 2001; Strom & Frenkel, 1987). Viral 
mRNA is also degraded, however its rate of synthesis is greater than that of VHS- 
induced degradation (Elgadi et al., 1999; Karr & Read, 1999; Krikorian & Read, 1991; 
Lam et al., 1996). The effect of VHS is magnified by virus-induced suppression of host 
mRNA synthesis, mediated through repression of primary transcription (Spencer et a l , 
1997) and pre-mRNA splicing (Hardy & Sandri-Goldin, 1994). The affect of VHS is 
enhanced by additive effects of ICP27, so that the two functions lead to a reduction in 
the abundance of host mRNA during infection (Hardwicke & Sandri-Goldin, 1994; 
Song et a l , 2001). The available data suggest that VHS functions as an RNase or as a 
subunit of an RNase. Its amino acid sequence contains similarity to a family of cellular 
nucleases that are involved in DNA replication and repair (Doherty et a l , 1996; Everly 
et a l , 2002; Everly & Read, 1997), in particular to FEN-1, an endo/exonuclease that 
helps remove RNA primers from Okazaki fragments during DNA replication in 
eukaryotes (Lieber, 1997).
The process by which VHS-dependent RNase mediated degradation selectively targets 
mRNAs as opposed to other cellular RNAs remains unclear, as it cannot discriminate 
the 5’ cap or 3’ poly(A) tail of mRNA (Smiley, 2004). However, some evidence 
suggests that VHS is preferentially targeted to regions of translation initiation on 
mRNAs, as the 5’ end of HSV thymidine kinase mRNA is degraded before the 3’ end in 
vivo (Karr & Read, 1999). It was proposed that VHS is targeted to mRNAs through
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interactions with one or more components of the cellular translation initiation 
machinery. This is illustrated by the fact that VHS has been shown to directly bind the 
cellular translation initiation factor eIF4H (Feng et a l, 2001).
VHS is present in all neurotropic alphaherpesviruses and therefore is likely to play a 
fundamental role during infections. However, the phenotype of a HSV-1 VHS null 
mutant in cell culture, unlike in animal models, is still relatively similar to wild type 
HSV-1 (Read & Frenkel, 1983; Read et a l, 1993; Smibert et a l, 1994). The distinct 
difference in the virulence of the virus in vitro to that of in vivo indicated that VHS 
plays a crucial role as a HSV-1 virulence factor (Strelow et a l, 1997; Strelow & Leib, 
1995, 1996). VHS has been shown to affect host immunity in a number of ways, in 
particular mRNA degradation induced by VHS and the effects of ICP47 contribute to 
the loss of major histocompatibility complex (MHC) class I and reduce the levels of 
MHC class II at the cell surface (Hinkley et a l, 2000; Koppers-Lalic et a l, 2001; 
Tigges et a l, 1996). This renders infected cells resistant to lysis by cytotoxic T 
lymphocytes, an effect that is predicted to impair antigen presentation and lessen both 
cellular and humoral responses (Trgovcich et a l, 2002). The biological affects of VHS 
are reviewed in further detail elsewhere (Smiley, 2004).
1.2.8. DNA replication.
The viral DNA reaches the nucleus as soon as 30 minutes post-infection where it forms 
a circular episome (Uprichard & Knipe, 1996). HSV DNA replication occurs in 
specialised structures formed in the nucleus of infected cells, called replication 
compartments (Quinlan et a l, 1984), which are located adjacent to subnuclear structures 
called ND10 (Maul et a l, 1996). Within the replication compartments are protein 
products of the early genes that are essential for viral DNA replication.
Several HSV-1 proteins are required for ori (origin of replication) dependent DNA 
replication. These are components of the helicase primase complex (U l5 , U l8 , U l5 2 ) ,  
an origin binding protein (U l9 ) , a single stranded DNA binding protein (U l2 9  or ICP8), 
DNA polymerase (U l3 0 ) and its processivity factor (U l4 2 ) . All the genes encoding 
these proteins are located in the U l segment of the genome (Challberg, 1986; Crute et 
al, 1989; Wu et a l, 1988).
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Figure 1.2.8A. Schematic representation o f HSV-1 DNA Replication.
1), UL9, the origin binding protein, binds to specific sites at an origin of DNA 
replication (either oriL or oriS) and starts to unwind the DNA. 2) ICP8, the single­
stranded DNA binding protein, is recruited to the unwound DNA. 3) UL9 and ICP8 
recruit the helicase-primase complex and the polymerase holoenzyme replication 
proteins to the replication forks. 4) DNA synthesis initially proceeds via a theta 
replication mechanism, but then switches to a rolling-circle replication mechanism. 
(Diagram adapted from Taylor et al, 2001).
DNA replication is thought to be initiated by the theta mode of replication (Roizman & 
Sears, 1996) and occurs at one of the three cis-acting elements within the HSV-1 
genome that function as origins of replication (ori) (see figure 1.2.8A). The origin 
binding protein (UL9) forms a homodimer and binds via its N-terminal region to 
specific sequences within the ori sequence (Elias et al., 1992), in association with the 
single stranded DNA binding protein ICP8 (UL29). Helicase activity associated with 
UL9 is stimulated by the presence of ICP8, which binds to the C-terminal segment of 
UL9 and enables the separation of the two DNA strands permitting entry of the host 
DNA polymerase complex (a heterodimer of UL30/UL40) (Boehmer et al., 1994; 
Boehmer & Lehman, 1997). Theta replication begins before switching to the rolling 
circle mode and the addition of the DNA helicase-primase (primosome) complex 
comprising of a 1:1:1 ratio of the UL5/UL8/UL52 gene products (Boehmer & 
Nimonkar, 2003). DNA synthesis is continuous along one strand and discontinuous 
along the other strand. The growth of the DNA fork is maintained by ICP8 and results in 
accumulations of large concatemeric DNA molecules at specific sites within the nucleus 
(de Bruyn Kops & Knipe, 1988; Quinlan et al., 1984).
Other HSV-1 viral proteins important for DNA replication include those involved in 
nucleic acid metabolism, such as thymidine kinase (UL23), ribonucleotide reductase 
(UL39 and UL40), dUTPase (UL50), uracil DNA glcosylase (UL2) and alkaline 
exonuclease (UL12). The functions of these proteins have been reviewed recently 
elsewhere (Boehmer & Nimonkar, 2003).
The hypothesis of circularization of the HSV-1 genome upon its entry into the nucleus 
has recently been challenged. Instead it has been suggested that replication initially 
occurs from linear genome templates and that the genome only circularises in the 
absence of ICPO (Jackson & DeLuca, 2003); this is discussed in more detail in section 
1.4.11.
1.2,9, Viral capsid assembly.
Expression of the late proteins drives capsid assembly and occurs within the nucleus. 
However, the capsid proteins VP5, VP26, VP23 lack nuclear localisation signals and 
consequently form complexes with NLS-containing proteins VP19C or pre-VP22a in 
the cytoplasm for transport into the nucleus (Rixon et al., 1996). A mature HSV-1
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capsid is comprised of an outer shell containing penton-shaped subunits of the major 
capsid protein, VP5 and hexons of VP5 and VP26 (Newcomb et a l, 1996; Newcomb et 
al., 1999). These subunits are connected by triplex structures formed by the two minor 
capsid proteins, VP19C (UL38) in one copy and VP23 (UL18) in two copies. Two 
genes encoding multiple non-structural proteins, UL26 (VP21 and VP24) and UL26.5 
(pre-VP22a, VP22a), are also necessary for efficient capsid formation. VP21, pre- 
VP22a, and VP22a are scaffolding proteins (Thomsen et al., 1994). VP24 is a serine 
protease required for capsid maturation (Taylor et a l, 2002). Cellular factors are not 
required for capsid assembly since the process can be completed in vitro using purified 
viral protein components (Newcomb et a l, 1999). Capsid shells containing the scaffold 
proteins are then loaded with viral DNA, with concomitant loss of the scaffold. A 
schematic representation of capsid assembly is shown in figure 1.2.9A.
1.2.10. Packaging o f  progeny DNA
The UL12 and UL12.5 genes encode alkaline nucleases, which aid the processing of 
branched DNA molecules prior to cleavage, although these proteins are not essential for 
cleavage or packaging of viral DNA. Mutants that fail to express an alkaline nuclease 
(AN) exhibit a reduced viral yield by 100- to 1000-fold, which is thought to be from the 
cumulative effects of relatively small reductions in viral DNA synthesis, DNA 
packaging, capsid egress from the nucleus and the ability of progeny particles to initiate 
new cycles of infection (Bronstein et a l, 1997; Martinez et a l,  1996; Porter & Stow, 
2004b). DNA replication results in the production of large, branched, head-to-tail 
concatamers of viral DNA (Zhang et a l, 1994). However, in the absence of AN gene 
the DNA replicative intermediates have a more complex structure with an increased 
frequency of branches (Martinez et a l, 1996) and appear to be more prone to 
recombination events (Porter & Stow, 2004a). Furthermore, structural abnormalities 
have also been detected in the genomes of progeny virions (Porter & Stow, 2004b)
The replicated DNA is packaged into the capsid and cleaved into unit length monomers 
at the novel a-a junction. This results in a single copy of the genome being packaged per 
capsid, with an “a” sequence being present at each terminus of the DNA molecule 
(Mocarski & Roizman, 1982). The “a” sequence is thought to act as a marker in order to 
determine when a full genome length has been packaged and should be cleaved. The 
cleavage of DNA is also dependent upon capsid formation as mutants that fail to express
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Figure 1.2.10A. Schematic illustration o f the hypothesised routes o f 
virion egress from the cell nucleus.
Pathway A - envelopment, de-envelopment, and re- envelopment (EDR) 
pathway. This involves the enveloped particle in the inter-membrane 
space of the nuclear envelope becoming de-enveloped by fusing with the 
outer nuclear membrane, causing release of the free nuclear capsid into 
the cytoplasm. This nucleocapsid becomes enveloped by fusion to the 
Golgi apparatus. Pathway B- The lumenal pathway. This involves the 
enveloped particle in the inter-membrane space of the nuclear envelope 
budding into a cytosolic vesicle. The vesicle moves or is transported to 
the Golgi apparatus where it fuses with the Golgi membrane, releasing 
an enveloped particle into the lumen of the Golgi apparatus. At this point 
the two pathways converge. Pathway A predicts that the virion envelope 
derives from the Golgi apparatus membrane while pathway B predicts 
that the virion envelope derives from the inner nuclear membrane. The 
diagram was adapted from Knipe, et al. 1996.
either the VP5 or VP23 capsid proteins appear to be unable to cleave concatemeric 
DNA (Desai et al., 1993). In addition to the major components of the procapsid, several 
DNA packaging proteins (UL6, UL15, UL17, UL25, UL28, UL32 and UL38) are 
necessary for cleavage and packaging of concatemeric HSV-1 DNA. Studies have 
shown that UL6 protein is localized at a single vertex of the capsid and purified UL6 
product forms a dodecameric ring and probably acts as portal protein, which acts as a 
docking site for the other components of the DNA-packaging machinery and the viral 
genome (Newcomb et al., 2001). This is further supported by research that showed UL6 
interacts with UL15 and UL28, proteins that are thought to also play a role in 
establishing a functional DNA packaging complex (White et al., 2003). Studies have 
also suggested UL25 plays an important role in generation of capsids containing DNA 
(Addison 1984). It is thought to occur during the later stages of infection when the DNA 
is added to the capsid, prior to their release into the cytoplasm (Stow, 2001), with UL25 
acting to ensure the DNA is retained in the capsids (McNab et a l , 1998). Additionally 
UL25 has been shown to interact with specific capsid proteins and viral DNA, thereby 
anchoring the viral DNA to the capsid (Ogasawara et a l , 2001). The exact mechanism 
by which DNA enters the capsid has yet to be identified. However, the structure of the 
DNA within virions would suggest that the DNA is packaged by a spooling mechanism 
forming coiled layers (Zhou et al., 1999). During infection the DNA is thought to be 
released from the capsid in a reverse process, whereby the DNA uncoils from the centre 
outwards (Zhou et a l , 1999).
1.2.11. Tegument acquisition and virion egress.
Following DNA packaging, the HSV-1 nucleocapsid acquires an envelope by budding 
through the inner nuclear membrane, but it is uncertain whether this envelope is retained 
during virus maturation and egress or whether mature progeny virions are derived by 
de-envelopment at the outer nuclear membrane followed by re-envelopment in a 
cytoplasmic compartment (Skepper et al., 2001). Although the exact mode of tegument 
and envelope acquisition is not known, there are currently two popular models to 
describe this stage of the reproductive cycle. An overview of both pathways is shown in 
figure 1.2.10A. One model, the luminal pathway, proposes that capsids acquire an 
envelope at the inner nuclear membrane, with subsequent modifications to the tegument 
and envelope glycoproteins occurring as the virion exits the cell through the Golgi 
apparatus by the exocytic pathway. Research supporting this hypothesis includes a
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comparative ultra-structural study showing that after intranuclear assembly, progeny 
nucleocapsids exit by budding at the inner leaflet of the nuclear membrane into the 
perinuclear space, resulting in acquisition of a primary envelope (Granzow et a l , 2001).
The second model, the envelopment, de-envelopment, and re-envelopment (EDR) 
pathway, proposes that capsids exiting the nucleus acquire an envelope by budding 
through the inner nuclear membrane into the perinuclear space. These membrane bound 
capsids are then de-enveloped at the outer nuclear membrane and naked capsids are 
released into the cytoplasm. Capsids acquire a tegument on route to the Golgi apparatus 
where they are re-enveloped and acquire membrane-associated proteins before exiting 
the cell via an exocytic pathway. Research to support this model includes a study using 
immunogold labelling to track the distribution of gD that was expressed in conjunction 
with an endoplasmic reticulum retention signal. Most ER-tagged gD was found between 
the inner and outer nuclear membranes, whereas very little of the protein was present on 
the extracellular virus particles. This implies that the primary envelope acquired during 
egress through the nuclear membrane had been lost and the mature virion must have 
obtained an envelope from a post-ER cytoplasmic compartment (Skepper et a l , 2001).
To add further confusion to which is the correct model of virion egress, electron 
microscopy studies carried out previously to the ones mentioned above supported both 
models, as enveloped capsids were identified within cytoplasmic vesicles and naked 
capsids were observed in the perinuclear space (Campadelli-Fiume et al., 1991; Steven 
& Spear, 1997). More detailed reviews of virion maturation and egress can be found 
elsewhere (Roizman & Sears, 1996).
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1.3.0. Latent infection.
A key characteristic of HSV-1 is that it has two states of infection, lytic and latent. The 
vims can establish a latent infection in the ganglion tissue of sensory neurons that lasts 
for the lifetime of the host. All persons seropositive for HSV-1 harbour a latent 
infection.
Unlike a persistent lytic infection, during latency, no viral progeny are produced and 
only very limited amounts of gene transcription can be detected. Following primary 
infection at an oral or genital mucosal surface, the vims travels along the innervating 
neuronal axon to the neuronal cell body (see figure 1.3.0A). Once within the neuron, the 
vims enters a quiescent state in which the lytic gene products are not produced. In a 
subset of seropositive individuals, clinically apparent re-activation events occur 
periodically, and vims, or at least viral genetic information, is thought to pass intra- 
atonally to neuroepithelial junctions where infection of epithelial cells results in 
productive infection and, ultimately, lesions typical of a reactivated infection (Preston,
2000) (see figure 1.3.0A).
The establishment of latent herpesvirus infections can be essentially viewed as a passive 
phenomenon i.e. it requires no viral gene expression or gene products, as replication- 
defective vims can establish latent infections (Garber et a l, 1997). Vims resides in 
latently infected ganglia in a non-replicating state, with expression of the lytic genes 
being extremely low or undetectable (Wagner et a l, 1995). This is in keeping with the 
fact that latent HSV genomes are harboured within the nucleus of a non-dividing 
sensory neurone and do not need to replicate; indeed the challenge arises from the need 
for the vims to reactivate from a transcriptionally quiescent, non-replicating cell 
(Wagner et a l, 1995). This transcriptional silence may allow the vims to remain hidden 
in the cell, thus avoiding immunodetection.
Certain stimuli can reactivate the vims from the latent state. Following these stimuli, 
newly synthesised vims follows axons back to the peripheral site and replication 
proceeds at the skin or mucous membranes (Mellerick & Fraser, 1987; Rock & Fraser, 
1985). The signals and mechanisms involved in this process are poorly understood, but 
it appears that certain physical stresses, such as illness or exposure to ultraviolet light,
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Figure 1.3.0A. Schematic illustration o f  the establishment and 
reactivation o f  HSV-1 latent infection.
(A). HSV-1 replicates initially in epithelial cells at the genital or oral 
mucosal surface. The virus enters innervating sensory neurons where it 
travels up the axon to the neuronal cell body. Once in the neuron, the 
virus establishes a latent infection that may last the lifetime of the host.
(B). Upon the proper stimulus, the virus can reactivate, travel back 
down the axon, and establish another round of lytic replication.
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Diagram adapted from Taylor, et al. 2001.
increase the chance of reactivation. Spontaneous reactivation occurs in spite of specific 
humoral and cellular immunity in the host. However, the body’s immune system limits 
local virus replication so that recurrent infections are less extensive and severe, 
furthermore reactivation can be of a symptomatic or an asymptomatic nature (Wagner et 
a l, 1995)
1.3.1. The role o f  latency associated transcripts (LAT).
Within the latently infected cell, the alphaherpesvirus genome is maintained as a 
nucleosomal, circular episome. Low levels of genome replication might occur or be 
necessary for the establishment or maintenance of a latent infection from which virus 
can be efficiently reactivated (Mellerick & Fraser, 1987; Rock & Fraser, 1985). Latent 
infection with a member of the alphaherpesvirus family can be viewed as having three 
separable phases: establishment, maintenance and reactivation. In the establishment 
phase, the virus must enter a sensory neurone, and following entry, there must be a 
profound restriction of viral gene expression so that the cytopathic results of productive 
infection do not occur (Preston, 2000).
Thus, productive cycle genes are transcriptionally and functionally quiescent and only a 
8.3 Kbp latency associated transcript (LAT) is expressed and accumulates to low levels 
in latently infected neurons. However, the 2.0 and 1.5 Kbp introns derived from the 8.5 
Kbp are abundant and very stable (Krause et al., 1988; Rock et al., 1987; Stevens et al.,
1987). The expression of LAT is controlled by the latency specific promoter, which has 
a number of regulatory elements important in neuronal expression over extended 
periods. Currently, no LAT-encoded protein has been conclusively demonstrated to 
exist, therefore it is thought that LAT transcripts may have other functions or activities. 
It has been shown that LAT negative viruses have increased immediate early gene 
expression in neurons, suggesting that LATs may limit viral gene expression (Garber et 
al., 1997) and promote a latent state. An alternate view is that LATs are an antisense 
mechanism, because most of the 8.3-kb LAT transcript is transcribed from the long 
terminal repeat region of the viral genome and its transcription continues into the short 
terminal repeat region. On the opposite DNA strand to that of the LATs is the gene that 
encodes the immediate early regulatory protein ICPO. The LAT transcript extends across 
the ICPO coding region and continues to just downstream from the termination of the 
ICP4 coding region (see figure 1.3.1 A) (Chen et al., 1997). It has been proposed that
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Figure 1.3.1A. Schematic illustration o f the establishment o f HSV-1 latent 
infection.
Location of transcripts in the long repeat region of HSV-1 DNA. The internal 
repeat of HSV-1 is depicted, although the same gene arrangement exists in the 
terminal repeat. The horizontal line below represents the relative position of 
sequences within the ICPO/LAT region. The various LAT transcripts are shown. 
See text for further details.
LATs prevent the induction of the lytic cycle by acting as anti-sense RNA to block the 
expression of ICPO (Stevens et al., 1987). This theory is supported by transient 
transfection assays, which suggested that LATs inhibit the transactivating ability of 
ICPO (Farrell et al., 1991). Although studies carried out using a LAT deletion mutant 
were unable to detect an increase in levels of the ICPO transcript in infected cells (Chen 
et al., 2002b). However, it has recently been suggested that LAT may play a role in 
controlling the expression of ICPO at the post-transcriptional level during HSV-1 
reactivation from latency (Thompson et al., 2003).
The view that LAT are in some way involved in establishing latent infection and 
preserving the primary nervous system is supported by reports that have suggested in 
rabbit trigeminal ganglia and certain animal models that LAT negative viruses more 
efficiently initiate lytic infection than LAT positive viruses, (Pemg et al., 2000a; Pemg 
et al., 2000b). Interestingly, it has been recently shown that no difference in the 
induction of apoptosis could be observed between a LAT exon 1 deletion virus and wild 
type. However, when the deletion was extended to include the 5’ end of 2.0 Kbp LAT, 
the number of infected cells undergoing apoptosis increased (Ahmed et al., 2002). The 
potential anti-apoptotic role of LAT is further supported by research that showed that 
following infection of a HSV-1 mutant, where the LAT promoter and part of the 5’ end 
of the LAT primary transcript had been deleted, there was an increase in neuronal cell 
death during the acute stage of infection of mice (Pemg et al., 2000b). In contrast, using 
the same mutant vims when compared to wild-type, it was reported that there was not a 
significant increase in the level of neuronal death, in fact only a very few cells were 
undergoing apoptosis (Thompson & Sawtell, 2000, 2001). Therefore, the role of LAT in 
protecting neurones from apoptosis remains a controversial issue.
The molecular basis of reactivation is not known. Stimuli that are effective in inducing 
reactivation in human subjects include axonal injury, fever, physical or emotional stress 
and exposure to ultraviolet light. Expression of only a 350 bp region of LAT near its 5' 
end is both necessary and sufficient to facilitate reactivation in several animal models 
(Davido & Leib, 1996). Thus, vimses with deletions in the transcription unit do not re­
activate as efficiently as the wild type following the induction process (Chen et al.,
1997).
It has been observed from the analysis of infected mice trigeminal ganglia that a small 
number of cells could be detected that were expressing productive cycle genes during 
latent infection (Feldman et al., 2002). It was proposed that this may represent a 
population of cells where reactivation can occur to allow low levels of gene expression, 
but these are insufficient to initiate a recurrent infection (Feldman et al., 2002). The 
significance of this observation remains unclear. The role of LATs has been reviewed in 
more detail elsewhere (Kent et al., 2003; Preston, 2000).
rChapter 1- Part II -  A review of the biological 
properties of the immediate early protein ICPO.
i
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1.4.0. Introduction to ICPO.
ICPO is a member of the HSV-1 immediate early class proteins and its expression is 
initiated by the trimeric association of VP 16, Oct-1 and the cellular protein HCF (see 
figure 1.2.4A). It has a multi-functional role during both the lytic and latent stages of 
HSV-1 infection. Key features of ICPO and its various biological functions are outlined 
below.
1.4.1. The IE-1 gene.
The gene encoding ICPO (IE-1 or a0) is diploid and maps to the inverted repeats, which 
flank the unique sequences of U l , I R l  and TRL (see figure 1.2.4A). The IE-1 gene 
encodes a protein of 775 amino acids in size and the primary IE-1 transcript is only one 
of four to be transcribed from the HSV-1 genome that includes introns and becomes 
spliced (Perry et a l , 1986). The two introns are between codons 19 and 20, and 241 and 
242 in the ICPO open reading frame (Perry et a l, 1986). The intron 1 RNA is 767 bp in 
size (Perry et a l, 1986) and has been shown to accumulate in the cytoplasm and contain 
elements that may regulate the expression of the gene (Gu et a l, 1995b; Poon et a l, 
2002). Both introns contain in-frame stop codons, therefore if alternate or incomplete 
splicing of the primary transcript occurs it is possible that multiple ICPO related protein 
products could be generated. If the first or second intron of ICPO was incompletely 
spliced this would cause the premature termination of translation, thus generating a 
product of either 72 or 262 residues in size. Studies were carried out using a mutant 
strain of HSV-1, which only contained intron 2. It was shown the 262 residue product of 
an unspliced transcript that includes intron 2 could be detected at low levels in BHK 
cells infected with wild type virus. Additionally, low level accumulation of the 262 
residue product is cell type dependent and does not occur following infections with 
viruses that have lost intron 1 and 2 or intron 2 alone (Everett et a l, 1993b).
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The ICPO 262 residue protein is also known as ICPOR and is thought to function as a 
promiscuous repressor of transcriptional activation by ICPO and heterologous 
transcriptional activators (Weber et al., 1992), potentially by titrating cellular factor(s) 
away from ICPO (Spatz et al., 1996). Furthermore, ICPOR has been shown to be 
modified by ubiquitination (Weber et al., 1999), although its mechanism of action is not 
yet fully understood.
1.4.2. The structure o f the ICPO protein.
The ICPO protein contains 775 a.a. residues and has a predicted molecular weight of 78 
KDa, although its electrophoretic mobility in denaturing gels indicates that its size is 
approximately 110 kDa (Heine et al., 1974). The variation between the predicted and 
actual size is thought to be due to phosphorylation of a serine rich region between 
residues 554-591 (Ackermann et a l, 1984), but it is also due to the nature of the 
intrinsic amino acid composition and sequence of the protein. Phosphorylation is carried 
by a number of proteins including the viral protein kinase UL13 (Ogle et a l, 1997) and 
the cell cycle kinase cdc2 (Advani et al., 2001; Advani et al., 2000). Throughout the 
infection cycle ICPO becomes sequentially phosphorylated and it has been proposed that 
phosphorylation status correlates with the cellular localisation of the protein (Advani et 
al., 2001). Phosphorylation is also thought to play an important role in determining the 
activity of the protein, such as in gene expression assays (Davido et al., 2002). Other 
post-translational modifications of ICPO include nucleotidylation (Blaho et al., 1993) 
and ubiquitination (Canning et al., 2004). Post-translational modification of ICPO will 
be discussed in further detail later in this section.
ICPO carries out various functions within the cell, a result of containing multiple 
functional domains (see figure 1.4.2A). Mutational studies have shown that ICPO 
includes a basic a.a. cluster that acts as a nuclear localization signal (residues 501 to 
506) (Everett, 1988a); an USP7 interaction domain (Everett et al., 1997; Meredith et al., 
1995; Meredith et al., 1994); a multimerisation domain (residues 633 to 775) (Ciufo et 
al., 1994; Everett et al., 1991) and a C3HC4 zinc-binding RING finger motif (between 
residues 116 and 156) which is crucial for the majority of ICPO biological functions 
(Barlow et al., 1994). The cysteine-histidine motif classifies the protein as a member of 
the RING finger family and this motif is conserved within the ICPO family of proteins 
throughout the alphaherpesvirus family. Furthermore, ICPO also shares homology with
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Figure 1.4.2A. Schematic illustration o f the functional domains within 
ICPO and the structure o f  the RING finger domain o f Eg63.
A) The relative position of the functional domains of ICPO are illustrated.
B) The structure of the RING finger domain Eg63 was determined by 
NMR. The coordinating zinc residues are shown in blue and the cysteine 
and histidine residues in yellow. The secondary structure features of the 
RING finger domain are also shown.
RING finger domains in proteins expressed by a wide range of other organisms 
(Freemont, 1993). Recently, downstream of the ICPO RING finger domain and before 
the nuclear localisation signal, three segments have been mapped to contain dominant 
phosphorylation sites (Davido and Schaffer, in press). The various domains of ICPO are 
discussed in more detail in the following section.
1.4.3. The structure o f the RING finger domain o f ICPO.
The presence of the conserved cysteine -  histidine zinc chelating domain attributes ICPO 
to the RING finger family of proteins. The term RING is an acronym for ‘really 
interesting new gene’ as the domain was initially identified in the protein encoded by 
the human gene, RING1 (Lovering et a l, 1993). The consensus sequence for RING 
finger motifs is C-X2-C-X(9-39)-C-X(i-3).H-X(2-3)-C-X2-C-X(4-48)-C-X2-C, where X 
denotes any amino acid (Freemont, 1993). The alphaherpesvirus EHV-1 ICPO 
homologue, Eg63, was used to resolve the structure of the RING finger domain (see 
figure 1.4.0A). The NMR analysis of the secondary structure of the homologue showed, 
starting from the N-terminus, that this motif consists of an irregular loop, two strands of 
/3-sheet, two turns of an a-helix (two zinc atoms are present, one at either end) and a 
second irregular loop and the third strand of /3-sheet (Barlow et a l, 1994; Everett et a l, 
1993a).
1.4.4. The RING finger protein family.
RING finger domains can be found in a large number of proteins expressed by different 
species ranging from yeast to mammals and including double-stranded DNA viruses 
(Freemont, 2000). In many cases so far analysed, RING finger proteins play a crucial 
role in ubiquitin conjugation pathway which is thought to reflect their absence in 
prokaryotes as they do not utilise this biochemical pathway (Freemont, 2000). RING 
finger proteins are also involved in a range of cellular processes including development, 
oncogenesis, apoptosis, and viral replication (Borden & Freemont, 1996). However, the 
first protein to implicate RING finger domains as E3 ubiquitin ligase enzymes and thus 
play a crucial role in the ubiquitin conjugation pathway was c-Cbl, which was shown to 
undergo a protein-protein interaction with components of the ubiquitination conjugation 
pathway (Joazeiro et a l, 1999). From the initial identification, a growing number of 
RING finger proteins with similar functions have been identified.
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1.4.5 The role o f the RING finger domain o f ICPO in HSV-1 infection.
The various biological properties of ICPO that have been observed over the years have 
largely been shown to be RING finger dependent. In cell culture, an ICPO RING finger 
negative virus (FXE) has been shown to have greatly reduced growth characteristics 
causing a 1000-fold reduction in the yield of progeny virus (Everett, 1989). 
Furthermore, FXE is unable to reactivate HSV-2 latent genomes in vitro, thus 
highlighting the important role the RING finger domain plays in reactivation (Harris et 
al., 1989). Also using an in vitro neuronal model it was shown the ability of FXE to 
establish a latent infection was impaired by approximately 10-fold compared to wild- 
type virus, as measured by cellular expression of the LATs and also the amount of viral 
DNA in neuronal culture during latency (Wilcox et a l, 1997). The role of ICPO in HSV- 
1 infection is discussed in detail later in this section.
1.4.6. The RING finger domain is crucial for the functions o f ICPO.
ICPO’s ability to act as a transactivator of HSV-1 gene expression is dependent on the 
presence of its RING finger domain (Cai & Schaffer, 1989; Everett, 1987, 1988a). 
Furthermore, studies have shown that mutation of lysine 144, glutamine 148 and 
asparagine 151 within the RING finger domain reduces the transactivation ability of 
ICPO (Everett et a l, 1995a). The mutation of lysine residue 144 had the most 
deleterious affect, causing a reduction in the transactivation ability of the protein to 
levels similar to the RING finger mutant FXE. It was concluded the alpha helix region 
of the RING finger domain must be crucial for ICPO’s transactivation ability (Everett et 
a l, 1995a). The role of ICPO as a transactivator of gene expression will be discussed in 
further detail later in this section.
1.4.7. The ICPO RING finger domain and its role in the degradation o f cellular 
proteins.
During the early stages of HSV-1 infection ICPO localises to and disrupts cellular 
nuclear sub-structures called PML nuclear bodies or ND10 (Maul et a l, 1993). The 
ability of ICPO to dismpt ND10 was shown to be RING finger dependent, although
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localisation of ICPO to ND10 was not (Maul & Everett, 1994). Disruption of ND10 by 
ICPO is caused by the RING finger dependent degradation of cellular proteins PML and 
SplOO. Centromere proteins CENP-C and CENP-A are also degraded in response to 
ICPO, resulting in the disruption of centromeres (Everett et al., 1999a; Everett et al., 
1999b; Lomonte et al., 2001; Parkinson et al., 1999). The effect of ICPO on cellular 
proteins is described in more detail in section 1.5.11.
1.4.8. ICPO nuclear localisation signal.
The nuclear localisation signal (NLS) of ICPO is a highly basic region encoded by 
residues 501-506 and is similar to the SV40 large T antigen NLS. Its activity was 
deduced from deletion studies, which showed that its removal caused the retention of 
ICPO in the cytoplasm (Everett, 1988a). Further studies showed that insertion of a short 
oligopeptide (VRPRKRR) at amino acid residue 500 in an ICPO NLS deletion mutant 
causes restoration of wild type characteristics (Mullen et al., 1994). However, residues 
flanking the nuclear localisation signal on its C-terminal side were also shown to be 
crucial for NLS activity (Everett, 1988a). Additionally, ICPO’s ability to act as a 
transactivater of gene expression in the presence of ICP4 was also reduced by removal 
of the NLS (Everett, 1988a). Studies using a virus that expressed a mutant form of ICPO 
containing a NLS deletion exhibited a reduction in synthesis of viral proteins, formation 
of plaques (in tissue culture) and the level of progeny virus (Mullen et al., 1994).
1.4.9. Multimerisation domain o f ICPO.
Glycerol gradient studies have shown purified ICPO exists as a dimer or higher order 
oligomer in solution (Everett et al., 1991). The region 617-712 of ICPO was shown to be 
crucial, while adjacent residues enhanced multimerisation activity (Ciufo et al., 1994). 
Studies carried out elsewhere mapped the multimerisation domain to a similar region, 
between residues 633-755 (Meredith et al., 1995). Deletion of residues 633-680 from 
ICPO when expressed from a HSV-1 mutant, caused a diffuse nuclear staining pattern of 
the protein instead of the normal punctuate foci (Maul & Everett, 1994). The C-terminal 
deletion of the multimerisation domain of ICPO reduced its ability to act as a 
transactivator of gene expression (Everett, 1988a). Furthermore, a series of mutant 
HSV-1 viruses containing deletions of the multimerisation domain exhibited reduced
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&growth efficiency compared to wild type. It was concluded the C-terminal region of 
ICPO is important for viral gene expression and growth (Everett, 1989).
1.4.10. The USP7 interaction domain o f ICPO.
Following HSV-1 infection of multiple cell types, ICPO has been shown to bind to a 135 
KDa cellular protein (Meredith et a l , 1994), via residues 594-633 in the C-terminal 
region of ICPO (Meredith et al., 1995). The cellular protein was later identified to be 
ubiquitin specific protease 7 (USP7), a member of a large family of enzymes that cleave 
ubiquitin from either alpha- or isopeptide linked chains (Everett et a l , 1997),
Studies using HSV-1 strains that contained mutations within this domain exhibited 
impaired growth compared to wild-type HSV-1 in cell culture (Meredith et al., 1995). 
Transfection studies showed mutations of the USP7 binding motif reduced ICPO’s 
ability to act as a promiscuous transactivator of gene expression, when compared to the 
wild-type protein (Everett, 1988a; Everett et a l,  1999d). Mutation of the USP7 binding 
domain, in particular of either of two lysine residues at positions 620 and 624 of ICPO 
severely impairs ICPO binding efficiency to USP7 and growth of virus carrying these 
lesions in cell culture, suggesting that the interaction between ICPO and USP7 is 
biologically relevant (Everett et a l, 1999d).
Interestingly, even though the USP7 domain of ICPO contributes to the efficiency of 
viral growth, it is only conserved in HSV-1, HSV-2 and HVB, may be a reflection of the 
viruses being closely related. No other member of the alphaherpesvirus ICPO family of 
proteins where detailed sequence information exists has been so far identified to contain 
this domain. The biological significance of the relationship between ICPO and USP7 is 
discussed in further detail in section 1.5.7.
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1.5.0. The role of ICPO in HSV-1 infection.
As our understanding of ICPO has developed, it has become apparent that it is a 
multifunctional protein. It has been implicated to have crucial roles in viral growth, gene 
expression, reactivation from latent or quiescent infection and interaction with an ever­
growing list of cellular proteins. The aim of this section is to review the diverse cellular 
roles of ICPO.
1.5.1. ICPO is not essential for HSV-1 growth following high multiplicity infection.
To understand the biological function of ICPO it is necessary to characterise the 
phenotype of an ICPO-null virus. Various studies have attempted to characterise the 
phenotype of an ICPO-null virus, the aim of this section is to outline these findings.
ICPO is required for low multiplicity infections.
One of the first studies carried out used the HSV-1 mutant d ll403, which contains a 2 
Kbp deletion in both the TRL and I R l  copies of the ICPO gene. The mutant virus was 
shown to infect BHK cells, however the apparent titre of the progeny virus was 20 to 
100-fold lower than that of wild type HSV-1 (Stow & Stow, 1986). However, following 
high M.O.I. infection (5 p.f.u./cell) with dll403 it was shown that the efficiency of viral 
protein production was quantitatively similar to that of wild type HSV-1, as was 
replication and encapsidation of the virus (Stow & Stow, 1986). The difference in 
phenotype of d ll403 to wild-type HSV-1 was most noticeable following infection 
carried out at a low multiplicity and in certain cell types, as at a high M.O.I. the 
phenotype of the mutant was similar to that of wild type HSV-1 (Stow & Stow, 1986). 
Following low M.O.I., it was shown that dll403 displays reduced plaque forming 
efficiency, in particular in human foetal lung cells (HFL) and less so in BHK cells and 
Vero cells (Stow & Stow, 1986). The conclusions from these studies were supported by 
similar findings from research that was carried out elsewhere (Sacks & Schaffer, 1987). 
The work carried out by both research groups implies firstly, that ICPO has a cell type 
dependent affect, being required in different cells to varying degrees. Second, a 
multiplicity dependent affect, being essential for progression of infection at low M.O.I., 
but not at a high M.O.I. Importantly, these studies identified for the first time that ICP0-
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null viruses exhibit a high particle to plaque forming unit ratio (Sacks & Schaffer, 1987; 
Stow & Stow, 1986).
Later studies examined the growth characteristics of mutants with defined lesions in the 
ICPO gene. The mutant viruses were studied in single-step growth curve experiments, by 
assaying for plaques in a variety of cell types and by analysis of viral polypeptide 
synthesis during productive infection at high and low multiplicities (Everett, 1989). At 
low multiplicity, mutations in ICPO reduced viral gene expression in certain cell types, 
in particular HFL cells. Mutations within the RING finger domain had the most 
dramatic affect on the growth characteristics. However, at a high M.O.I. the mutant 
viruses exhibited a phenotype similar to that of wild type virus. It was suggested that 
following low multiplicity infections of cells in culture the inactivity of ICPO leads to 
failure to progress into lytic infection in certain cell types (Everett, 1989).
The requirement for ICPO, following low multiplicity infections was further supported 
elsewhere. It was shown in Vero cells transfected with infectious ICPO-null mutant viral 
DNA, virus production was delayed for 2 days and the levels of de novo synthesis of 
viral proteins were reduced. Furthermore, at low M.O.I. (0.004 p.f.u./cell) it was shown 
that 90% or more of the coding sequence of ICPO was required for efficient replication 
of HSV-1 (Cai & Schaffer, 1989).
In conclusion, the aforementioned studies highlight that ICPO is essential for low 
multiplicity infection, however this defect can be overcome at high multiplicity of 
infection. Furthermore, once an ICPO-null virus has entered lytic infection, viral gene 
expression and yield of progeny particles are similar to those of wild-type HSV-1 (Cai 
& Schaffer, 1992; Everett, 1989; Stow & Stow, 1986). This suggests that a high dose of 
ICPO-null viral genomes can overcome any potential cellular repression mechanism that 
would normally inhibit the same infection at a low multiplicity, thereby not able to 
prevent the cell committing to the lytic cycle.
ICPO-null virus replicates as efficiently as wild-type HSV-1 in U20S cells.
Following low multiplicity infection of the osteosarcoma cell line U20S, an ICPO-null 
mutant virus exhibits growth characteristics similar to that of a wild type virus (Yao & 
Schaffer, 1995). Compared with Vero cells, U20S cells significantly enhanced the
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plaque-forming efficiency of an ICPO-null mutant by over 100-fold. In contrast, the 
plaque-forming efficiencies of wild-type virus in both cell types remained similar (Yao 
& Schaffer, 1995). Further analysis showed the IE and E promoters, (but not the L 
promoters) were responsive to a cellular activity in U20S cells, as they exhibited 
increased basal levels of expression (Yao & Schaffer, 1995). These results suggested 
that there is cellular activity in U20S cells that can substitute for the function of ICPO at 
low M.O.I. Alternatively, there may be cellular repression mechanisms, which are 
normally targeted by ICPO in other cell types, e.g. HFL cells that are not present to 
inhibit the progression of infection in U20S cells. Furthermore, these studies highlight 
that an ICPO-null virus is intrinsically as infectious as wild-type virus. However, in 
restrictive cell lines such as HFL or Vero cells, the probability that a potentially 
infectious ICPO-null mutant virus particle will initiate plaque formation is greatly 
reduced. Consequently, the majority of cells harbour the viral genome in a quiescent 
state; however, the addition of ICPO can cause their reactivation.
1.5.2. The concept o f threshold in ICPO-null mutant HSV-1 infections.
A recent study has identified the importance of threshold when characterising the 
phenotype of an ICPO-null virus (Everett et al., 2004). Initially the titres of an ICPO-null 
mutant virus and wild-type HSV-1 were determined on U20S cells, as the absence of 
ICPO from the mutant virus does not impair its growth in this cell line; therefore, an 
equivalent titre on the basis of potentially infectious virus particles for the two viruses 
can be obtained (Everett et al., 2004).
The particle to p.f.u. ratio of an ICPO-null virus was shown to be about 500 times 
greater in HFFF-2 human fibroblast cells than in U20S cells. This reflects a much 
reduced probability that a potentially infectious mutant virus particle will initiate a 
productive infection in the restrictive cell type (Everett et a l,  2004). However, when 
HFFF-2 cells were infected with wild-type HSV-1 and ICPO-null virus at multiplicity of 
10 p.f.u. per cell (based on titres in U20S cells), equivalent levels of progeny virus and 
gene expression could be detected. This was despite the fact that 10 p.f.u. per cell of the 
wild type and mutant viruses equates to about 0.5 and only 0.01 p.f.u. per cell, 
respectively, if the titrations had been conducted in HFFF-2 cells (Everett et al., 2004). 
However, if the infections were performed at 1 p.f.u. per cell (based on titres in U20S 
cells), viral gene expression and the production of viral progeny were shown to proceed
57
much more efficiently in a wild-type HSV-1 than in the ICPO-null mutant virus 
infection. Therefore, the 500-fold defect in plaque forming efficiency of an ICPO-null 
mutant virus does not mean that 500-fold more virus is required to initiate a productive 
infection, as viral expression and progeny virus production of the ICPO-null virus occurs 
at a similar efficiency to that of the wild type virus, if the multiplicity is above a certain 
threshold, which in the case of HFFF-2 cells is about 10 U20S cell p.f.u. per cell. 
Below this threshold the phenotype of the ICPO-null mutant virus is increasingly 
exemplified (Everett et al., 2004). Overall it was concluded that the multiplicity- 
dependent defect of ICPO-null mutant HSV-1 is not linear and that there is a broad 
threshold of input virus above which infection becomes ICPO independent (Everett et 
al., 2004). This threshold was shown to vary between cell types. When an ICPO-null 
mutant vims is used to infect cells below threshold, the tme consequences of an ICP0- 
dependent infection can be studied. However, above the threshold, the infection 
becomes ICPO-independent and the rate of the developing infection is proportional to 
the viral input copy number.
The phenotype o f an ICPO-null virus.
It was originally shown the number of Vero cells that were infected by an ICPO-null 
mutant viruses, as judged by expression of ICP4, far exceeded the number expected on 
the basis of the input p.f.u. (based on titrations in Vero cells) (Cai & Schaffer, 1992). 
Similarly, from examining the fate of individually infected cells, it was shown that even 
in the most restrictive cell type, HFFF-2, the number of cells expressing viral proteins 
following a low M.O.I. infection with ICPO-null mutant HSV-1 d ll403 far exceeds the 
number of cells that enter productive infection (Everett et al., 2004). Further analysis of 
the non-productively infected cells revealed viral proteins could be detected for 
extended periods, in particular, ICP4 levels were similar to those in productively 
infected cells (Everett et al., 2004). The non-productively infected cells were assigned 
to four classes: quiescent, with no detectable viral protein expression; stalled and 
expressing an apparently incomplete set of IE proteins; stalled at the IE stage; or stalled 
at a stage at which expression of some early proteins has occurred but DNA replication 
has not been initiated (Everett et al., 2004). This study highlights that cells infected with 
an ICPO-null vims can undergo a multitude of fates. Therefore single-cell assays at a 
low MOI may provide a more realistic description of the phenotype of an ICPO-null 
vims than methods that utilise whole cell population approaches (Everett et al., 2004).
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1.5.3. ICPO is a transactivator o f gene expression.
The first significant discovery in understanding the role of ICPO in HSV-1 infection, 
was the identification that it acts as a potent transactivator of gene expression in 
transfection assays (Everett, 1984). These assays were important in identifying the 
synergistic relationship between ICP4 and ICPO. Alone ICP4 could activate the gD early 
promoter, however in the presence of ICPO the level of activation was increased 20-fold. 
Besides these studies, ICPO was shown to able to independently transactivate all three 
classes of HSV-1 genes, including the thymidine kinase promoter (Chen et a l, 1991; 
Everett, 1984; Gelman & Silverstein, 1985; O'Hare & Hayward, 1985; Quinlan & 
Knipe, 1985).
Later studies showed that ICPO is capable of being a promiscuous transactivator of gene 
expression. A variety of promoters other than those of HSV-1 were reported to be 
transactivated by ICPO, these include the SV40 early promoter, HSV-2 28K promoter, 
the HIV long terminal repeat and the long terminal repeat of human endogenous 
retrovirus K (Everett, 1988b; Kwun et a l, 2002; Mosca et a l, 1987; O'Hare & 
Hayward, 1985). Interestingly, the cellular rabbit e-globin and human p-globin 
promoters have also been reported to be transactivated by ICPO (Everett, 1985). The 
analysis of the diverse promoter types transactivated by ICPO has not led to the 
identification of a consensus motif that is required for ICPO to activate gene expression, 
but instead any reporter cassette with a promoter containing elements recognised by the 
basal RNA polymerase II transcription machinery appears to be responsive to ICPO. 
This implies that ICPO does not act by binding directly to the DNA, this is further 
supported by research that showed that ICPO does not form a stable complex with DNA 
in solution (Everett et a l, 1991). Later studies analysed the level by which ICPO 
activates viral gene expression by comparing the activation level of specific promoters 
from all three classes of HSV genes. Using CAT and RNase protection assays, it was 
shown that ICPO activates gene expression by increasing the amount of mRNA 
synthesis, but not translation (Jordan & Schaffer, 1997). These results indicated ICPO 
must target a shared mechanism or acts prior to the transcription factors commencing 
transcriptional stimulation.
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Studies that are more recent have implicated cyclin dependent kinases (cdks) to have a 
role in the mechanism by which ICPO acts as a transactivator. Cdks are intrinsically 
associated with the cell cycle and are thought to regulate certain cellular proteins that 
are involved in many viral pathways or processes necessary for their replication. It was 
shown that in the presence of the cdk inhibitor roscovitine, ICPO’s transactivating ability 
was inhibited. It was hypothesised that certain cdks regulate the function of cellular 
enzymes which modify ICPO, and are required for its transactivating ability (Davido et 
a l , 2002).
1.5.4. The role o f ICPO in the reactivation ofHSV-1 from quiescent infections.
It has been shown that ICPO is required for reactivation ofHSV-1 from quiescence in 
cultured cells. The model involved wild-type HSV-1, HSV-2 or ICPO negative virus, 
infection of HFL cells, which were subsequently grown at 42°C, a temperature non- 
permissive for viral replication, thus preventing the onset of the lytic infection. The 
wild-type virus and the ICPO-null virus established latent infection equally as efficiently 
as one another, indicating that ICPO is not required for the establishment of latency in 
vitro (Russell et a l, 1987). Further supporting this premise were results that showed that 
cultured cells quiescently infected with HSV-2 could be induced to reactivate when 
super-infected with HSV-1, but not with an ICPO-null virus.
The ICPO-null virus used in the aforementioned study was d ll403, which contains a 
deletion that includes the 3’ end of the ICPO gene, which is complementary to the 5’ end 
of the LAT. It was therefore proposed that the phenotype observed could be a result of a 
loss of LAT function (Harris et a l, 1989). Therefore, follow on studies involved 
constructing HSV-1 mutants with more defined lesions in the ICPO gene. Using the 
same in vitro latency system as used previously (Russell et a l, 1987) it was shown that 
adenovirus recombinants expressing ICPO could reactivate HSV-2 from latent infection. 
Furthermore, it was identified the RING finger domain of ICPO was essential for the 
reactivation of latent genomes, while the 3’ region of the ICPO gene that overlaps with 
LAT or the sequence involved in self-multimerisation and nuclear localisation was not 
(Harris et a l, 1989).
Studies carried out using integrated quiescent adeno-associated virus (AAV) genomes 
have shown that expression of the AAV replication proteins can be induced by infection
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of HSV-1 or by transfection of plasmids expressing ICPO. Interestingly it was shown 
that this process was RING finger dependent, but in addition the presence of the USP7 
binding motif in the ICPO mutants was also required (Geoffroy et al., 2004).
1.5.5. The role of ICPO in the reactivation ofHSV-1 from latent infections.
The role of ICPO in latent infection has been most extensively studied using the mouse 
model. It was shown using the mouse ocular model that ICPO-null HSV-1 viruses are 
able to replicate in ganglia with reduced efficiency. These results suggested that ICPO 
might play an important role in establishment and/or reactivation from latency (Leib et 
a l,  1989). Interestingly, contradictory findings were published elsewhere, using the 
mouse footpad model it was shown that ICPO is dispensable for the establishment, 
maintenance and reactivation from latency in infected mouse ganglia. However, the 
ICPO-null virus exhibited a reduced virulence, as the time taken to reactivate was greater 
than that of wild-type HSV-1 (Clements & Stow, 1989). Variations in the results 
between the two research groups may be a reflection of the mouse model used, 
multiplicity of infection or the strain from which the ICPO-null virus was derived.
Later studies supported previous findings that have suggested ICPO does not play a role 
in the establishment of latent infection. The virulence of a series of ICPO mutants with 
C-terminal truncations, but retaining the region that partially encodes the LAT, was 
assessed using the mouse ocular model. The results indicated that all mutants enter and 
reactivate from latent infection, albeit less efficiently than wild type HSV-1 (Cai et al.,
1993). Interestingly, it was also shown that an ICPO LAT double mutant’s ability to 
reactivate from latency could be restored by the addition of one copy of the ICPO gene 
into the viral genome. These results allowed a distinct difference to be identified in the 
role that ICPO and LATs play in the establishment and reactivation of HSV-1 from 
latency (Cai et al., 1993).
Studies that are more recent have indicated that an ICPO-null virus displays a phenotype 
similar to wild-type HSV-1 in vivo. Using the mouse ocular model transiently immuno- 
suppressed mice were inoculated with an ICPO-null virus, which was able to reach wild 
type levels of viral load in trigeminal ganglia of latently infected mice (Halford & 
Schaffer, 2000). Additionally it was shown that infection of an ICPO-null virus at high 
multiplicities was detrimental for the establishment of latency in mice (Halford &
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Schaffer, 2000). Subsequent studies showed that following infection with an ICPO-null 
virus and wild-type HSV-1 with the same latent viral loads that ICPO is essential for 
efficient reactivation from trigeminal ganglia (Halford & Schaffer, 2001). Furthermore, 
latent ICPO-null HSV-1 could be 100% reactivated from trigeminal ganglia by super­
infection with an ICP4-null mutant that expresses ICPO. These results support the theory 
that ICPO is required for efficient reactivation of HSV-1 from latency (Halford & 
Schaffer, 2001).
Additional studies from the same group showed that latent HSV-1 could be reactivated 
from latently infected primary trigeminal ganglia cultures by super-infection with 
adenoviruses vectors expressing ICPO, ICP4 or VP 16. By using an adenovirus 
expressing GFP it was shown that super-infection with the parent adenovirus vector 
alone was not sufficient to induce reactivation (Halford et al., 2001).
On the assumption ICPO is responsible for reactivation ofHSV-1 from latency, research 
has been carried out to determine what induces ICPO’s expression. It has been shown 
that factors in the trigeminal ganglia of transgenic mice can differentially regulate the 
IE-1 and the IE-4 promoters, in the absence of all other viral proteins (Loiacono et al.,
2002). Reporter transgenic mice were exposed to UV irradiation or hyperthermia to test 
whether stimuli known to reactivate HSV-1 could activate viral IE promoters. By 
measuring the beta-galactosidase levels, it was shown that ICPO promoter activity was 
significantly increased in the trigeminal ganglia of mice, which have undergone UV 
irradiation or been subjected to hyperthermia. Interestingly, parallel studies showed that 
the IE-3, IE-2 and gC gene promoters driving the reporter transgene failed to be 
activated. It was subsequently hypothesized that ICPO's promoter is a target for 
activation by host transcription factors in sensory neurons that have undergone damage 
(Loiacono et al., 2003).
1.5.6. The effects o f  ICPO on cellular proteins and cells.
ICPO is a multifunctional protein, which is a reflection of the fact that it has been 
implicated in interacting with a diverse range of cellular factors. In the following 
section, the different cellular proteins that ICPO has been reported to interact with and 
the possible implications of these interactions on HSV-1 replication will be reviewed.
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1.5.7. ICPO interacts with a member o f the ubiquitin specific protease family o f  
proteins.
ICPO interacts via a motif located at in its C-terminal third with ubiquitin specific 
protease 7 (USP7), also known as herpes associated ubiquitin specific protease 
(HAUSP). It was shown using indirect immunofluorescence that USP7 is predominantly 
a nuclear protein and that in some cell types it can form punctate structures that are 
associated with ND10 (Everett et al., 1997). Mutation or deletion of the USP7 binding 
domain causes ICPO function in virus growth and gene expression assays to be reduced. 
(Everett et al., 1999d). These studies indicated that the ICP0-USP7 interaction is 
biologically relevant.
However, until recently the exact function of USP7 in relation to ICPO was unclear. 
Normally USP enzymes have two functions, firstly to cleave ubiquitin chains from 
substrate proteins, thereby preventing proteasome mediated degradation of substrate 
proteins and increasing the pool of free cellular ubiquitin. Secondly, USP enzymes 
cleave ubiquitin precursor molecules to generate free ubiquitin for use in the ubiquitin 
conjugation pathway. As both USP7 and ICPO associate at ND10, it was conceivable 
that USP7 might be involved in cleaving SUMO-1 from isoforms of PML, however this 
was shown not to be the case (Everett et al., 1998b).
It was not until recently that the real breakthrough in understanding the significance of 
the ICP0-USP7 relationship occurred. It was found that ICPO efficiently ubiquitinates 
itself in vitro through its E3 ubiquitin ligase activity, and that USP7 protected ICPO 
from this activity be removing the polyubiquitin chains. Furthermore, the instability of 
ICPO in infected cells was greatly increased if it was unable to bind to USP7, or if 
siRNA treatment was used to reduce the cellular levels of USP7 (Canning et al., 2004). 
This effect was later shown to be particularly pronounced during early times of low 
multiplicity infections (Boutell et al., submitted). It was also shown that, following 
infection with a mutant ofHSV-1 expressing a form of ICPO that is unable to bind to 
USP7, the mutant ICPO proteins accumulated to lower levels than the wt protein, 
causing a reduction in the level of expression of other viral proteins in a cell type 
dependent manner (Boutell et al., submitted). These results may be due to an increased 
level of ICPO degradation in the cell, a result of the failure to bind to USP7. 
Consequently, if  less ICPO were present, it would be predicted that a reduction in the
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level of viral protein expression would occur. In very low multiplicity infections, this 
effect would cause reductions in the number of viral genomes entering the lytic 
infection and the level of plaque formation. These effects were indeed observed (Boutell 
et al., submitted).
1.5.8. Reciprocal activities ofUSP7 and ICPO.
Following the studies that showed that the interaction with USP7 is biologically relevant 
for optimum function of ICPO, it was shown that USP7 is ubiquitinated in vitro and 
degraded during HSV-1 infection. ICPO was shown to degrade USP7 in a RING finger 
dependent manner, which was reliant on the two proteins being able to interact (Boutell 
et al., submitted). It was shown that stabilisation of ICPO during the early stages of 
infection was particularly important following low M.O.I., but not at a high M.O.I. It 
was proposed that the latter was observed because the increased levels of synthesis of 
ICPO could compensate for instability caused by increased levels of USP7 degradation 
(Boutell et al., submitted).
1.5.9. The role o f ICPO in cell cycle regulation.
It has been shown the phenotype of an ICPO-null virus (impaired growth and synthesis 
of viral proteins) was partially restored to that of wild-type HSV-1 when Vero cells at 
the G0/G1 stage of the cell cycle were used as hosts (Cai & Schaffer, 1991; Ralph et al.,
1994). It was suggested that putative cellular functions are expressed at the transition of 
GO into G1 phase of the cell cycle that can functionally substitute for ICPO 
transactivation. Conversely, this also suggested that ICPO might be able to mimic or 
promote cellular conditions that are present during specific stages of the cell cycle.
It was shown by yeast two-hybrid assays and glutathione S-transferase pull down assays 
that ICPO is able to form complexes with cyclin D3 in vitro (Kawaguchi et a l , 1997b). 
Furthermore, when ICPO and cyclin D3 were expressed together from a recombinant 
HSV-1 mutant, both proteins were shown to localise to ND10. Using the same mutant 
virus, it was shown that substitution mutation D199A caused ICPO to remain at ND10 
and cyclin D3 was prevented from colocalising with ICPO (Van Sant et al., 1999). 
Studies using an ICPO-null or D199A ICPO mutant strain ofHSV-1 indicated that cyclin 
D1 and D3 were degraded more rapidly than in wild type infections, suggesting that
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ICPO plays a role in promoting their stability (Van Sant et al., 1999; Van Sant et al., 
2001b).
Based on the previous studies, the same group carried out research to elucidate the 
mechanism by which ICPO promotes D-type cyclin stability. It was shown that ICPO 
acts as an E3 ubiquitin ligase (Boutell et al., 2002; Hagglund et al., 2002) and promotes 
the autoubiquitination of cdc34 (Hagglund et al., 2002). It was interpreted that the ICP0- 
mediated autoubiquitination and subsequent degradation of cdc34 must promote cyclin 
D1 and D3 stability (Van Sant et al., 2001b), as in other systems cdc34 has been 
implicated in their degradation (Jackson & Eldridge, 2002). However, research carried 
out elsewhere has conclusively proved that ICPO does not promote the stability of D- 
type cyclins. A variety of cell types was infected with an ICPO-null and wild-type HSV- 
1 at equivalent multiplicities that ensured that both infections were proceeding at 
equivalent rates (see section 1.5.1. for further details). When carefully controlled in this 
manner, it was found that the D-type cyclins were equally unstable during wt and ICP0- 
mutant HSV-1 infections (Everett, 2004). The author was unable to find evidence to 
support the theory that ICPO promoted the stability of either cyclin D1 or cyclin D3, by 
preventing their degradation. Furthermore, following varying M.O.I. and even when 
high levels of ICPO were expressed, no affect on cdc34 could be observed throughout 
HSV-1 infection (Everett, 2004).
Research carried out elsewhere has studied different aspects of how ICPO affects the cell 
cycle. It was reported that infection of a mutant virus that expresses ICPO as the only IE 
protein causes cell cycle arrest at Gl/S and G2/M. However, a HSV-1 mutant variant 
expressing no IE proteins failed to induce this phenotype (Hobbs & DeLuca, 1999). 
Supporting the previous findings, it was shown that by transfecting plasmids expressing 
ICPO, the cell cycle could be stalled at the Gl/S boundary. Furthermore, by using wt and 
ICPO-null mutant HSV-1 to infect synchronised cells it was found that ICPO resulted in 
the cell cycle becoming stalled at the pseudo-prometaphase stage (Lomonte & Everett, 
1999). The mitotic arrest was shown to be caused by ICPO-induced proteasome- 
mediated degradation of centromere proteins CENP-C and CENP-A (Everett et al., 
1999a; Lomonte et al., 2001), both of which are associated with the inner kinetochore 
plate, which has an essential role in cell division.
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1.5.10 ICPO interacts with and regulates components o f transcription and translation.
ICPO has been shown to target various cellular factors involved in the regulation of gene 
expression. Studies have shown that ICPO degrades the catalytic subunit of DNA- 
dependent protein kinase (DNA-PKs) during HSV-1 infection (Lees-Miller et al., 1996) 
in a RING finger dependent manner (Parkinson et al., 1999). Furthermore, it was shown 
the ICPO-induced degradation of DNA-PKs appeared to be beneficial for HSV-1 
infection, as the virus replicates slightly more efficiently in cell lines that do not express 
DNA-PKs, especially at low multiplicities of infection (Parkinson et al., 1999).
Other studies have shown using the yeast two hybrid system that ICPO interacts with the 
cytoplasmic translation regulation protein elongation factor 15 (EF-15), via the C- 
terminal region of ICPO (Kawaguchi et al., 1997a). The interaction between ICPO and 
EF-15 is thought to occur during the later stages of HSV-1 infection, when ICPO 
migrates to the cytoplasm. The HSV-1 protein, UL13 is thought to be involved in the 
hyperphosphorylation of EF-15 (Kawaguchi et al., 1998), an effect that is associated 
with efficient translation. However, the implications of EF-15 interaction with ICPO are 
not fully understood.
Using the yeast two hybrid system it was shown that ICPO interacts with transcription 
factor BMAL1, via residues located between amino acids 95 and 450 (Kawaguchi et al., 
2001). Furthermore, ICPO and BMAL1 when coexpressed together significantly 
increased transcription of a luciferase reporter construct compared to ICPO or BMAL1 
alone. It was suggested this activity was due to ICPO forming a transcriptionally active 
complex with BMAL1 in cell culture. It was also inferred that ICPO acts to stabilize 
BMAL1, as it was more prone to degradation in cells that had been previously infected 
by an ICPO-null virus. The biological significance of these observations is not clear, as 
binding sites for BMAL1 in the HSV-1 genome have not been characterised and, as 
discussed previously, no specific transcription factor binding sites are required for 
regulation of gene expression by ICPO.
Using transfection assays it was shown that ICPO recruits and colocalises with class I 
and II histone deacetylase (HDAC) enzymes (Lomonte et al., 2004). Furthermore, type 
II HD AC enzymes were shown to interact with ICPO in vitro, via a domain associated 
with regulation of MEF-2, a transcription factor involved in muscle development and
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neuronal survival (Lomonte et a l , 2004). Using transfection reporter assays it was 
shown that ICPO can overcome HDAC5 mediated repression of MEF-2. It was 
concluded this mechanism could be involved in the relief from repression of viral 
chromatin that is widely thought to be a consequence of ICPO activity (Lomonte et a l, 
2004).
1.5.11. The affect o f ICPO on ND10 and centromeric proteins.
During HSV-1 infection, disruption of ND10 occurs via a mechanism that is dependent 
on ICPO and its RING finger domain (Maul et a l, 1993) (Everett & Maul, 1994; Maul 
& Everett, 1994). This disruption of ND10 is brought about by ICPO inducing the 
proteasome-dependent degradation of its major constituents PML and SplOO, 
particularly their SUMO-1 modified forms (Chelbi-Alix & de The, 1999; Everett et a l, 
1998a; Parkinson & Everett, 2000). The dependence on the proteasome degradation 
pathway was proved by research that showed the integrity of ND10 could be preserved 
in the presence of the proteasome inhibitor MG132 (Everett et a l, 1998a). Furthermore, 
the ability of ICPO to disrupt ND10 correlates very well with its ability to initiate lytic 
infection and induce reactivation, as these function were also inhibited by MG132 
(Everett et a l, 1998a). Centromeric proteins CENP-C and CENP-A are also degraded 
by the proteasome pathway in response to ICPO, leading to the disruption of centromere 
structure and concomitant mitotic delay and failure (Everett et a l, 1999a; Lomonte & 
Everett, 1999; Lomonte et a l, 2001). Consistent with these observations it was later 
shown that ICPO can cause the formation of colocalising, conjugated ubiquitin in both 
transfected and infected cells, at ND10 and centromeres (Everett, 2000). It has also been 
shown that ICPO recruits USP7 following transfection of ICPO or during HSV-1 
infection of cultured cells. The binding of USP7 by ICPO was shown to contribute to, 
but not be essential for, ICPO-mediated disruption of ND10 (Everett et a l, 1999d; 
Everett et a l, 1997; Parkinson & Everett, 2001).
1.5.12. Why does ICPO disrupt ND10 bodies?
The ability to disrupt ND10 correlates very well with the biological activities of ICPO. 
Why this should be the case remains a matter of debate. One possibility is that ND10 are 
disrupted in order to release factors that are essential for the continued progression of 
HSV-1 infection (Negorev & Maul, 2001). However, it has also been proposed that
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ND10 structures play an essential role as part of a cellular repression mechanism, which 
prevents or stalls the progression of viral infection. It has been shown that ND10 
proteins become deposited at sites juxtaposed to parental HSV-1 genomes early during 
infection, whereupon viral transcription and the formation of replication compartments 
occurs (Everett & Zafiropoulos, 2004; Ishov & Maul, 1996; Maul et al., 1996). The role 
of ND10 proteins being part of a potential anti-viral mechanism is supported by research 
that has shown the ND10 components SplOO and PML are interferon-induced and have 
been implicated in the repression of gene expression. Additionally, various studies have 
linked ICPO with resistance to the effects of interferon (Eidson et al., 2002; Harle et al., 
2002; Mossman et al., 2000; Mossman & Smiley, 2002; Nicholl et a l , 2000; Preston et 
a l , 2001; Taylor et a l , 1998). In contrast, high-level PML expression does not appear to 
inhibit HSV-1 infection (Chelbi-Alix & de The, 1999; Lopez et a l , 2002). Furthermore, 
ICPO-null mutant HSV-1 does not appear to replicate more efficiently in mouse 
fibroblasts that do not express PML (Chee et a l , 2003). It is possible that no affect was 
observed after PML over-expression because ND10 proteins do not have a role in viral 
gene expression, or perhaps because PML may not be the major component of the 
suggested repression mechanism. Degradation of PML may be a side affect of an ICP0- 
mediated activity towards other cellular components.
1.5.13. The disruption ofNDIO by other viruses.
As mentioned in the previous section, ND10 are disrupted by many viruses, including 
other members of the alphaherpesvirinae. This section will briefly review the affect of 
other DNA viruses on ND10 structures.
HCMV and its immediate early protein IE1.
The beta herpesvirus HCMV disrupts ND10 early during infection by the action of IE 
regulatory protein IE1 (Ahn & Hayward, 2000; Korioth et a l , 1996; Wilkinson et a l ,
1998). The properties of an ICPO-null HSV-1 mutant are similar to those of an HCMV 
IE1 negative virus; both mutant viruses enter the lytic cycle inefficiently, but the defect 
can be overcome by using a high multiplicity of infection (Mocarski & Courcelle, 
1996). The similarities are extended to the fact that HCMV genomes are found at the 
periphery ofNDIO, whereupon replication compartments were formed (Ahn et a l , 
1998; Ishov & Maul, 1996). The potential for ND10 to act as a repressor of HCMV
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replication is suggested by the fact that cell lines expressing high levels of PML are 
poorly infected by HCMV (Ahn & Hayward, 2000), although this has been shown not to 
be the case for HSV-1 (Chelbi-Alix & de The, 1999; Lopez et al., 2002). Furthermore, 
using transfection assays it was shown that expression of the IE1 protein inhibits the 
transcriptional repression function of PML (Lee et a l , 2004).
EBV and HHV-8 and their regulatory proteins.
The gamma herpesvirus Epstein Barr Virus (EBV) and Human Herpes Virus-8 are 
lymphotrophic viruses and replicate persistently to a greater extent than other members 
of the alpha or betaherpesviruses. The key biological differences that exist may reflect 
the differing relationships of the viruses with ND10. Upon infection the EBV protein, 
EBNA-5 becomes associated with ND10, although it does not affect their stability 
(Szekely et al., 1993). However, using transfection assays, it was shown that high level 
expression of the BZLF1 protein causes ND10 disruption (Adamson & Kenney, 2001; 
Bell et al., 2000).
During EBV lytic infection several ND10 components have been shown to be disrupted 
including SplOO, hDaxx and NDP55, which are lost rapidly, while PML is dispersed 
more slowly (Bell et al., 2000). A more recent study has suggested that EBV nuclear 
protein SM induces the expression of SpllOb (a member of the SplOO family of 
proteins), and recruits it to replication compartments. SM utilises SpllO to increase the 
stability of lytic EBV transcripts (Nicewonger et al., 2004).
Key differences occur that distinguish the relationship of EBV genomes with ND10 
during lytic and latent infection. It was shown that EBV genomes do not associate with 
ND10 components during latency, and instead they become attached to interphase 
chromosomes, ensuring the passage of their genome into daughter cells (Bell et al., 
2000; Wu et al., 2000). When the lytic cycle is resumed, as with HSV-1 and HCMV, 
replication compartments juxtaposed to ND10 are formed. In a similar manner to that of 
EBV, HHV-8 has been shown to form structures that resemble replication compartments 
juxtaposed to ND10 and that contain the latency associated nuclear antigen, LANA (Wu 
et al., 2001).
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Papovaviruses.
Papovaviruses undergo episomal replication and rely on the presence of various cellular 
host proteins for viral DNA synthesis. During SV40 replication, foci containing the viral 
genome are formed and these are juxtaposed to ND10. This process is reliant on the 
SV40 large T antigen and an intact SV40 origin of DNA replication.
The human papilloma virus genome also associates with ND10, and this is thought to be 
a result of the El and E2 proteins that are involved in DNA replication. The HPV L2 
protein was also shown to accumulate at ND10, which then recruits the LI protein. L2 
induces the dispersal ofNDIO component SplOO and the recruitment of Daxx (Swindle 
et al., 1999). Interestingly it has recently been shown that using a PML negative cell 
line, L2 can still recruit Daxx in the absence of functional PML proteins (Becker et al., 
2004).
Studies on the HPV-1 E4 protein have shown that it also induces ND10 reorganisation 
in vitro and in vivo, relocating PML from ND10 bodies to inclusion bodies during the 
lytic cycle. These studies indicate that, as with other DNA viruses, ND10 reorganisation 
is part of the HPV replication cycle (Roberts et al., 2003). Again, similar to HHV-8 and 
EBV, HPV genomes associate with chromosomes during mitosis to ensure their passage 
into daughter cells.
Adenoviruses.
The adenovirus type 5 (Ad5) open reading frame 3 (orf3) product disrupts ND10 and 
causes the redistribution of PML to ‘fibrous-like’ structures during the early phase of 
infection (Carvalho et al., 1995). During the late phase of infection the protein pIX is 
thought to participate in the potential neutralisation ofNDIO, by participating in the 
relocation of PML to clear-amorphous (c.a.) inclusions bodies located in the nucleus 
(Rosa-Calatrava et al., 2003). It was suggested that role of pIX was essential for 
efficient viral infection as prevention of this process caused a reduction in viral yield 
(Rosa-Calatrava et al., 2003). Interestingly other ND10 constituents, including the 
interferon induced SplOO, have been found at c.a. inclusion bodies (Souquere-Besse et 
al, 2002).
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1.5.14 Introduction to the SUMO modification pathway.
Both PML and SplOO, which are major components ofNDIO, are major substrates for 
SUMO-modification, and during HSV-1 infection the action of ICPO leads to 
I preferential loss of the SUMO-modified species of these proteins (Everett et al., 1998).
| The aim of this section is briefly to outline the cellular role of SUMO and the purpose it
plays in viral infection with particular reference to that of ICPO.
i
II
The best-characterised members of the SUMO (Small Ubiquitin-like Modifier) family 
are SUMO-1, SUMO-2, and SUMO-3. The enzymatic process is biochemically 
analogous to, but functionally distinct from ubiquitination conjugation (Schwartz & 
Hochstrasser, 2003). As with ubiquitination, there is an El enzyme that activates 
SUMO-1 by a forming a thiolester linkage in an analogous manner to that of the 
I ubiquitin El enzyme. Unlike in the ubiquitination pathway, there is only a single E2
i enzyme (UbcH9) and only a handful of SUMO E3 enzymes have been defined. A
further difference between the two pathways is that, unlike in ubiquitination, SUMO is 
frequently joined to target proteins via a lysine residue situated in a specific amino acid 
sequence motif (Rodriguez et a l , 2001). However, unlike ubiquitin modification of a 
target substrate, the fate of the SUMO-modified protein does not normally result in 
degradation, in fact, it can have multiple and quite diverse affects on the protein. These 
include enhancing the stability of a protein (Bies & Wolff, 1997; Bresnahan et al., 
1996), and modulation of the transactivation activity and/or subcellular localisation of a 
protein (Schwartz & Hochstrasser, 2003). Interestingly, enhanced stability of a SUMO- 
modified substrate can be a direct consequence of competing with the ubiquitin 
conjugation pathway. If SUMO-modification takes place on the same lysine residue that 
is a preferential target for ubiquitination, this protects the lysine residue from 
ubiquitination and this may prevent or delay the initiation of proteasome mediated 
degradation of the protein (Pickart, 2001a).
PML is a major constituent of ND10 and its expression is sharply up-regulated by 
interferon (Chee et al., 2003; Regad & Chelbi-Alix, 2001). SUMO-modification is a 
crucial part of PML biological function, because mutation of the major SUMO- 
modification sites of PML affects its ability to form foci with ND10 and for it to recruit 
specific proteasome regulatory components (Lallemand-Breitenbach et a l , 2001).
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Multiple viruses utilise the SUMO-modification pathway to modify their regulatory 
proteins. It has been shown that bovine papillomavirus protein El relies on SUMO-1 
modification for its import into the nucleus (Rangasamy & Wilson, 2000; Rangasamy et 
a l , 2000) and adenovirus ElB-55KDa utilises it for nuclear accumulation and for its 
cellular transforming functions (Endter et al., 2001). It has been shown that the HCMV 
immediate early-1 protein (IE1) is modified by SUMO-1 and immediate early-2 protein 
(IE2) is modified by SUMO-1, SUMO-2 and SUMO-3 (Ahn et al., 2001; Hofmann et 
a l, 2000; Muller & Dejean, 1999; Spengler et a l, 2002; Xu et a l, 2001). SUMO- 
modification of IE2 is thought to enhance its transactivation capacity (Ahn et a l, 2001; 
Hofmann et a l, 2000). Interestingly, recent studies from mutating the lysine residue of 
the SUMO-modification motif of IE1 showed that viruses containing this mutation 
exhibited reduced rates of growth compared to wild type, suggesting that SUMO- 
modification is required for the full activity of IE1 (Nevels et a l, 2004). However, this 
mutation did not affect the ability of IE1 to localise to and disrupt ND10 and to bind to 
chromatin (Nevels et a l, 2004). However, most interestingly, the failure to modify IE1 
with SUMO-1 resulted in reduced levels of expression of IE2, indicating that IE1 
SUMO modification is essential for IE2 accumulation and the progression of efficient 
HCMV replication (Nevels et a l, 2004).
1.5.15 ICPO and SUMO-modification.
Unlike some of the other viral regulatory proteins mentioned previously, ICPO does not 
contain a SUMO modification motif. ICPO induces the proteasome-mediated 
degradation of PML and SplOO and in particular their SUMO-1 modified isoforms 
(Everett et a l, 1999c; Parkinson & Everett, 2000). Recently, it was shown that ICPO 
increases the level of ubiquitinated PML in transfected cells and mutation of a SUMO- 
modification site in PML reduced the level of its degradation by ICPO (Boutell et a l,
2003). Furthermore, ICPO mutants that don’t locate to ND10 efficiently have a reduced 
ability to induce PML degradation (Everett et a l,  1998a; Parkinson et a l, 1999).
The available data indicate that it is important for PML and ICPO to locate to and 
accumulate in the same nuclear substructure, however as degradation still occurs at a 
reduced level when this process is inhibited, this suggests there may be additional 
factors that play a part. It has been shown that isopeptidase SENP-1, an enzyme capable 
of deconjugating SUMO-modified isoforms of PML, can be recruited to and colocalise
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with ICPO at defined foci during the early stages of infection, although it remains to be 
determined if this plays a role in ICPO induced loss of PML-SUMO-1 conjugates 
(Bailey & O'Hare, 2002).
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Chapter 1- Part III -  The biology of ubiquitination.
1.6.0. Introduction to ubiquitination.
Ubiquitin is a small 76-residue polypeptide that plays an essential role in eukaryotes 
through its covalent conjugation to other intracellular proteins. Substrate proteins 
become ubiquitinated via the ubiquitin conjugation pathway, which generally involves 
three defined sets of enzyme, an El (ubiquitin activating enzyme), an E2 (ubiquitin 
conjugating enzyme) and an E3 (ubiquitin ligase), which determines substrate 
specificity. The fate of a substrate protein arises primarily at the stage of ubiquitination, 
which is mediated by a specific E2-E3 interaction occurring, as this determines how 
many ubiquitin molecules and to which lysine residue the ubiquitin is added to the 
substrate (see figure 1.6.0A). When more than one ubiquitin molecule is added to a 
substrate, it becomes marked with a polymer of ubiquitin peptides, a polyubiquitin 
chain, which is an intracellular signal to target the protein for proteasome-mediated 
degradation by a multi-subunit ATP-dependent protease known as the 26S proteasome. 
However, when a substrate is only marked with a single or a few ubiquitin molecules, 
this can cause proteolysis in the lysosome. Furthermore, the lysine residues targeted for 
ubiquitination play a crucial role in determining the fate of the protein. If polyubiquitin 
chains are linked via lysine 48 of ubiquitin, the substrate will be targeted for proteasome 
mediated degradation, but if linked via lysine 63 the substrate may become involved in 
non-proteolytic signalling (Pickart, 2001a).
The ubiquitin conjugation pathway is associated with the regulation of a diverse number 
of critical cellular functions including the progression of the cell cycle and antigen 
presentation (Pickart, 2001a). It is thought to act as a regulator in these various cellular 
processes by mediating the selective proteasome-mediated degradation of regulatory 
proteins involved in these diverse cellular processes (Pickart, 2001a). Non-proteolytic 
fates of a ubiquitinated proteins include ribosomal function (Spence et a l , 2000), post­
replication DNA repair (Hofmann & Pickart, 1999; Spence et a l , 2000), the initiation of 
the inflammatory response (Deng et a l, 2000), and the function of certain transcription 
factors (Kaiser et a l, 2000).
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Figure 1.6.0 A The fate o f a substrate protein following ubiquitination.
The initially the fate of a protein is partially determined by which lysine 
(Lys) residue the ubiquitin is linked to the substrate protein, which is 
mediate by the specific E2-E3 interaction. The functions of Lys 11 and 
Lys29-linked chains are unknown. Lys 48-linked chains target proteins to 
proteasome-mediated degradation and Lys 63-linked chains have a range 
of fates. The diagram was adapted from Weissman, 2001.
As ubiquitin-dependent proteolysis plays an important role in many diverse cellular 
functions, when it becomes deregulated it can have dire affects on the host organism. 
Previously it has been implicated as a causative factor in certain cancers and several 
genetic diseases (including cystic fibrosis, Angelman's syndrome, and Liddle 
syndrome). Reviews of these issues can be found elsewhere (Ciechanover & Brundin, 
2003; Liu, 2004; Schwartz & Ciechanover, 1999).
1.6.1 The machinery o f ubiquitination.
Ubiquitination of a substrate protein occurs as follows (see figure 1.6.1 A): The first 
enzyme in the ubiquitination pathway, the E l, via an ATP-dependent reaction forms a 
thiolester bond between its active site cysteine and the carboxyl-terminal glycine of an 
ubiquitin molecule. The activated ubiquitin on the El is subsequently transferred to the 
active site cysteine of any number of E2 enzymes. Then a generalised view to what 
happens next is that the E3 ubiquitin ligase binds to both the ubiquitin-charged E2 and 
the substrate, then the E3 facilitates formation of an isopeptide linkage between the 
carboxyl-terminal glycine residue of ubiquitin and the €-amino group of an internal 
lysine residue on the substrate, or in an ubiquitin molecule already attached to the 
substrate (Hershko & Ciechanover, 1998; Pickart, 2001a).
The final enzyme involved in the enzymatic cascade that leads to the ubiquitination of a 
target substrate is the E3 ubiquitin ligase. These enzymes can be classified into two 
families of proteins, those containing HECT (Homologous to E6-AP Carboxyl 
Terminus) domains (Huibregtse et a l , 1995), and the members of the RING finger 
related protein family (Freemont, 2000; Joazeiro & Weissman, 2000). Both families of 
E3 ubiquitin ligases have a distinct amino acid motif that has led to their identification 
in various eukaryotic organisms and viruses. HECT and RING finger domain proteins 
serve the same purpose of targeting substrates for ubiquitination, despite using different 
mechanisms of action.
1.6.2 An overview o f the enzymes involved in the ubiquitin conjugation pathway.
The organisation of the ubiquitin conjugation enzymes is hierarchical (see figure 
1.6.2A). In both humans and yeast, there is only one El enzyme that activates ubiquitin 
for the entire array of downstream E2 and E3 enzymes (McGrath et al., 1991;
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Figure 1.6.2A. Hierarchical relationship between the enzymes inolved in 
ubiquitin conjugation.
Many organisms encode within their genomes only a single El (ubiquitin 
activating enzyme), and a few E2 (ubiquitin conjugating enzymes). However, 
the number of E3s (ubiquitin ligase) enzymes that they encode, depends on the 
organism and can range into hundreds.

Zacksenhaus & Sheinin, 1990). There are greater numbers of E2 enzymes, with around 
30 predicted to be encoded by the human genome. Each E2 is thought to serve several 
E3 enzymes. Finally there is a large, ever growing number of E3 ubiquitin ligase 
enzymes (Pickart, 2001a), which recognise a set of substrates that share one or more 
ubiquitination signals (Hershko & Ciechanover, 1998; Hochstrasser, 1996).
1.6.3. The E l ubiquitin activating enzyme.
Cells expressing a temperature-sensitive El first led to the discovery that ubiquitination 
is essential for cell cycle progression (Mayer et al., 1989). It has been shown the El has 
a poor affinity for ubiquitin prior to the binding of ATP (Haas et a l , 1982; Hershko, 
1983), whereupon it can bind two molecules of ubiquitin, one as a thiolester and the 
other as an adenylate. The activated ubiquitin is then transferred to the active site 
cysteine in the E2 via an ATP-dependent reaction. The carboxyl-terminal glycine 
residue of ubiquitin is essential for its activation by E l. The chemistry of El activation 
is reviewed in more detail elsewhere (Haas et al., 1982).
1.6.3 The E2 ubiquitin conjugating enzyme.
The E2 family of enzymes share a highly conserved core domain consisting of 150 
amino acids (Pickart, 2001a). The members of the UbcH5 family of E2 enzymes 
(UbcH5a, b and c) share over 90% sequence homology to one another and over 70% 
similarity with UbcH6. Some E2 enzymes have substantial amino- or carboxyl-terminal 
extensions or insertions within their core domain (Pickart, 2001a), which are thought to 
determine E3 specificity. However, substrate specificity is determined by the E3, 
therefore one E2 can have diverse biological functions depending on which E3 it 
interacts with. For example, the E2 UbcHl is upregulated in wasting muscle and 
implicated in spermatogenesis (Pickart, 2001a).
1.6.4. The E3 ubiquitin ligase enzymes.
Eukaryotic genomes encode a vast number of E3 ubiquitin ligase enzymes, which are 
classified as either HECT or RING finger domain proteins on the basis of their subunit 
composition (Pickart, 2001a). Both the HECT and RING finger domains serve the same 
purpose of targeting substrate proteins for ubiquitination, although they achieve this
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through different mechanisms (see figure 1.6.4A). In this section, the key characteristics 
of HECT and RING finger domains are discussed.
HECT Domains.
Studies into Human Papilloma Virus (HPV) E6-dependent ubiquitination of p53 led to 
the identification of the first HECT E3 ligase, E6-AP (E6-Associated Protein) 
(Scheffner, 1998). It was initially shown that a domain of about 350 residues at the 
carboxyl-terminus of E6-AP contained large degree of homology to domains that exist 
in otherwise unrelated proteins (Huibregtse et a l , 1995). Henceforth the name HECT 
domain was used, as these regions were shown to be Homologous to E6-AP Carboxyl 
Terminus.
It has been shown that the active site of a HECT domain contains a conserved lysine 
residue situated 35 amino acids upstream of the carboxyl-terminus, which is essential 
for its function. The N-terminal portion of the HECT domain is involved in substrate 
recognition, E2 specificity and it also regulates subcellular localisation (Weissman,
2001). During the ubiquitination process, the HECT domain interacts with a specific E2 
partner, then mediates the transfer of a ubiquitin molecule from the E2 to the conserved 
lysine residue within its active site and then finally to a lysine reside within the substrate 
protein (Pickart, 2001a). Compared to the large number of RING finger related proteins, 
only around 50 HECT domain E3 ubiquitin ligase enzymes have been identified in 
mammals, and they are also less numerous in other organisms such as yeast (Sullivan et 
a l , 2003).
The zinc-binding RING finger domain E3 ubiquitin ligases.
The members of the largest family of E3 ubiquitin ligase enzymes are characterised by 
the presence of a RING finger domain (see figure 1.6.4A), a conserved motif of 
generally seven cysteine and one histidine residues, CX2CX(9-39)CX(1-3)HX(2- 
3)C/HX2CX(4-48)CX2C (X is any amino acid) that coordinate two zinc atoms in a 
cross-braced fashion (Borden & Freemont, 1996). Unlike HECT domains, RING fingers 
do not participate directly in the transfer of ubiquitin, instead act as mediators to ensure 
the correct interaction of the E2 and target substrate.
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The are several types of RING finger domain proteins, which include the multi sub-unit 
based E3 complexes such as SCF (Skipl-Cullin-F box) (Jackson & Eldridge, 2002). The 
cullin and Skip-1 proteins provide a core scaffold, where the Rbxl acts as a mediator to 
ensure ubiquitination of the target substrate. However, the substrate specificity is 
determined by the F-box protein, which contains the appropriate protein-interaction 
domain (Craig & Tyers, 1999; Willems et al., 1999).
Two further types of domain that are related to the RING finger are the U-box and PHD 
domains, several of which have been found in proteins expressed by viruses and 
mammals. Interestingly transcription factor NF-X1 has been shown to contain 
overlapping RING and PHD finger consensus sequences, however only the PHD 
domain is required for its in vitro ubiquitination activity (Fang et al., 2003). The U-box 
is distantly related to the RING finger in sequence and functions in a similar fashion 
(Hatakeyama et al., 2001), but it does not require chelated zinc atoms, instead it uses 
intra-molecular interactions to maintain structural integrity (Ohi et al., 2003). 
Furthermore, unlike the other RING finger proteins, many of which contain a conserved 
tryptophan residue, U-box domains contain a cysteine residue in its place. The number 
of RING finger domain proteins found in diverse organisms, including viruses, is 
rapidly growing. Detailed reviews can be found elsewhere (Fang & Weissmann, 2004; 
Freemont, 2000; Pickart, 2001b; Weissman, 2001).
Single and multi-subunit E3 ubiquitin ligase enzymes.
E3 ubiquitin ligase enzymes can be generally classified as either single or multi-subunit. 
Essentially, what determines a single subunit E3 is its ability to interact with both the 
appropriate E2 and the substrate. An example of such a E3 is Mdm2, a RING finger E3 
that has an amino-terminal p53 binding domain and a carboxyl-terminal RING finger 
that together with an E2 enzyme leads to the ubiquitination p53 (Fang et al., 2000; 
Honda et al., 1997). Other proteins, which are predicted to function in a similar fashion, 
include c-Cbl and perhaps ICP0. Importantly, single subunit E3 enzymes also include 
HECT domain proteins such as Nedd4 (Fang & Weissmann, 2004).
Multi-subunit E3 ubiquitin ligases, such SCF, require additional factors other than the 
substrate and the E2 to provide the correct interactions and regulatory apparatus. The 
benefit of a multi-subunit E3 is that their structural organisation that enables the
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ubiquitin ligase associated with it to target multiple substrates for degradation (Jackson 
& Eldridge, 2002; Kamura et al., 2002). For example, with the SCF complex, substrate 
specificity is provided by the F-box protein, of which there are at least 46 in humans 
(Sullivan et a l, 2003).
1.6.5. Deubiquitinating enzymes.
The final component of ubiquitin cycle is provided by the deubiquitinating enzymes 
(DUBs). Figure 1.6.5 A gives an overview of their function. The mammalian genome is 
thought to encode over 65 deubiquitinating enzymes (Wing, 2003), which comprise of 
two classes of thiol proteases - the ubiquitin carboxy-terminal hydrolases (UCH) and the 
ubiquitin processing proteases, also referred to as ubiquitin specific proteases (USPs). 
Even though two classes of enzymes have been defined, key functional differences have 
not yet been defined (Wing, 2003).
The roles of the DUBs include cleavage of multi-ubiquitin chains from residual peptides 
(Papa & Hochstrasser, 1993), shortening of protein-bound multi-ubiquitin chains by 
sequentially removing the terminal ubiquitin group (Lam et al., 1997), and removal of 
complete polyubiquitin chains from an intact substrate molecule (Canning et al., 2004). 
The role of UCHs is to catalyse the removal of carboxy-terminal extensions from 
ubiquitin precursors, as ubiquitin is initially expressed either fused to itself or to a 
ribosomal subunit (Pickart, 2001a). USPs are generally thought to be involved in 
removing ubiquitin from larger proteins and the disassembly of multi-ubiquitin chains 
(Chung & Baek, 1999).
DUBs also play a role in preventing the accumulation of residual multi-ubiquitin chains 
at the proteasome, thus ensuring the normal movement of ubiquitinated proteins to and 
through the proteasome (Weissman, 2001). In addition, DUBs have been shown to be 
constitutively active in the removal of ubiquitin from substrates, as inhibition of 
proteasome function causes the accumulation of mostly non-ubiquitinated proteins 
(Wing, 2003). An overview of the roles of the DUBs is shown in figure 1.6.4A.
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Figure 1.6.5 A. The many functions o f  deubiquitinating enzymes.
The roles of deubiquitinating (DUB) enzymes is as follows: Initially the 
ubiquitin protein is synthesized fused to a additional ubiquitin protein 
(polyubiquitin) or with small ribosomal subunits, which are then processed 
by cleavage at the carboxy-terminal glycine by the DUB to free the 
ubiquitin. Once the substrate protein has been degraded, ubiquitin must be 
freed from residual peptides and disassembled. DUB enzymes also reverse 
the activity of E3 enzymes, by removing the poly-ubiquitin chains from 
substrates (S). This may occur in specific cellular locations where 
ubiquitination is occurring or at the proteasome. Adapted from Weissman, 
2001 .
Chapter 1- Part IV -  ICPO functions as an E3 
ubiquitin ligase.
1.7.0. Introduction.
Previous research has shown that ICPO disrupts ND10 and degrades its major 
constituents SplOO and PML (Chelbi-Alix & de The, 1999; Everett et a l, 1998a; Everett 
et a l, 1999c). ICPO also causes the cell cycle to stall at the pseudo-prometaphase stage 
by inducing the degradation of the centromere proteins CENP-C and CENP-A (Everett 
et a l, 1999a; Everett et a l, 1999b; Lomonte & Everett, 1999; Lomonte et a l, 2001). All 
of the aforementioned activities were shown to occur in a proteasome-dependent 
manner, as the presence of MG 132 (a proteasome inhibitor) preserved the integrity of 
cellular structures targeted by ICPO. Furthermore, the RING finger was shown to be 
crucial, as mutation of this region abolished the ability of ICPO to disrupt cellular 
structures. Shortly afterwards it was shown that ICPO induces and colocalises with 
conjugated ubiquitin at centromeres and ND10 structures (Everett, 2000; Parkinson & 
Everett, 2001). Taken together, these data provided compelling evidence that ICPO acts 
as an ubiquitin E3 ligase. This was conclusively proven when ICPO and its isolated 
RING finger domain were shown to catalyse the formation of polyubiquitin chains in 
vitro (Boutell et a l, 2002; Hagglund et a l, 2002). The aim of this section will be to 
review the work carried out to characterise the E3 ubiquitin ligase activity of ICPO.
1.7.1. The E3 ubiquitin ligase activity o f ICPO.
It is possible to assess the activity of a potential E3 ligase by using a simple in vitro 
assay, since substrate-independent polyubiquitin chain formation can occur in a buffer 
containing ATP, El, the appropriate member of the E2 family of proteins and the E3 
ubiquitin ligase itself. Polyubiquitin chain formation can be easily detected via SDS- 
PAGE analysis and Western blotting (Lorick et a l, 1999). The approach was 
undertaken to assess if ICPO acts as an E3 ligase in vitro, using a truncated version of 
ICPO (ICPO-262), which was expressed as a GST fusion protein in bacteria. ICPO-262 
contains the residues of ICPO exons 1 and 2, plus 21 residues derived from intron 
sequences, fused to GST. Purified ICPO-262 was incubated with a range of human E2
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enzymes and was shown to stimulate UbcH5a and UbcH6 and cause the formation of 
variable length polyubiquitin chains (Boutell et al., 2002). The studies also showed that 
the isolated residues of exons 1 and 2 of ICPO [ICP0(241)], and full length ICPO had 
identical E3 ligase activity to that of ICPO-262 (Boutell et a l , 2002). It should be noted 
that another study also identified that the RING finger domain of ICPO stimulates 
UbcH5a and UbcH6 to form polyubiquitin chains in vitro (Hagglund et al., 2002).
Transfection studies showed full-length ICPO in a RING finger dependent manner 
clearly sequesters UbcH5a and UbcH6 in HEp-2 cells (Boutell et al., 2002). 
Furthermore, studies carried out elsewhere have provided a link between E2 specificity 
and degradation of constituents of ND10. It was shown that mutation of the cysteine 
residue within the active site of UbcH5a delayed or blocked the degradation of PML and 
SplOO and the subsequent dispersal of ND10 (Gu & Roizman, 2003). However, the 
same mutation in UbcH6 had no affect on the integrity of ND10 or indeed its 
constituents. Therefore it was concluded that functional UbcH5a is essential for the E3 
activities of ICPO that are required for the degradation of PML and SplOO and the 
dispersal of ND10 (Gu & Roizman, 2003).
The RING finger domain of an E3 ligase plays a central role in mediating interaction 
with the required E2 ubiquitin-conjugating enzyme and the transfer of ubiquitin to 
substrate proteins (Freemont, 2000; Joazeiro & Weissman, 2000). As the RING finger 
domain is the hub of an E3 ligase’s activity, mutation within this region has generally 
been shown to be deleterious, such as preventing the formation of polyubiquitin chains 
in vitro in the presence of active E2 partners. (Pickart, 2001a). Therefore, mutational 
analysis was carried out on the RING finger domain of ICPO (241), to deduce the role of 
specific amino acids in polyubiquitin chain formation. It was shown that only deletion 
of the RING finger domain and insertion of 4 residues at ICPO codons 150 and 162 
abrogated ICPO’s ability to act as an E3 ligase in the presence of UbcH5a (Boutell et al., 
2002). Furthermore, point mutations within the RING finger domain of ICPO-241 
(K144E, W146A, Q148E and N151D) and some insertion mutants (z'hs 188 and ms 197) 
had little deleterious affect (Boutell et al., 2002). Even mutation of the conserved 
tryptophan residue which is present in the majority of E3 ligase enzymes and is thought 
to be particularly important for activity (Freemont, 2000; Joazeiro & Weissman, 2000; 
Pickart, 2001a) had no effect on the E3 ligase activity of ICPO (241) (Boutell et al.,
2002). However, in contrast to having little affect on the E3 ligase activity of ICPO
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(241) in vitro, the majority of the aforementioned mutations had deleterious affects on 
ICPO’s ability to simulate gene expression and disrupt ND10 (Everett et al., 1995a; 
Everett, 1987; O’Rourke et al., 1998). The fact that ICPO appeared to retain E3 ligase 
activity in vitro despite the presence of certain mutations in the RING finger domain 
was probably due to the ubiquitin E3 ligase assay being insufficiently sensitive to detect 
subtle variations in activity (Boutell et al., 2002).
The interaction between an E2 and an E3 protein is an integral part of the ubiquitination 
process and this can normally be detected via such means as yeast-two hybrid, GST-pull 
down and immunoprecipitation assays. However, no stable interaction between ICPO or 
its RING finger domain with UbcH5a or UbcH6 was detected (Boutell et al., 2002; 
Hagglund & Roizman, 2002). However, these studies conclusively prove that ICPO acts 
in a RING finger dependent manner to utilise the ubiquitin conjugation pathway, which 
is essential for its major functions, such as gene expression during the lytic cycle and 
reactivation from quiescence (Boutell et al., 2002; Everett et al., 1998a; Hagglund et al., 
2002).
1.7.2. The E2 partners o f ICPO.
ICPO causes polyubiquitin chain formation in the presence of UbcH5a and UbcH6 
which, as noted above, are highly related (Boutell et al., 2002; Hagglund et al., 2002). It 
is probably the conserved sequence similarity between UbcH5a and UbcH6 that enables 
ICPO to stimulate polyubiquitin chain formation in their presence (Boutell et al., 2002).
UbcH5a has also been implemented as a cognate E2 partner of a growing number of E3 
ligases (Hakli et al., 2004; Itoh et al., 2003; Lorick et al., 1999; Spencer et al., 1999; 
Vandenberg et al., 2003; Yang & Du, 2004; You & Pickart, 2001), as has UbcH6 (Anan 
et al., 1998; Nuber et al., 1996; Yang & Du, 2004). HPV E6 has also been shown to 
require members of the UbcH5 family for the ubiquitination of p53 (Jensen et al., 1995; 
Rolfbetal., 1995; Scheffner et a l, 1994)
Apart from the fact that many RING finger E3 ubiquitin ligases use these same two E2 
enzymes, it is unclear why ICPO should use UbcH5a and UbcH6 in preference to other 
E2 enzymes, as one E2 can serve several different E3 ligases. It is possible that ICPO 
has additional E2 partners, as within the relatively small genome of S.cerevisiae there
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are 13 genes that encode E2 enzymes and more are likely to be found in higher 
eukaryotes (Hochstrasser, 1996). Therefore as the number of characterised E2 enzymes 
increases so may the number of ICPO’s E2 partners.
Other studies have suggested that there may be a third E2 partner of ICPO, namely 
cdc34 (Hagglund & Roizman, 2002). This conclusion was originated from data that 
showed cdc34 could be immunoprecipitated with proteasomes from HSV-1-infected 
cells (Van Sant et a l, 2001a). It was shown that the ICPO RING finger domain could 
not stimulate cdc34 in vitro (Boutell et a l, 2002; Hagglund & Roizman, 2002), but 
despite this an interaction was identified between the two proteins (Hagglund & 
Roizman, 2002; Hagglund et a l, 2002). It was reported that ICPO residues 543 to 768 
stimulated autoubiquitination of cdc34, despite the lack of an interaction between cdc34 
and this segment of ICPO (Hagglund & Roizman, 2002; Hagglund et a l, 2002). Despite 
this, it was proposed that ICPO must interact with cdc34 via its RING finger domain and 
stimulate cdc34 by residues located near its C-terminus (Hagglund & Roizman, 2002; 
Hagglund et a l, 2002; Van Sant et a l, 2001a). Contrary to this, results published 
elsewhere showed that full-length ICPO neither stimulated cdc34 activity in vitro nor 
recruited cdc34 to ICPO foci in transfected cells (Boutell et a l, 2002). The region of 
ICPO between residues 543 and 768 does not contain any homology to a motif from 
either the HECT domain or RING finger family of proteins. However, a possible 
explanation of the cdc34 stimulation is the amount of the GST-fusion component used. 
In optimum ubiquitin ligase assay conditions, amounts of an E3 ligase as low as 3.5 ng 
can stimulate polyubiquitin formation. However, Hagglund and Roizman (2002) used 5 
pg of the GST fusion protein containing ICPO residues 543 to 768 in their study. In such 
high amounts, GST fusion proteins that lack authentic E3 ligase activity have been 
shown to induce cdc34 stimulation in vitro (Deffenbaugh et a l, 2003).
1.7.3. Substrates o f ICPO mediated ubiquitination.
After initial studies identified that ICPO has E3 ligase activity, the next step was to 
identify the substrates of ICPO. On the basis that ICPO induces the degradation of PML 
during HSV-1 infection, PML was investigated as a potential substrate of ICPO in vitro. 
Initial studies using purified E l, E2, ICPO and SUMO-1 modified or unmodified PML 
failed to detect ubiquitination of PML in vitro. However, it was found that ICPO 
increased the levels of ubiquitinated PML in transfected cells (Boutell et a l, 2003). It
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was concluded that ICPO-mediated degradation of PML in vivo is either indirect or 
requires additional factors that are yet to be identified (Boutell et al., 2003).
The same study went on further to characterise the affect SUMO-modification had on 
the integrity of PML in the presence of ICPO (Boutell et al., 2003). Co-expression 
studies showed that isoforms of PML that contained a mutation at lysine 160, which 
normally becomes SUMO-modified, were degraded by ICPO to a lesser degree than 
wild-type PML. It was therefore implied that SUMO-modification plays an important 
role in the efficiency of ICPO-induced degradation of PML (Boutell et a l, 2003).
Because it had been reported that p53 is protected from mdm2-induced degradation via 
binding to USP7 (Li et al., 2002), and because USP7 interaction contributes to ICPO 
activity (Canning et a l, 2004; Everett et a l, 1998b, 1999d), it was investigated whether 
ICPO had any affect on p53. It was shown that in a RING finger dependent manner and 
in the presence of UbcH5a or UbcH6, ICPO ubiquitinates p53 in vitro. Furthermore, 
ICPO-induced ubiquitination of p53 could also be detected in vivo, albeit to a much 
lesser degree than that induced by mdm2 (Boutell & Everett, 2003b). Further studies 
demonstrated that p53 metabolism during HSV-1 infection is a complicated issue. It was 
found that p53 becomes stabilized during HSV-1 infection by a mechanism that is 
dominant over any potential ICPO-mediated ubiquitination of p53 (Boutell & Everett, 
2004). The purpose of the relationship between ICPO and p53 currently remains unclear. 
However, it should be noted that several viruses affect the stability of p53 by targeting it 
for ubiquitination and subsequent proteasome degradation, such as E6-AP in 
conjunction the E6 protein of HPV 16 and 18 and the adenovirus ElB-55K/E4-orf6 
complex.
1.7.4. Other viruses and the proteasome degradation pathway.
A number of viruses across a wide spectrum of host and tissue tropisms utilise the 
ubiquitin-proteasome pathway for a range of different functions (see figure 1.7.4A) such 
as host cell entry, transcription and reactivation, avoidance of apoptosis and the immune 
response, and virus release and budding (Banks et al., 2003). How the pathway is 
manipulated varies between viruses, for instance HPV encodes a protein that redirects a 
cellular E3 ligase to ubiquitinate substrates that would not normally be targeted in a 
non-infected cell. However, EBV encodes proteins that manipulate the proteasome
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Figure 1.7.4A. Overview o f how specific DNA viruses manipulate the proteasome 
degradation pathway.
The substrate becomes ubiquitinated via the sequential activity of a ubiquitin 
activating enzyme (El), a ubiquitin conjugating enzyme (E2) and a ubiquitin ligase 
(E3). The ubiquitinated protein can under go numerous fates including endocytois 
and proteasome mediated degradation. Ubiquitin is recycled through the activity of 
deubiquitinating enzymes (DUB). Different viruses utilises the pathway at different 
points and for different outcomes. This is discussed in further detail in the text. 
Based on a diagram from Maccuri, et al., 2004.
degradation pathway at multiple points, such as mediating ubiquitination of target 
substrates and also preventing specific substrates from becoming ubiquitinated. The aim 
of this section will be to outline specific examples of viruses other than HSV-1 that 
utilise the proteasome pathway, with particular reference to the herpesvirus family.
Human Papilloma Virus.
HPV provided perhaps the earliest characterised example of a virus that utilises the 
proteasome degradation pathway. The HPV E6 protein mediates the ubiquitination of 
target substrates by associating with the cellular HECT domain E6-accessory protein 
(E6-AP) to target p53 for degradation (Thomas et al., 1999). E6 binds to residues 391 
and 408 of E6-AP, which are flanked by hydrophobic residues that are essential for 
binding (Elston et al., 1998). E6 additionally binds to p53 and an ubiquitin conjugating 
enzyme and mediates the transfer of ubiquitin from the E2, via a thiolester intermediate, 
to p53. It has been shown that E6-AP utilises a number of E2 enzymes including UbcH5 
and UbcH6 (Jensen et a l, 1995; Rolfe et a l, 1995; Scheffher et a l, 1994), and also 
UbcH7 and UbcH8. The E6-AP protein is thought to determine E2 specificity in 
conjunction with the E6 protein, which additionally provides substrate specificity 
(Kumar et a l, 1997). This is supported by research that has shown that unless E6 
binding occurs, E6-AP does not normally target p53 (Scheffher & Whitaker, 2003). 
Furthermore, during specific stages during the HPV lifecycle, p53 becomes 
phosphorylated and only then is it susceptible to E6/E6-AP mediated degradation, 
therefore indicating a precise mechanism of p53 regulation (Bech-Otschir et a l,  2001). 
The ability of HPV to degrade p53 is crucial for ensuring the progress of the viral life 
cycle as otherwise p53 would induce apoptosis.
Other proteins have been shown to be subject to indirect ubiquitination by E6, including 
the apoptosis-promoting Bak protein. It was shown that Bak is targeted by E6-AP in the 
absence of E6, but in its presence this activity is enhanced (Thomas & Banks, 1998). 
Furthermore, similar to ICPO, E6-AP has been shown to autoubiquitinate itself, which is 
thought to represent a feedback control mechanism (Kao et a l, 2000).
The prevention of apoptosis via the E6/E6-AP interaction is not the only function for 
which HPV uses the proteasome degradation pathway. It has been shown that the E7 
protein mediates the degradation of a number of proteins associated with the cell cycle
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via binding to the 19S proteasome subunit (Munger et al., 2001). This causes the cell to 
enter the S phase of the cell cycle, creating an environment ideal for viral DNA 
replication (Munger et al., 2001). More detailed reviews of the significance of the 
E6/E6-AP interaction and the function of E7 can be found elsewhere (Banks et al., 
2003; Scheffher & Whitaker, 2003).
Human Cytomegalovirus.
The HCMV UL82 gene product pp71 stimulates quiescent cells to enter the cell cycle. It 
has been shown to target hyper-phosphorylated forms of the retinoblastoma (Rb) family 
of proteins for proteasome-mediated degradation (Kalejta et al., 2003; Kalejta & Shenk,
2003). It is not currently clear by what mechanism pp71 achieves this activity.
Epstein Barr Virus.
Epstein Barr Virus (EBV) is probably more intrinsically involved in the ubiquitin 
conjugation pathway than any other virus so far characterised, manipulating the pathway 
at different points depending on the stage of its infection cycle.
EBV establishes a persistent infection within the B cell population of the host, therefore 
latency and reactivation must be tightly regulated since virus production is associated 
with cell death. A number of virally encoded proteins are associated with maintaining 
the balance between lytic and latent infection, such as the latency membrane protein 2A 
(LMP-2A). The stimulation of the B-cell receptor (BCR) on infected B cells is thought 
to initiate a cell signalling cascade, which triggers productive infection (Masucci, 2004). 
It has been suggested LMP-2A regulates this process through its ability to inhibit BCR 
signalling by interfering with the activity of BCR-associated tyrosine kinases, Lyn and 
Syk (Miller et al., 1994). LMP-2A binds to a member of the HECT Nedd4 ubiquitin E3 
ligase family and via its amino terminal sequences to Lyn or Syk, which results in their 
eventual degradation (Winberg et al., 2000). LMP-2A also undergoes ubiquitination by 
members of Nedd4 family of E3 ligases and this is thought to be important in the 
modulation of BCR signalling (Masucci, 2004). By preventing exit from latency, it is 
thought that LMP-2A may rescue antigen-triggered EBV-carrying memory B cells and 
allow their homing to lymphoid follicles where other EBV proteins play a crucial role in 
preventing apoptosis (Winberg et al., 2000).
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EBNA-1 is an essential protein expressed throughout the EBV life cycle and it interacts 
with different components of the ubiquitin pathway. The N-terminal half of EBNA-1 
contains a long repetitive sequence exclusively composed of Gly and Ala residues 
(GAr) that varies in length between different EBV isolates (Falk et a l , 1995). The GAr 
region is thought to play an important role in preventing immunodetection of infected B 
cells. Interestingly one of its mechanisms of action is to inhibit ubiquitin-dependent 
proteolysis, as when linked to other viral or cellular proteasome substrates their 
degradation was severely inhibited (Levitskaya et al., 1997). The GAr sequences do not 
require any of the enzymes involved in the ubiquitin conjugation pathway for their 
affect. It is thought to inhibit proteasome-mediated degradation by interfering with the 
interaction of the ubiquitinated substrate with the 19S proteasome subunit thereby 
promoting the premature release of the substrate (Masucci, 2004). Like ICPO, it has 
recently been shown that EBNA-1 interacts with USP7 (Holowaty et a l , 2003b). 
Although the significance of this interaction remains unclear, it was proposed that USP7 
is involved in regulating EBNA-1 during transcription and translation of the viral 
genome (Holowaty et a l, 2003b). Additional studies from the same group showed that 
EBNA-1 competes with p53 for USP7, thus affecting the function of p53 in vivo 
(Holowaty et a l, 2003a). It is possible that EBNA-1 is increasing the degradation of p53 
by reducing the cellular pool of available USP7 and preventing the deubiquitination of 
p53, thus inhibiting the induction of apoptosis.
EBV-infected B cells can become oncogenic, resulting in uncontrolled proliferation. To 
contain this hazard, the viral proteins initiate a plethora of B-cell activation markers, 
rendering the infected cells highly immunogenic and therefore easily attacked by T-cell- 
mediated immune responses (Masucci, 2004). LMP-1 is crucial for regulating this 
mechanism by various methods, including being subjected to proteasome-mediated 
degradation. This process causes the generation of peptides involved in signalling 
cascade that in turn affects the immunogenicity of the infected cell (Dukers et a l, 2000).
Kaposi’s Sarcoma-Associated Herpes Virus.
Kaposi’s Sarcoma-Associated Herpes Virus (KSHV) encodes two membrane-bound 
proteins, K3 and K5, which modulate immune recognition of infected cells (Coscoy et 
al, 2001). K3 and K5 both include N-terminal PHD domains that are related to the
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RING finger domain family (Coscoy & Ganem, 2003). K5 was shown to cause the 
formation of substrate-independent polyubiquitin chains in the presence of UbcH5a 
(Coscoy et al., 2001). Both K3 and K5 promote evasion of the immune system by 
ubiquitinating the major histocompatibility complex class I chains, which leads not to 
proteasomal, but to endosomal degradation (Coscoy & Ganem, 2003; Coscoy et a l, 
2001). Furthermore, it has been recently reported that K7 targets a regulator of the 
ubiquitin conjugation pathway to ubiquitinate p53, which is thought to prevent the 
induction of cellular apoptosis in KSHV-infected cells (Feng et al., 2004).
1.8.0. The ICPO Family of Proteins.
1.8.1. Sequence comparisons o f the members o f the ICPO family ofproteins.
All the alphaherpesviruses for which appropriate DNA sequences are available encode a 
protein related to ICPO by virtue of their possession of a RING finger domain: BICPO in 
bovine herpes virus (BHV) -1 (Wirth et al., 1992) and its homologue in BHV-5 (Delhon 
et al., 2003); the product of gene 63, Eg63, in EHV-1 (Telford et al., 1992); the product 
of gene 61, Vg61, in VZV (Davison & Scott, 1986); EPO in PRV (Cheung, 1991); 
CICPO in CHV (Miyoshi et al., 2000); FICP0 in FHV-1 (Sussman & Maes, 1997); and 
the product of the RL2 gene in HVB (Perelygina et al., 2003). All of these proteins are 
expressed from genomes that are composed of unique long and unique short regions, 
and gene expression is divided into three classes in a similar manner to that of HSV-1. 
However, only ICPO, Eg63, Vg61 are IE products, while CICPO and EPO have been 
shown to be transcribed during the early phase of gene expression (Cheung, 1991; 
Honess & Roizman, 1974; Miyoshi et al., 2000; Nagpal & Ostrove, 1991). BICPO is 
classed as an immediate early gene even though it can be translated from immediate 
early and early mRNA transcripts (Koppel et a l, 1997; Wirth et al., 1992).
By comparison of the amino acid sequences of these related proteins using the ClustalW 
alignment program (Thompson et al., 1994) it is possible to identify the RING finger 
motif (Figure 1.8.1 A). Apart from core residues within the RING finger motif, the only 
readily apparent homology shared amongst the ICPO related proteins is that of the 
nuclear localisation signal. It is striking that the majority of the members of the ICPO 
protein family do not contain a sequence similar to that of the USP7 binding region or 
the multimerisation domain; these sequences are limited to the proteins encoded by 
HSV-1, HSV-2 and HVB (Everett et al., 1998a; Parkinson & Everett, 2000, 2001). This 
may be a reflection of the fact that HVB is more closely related to HSV-1 than any other 
member of the alphaherpesvirus family. Examination of the RING finger sequences 
revealed that even within this conserved motif, with the exception of the zinc- 
coordinating and a few other structurally important residues, the sequence similarity 
amongst the ICPO related proteins is limited. Because of this extensive sequence 
divergence, it was unclear whether all the proteins in the ICPO family shared the same 
biological functions (Everett et al., 1995b).
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1.8.2 The biological functions o f the alphaherpesvirus ICPO related proteins.
Of all of the members of the ICPO family so far identified, the most extensively studied 
proteins are BICPO, Eg63, EPO and Vg61. This section will review their known 
biological functions.
1.8.3. The role o f Vg61.
Vg61 is encoded by ORF61 of the VZV genome. There are conflicting reports about the 
ability of this protein to activate or repress gene expression. In transient expression 
assays it was shown that ORF61 acts as a transactivator of gene expression, and acts as 
a repressor of the transactivating ability of ORF62 (the VZV equivalent of HSV-1 ICP4) 
and ORF4 (Moriuchi et al., 1992; Moriuchi et al., 1993). This is unlike ICPO, which 
does not have a transrepressing function and can function in synergy with the HSV-1 
transactivator ICP4.
However despite these differing results, it has been reported that cell lines expressing 
ORF61 complement the growth of HSV-1 mutants which fail to express functional ICPO 
or VP 16 (Moriuchi et al., 1993). However, strains of HSV-1 that had mutations within 
the ICP4 and ICP27 genes were unable to grow in these cells. It was therefore 
concluded that despite the differences in their sequences and effects on the cognate 
promoters in transient expression assays, VZV ORF61 is the functional homologue of 
ICPO (Moriuchi et al., 1992). To analyse how the cysteine and histidine residues 
contribute to the function of the Vg61 RING finger domain, each of the residues were 
individually mutated. None of the mutants retained the ability to act as a transactivator 
of gene expression (Moriuchi et al., 1994). Furthermore, it was shown that a functional 
chimera protein could be made by exchanging the N-terminal portion (which contains 
the RING fmger domain) of the Vg61 protein with that of ICPO. The fusion protein 
retained its transregulatory function (Moriuchi et al., 1994). This probably reflects the 
fact that the Vg61 RING finger domain, like the corresponding domain in ICPO, is 
crucial for the majority, if not all of its biological functions.
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1.8.4. The role of Eg63.
The Eg63 protein of EHV-1 has been shown partially to complement an HSV-1 ICPO 
deficient virus. A recombinant HSV-1 vims was constructed that expressed the Eg63 
protein in place of ICPO. Comparison of the growth properties to that of wild type 
indicated that Eg63 is able to fulfil partially, but not completely, the roles of ICPO 
during vims growth in tissue culture (Everett et al., 1995b). Similar to ICPO, Eg63 is 
able to act as a transactivator of gene expression of all three classes of viral promoters in 
the EHV-1 genome; up-regulating the expression of the immediate-early promoter 
(driving expression of the EHV-1 homologue of ICP4), the early thymidine kinase 
promoter, the late IR5 promoter and the late glycoprotein K promoter (Bowles et a l , 
1997; Bowles et al., 2000). Furthermore, Eg63 also acts as promiscuous transactivator 
of gene expression in transfection assays, up regulating gene expression from the ICP6 
promoter of HSV-1 (Bowles et al., 1997; Everett et a l , 1995b). Using transfection 
assays it was shown that individually the Eg63 and EHV-1 ICP4 homologue proteins 
are powerful regulators of gene expression. However, when expressed together EHV-1 
ICP4 inhibited the ability of the Eg63 protein to transactivate the IE and late promoters 
(Kim et a l , 1999). However, in the presence of the EHV-1 ICP27 homologue, ICP4 acts 
as synergistic transactivator to regulate the expression of the early and late promoters 
(Bowles et al., 2000). The mechanism of the antagonistic relationship between Eg63 
and the ICP4 homologue may be due to their interactions with components of the 
cellular transcriptional machinery. The transcription factors TFIID and TFIIB are 
components of the pre-initiation complex (PIC), which is essential for gene expression. 
These transcription factors indirectly mediated the binding to specific promoter 
complexes, interacting with TATA binding protein (TBP). It was shown that regions of 
Eg63 interact directly with TFIIB and TBP and may contribute to the transactivation 
properties of Eg63 (Kim et al., 2003). However, regions of the EHV-1 ICP4 homologue 
has also been shown to bind to TBP and the same region of TFIIB, and this interaction 
is necessary for its full transactivation properties (Albrecht et a l, 2003; Jang et a l, 
2001). Furthermore, it was shown that Eg63 and the EHV-1 ICP4 homologue also 
interact with one another. It was proposed that this binding of the ICP4 homologue in 
some way sequesters Eg63 and prevents it interacting with the aforementioned 
transcription factors or they compete for binding to the transcription factors and mediate 
the initiation of gene expression (Kim et a l, 2003). The EHV-1 ICP4 homologue is only 
able to activate the E promoters, however Eg63 is able to activate all promoters types,
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therefore it was proposed that the antagonistic relationship between Eg63 and the ICP4 
homologue may prevent Eg63 inappropriately activating L promoters during early times 
of infection (Kim et al., 2003). If the assumption is made that this hypothesis is correct 
and we extend it to other members of the alphaherpesvirus family, it becomes 
confusing. HSV-1 ICP4 has also been shown to interact with TFIIB and TBP (Smith et 
a l, 1993), and furthermore it has been suggested to interact with ICPO (Yao & Schaffer,
1994) and synergistically they promote gene expression of early and late promoters 
(Everett, 1986). Furthermore, the ability of the EHV-1 ICP4 homologue to act as a 
transrepressor of late gene expression is unique, as no other alphaherpesvirus ICP4 
homologue have shown to have this function (Bowles et al., 2000). It is likely that the 
confusion that arises from these results is a consequence of the limitations of the 
plasmid reporter transfection assays and in vitro protein-protein interaction methods that 
have been employed.
It has been shown, as with the other ICPO homologue that Eg63’s ability to act as a 
transactivator is dependent on a functional zinc RING finger domain, as a series of 
deletion mutants spanning this region were unable to activate the E and L promoters of 
EHV-1 genome (Bowles et al., 2000). Like ICPO, the Eg63 protein is phosphorylated 
during infection and deletion of a serine rich region (residues 210 to 217) reduced by 
over 70% the ability of Eg63 protein to activate gene expression (Bowles et al., 2000).
Studies carried out recently have used an EHV-1 Eg63-null mutant virus. The initial 
studies have shown that transfection of rabbit kidney cells with a BAC encoding an 
EHV-1 Eg63 null genome causes the production of infectious progeny. This indicates 
that Eg63 is not essential for EHV-1 replication (Yao et al., 2003). Experiments to 
assess the effect of the Eg63 deletion on EHV-1 gene expression revealed that mRNA 
expression of the all three major classes was reduced when compared to that of wild 
type virus. It has also been shown that the absence of ICPO causes a reduction in mRNA 
synthesis during HSV-1 infection (Jordan & Schaffer, 1997). Furthermore, plaque 
number and plaque size of Eg63-null virus were less than that of wild type EHV-1. 
However, the temporal cascade from early to late viral gene expression in the EHV-1 
genome was not prevented or delayed by the absence of Eg63. The authors suggested 
that Eg63 gene did not disrupt the temporal aspects of EHV-1 gene regulation (Yao et 
a l, 2003). However, for future research it will be important to consider how the M.O.I. 
and cell type affect the phenotype of an Eg63-null virus.
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1.8.5. The role o f EPO.
A PRV EPO knock out virus was shown to replicate less efficiently in tissue culture and 
swine. Furthermore, it was shown to have a similar growth cycle to wild type PRV in 
vivo, however in cell culture, plaques were smaller and the titre of the progeny virus was 
distinctly lower than that of the wild type. It was concluded that EPO is non-essential for 
PRV replication; however, viral growth is greatly enhanced in its presence (Cheung et 
al., 1994). The restricted growth characteristics were thought to be analogous to those of 
ICPO-deficient HSV-1 viruses (Cheung, 1996). It was also demonstrated that, as in the 
case of ICPO, the RING finger of EPO is essential for its ability to transactivate gene 
expression of the thymidine kinase (TK) and glycoprotein X (gX) promoters (Watanabe 
et al., 1995). More recently it was suggested that EPO could also act as a transrepressor 
and inhibit the activity of glycoprotein E gene (Chang et al., 2002) and VHS (virion 
host shutoff protein) promoters (Chang et a l, 2004).
Furthermore, it has been shown in transfection assays using an EPO-deficient PRV virus 
that growth could be complemented in cells expressing Eg63 or ICPO (Moriuchi et a l,
1995). EPO was also shown, using transient expression assays, to be able to increase 
expression from both HSV-1 and VZV promoter reporter cassettes, indicating its 
functional homology to Eg63 and ICPO (Moriuchi et a l, 1995). It has also been shown 
that EPO acts synergistically with the PRV ICP4 homologue IE 180 to enhance the 
transcription of early and late genes in a manner similar to that of ICPO and ICP4 (Ono 
et al., 1998).
1.8.6 The role o f  BICPO.
The BHV-1 homologue BICPO has also been shown to be an IE, zinc-binding nuclear 
protein that functions in transient transfection assays as either a transactivator or 
transrepressor of all classes of BHV-1 promoters (Fraefel et a l, 1994) and also of 
certain heterologous promoters (Zhang & Jones, 2001) including the HSV-1 TK 
promoter (Inman et a l, 2001).
Functional requirement for zinc ions has not yet been shown for any of the 
aforementioned ICPO homologues; it has only been shown that the RING finger
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domains of Eg63, ICPO and Vg61 bind zinc (Everett et a l, 1993a). However, in BICPO 
it was demonstrated that its ability to act as a transactivator of gene expression is 
dependent on the presence of zinc ions (Fraefel et al., 1994). This conclusion may 
reflect the fact that the zinc atoms are structurally important for the integrity of the 
RING finger domain.
It has been shown that BICPO can induce aggregation of chromatin structures in 
transfected cells in a RING finger dependent manner (Inman et a l, 2001). This activity 
may be related to BICPO’s ability to interact with class I histone deacetylase (HDAC), 
which plays a role in many important cellular functions including chromatin assembly 
(Zhang & Jones, 2001). ICPO has also been shown to colocalise and reorganise type I 
and type II HD AC enzymes, and to interact with specific members of the HD AC type II 
family (Lomonte et al., 2004). BICPO and ICPO may target HD AC family members as 
the may be part of a cellular repression mechanism. It has been shown that ICPO 
negative virus can be reactivated from quiescence by expression of ICPO from an 
external source or, albeit to a lesser degree by the addition of trichostatin A, an HD AC 
inhibitor (Everett et a l, 1998c; Harris et al., 1989; Hobbs & DeLuca, 1999; Preston & 
Nicholl, 1997; Samaniego et al., 1998).
It has also been shown that deletion of amino acids spanning residues 356-677 at the C- 
terminus of BICPO prevents the translocation of the protein to the nucleus (Inman et al., 
2001). This phenotype would suggest that BICPO contains a nuclear localisation signal 
(NLS) within its C-terminal region.
Interestingly, the function of BICPO was shown to be blocked by prostaglandin D2. 
Prostaglandins are a class of naturally occurring carbon fatty acids that are produced in 
response to various external stimuli, such as cell injury and inflammation. They have 
also been implicated in regulating the replication of several DNA and RNA viruses, 
including HSV-1 in cultured cells (Santoro, 1997). It was shown that wild-type BHV-1 
infection, increased PGD(2) levels in cells in culture and this affect was BICP0- 
dependent, as it was not observed with a BICPO negative virus. Furthermore, PGD(2) 
added exogenously repressed BHV-1 replication in cultured cells. It was therefore 
suggested that PGD(2) impairs the ability of BICPO to act as a transactivator of gene 
expression, by an as yet uncharacterised mechanism (Saydam et a l, 2004).
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From outlining what is known about the activities of the members of the ICPO family of 
proteins it appears that they have many functional similarities. However, there are also 
differences in their activities that may be explained by their limited homology outside or 
indeed even within their RING finger domains.
1.8.7. The effect o f  the ICPO homologues on cellular structures.
It is likely that ICPO carries out its role in activation of transcription and reactivation 
from latency by interacting with various cellular components (as reviewed in section 
1.5.6), such as its strong binding to USP7, and the degradation of specific constituents 
of ND10. Studies have been carried out to assess whether BICPO, Eg63, EPO and Vg61 
have the same effects as ICPO on protein stability and cellular sub-structures. A 
summary of these results is shown in figure 1.8.8A. No obvious sequence homology to 
the USP7 binding domain of ICPO has been found in the aforementioned homologues, 
but it was investigated whether the related proteins still affect USP7 by interacting via 
an uncharacterised binding domains. The following conclusions were made: BICPO, 
Eg63, EPO and Vg61 all cause changes to ND10 structures in transfected cells. It was 
shown that SplOO was affected more readily than PML, and even more so than CENP-C 
in centromeres. Using a mutant HSV-1 virus that expressed Eg63 in place of ICPO it 
was shown that PML, SplOO and CENP-C were disrupted in a fashion similar to that of 
ICPO, therefore it was proposed that Eg63 might also be dependent on proteasome 
degradation pathway for disruption of cellular components. It was proposed that the 
difference in specificity of the ICPO homologues on components of ND10 suggests that 
there may be additional components that are more preferentially targeted. This facet 
may reflect the differences in hosts and cell types that are infected by the viruses 
(Parkinson & Everett, 2000).
Despite the variations between the properties of these particular members of the ICPO 
family of proteins, the data indicate that the ICPO homologues may function via similar 
biochemical pathways. Indeed, all these proteins induced the formation of co-localising 
conjugated ubiquitin. It was therefore suggested that like ICPO, the ICPO family of 
proteins function via a related mechanism involving the E3 ubiquitin ligase pathway 
(Parkinson & Everett, 2001).
95
Properties ICPO BICPO Eg63 EPO Vg61
Dispersal of 
PML
+ + + + + + + + + No
Dispersal of 
SplOO
+ + +
------------
+ + +
------------1
+ + +
------------
+ +
r -----------
+
Dispersal of 
CENP-C
+ + +
------------
+ + +
r ~ — - _ i
+ +
------------
+ +
------------
+
Redistribution of 
USP7
+ + +
------------
No No
------------
/Vo
------------
No
Induce loss of 
SUMO modified 
PML
+ + +
------------
No
------------1
No
------------
No
---------------------
No
Induce 
colocalisation of 
conjugated 
ubiquitin
+ + +
------------
+ + +
— ----------— 1
+ + +
------------
+ +
r— ------
+
Figure 1.8.7A. Summation o f the biological properties o f the ICPO 
homologues.
A series of studies were carried out (Parkinson & Everett, 2000,
2001) to characterise the affect of selected members of the ICPO 
family of proteins on constituents of ND10 domains and centromeres. 
The activity of ICPO is shown as a comparison.
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1.8.8. Conclusion o f the comparison o f the biological properties o f the ICPO 
homologues.
The previous sections have shown that there are a distinct number of similarities shared 
amongst the ICPO related proteins. However, there are differences between the intrinsic 
activities of the ICPO homologues that may be a reflection of the sequence divergence 
within the RING finger domains and their flanking sequences. It is clear from the 
studies by Parkinson & Everett (2000 & 2001) that the members of the ICPO family of 
proteins are all likely to function through the ubiquitin- proteasome pathway; however it 
remained to be established that this was indeed the case at the biochemical level.
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Chapter 2.0 Materials and Methods 
2.1 Materials.
2.1 A Plasmids.
The following plasmids were provided by the acknowledged authors:
pGEX2TNMCR (Everett et al., 1997; Meredith et al., 1994). This vector is designed for 
inducible, high-level bacterial expression of proteins or protein fragments as fusions 
with Schistosoma japonicum  glutathione S-transferase (GST). Expression of GST 
fusion proteins is under the control of the IPTG-inducible tac promoter and an internal 
lac Iq gene, which ensures that expression is inducible when, transformed into certain 
strains of E.coli. Plasmid pGEX2TNMCR was derived from pGEX2T, which is 
commercially available from Pharmacia.
pGEX241 (Boutell et al., 2002). A derivative of pGEX2TNMCR in which the GST 
open reading frame is fused to the N-terminal 241 codons of ICPO (encoded by the gene 
IE1 exons 1 and 2),
pGEX211 (Boutell et al., 2002). A derivative of pGEX241 from which the ICPO coding 
sequence beyond the Kpnl site in codon 212 has been deleted.
pGEX241K144E, pGEX241W146A, pGEX241Q148E, pGEX241N151D,
pGEX241msl50, pGEX241z'«sl62, pGEX241insl88, pGEX24h'«sl97 (Boutell et al.,
2002). A series of plasmids derived from pGEX241 containing point and insertion 
mutations in the core RING finger domain coding region of ICPO. The mutants and their 
derivatives were constructed by inserting exon 2 fragments from previously 
characterised mutant plasmids (Everett et al., 1995a; O'Rourke et al., 1998) in the place 
of the wild type fragment.
pGEXENX (R.D. Everett, unpublished). A derivative of pGEX2TNMCR containing the 
Ncol-Dral fragment encoding the first 63 residues of the EHV-1 gene 63 protein (Eg63) 
linked to the GST open reading frame. The plasmid was derived from the previously 
characterised pi 10ENX (Everett et al, 1995b).
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pCIrtagBICPO, pCIrtagEg63, pCIrtagEPO, pCIrtagVg61 (Parkinson & Everett, 2001). A 
series of plasmids expressing N- terminal tagged proteins of the ICPO family expressed 
by BHV-1, EHV-1, PRV and VZV respectively. The tag sequence encodes an epitope 
from the C-terminal peptide of the HSV-1 UL30 protein that is recognised by rabbit 
polyclonal serum rl 13 (Marsden et al., 1994). The vector is pCIneo (Promega), in 
which open reading frames of choice can be inserted downstream of the HCMV IE 
promoter to allow expression in mammalian cells.
pPP65BICP0, pPP65Eg63, pPP65EP0, pPP65Vg61. (Parkinson & Everett, 2000). A 
series of plasmids expressing the ICPO family of proteins with an N-terminal tag derived 
from the HCMV pp65 protein. Expression is driven by the HCMV IE promoter.
pET24aUbcH5a, pET24aUbcH6, pET24aUbcH7, pET24aUbclO, pET24acdc34 
(Boutell et al., 2002). A series of plasmids allowing high-level expression of 
polyhistidine tagged E2 enzymes in bacteria. Expression of the coding sequence of the 
E2s is under control of IPTG-inducible T7 promoter. The vector plasmid is pET24a 
(Novagen).
pFastBac-HTa. This vector contains a pUC9 origin of replication for propagation in E. 
coli. It also contains mini Tn7 elements that permit site-specific transposition of the 
gene of interest into a bacmid containing the entire baculovirus genome (Luckow et al.,
1993), propagated in DHlOBac bacteria (see section 2. IF). Cloning of an open reading 
frame into the multi-cloning site introduces a polyhistidine tag onto the N-terminus of 
the expressed protein, allowing purification by metal chelate affinity chromatography. 
Upstream of the inserted open reading frame site lies the baculovirus polyhedron 
promoter to allow high-level expression within insect cells. The plasmid was purchased 
from Invitrogen.
pCMV2UbcH6 (Boutell et al., 2002), pCMV2cdc34 (R.D. Everett, unpublished). These 
plasmids express FLAG-tagged E2 enzymes UbcH6 and cdc34 in transfected 
mammalian cells by virtue of the HCMV IE promoter.
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2.1 B Enzymes.
Restriction enzymes were obtained from Boehringer Mannheim or New England 
Biolabs. DNase, RNase A and lysozyme were purchased from Sigma and T4 
polynucleotide kinase, T4 DNA ligase, calf intestine phosphatase, E.coli DNA 
polymerase I Klenow fragment and proteinase K were purchased from Boehringer 
Mannheim. PCR was carried out using Thermus aquaticus T4 DNA polymerase (Taq 
polymerase) obtained from Boehringer Mannheim.
2.2C Synthetic oligonucleotides.
Oligonucleotides for PCR amplification and sequencing were synthesised and purified 
by MWG Biotech and Sigma-Genosys.
2.3D Cell lines.
All cell media and supplements were obtained from Gibco-BRL. The following cell 
lines were used in experimental work and were obtained from the cytology department 
of the Institute of Virology. The formulations of the media are described below, and in 
future sections of the text the supplemented media used for cell growth are referred to as 
complete media.
HEp-2. An epithelial cell line which was grown in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% FCS and 100 units/ml penicillin and 100 pg/ml 
streptomycin.
Spodoptera frugiperda 21 (Sf21). An insect cell line derived from larval ovarian tissue 
grown in complete TC-100 medium, supplemented with 10% FCS and 100 units/ml 
penicillin and 100 pg/ml streptomycin.
Vero. A cell line derived from African green monkey kidney cells; grown in DMEM 
supplemented with 10% FCS and 100 units/ml penicillin and 100 pg/ml streptomycin.
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2.1 E Bacterial strains.
The following strains of E. coli were used:
E. coli DH5a (V'/endAA h s d K ll  (rk'mk+) supEAA thil recAX gyrA  (Nalr) relAlA 
(lacZYA-argF) U169 (4>80<7/<2cA(lacZ)M15) was purchased from Invitrogen and was 
used for maintenance and propagation of plasmid DNA.
E. coli BL21 (DE3) pLysS (F" ompT r'em'e) was used for bacterial expression of 
proteins. The bacterial strain contains an integrated lysogenic X bacteriophage DE3 that 
has an IPTG-inducible promoter from which T7 RNA polymerase is expressed and the 
plasmid pLysS that encodes T7 lysozyme. The bacteria were purchased from Novagen.
E. coli DH10 Bac (F- mcrA.{mrr-hsdRMS-mcrQC) o80/acZ.M15 .lacX74 deoR recAl 
endAl araT>\29 .(ara, leu)1691 gal\J galK e- rpsL «M/?G/bMON14272/pMON7124) 
contains a baculovirus shuttle vector (bacmid) and a helper plasmid that provides the 
Tn7 transposition function (Barry, 1988). The bacteria were purchased from Invitrogen.
2. IF  Bacterial culture media.
The DH5a E. coli strain was grown in LB medium (10 g NaCl, 10 g Bactopeptone, 5 g 
yeast extract in 1 L water, pH 7.5) and all other strains in 2YT broth (5 g NaCl, 16 g 
Bactotryptone, 10 g yeast extract in 1 L water). Agar plates were made with 1.5% (w/v) 
agar in LB. Where necessary, media and agar plates were supplemented with antibiotics 
at the following concentrations: 70 pg/ml Ampicillin, 50 fig/ml of Kanamycin, 10 jig/ml 
Tetracycline, 7 pg/ml Gentamycin. The antibiotics used depended on the resistance 
being conferred by the plasmid being harboured by the bacteria. When blue/white 
screening was used to detect positive colonies, agar plates were supplemented with the 
following reagents: 100 pg/ml Bluo-gal (Novagen), 40 pg/ml IPTG.
2.1G Solutions.
Recipes of general solutions have been listed below, the details of all other solutions 
have been included either in the text or at the end of the relevant section.
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Formamide dye mix:
lOx Loading buffer:
PBS (A):
STET:
20x TBE: 
lx  TE:
Transfer buffer:
EPO 265 buffer:
10 mM EDTA, 1 pg/ml xylene cyanol FF, 1 pg/ml bromophenol 
blue in formamide.
(for agarose gels and non-denaturing polyacrylamide gels): 
lx TBE, 1% SDS, 50% glycerol, 1 pg/ml bromophenol blue.
170 mM NaCl, 3.4 mM KC1, 10 mM Na2HP04, 1.8 mM KH2P04, 
pH 7.2.
8% sucrose, 5% Triton-X 100, 50 mM EDTA, 50 mM Tris-HCl 
(pH 8).
2.5 M Tris, 0.8 M boric acid, 54 mM EDTA.
10 mM Tris-HCl, 1 mM EDTA (pH 8).
40mM Tris, 48mM glycine, 20% methanol, 0.4% SDS 
100 mM Tris-HCl, 150 mM NaCl, 10% Glycerol, 0.1% NP40,
20 mM /3-mercaptoethanol.
2.1H Radiochemicals.
Chemical Stock concentration Supplier
[35S]-L-methionine (10p,Ci/pl) Amersham
2.11 Chemicals.
All chemicals and reagents were purchased from BDH Chemicals UK or Sigma 
Chemical Company, unless otherwise stated below or in relevant sections:
Amersham Life Science: 
Beecham Research: 
Bio-Rad:
Boehringer Mannheim: 
Difco:
Fisons:
Fluka:
Invitrogen:
Rainbow protein markers.
Ampicillin.
Ammonium perisulphate (APS), N,N,N',N'- 
tetramethylethylenediamine (TEMED), coomassie 
brilliant blue.
Protease inhibitors.
Agar.
Ammonium hydroxide, acetone.
Formaldehyde
IPTG, Lipofectamine PLUS liposomal transfection 
reagent.
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Marvel:
Melford Laboratories Ltd: 
National Diagnostics: 
Prolabo:
Scotlab:
Dried skimmed milk 
Caesium chloride
30% acrylamide (2.5% cross-linker)
Boric acid, butanol, chloroform, ethanol, glacial acetic 
acid, glycerol, hydrochloric acid, isopropanol, methanol 
N, N'-methylene-bis-acrylamide 19:1
UKC Chemical Laboratories: Citifluor
2.1 J  Antibodies.
Anti-FLAG (M2): 
Anti-UL30 (rll3): 
Anti-c-myc (9E10):
Penta-HIS: Commercially available (Novagen) mouse monoclonal antibody
used against polyhistidine epitope tagged proteins.
A mouse monoclonal antibody commercially available from 
Sigma that recognises the FLAG epitope tag.
A rabbit polyclonal antibody raised against an epitope from the 
C-terminal peptide of HSV-1 UL30 gene (Marsden et al., 1994).
A mouse monoclonal antibody commercially available from 
Santa Cruz Biotechnology.
Anti-Ubiquitin (FK2): A mouse monoclonal antibody that targets polyubiquitinated or
monoubquitinated proteins (Fujimuro et al., 1994). The antibody 
recognises the isopeptide link between ubiquitin and a protein to 
which it is conjugated. It is commercially available from Affmiti.
Anti-Ubiquitin(P4Dl) A mouse monoclonal antibody that recognises all forms of
ubiquitin. It is commercially available from Santa Cruz 
Biotechnology.
2. IK  Commonly used proteins.
The ubiquitin activating enzyme (El) and the ubiquitin conjugating enzymes (E2) used 
in the studies described herein were sourced from communal lab stocks. A detailed 
overview of the methods used to express and purify the El and E2 enzymes is described 
elsewhere (Boutell et a l, 2002).
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2.2. Methods.
v i i u p i v r  <■
The Use of Centrifuges.
In the following section, specific centrifuges are used frequently and are referred to as 
follows: A ‘microfuge’ is a MSE Micro Centaur. A ‘bench top centrifuge’ is a Sorvall 
RT7. All other types of centrifuges are described fully in the text where used.
2.2 Nucleic Acid Manipulation
2.2A Nucleic acid restriction enzyme digestion.
Restriction enzyme digestion was carried out according to manufacturer’s instructions. 
Normally, 0.5 pg of plasmid DNA was used in diagnostic restriction digestion of cloned 
DNA. 10 pg - 20 pg of DNA was digested to generate DNA fragments for cloning 
purposes.
2.2B Blunt-end formation at DNA 5 ’ overhangs.
Blunt-ending of 5’ DNA overhangs was used to enable the ligation of DNA fragments 
with incompatible cohesive ends. The restriction digestion of the DNA was allowed to 
proceed as normal. Upon completion, the mixture was incubated in the presence of 50 
pM of all four dNTPs and 2 units of DNA polymerase I Klenow fragments for 30 min to 
1 hr.
2.2C Dephosphorylation o f DNA fragments.
The 5’ and 3’ ends of vector DNA were dephosphorylated to prevent re-circularisation 
of vector fragments during ligation reactions. Restriction digestion of the vector was 
allowed to proceed as normal (see section 2.2A) in the presence of 1 unit of calf 
intestinal phosphatase, added at the start of the restriction digestion reaction, and a 
second unit was added halfway through the reaction.
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2.2D Ligation of DNA fragments.
DNA ligation reactions were carried out with a vector/insert ratio of usually 3:1, in the 
presence of lx ligase buffer and 1 unit of T4 DNA polymerase in a total volume of 20 
pi. The reaction was incubated at RT for 30 min to overnight.
2.2E Annealing and purification o f oligonucleotide linkers.
To make a double-stranded oligonucleotide linker, the two complementary 
oligonucleotides were annealed in the following reaction mix: 2 pi of 5’ phosphorylated 
synthetic oligonucleotides (100 pM/pl), 3 pi of 500 pM ATP, 2 pi 1 Ox T4 Phosphate 
Nucleotide Kinase (T4 PNK) buffer and 2 units of T4 PNK in a total volume of 20 pi. 
The reaction was incubated at 37°C for 30 min, then at 95°C for 5 min and then left to 
cool to RT. The samples were supplemented with lx loading buffer then subjected to 
electrophoresis on a non-denaturing acrylamide gel (see section 2.4C). The gel was 
stained in ethidium bromide at a concentration 1 pg/ml and visualised on a long wave 
U.V. transilluminator. The annealed oligonucleotide band was excised and eluted as 
follows: Initially the gel fragment containing the band was crushed to a pulp, 400 pi of 
lx TE was added, and the mixture was placed into a 1.5 ml reaction tube. The tube was 
placed in a shaking incubator and incubated overnight. The eluted DNA was separated 
from the gel pulp by filtering the mix through siliconised glass wool and the annealed 
oligonucleotide was concentrated and recovered by ethanol precipitation (see section 
2 .21).
2.2F PCR o f DNA fragments.
PCR was performed using P.fu. Turbo DNA polymerase (Stratagene). In each case the 
reaction was carried out in buffers supplied and under conditions recommended by the 
manufacturer. Reactions were performed in thin-wall 0.5 ml reaction tubes, overlaid 
with mineral oil and placed in a Techne thermal cycler. A typical reaction protocol with 
P.fu. Turbo polymerase is shown in Table 2.2F
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dH20 11.5pl
lOx P.f.u. buffer 2.5pl
10 mM dNTPs 5 pi
DMSO (2% final) lpl
DNA (20 ng/pl final) 5 pi
Forward primer. lOpmol/pl lpl
Reverse primer. lOpmol/pl lpl
Table 2.2F. Reaction components o f a typical 
PCR reaction.
The cycling conditions were as follows: 1 x 94°C for 30 sec, 35 x (94°C for 30 sec + 
57°C for 1 min + 72 °C 1 min), and a final extension step of 72°C for 10 min.
2.4GDNA purification from agarose gels
Agarose gel electrophoresis (see section 2.4A) was initially used to resolve digested 
DNA fragments. The DNA fragment of interest was excised from gels under long wave 
U.V. using a U.V. Products Inc transilluminator and the DNA was recovered using 
Qiagen Qiaquick gel extraction kit.
2.2H Phenol/chloroform extraction o f DNA.
This procedure was usually carried out during multiple restriction digestions, where the 
enzymes used shared incompatible buffers. Consequently, it was necessary to remove 
the incompatible buffer before proceeding to the next digestion. Initially the volume of 
the DNA was increased to 200 pi by the addition of CIH2O. An equal volume of 
phenol/chloroform (1:1) was added to the DNA solution and briefly vortexed before 
being centrifuged at 13,000 r.p.m. for 5 min at RT in a microfuge and then the upper 
aqueous phase was removed; this step was repeated a further 2-3 times. Upon 
completion, to remove traces of the phenol/chloroform the DNA was precipitated with 
ethanol (see section 2.21).
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2.21 Ethanol precipitation,
\
I The sample to be precipitated was increased in volume to 500 pi with dH20. The DNA
I
was precipitated by the addition of 0.1 volumes of 3 M sodium acetate and 2 volumes of 
I 100% ethanol. The mixture was vortexed and incubated for 20 min on dry ice. The
i
| precipitated DNA was pelleted by centrifugation at 13,000 r.p.m. for 10 min at RT in a
microfuge. The supernatant was discarded and approximately 500 pi of 70%-80% 
ethanol was added to remove excess salts. The DNA was pelleted again by 
centrifugation at 13,000 r.p.m. for 5 min at RT. The DNA pellet was air dried for 
approximately 5 - 1 0  min before being resuspended in the appropriate volume of dt^O. 
The DNA was stored at -20°C until required.
2.3 Plasmid preparation.
2.3A Small scale preparation o f plasmid DNA.
The small scale DNA preparation method was generally used for diagnostic purposes. A 
single bacterial colony from a selective plate was inoculated into 10 ml of YTB
(supplemented with the appropriate antibiotic) and incubated at 37°C overnight. The
following day 1.5 ml of the bacterial culture was dispensed into a 1.5 ml reaction tube 
and centrifuged for 1 min at 13,000 r.p.m. in a microfuge. The supernatant was 
discarded and 200 pi of STET and 10 pi of 10 mg/ml lysozyme was added and the 
samples were vortexed and incubated at RT for 1 min. The samples were then boiled for 
1 min and then centrifuged for 15 min at 13,000 r.p.m. The supernatant was transferred 
to a fresh 1.5 ml reaction tube, and an equal volume of isopropanol was added, and the 
tubes were inverted several times and centrifuged at 13,000 r.p.m. for 10 min. The 
supernatant was discarded and 400 pi of 80% ethanol was added and the samples were 
centrifuged for 5 min at 10,000 r.p.m. The ethanol was removed and the pellets were air 
dried for approximately 2 min. The pellets were resuspended in 30-40 pi of (IH2O or lx 
TE and 1 pi of 1 mg/ml RNase was added. The preparations were stored at -20°C.
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2.3B Large scale preparation o f plasmid DNA
Large scale plasmid preparations were usually carried out on cultures of E. coli DH5a 
bacteria derived from colonies containing plasmids the identity of which had been 
initially confirmed by the miniprep method (see section 2.3A). 300 ml of LB 
(supplemented with relevant antibiotics) was inoculated with a single bacterial colony 
and incubated overnight. The culture was transferred to a GSA centrifuge tube and 
centrifuged at 10,000 r.p.m. for 10 min (Beckman GPR centrifuge). The supernatant 
was discarded and the pellet was resuspended in 20 ml of STET. The resuspended 
culture was transferred to a 50 ml Falcon tube and 2.5 ml of 10 mg/ml of lysozyme was 
added and incubated at RT for 1 min. The mixture was brought to the boil and placed in 
a boiling water bath for 1 min, then transferred to a Beckman SS34 rotor tube and 
centrifuged at 18,000 r.p.m. for 45 min at 4°C in a Beckman GPR centrifuge. The 
supernatant was transferred to a 50 ml Falcon tube and 0.9 volumes of isopropanol were 
added and centrifuged at 3,000 r.p.m. for 5 min for 4°C (Bench top centrifuge). The 
supernatant was then discarded and the pellet was resuspended in 5 ml of lx TE and 
brought up to 6.3 ml in volume with lx TE. 7 g of CsCl was added and swirled gently to 
dissolve and 0.2 ml 10 mg/ml ethidium bromide was added and the tube was placed on 
ice for 1 0 - 1 5  min. The sample was centrifuged at 3,000 r.p.m. for 10 min at 4°C 
(Bench top centrifuge). Using a 10 ml syringe the sample was transferred to a 6 ml 
65V I3 tube that was then filled to the neck. The tubes were sealed, balanced and 
centrifuged overnight or for 16 hrs at 45,000 r.p.m. at 15°C (Beckman ultra centrifuge). 
The plasmid DNA band was removed from the tube by inserting a needle into the neck 
of the tube and a second needle with syringe just below the DNA band. The solution 
containing the band was removed then mixed thoroughly with an equivalent volume of 
butanol saturated with lx TE. The layers were separated by centrifuged at 3,000 r.p.m. 
at 4°C for 10 min (bench top centrifuge), then the upper layer containing butanol with 
extracted ethidium bromide was removed. This procedure was repeated 2-3 times to 
remove all of the ethidium bromide. The sample was placed in dialysis tubing (Pierce) 
and dialysed against lx TE for 2 hr, then transferred to a Starsdedt tube and treated with 
RNase A at 100 pg/ml at 65°C for 1 hr. The samples were cooled and treated with 
Proteinase K at 100 pg/ml in the presence of 0.1% SDS at 37°C for 1 hr. Subsequently, 
an equal volume of phenol saturated with lx  TE was added, and the tube was inverted 
several times and centrifuged at 3,000 r.p.m. for 10 min (Bench top centrifuge). The 
upper aqueous phase was added to a new Starstedt tube and an equal volume of
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chloroform was added, inverted several times and centrifuged at 3,000 r.p.m. for 10 min 
at 4°C. The upper aqueous phase was removed to a 15 ml Falcon tube and ethanol 
| precipitated (see section 2.21). The DNA was pelleted by centrifuging at 3,000 r.p.m. for
i
| 10 min at 4°C (Bench top centrifuge.). The precipitated DNA was resuspended in 400 pi
[ of lx TE containing 0.25M NaCl, and again ethanol precipitated (see section 2.21). The
j pellets were washed with 400 pi of 80% ethanol and the samples centrifuged for 2 min
; at 13,000 r.p.m. (Microfuge). The pellets were resuspended in 100 pi - 300 pi of lx TE.
[
i
2.4 DNA analysis.
2.4A Non-denaturing agarose gels.
DNA fragments produced by PCR or restriction digestion were resolved by non­
denaturing gel electrophoresis. Initially between 0.5% and 2% agarose mix was made in 
either lx TBE or lx TAE, the latter was used when gel purifying DNA fragments. After 
boiling to dissolve the agarose, the mixture was cooled, poured into a horizontal slab gel 
I apparatus with a suitable well-forming comb, and allowed to set. DNA samples were
supplemented with the appropriate amount of agarose gel loading buffer and always 
loaded on the gel in conjunction with a sample of a marker DNA ladder (1 Kbp, New 
England Biolabs). The gel was run at 12 V/cm in either lx  TBE or lx  TAE buffer 
depending on the corresponding gel type, lx TBE gels were generally used for 
diagnostic purposes to resolve cloned DNA that had been restriction digested, lx TAE 
gels were used for the resolution of DNA fragments that would be used for cloning 
purposes. Following electrophoresis the gel was stained in ethidium bromide solution (1 
pg/ml) for 2-3 min and then rinsed in water. The DNA was visualised under U.V. light 
(normally short wave, but long wave for preparative gels). Photography was carried out 
using The Imager (Appligene).
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2.4B Non-denaturing polyacrylamide gels.
Vertical non-denaturing 12% polyacrylamide gels (acrylamide: N, N ’-methylene-bis- 
acrylamide 19:1) gels prepared in lx TBE were used to purify annealed synthetic 
oligonucleotides. Polymerisation was initiated by adding 0.01 volumes 10% ammonium 
persulphate and 0.001 volumes TEMED, then the mixture was applied to a Bio-Rad 
Mini Protein II apparatus with a suitable comb. After electrophoresis, the DNA bands 
were visualised by ethidium bromide staining and eluted by the method described above 
(Section 2.2E).
2.4C Sequencing o f DNA.
Sequencing of DNA was carried out as a service using DNA sequence analysis 
machines either in house, or at the Molecular Biology Sequencing Unit, Institute of 
Biomedical Sciences, University of Glasgow.
2.5 Manipulation of Competent Bacteria.
2.5A Preparation o f electro-competent bacteria.
Initially a single E.coli DH10 Bac colony was inoculated into 10 ml of YTB 
(supplemented with the appropriate antibiotics when necessary) and incubated at 37°C 
overnight. The culture was then used to inoculate 1 litre of LB broth, again 
supplemented with the appropriate antibiotics when necessary. The culture was grown 
to mid-log phase and transferred to the appropriate number of 350 ml Falcon tubes and 
left on ice for 30 min, then centrifuged for 15 min at 3,500 r.p.m. (Bench top 
centrifuge). The supernatant was decanted and the pellets were resuspended in a total of 
160 ml of sterile dH20 and combined. The bacteria were pelleted again by centrifugation 
at 3,500 r.p.m. for 15 min at 4°C (Bench top centrifuge). The supernatant was discarded 
and the pellet was resuspended in a total volume of 500 ml of sterile dH20 in a GSA 
tube and centrifuged at 3,500 r.p.m. for 15 min at 4°C (Beckman GPR centrifuge). The 
supernatant was again discarded and the pellet was resuspended in 40 ml of dH20 and 
transferred to a pre-chilled 50 ml (SS34) tube and centrifuged for 6,000 r.p.m. for 15 
min at 0°C (Beckman GPR centrifuge). The supernatant was discarded and the pellet
109
was resuspended in 2 ml dH20 + 10 ml glycerol. The resuspended bacteria were 
iliquoted into 1.5 ml reaction tubes that were placed in a dry ice/methanol bath to snap 
Teeze. The frozen bacteria were stored at -70°C
2.5B Transformation o f electro-competent bacteria.
Typically 1-3 pi of DNA was mixed with approximately 80 pi of electro-competent 
bacteria and electroporated using a Hybond cell shock electroporator (following the 
manufacturer’s guidelines) in a 0.1 cm Gene Pulser® cuvette (Bio-Rad). Following 
electroporation the bacteria were resuspended in 1 ml YTB, and incubated at 37°C for 
45 min in an orbital shaker. Variable quantities of up to 200 pi of the culture were 
plated out onto an L-Broth agar plate containing the appropriate antibiotics and 
incubated overnight at 37°C.
2.5C Heat shock transformation o f competent bacteria.
Calcium chloride prepared competent bacteria were purchased from commercial 
sources. Initially 50 pi of E. coli DH5a (Invitrogen) or 15 pi of E. coli BL21 (pLysS) 
(Novagen) were thawed on ice. A volume of plasmid DNA or ligation reaction 
containing 20 - 30 ng of DNA was added to the thawed competent bacteria, mixed 
gently. The mixture was incubated on ice for 20 min, then heat shocked at 37°C for 20 
sec and returned to ice for a further 2-4 min. A 500 pi volume of YTB was promptly 
added to the bacteria, and then the mixture was incubated at 37°C for 30-60 min. A 100- 
200 pi aliquot of the bacterial suspension was plated onto LB Agar plates supplemented 
with the appropriate antibiotics and incubated at 37°C overnight.
2.6 Tissue Culture.
2.6A Growth o f mammalian cells in culture.
Mammalian derived cells were passaged in sterile, 175 cm2 plastic flasks (Nunc) in the 
appropriate media (see section 2.3D), and incubated at 37°C in a humidified incubator 
under 5% C 02. Confluent monolayers were harvested by washing first with versene (0.6 
mM EDTA in PBS(A), 0.2% phenol red) and then trypsin/versene (1:2) (supplied by the
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Institute of Virology Media Services) and then resuspended in 10 ml of the appropriate 
medium. For continual passage, HEp-2 and Vero cells were split in a 1:10 ratio every 3- 
4 days.
2.6B Growth o f insect cells in culture.
Insect derived Sf21 cells were passaged in sterile, 175 cm plastic flasks (Nunc) in 
complete TC-100 medium (see section 2.3D), and incubated at 28°C without venting. 
Confluent monolayers were harvested by removing the growth media and tapping 
sharply on the back of the flask multiple times, until the cells became detached from the 
flask surface. The cells were resuspended in 10 ml of appropriate growth media and 
split 1:10 to seed new flasks. Cells were also grown in suspension cultures in burrler 
roller bottles (Nunc). All cells were grown to a confluencey of 70%-80% before 
splitting.
2.6C Recovering Sf21 cells from liquid nitrogen.
Cryovials containing frozen cell suspensions were removed form liquid nitrogen storage 
and the cells were immediately thawed in a 37°C water bath. The thawed cells were 
transferred to a 15 ml Falcon tube and resuspended in 4 ml of complete TC-100 and 
centrifuged (Bench top centrifuge) at 1000 r.p.m. for 5 min, the supernatant was 
discarded and this step was repeated. The cell pellet was resuspended in 4 ml of growth 
medium and the suspension was added to a 125 cm2 flask (Nunc), then an additional 15 
ml of medium was added and the cells were incubated at 28°C until 70% confluent and 
then passaged.
2.7 Immunofluorescence and Transfection of Cells in Culture.
2.7A Transfection o f plasmid DNA
Cultured cells were transfected by the Lipofectamine PLUS method, as recommended 
by the supplier (Gibco-BRL). HEp-2 cells were seeded at a density of 7.5 x 104 the day 
prior to transfection into 24-well Linbro well units (Nunc) containing a sterile coverslip. 
The cells were supplemented with the appropriate medium and incubated overnight at
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37°C/5% CO2. The following method states the amount of transfection reagent for a 
single well, but normally the PLUS and lipofectamine mixes were made up in sufficient 
quantity for all the samples being transfected. Normally between 100 ng - 500 ng of 
plasmid DNA was dispensed into 15 ml Falcon tubes, then 1 pi of PLUS reagent was 
added to 25 pi of serum-free DMEM and this mixture was added to the DNA, mixed 
and then incubated at RT for 15 min. During the incubation 1 pi of Lipofectamine 
reagent was mixed with a further 25 pi of serum-free DMEM, then this mixture was 
added to the DNA-PLUS mix solution and incubation was continued for a further 15 
min at RT. During the incubation, the cells were washed with serum-free DMEM, first 
taking off and retaining at 37°C the ‘conditioned’ medium in which the cells had been 
growing. The Falcon tubes containing the DNA/Lipofectamine/PLUS reagent mix were 
supplemented with 200 pi of serum-free medium, then the whole 250 pi mix was added 
to the Linbro wells containing the washed cells, which were then incubated at 37°C/5% 
CO2 for 3 hr. Subsequently, 750 pi of the retained conditioned medium was added to 
each of the Linbro wells containing the transfected cells and incubation was continued 
for 16 hr.
2.7B Large scale transformation o f cells in culture.
The method mentioned in section 2.7A was modified for the transfection of 35 mm 
plates, as follows. The cells were seeded the day prior at 4 x 105 cells per plate. The 
volumes of the PLUS reagent and Lipofectamine were increased as follows: 4 pi PLUS 
reagent in 100 pi serum-free medium, and 4 pi Lipofectamine reagent in 100 pi serum- 
free medium per plate. At the time of addition of the mixtures to the cells, an extra 800 
pi serum free medium was included to ensure the cells were completely covered with 
medium. After the 3 hr incubation 1.5 ml of conditioned medium was added to the cells, 
and incubation was continued accordingly.
2. 7C Complementation assay.
Separately 1 pg of infectious viral d/1403 DNA (Stow and Stow, 1986) and 100 ng of 
plasmid DNA expressing one of the ICP0 family of proteins were mixed and made up to 
a total of 2 pg DNA with pUC9. The DNA was transfected into the cells as described in 
section 2.7B, except that at the end of the procedure 2 ml of medium supplemented with
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1% human serum was added. At 16 hr post transfection, the medium was removed and 
fresh medium containing 1% human serum was added. At 72 hr post transfection, the 
medium was removed and 1 ml of Giemsa stain was added to each of the wells for 
approximately 30 sec and removed by washing thoroughly in a large sink containing 
water. The plates were inverted and left to dry before the plaques were counted.
2.7D Fixation of cell for immunostaining.
Cells were grown on glass coverslips and transfected as described in preceding sections. 
Initially the growth medium was removed from the cells, which were then washed twice 
with 1 ml of PBS before the addition of 0.5 ml of formaldehyde fix solution (19 ml 
PBS(A), 1 ml formaldehyde and 0.4 g of sucrose). The cells were then incubated at 
room temperature for 10 min, the fix solution was discarded, the cells were washed 
twice with 1 ml of PBS(A), then 0.5 ml of permeablisation solution (19 ml PBS, 1 ml 
10% NP40, 2 g sucrose) was added to the cells which in turn were incubated at RT for 
10 min. Upon completion of this incubation the cells were washed twice in 1 ml PBS 
supplemented with 1% calf serum.
2. 7E Indirect immunofluorescence.
Dilutions of antibodies (see section 2.11) were made in PBS supplemented with 1% calf 
serum (PBS/1 % FCS). A 15-20 pi aliquot of the antibody dilution was placed in the 
centre of one of the raised circles in an up-turned lid of a 24-well Linbro dish. The 
coverslip was placed fixed cell side down onto the antibody and incubated at RT for 30- 
60 min. Following the antibody incubation, 15-20 ml of PBS/1 % FCS was gently 
pipetted onto the lid, immersing the coverslips. The first wash was immediately 
removed, and then the wash was repeated a further two times. The coverslips were then 
turned cell side up and washed 3 more times over a 15 min period. The secondary 
antibody dilution was made in PBS(A)/1% FCS (see appropriate section for details). 
Specific concentrations of antibody combinations are stated where used. A 15 - 20 pi 
volume of secondary antibody dilution mixture was placed in the centre of a well on a 
fresh upturned Linbro lid. The coverslip were placed cell side down on the antibody 
dilution and incubated for 30-60 min in the dark at RT. The coverslips were then 
washed as previously mentioned. Finally coverslips were washed once in water, air 
dried and mounted cell side down on a glass slide with 3 pl-5 pi of an anti-fade
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mounting agent in PBS/glycerol (Citifluor). The coverslips were fixed to the slide by 
applying clear nail varnish around their perimeters, and then stored a 4°C in the dark 
until required. Immunofluorescence analysis was carried out on a Zeiss LSM 510 
confocal microscope and the images were edited using PhotoShop 6.0 software.
2.8 Production of recombinant baculoviruses.
A synopsis of the methodology and theory behind creating a recombinant baculovirus is 
outlined in section 3.0.
2.8A Transposition o f expression cassettes to bacmid plasmids within E. coli DH10 
Bac bacteria.
E. coli DHlOa were electroporated according to the method stated in section 2.5B, with 
the exception of the bacteria having an extended final incubation of 3 hr at 37°C. The 
prolonged recovery period was to allow the transposition of the recombinant gene 
within the Tn7 elements of the pFastBacHTa plasmid, to the integration site in the 
bacmid containing the entire baculovirus genome within the E. coli DH10 Bac bacteria. 
To select for the desired recombinants, the bacteria were plated onto LB agar plates 
supplemented with 50 pg/ml kanamycin, 7 pg/ml gentamycin, 10 pg/ml tetracycline, 
100 pg/ml Bluo-gal, 40 pg/ml IPTG and incubated at 37°C for 24 hrs. The antibiotics 
select for the bacmid, the pFastBac plasmid, and the plasmid expressing the proteins 
necessary for the site-specific recombination. A recombination event occurring at the 
correct integration site results in failure to express functional P-galactosidase, therefore 
producing a white instead of a blue colony in the presence of IPTG and Bluo-Gal. White 
colonies were rare within a high background of blue ones. Normally, 5 white positive 
colonies were picked and purified on the selective plates to eliminate false positives and 
isolate clonally pure colonies.
2.8B Isolation o f recombinant bacmid DNA.
Single positive colonies containing recombinant bacmid DNA were used to inoculate 5 
ml of YTB supplemented with 50 pg/ml kanamycin, 7 jug/ml gentamycin and 10 pg/ml 
tetracycline, and then the cultures were incubated overnight. An aliquot of the culture
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v&s transferred to a 1.5 ml reaction tube and centrifuged at 3,000 r.p.m. for 5 min. The 
sipematant was removed and resuspended by gentle vortexing in 300 pi of solution I 
(15 mM Tris-HCl [pH 8.0], 10 mM EDTA, 100 pg/ml RNase A). This was followed by 
03 ml of solution II (0.2 N NaOH, 1% SDS), then the mixture was vortexed gently and 
iicubated at RT for 5 min. Finally, 300 pi of 3 M potassium acetate (pH 5.5) was added 
aid the mixture was placed on ice for 5 to 10 min. The sample was then centrifuged for 
li min at 14,000 x g in a bench top centrifuge. The supernatant was transferred to a 1.5 
ml reaction tube containing 0.8 ml isopropanol, the contents were mixed by inversion 
several times to mix, then the tube was placed on ice for 20 min or -20°C overnight. 
Tie sample was centrifuged for 15 min at 14,000 x g in a bench top centrifuge. The 
sipematant was removed and 0.5 ml 70% ethanol was added, followed by the inversion 
of the tube to wash the pellet. Again the sample was centrifuged for 5 min at 14,000 
r.p.m. in a bench top centrifuge. The supernatant was removed and the DNA pellet was 
led to air dry for 5 to 10 min. The pellet was resuspended in 40 pi of lx TE or distilled 
witer, and stored at -20°C.
2.SC Transfection o f Sf21 cells with recombinant bacmid DNA.
S121 cells were seeded 1 x 106 cells per 35 mm dish on the day prior to transfection in 2 
ml of complete TC-100 medium. Normally 3-5 pg of recombinant bacmid DNA was 
used for the transfection of Sf21 cells. The transfection protocol is described in section 
2.7A. Cells were left for 5-6 days or until signs of infection could be observed, 
whichever was the sooner. Following transfection a 10 ml syringe bung was used to 
scrape the cells from the dish. The cell supernatant mix was removed to a 15 ml Falcon 
tube and centrifuged at 3,000 r.p.m. for 10 min (Bench top centrifuge.). The supernatant 
was placed in a cryovial and left at 4°C, protected from light.
2.ID Amplification and harvesting o f recombinant baculoviruses.
Amplification o f Baculovirus stage /.
Sf21 cells were seeded 1 x 106 cells per 35 mm dish on the day prior to infection, in 2 
ml of complete TC-100 medium. The supernatant was removed from the cells and 
discarded, then 200 pi of supernatant from the initial supernatant harvest (section 2.8C) 
was added. The cells were rocked at RT for 1 hr, to aid viral adsorption, then 2 ml of
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complete TC-100 medium was added and the cells were incubated for 5-6 days at 28°C 
cr until cellular morphology was indicative of infection. The supernatant was harvested 
s  previously described (section 2.8C), however cell pellets were retained for 
recombinant protein expression analysis and the supernatant was stored at 4°C. Cell 
pellets were resuspended in 200 pil of PBS and 100 pi of 3x SDS-PAGE boiling mix and 
placed in a boiling bath for approximately 5 min. 15 pi of the resuspended cell pellet 
vas analysed by SDS-PAGE and Western blot analysis (sections 2.11A-2.11D). 
Expression of the recombinant proteins was detected by using anti-6HIS or anti-myc 
antibodies as relevant (section 2.11).
Amplification o f Baculovirus stage II.
Liitially 125 cm3 flasks (Nunc) were seeded with Sf21 cells at 1.0 x 106the day prior to 
infection with supernatant virus from amplification stage I stocks that had been shown 
to express the desired protein by Western blot analysis. The medium was removed from 
the flasks, then 300 pi of virus stock supernatant from amplification stage I was added 
to the cells in combination with 1 ml of complete TC-100 medium and the cells were 
rocked at RT for 1 hr, to aid viral adsorption. An additional 4 ml of complete TC-100 
medium was added to the cells, which were incubated for 3-5 days at 28°C or until a 
cytopathic effect due to virus infection was observed, whichever was sooner. The flasks 
were shaken firmly to remove the remaining cells from the surface. The cell suspension 
was transferred to a 15 ml Falcon tube which was centrifuged at 3,000 r.p.m. for 10 min 
(Bench top centrifuge). The supernatant was removed to a new 15 ml Falcon tube and 
stored at 4°C.
Amplification o f Baculovirus staee III.
Burrler roller bottles (Nunc) were seeded at 4.5 x 108 Sf21 cells in a total volume of 300 
ml complete TC-100 medium, then 1 ml of amplification stage II supernatant from an 
isolate positive for expression of the desired protein was added. The culture was 
incubated at 28°C for 4-5 days. The cell suspension was centrifuged at 5,000 r.p.m. for 
10 min in a sterile centrifuge bottle (GSA rotor, Beckman GPR centrifuge), then the 
supernatant was transferred to further sterile centrifuge tubes and centrifuged at 10,000 
r.p.m. for 3-4 hr at 4°C (Beckman GSA rotor; Beckman GPR centrifuge). The
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supernatant was discarded and the viral pellet was resuspended in 4 ml complete TC- 
100 medium. The viral suspension was stored in 1 ml aliquots in cryovials, and kept at 
4°C if for immediate use or at -70°C for long-term storage.
2.8E Titration o f baculovirus stocks.
Sf21 cells were seeded at 1 x 106 cells in 2 ml complete TC-100 medium onto 35 mm 
plates the day prior to infection, to attain 60%-70% confluence. Serial 10-fold dilutions
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of the original virus stock were prepared in complete TC-100 medium from neat to 10* 
in a total volume of 300 pi. The media from the 35 mm dishes containing the Sf21 cells 
was removed and 100 pi from each of the dilution series was added per 35 mm dish, in 
duplicate. An additional 100 pi of complete TC-100 medium was added per plate and 
the plates were rocked at RT for one hr. During virus absorption, 25 ml of complete TC- 
100 medium was heated to 42°C in a water bath, then 25 ml of sterile 5% (w/v) sea- 
plaque agarose was melted and equilibrated at 42°C. After virus adsorption, the 
supernatant was removed from the cells and the equilibrated complete TC-100 medium 
and sea-plaque agarose were mixed and 1.5 ml aliquots were added immediately to the 
cells. The plates were then left for 10-15 min at RT, then 1.5 ml of complete TC-100 
medium was added to the plates which were then incubated at 28°C for 5-6 days. The 
surface medium was removed and replaced with complete TC-100 medium 
supplemented with Neutral Red solution (2% v/v of stock), then incubation of the plates 
at 28°C was continued overnight. The stain solution was then removed and the plates 
were inverted on tissues to dry before the plaques were counted and the viral titre was 
calculated.
2.8FLabelling o f proteins in baculovirus infections with S methionine.
35 mm dishes were seeded with 1 x 1 0 ^  Sf21 cells the day prior to infection. The 
medium was removed and the virus was added at an m.o.i. of 5 p.f.u./cell in a total 
volume of 200 pi. The cells were rocked for 1 hr at RT to aid viral adsorption to the 
cells, whereupon 1.5 ml of complete TC-100 medium was added and the cells incubated 
at 28°C. At 24-30 hrs p.i., the medium was discarded and replaced with 1.5 ml of 
complete TC-100 medium formulated without added methionine. After 1 hr, the 
medium was removed and 1.5 ml of methionine-free complete TC-100 medium mixed
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with normal medium at a ratio of 4:1 and containing 30 pCi/ml of [ S]-methionine was 
added. The cells were incubated for 18 h. A 10 ml syringe bung was used to scrape the 
cells from the dish. The cell supernatant mix was transferred to a 1.5 ml reaction vial 
and pelleted at 6,500 r.p.m. in a microfuge for 3 min. The supernatant was discarded as 
radiochemical waste and the pellet was resuspended in 1 ml PBS-A, and centrifuged at 
6,500 r.p.m., this step was repeated and the pellet was retained. The cell pellet was
resuspended in 100-150 pi 3x boiling mix and the lysates were stored at -20°C prior to 
SDS-PAGE analysis (see 2.11 A). After electrophoresis, the gels were mounted on card 
and dried under vacuum, and exposed to Kodak X-OMAT film.
2.8G Purification o f baculovirus expressed recombinant proteins.
Sf21 cells were grown in burrlers (Nunc) to a density of 3 x 106 in 300 ml, and were 
infected at an M.O.I. of 3 and incubated at 28°C for 72 hr. Upon completion, the cell 
culture was transferred to a Beckman GSA tube and centrifuged at 3,000 r.p.m. for 5 
min (Beckman GPR centrifuge). The supernatant was removed and the cell pellet was 
resuspended in 5 ml of PBS-A and transferred to a 15 ml Falcon tube and centrifuged at
3,000 r.p.m. (Bench top centrifuge) for 5 min, this step was repeated. The retained cell 
pellet at this point could be stored at -70°C. The pellet was resuspended in 1 ml of 
buffer A (100 mM Tris-HCl [pH 8], 500 mM NaCl, 10% Glycerol, 1% NP40, 20 mM P- 
mercaptoethanol, 4% Complete™ (EDTA-free) protease inhibitors [Boehringer 
Mannheim]). The pellet was resuspended through a needle (26G 3/g) 15-20 times, to 
produce a homogenous mix. The volume of the extract was brought up to 7 ml in a 
Falcon tube with buffer A, and placed horizontally in soni-bath (Kerry) and sonicated 
for approximately 30 sec. The extract was placed on ice for 30 min, accompanied by 
intermittent vortexing. The supernatant was then transferred to a snap cap tube (Nunc) 
and centrifuged at 13,000 r.p.m. for 10 min at 4°C (Beckman GPR centrifuge). The 
supernatant was transferred to a 15 ml Falcon tube. The volume was increased to 14 ml 
by adding 100 mM Tris-HCl (pH 8) + 4% Protease inhibitors. Initially the buffer was 
added 1 ml at a time for the first 3 ml and the remainder was then added. Then 200 pi of 
Ni-NTA coupled to Sepharose® CL-6B (Qiagen) was washed in 3 x 1 ml in Buffer 
A/50% 100 mM Tris-HCl pH 8. Each wash step was accompanied by a centrifugation 
step to pellet the beads and discard the wash buffer (13,000 r.p.m. for 30 sec, 
microfuge). The washed beads were added to the protein extract, which was in turn
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incubated at RT for 1 - 2 hr accompanied by intermittent vortexing. The beads were then 
pelleted by centrifugation for 5 min at 1,000 r.p.m. (Bench top centrifuge). The 
supernatant was discarded and the beads were washed as follows; 4 x 1  ml, Buffer 
A/50% 100 mM Tris-HCl pH 8, and 4 xl ml in Buffer A/50% 100 mM Tris-HCl + 20 
mM imidazole pH 8. Each wash step was followed by centrifugation (10 sec at 13,000 
r.p.m., microfuge.) to pellet the beads and discard the wash buffer. The proteins were 
eluted for 5 min at RT in 300 pi of Buffer A/50% 100 mM Tris-HCl pH 8, 
supplemented with 250 mM imidazole. The beads were collected as previously 
mentioned and the eluate was retained. The elution step was carried out a further 3 times 
The eluates were placed in dialysis tubes (Pierce), and dialysed in 100 mM Tris-HCl 
(pH 8), 150 mM NaCl, 0.1 % NP40, 5 % Glycerol, 10 mM p-mercaptoethanol, for 2 hr 
at 4°C. Protein expression was analysed by SDS-PAGE analysis and/or Western 
blotting.
2.8H Infection o f mammalian cells with baculoviruses.
Mammalian cells were seeded on 13 mm glass cover slips in 24 well Limbro plates 
(Nunc) at 0.75 x 105 in 1 ml of medium and incubated overnight. The medium was 
removed and baculoviruses expressing members of the ICP0 family of proteins from the 
HCMV promoter were used to infect cells at an M.O.I. of 100-500 insect cell p.f.u. per 
cell. The viral dilutions were made up to 150 pi in volume with the appropriate cell 
growth medium before being added to the cells. The cells were incubated at 37°C for 1 
hr with regular mixing, whereupon an additional 750 pi of cell growth medium was 
added and the incubation was continued for a further 24 hrs.
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2.9 Biochemical assays.
The biochemical assays stated in this section are a generalisation of the experimental 
procedures used. Variations are stated clearly in the appropriate sections.
2.9A In vitro thiolester assay.
The in vitro thiolester assay was carried out in 1 x reaction buffer containing 50 mM 
Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM ATP in 1.5 ml reaction tubes. The individual 
assay components were as follows: 500 nM E l, 5 pg of ubiquitin and 3-5 pg E2 (The 
E2s used are stated in the results section) in a total volume of 10 pi. The El and E2 
enzymes were sourced from communal lab stocks (see section 2.IK). To attain working 
concentrations, where needed, assay components were diluted with lx  reaction buffer. 
The reaction was repeated twice for each E2. The mixtures were incubated at 28°C for 
20 min, one set of reactions was immediately stopped with 3 x gel loading buffer 
containing 500 mM DTT, the remaining set of reactions was stopped in 3 x gel loading 
buffer containing no reducing agent. The reactions were subjected to electrophoresis on 
10% BIS-Tris Nupage gels (Invitrogen). The gels were run according to the 
manufacturer’s instructions and in buffers also supplied by the manufacturer and then 
coomassie stained (see section 2.1 IB).
2.9B In vitro ubiquitination assay.
The reaction was carried out in 1.5 ml reaction tubes, in a total volume of 10 pi and its 
components were: 50 nM El (see section 2. IK), 500 ng of ubiquitin, 50-250 nM E2 (see 
section 2.IK) and 10-100 ng E3. The 10 x reaction buffer contained 50 mM Tris-HCl 
(pH 7.5), 50 mM NaCl, 5 mM ATP. To attain working concentrations, where needed 
assay components were diluted with 1 x reaction buffer. The reaction mix was incubated 
at 37°C for 1 hr and stopped by the addition of 3x gel loading buffer. The samples were 
resolved by SDS-PAGE analysis and the ubiquitin products were detected by Western 
blotting using either FK2 (Affiniti) or P4D1 (Santa Cruz Biotechnology) anti-ubiquitin 
antibodies.
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2.9C GST-pull down assays.
GST pull down assays (Smith & Johnson, 1988) were used to detect if the GST fusion 
protein interacted with specific target proteins. Initially soluble extracts were made of 
the GST fusion and target proteins (see section 2.10A). Glutathione agarose beads were 
rehydrated in PBS-A/1% NP40 at RT for 1-2 hr to make a 1:1 (v/v) slurry. Samples 
(200 pi) of bacterial extracts expressing the GST fusion and the target proteins were 
mixed separately in 1.5 ml reaction tubes with 50 pi of glutathione agarose bead slurry 
and mixed end-over-end for 1 hr at 4°C. The reaction tubes were centrifuged at 13,000 
r.p.m. for 30 sec (Microfuge.). The supernatants containing the target proteins were 
retained and the beads were discarded; this procedure ‘pre-cleared’ the extract of any 
insoluble or aggregated target proteins that could give artefactual positive results. The 
beads from the tube with the bacterial extract expressing GST-tagged proteins were 
retained and the supernatant was discarded. These beads were then washed 3 times with 
PBS-0.1% NP40, each time recovering the beads by centrifugation in a microfuge 
(13,000 r.p.m. for 30 sec). The GST beads were then mixed with the clarified soluble 
extract of the target proteins in a fresh 1.5 ml reaction tube. The reaction tube was 
mixed end-over-end at 4°C for 1 hr. The beads were recovered by centrifugation at
13.000 r.p.m. for 30 sec (Microfuge) and the supernatant was discarded. The beads were 
washed 3 times in 750 pi of buffer A (50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 5% 
Glycerol, 0.05% NP40). Each wash step was followed by centrifugation for 30 sec at
13.000 r.p.m. (Microfuge), with the beads being retained and the supernatant discarded. 
The proteins were eluted from the glutathione beads by the addition of 20 pi of buffer B 
(250 mM Tris pH 7.5, 0.1% NaCl, 0.1% NP40, 50 mM reduced glutathione) and then 
incubated at RT for 15 min. The beads were recovered as previously mentioned and the 
eluate was retained. The elution step was repeated. Finally, 3x SDS-PAGE loading 
buffer was added to the eluates and the samples were either stored at -20°C or resolved 
by SDS-PAGE analysis. The presence of a particular protein was detected by Western 
blot analysis.
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2.10 Purification of Recombinant Proteins.
2.10A Production of soluble extracts from E.coli BL21 expressing recombinant 
proteins.
Plasmids of the pGEX or pET24a series were transfected into BL21 (DE3) pLysS 
bacteria (see 2.5B) and the resultant colonies were grown overnight on agar plates 
supplemented with the appropriate antibiotics. From 5 to 10 fresh colonies were picked 
and inoculated into 100 ml of YTB, supplemented with the appropriate antibiotics and 
grown at 37°C, to mid-log phase. IPTG was added to a final concentration of 0.1 mM 
and incubation was continued for 4 hrs at 28°C. Bacteria were harvested in a bench top 
centrifuge at 5,000 r.p.m. for 10 min. The bacterial pellets were resuspended in EP0 265 
buffer and lysed using a Branson sonifier 450 soni-probe, giving a number of 20 second 
bursts set at the 50% duty cycle and an output of 5, and monitoring to avoid frothing of 
the sample. When the mixture showed clear signs of clarification, debris was removed 
by centrifugation for 20 min at 8,000 r.p.m. in a Beckman GPR centrifuge, and the 
soluble extracts were stored at -20°C.
2.10B Purification o f GST-tagged proteins from bacteria.
Bacterial lysates containing the GST-fusion proteins (see section 2.10A) were purified 
by mixing 300 pi of soluble protein extracts with 100 pi of pre-swollen glutathione 
agarose beads (50% [v/v] with PBS) in a 1.5 ml reaction tube, with regular mixing over 
a period of 30 min on ice. The mixture was then centrifuged in a microfuge at 13,000 
r.p.m. for 30 sec, the supernatant was then discarded and the beads were then washed 3 
times in 150 pi of EP0 265 buffer. Each wash step was followed by centrifugation at
13,000 r.p.m. for 30 sec to collect the beads. A 100 pi volume of EP0 265 buffer 
supplemented with 50 mM glutathione was used to elute the protein from the beads. The 
elution was carried out on ice, accompanied by intermittent resuspension, for 20 min. 
The eluate was clarified by microfuge centrifugation at 13,000 r.p.m. for 30 sec and 
then dialysed immediately in a dialysis tube (Pierce) against 50 mM Tris-HCl pH 7.5, 
50 mM NaCl, 2.5 mM p-mercaptoethanol for 2 hr and stored at -70°C.
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j  2.11 Analysis of Proteins.
2.11 A SDSpolyacrylamide gel electrophoresis.
i
Proteins were resolved by electrophoresis through SDS polyacrylamide mini gels 
(Laemmli, 1970) using the Bio-Rad miniprotein gel apparatus. The resolving gels were 
usually made at an acrylamide concentration of 10% (Table 2.11 A). The gel was set 
using a Bio-Rad Mini-Protean II gel former, the mix being poured between two glass 
plates and over laid with butanol. Once set the butanol was flushed away with water. 
The gel was then over laid with stacking gel (Table 2.11 A) and a gel comb inserted. 
Once the stacking gel had set the comb was removed and the wells were flushed with 
water. The gel cassette was placed in a Bio-Rad Mini Protean II gel apparatus and the 
gel tanks were filled with SDS-PAGE running buffer. Protein samples supplemented 
with 3x gel loading buffer were placed in a boiling bath for 2-5 min and loaded into the 
wells. The gels were subjected to electrophoresis at 150 V for approximately 75 min.
Solution 7.5% Resolving Gel Stacking Gel
30% Acrylamide 2.5 ml 0.4 ml
2.5% cross linker
RGB 2.5 ml NA
SGB NA 0.6 ml
(IH2O 5 ml 1.4 ml
Table 2.11A. Solutions used to make SDS-polyacrylamide gels. Amounts o f 30% acrylamide and water 
were adjusted accordingly for preparations of 6%, 10% or 12.5% resolving mixes. To each resolving mix 
80 pi 10% ammonium persulphate and 8 pi o f TEMED were added and 20pl 10% ammonium persulphate 
and 3 pi TEMED were added to stacking gel mixes, in order to catalyse setting o f the gel.
2.1 IB Coomassie brilliant blue staining o f SDS-PAGE gels.
Protein gels were stained with Coomassie Blue (0.2% Coomassie Brilliant Blue in 
50:50:7 ratio of methanol:water:acetic acid) for 5 min and destained in protein gel 
destain solution (5% methanol, 7% acetic acid in water).
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2.11C Transfer ofproteins from SDS-PAGE gels to nitrocellulose filters.
|
i
I
| Resolved proteins in SDS gels were detected by immunoblotting (Western blotting).
i
After electrophoresis, the gel was placed on a piece of nitrocellulose membrane, and 
j  both were sandwiched between pieces of Whatman 3mm filter paper; which in turn
! were sandwiched between two sponges (Bio-Rad). The whole procedure was carried out
with the items submerged in transfer buffer and care was taken to eliminate any air 
bubbles in the sandwich. A Bio-Rad Mini Protean II transblot cell was used to transfer 
; the proteins to a nitrocellulose filter (Hybond) by electrophoresis at 250 mA for a
minimum of 2 hrs (Towbin et a l , 1979).
!
2.1 ID Immunodetection o f proteins.
I
| Following the transfer of proteins to the nitrocellulose membrane, the membranes were
i
I placed in PBS-T containing 5% dried milk (Marvel) and incubated at RT for 1 hr or
overnight at 4°C. The filter was then incubated in 10 - 20 ml PBS-T / 5% dried milk 
containing the primary antibody (made up to the appropriate dilution) at RT for 3 hr or 
overnight at 4°C, with constant mixing. The blot was then washed five times in PBS-T 
for 15 min at RT per wash. Then secondary antibody in PBS-T / 2% dried milk was 
added to the filter and incubated at RT for 1 hr, again with constant shaking. The 
secondary antibodies were used at the following concentration: anti-mouse IgG whole 
molecule peroxides conjugates were used at 1/1,000 dilution and the rabbit anti-goat 
peroxidase were used at 1/80,000. Following incubation the blots were washed again as 
previously described. The bound antibodies were detected using the NEN enhanced 
chemiluminescence (ECL) system. Usually 1 ml of each of the two reagents provided in 
the kit were mixed, placed on the nitrocellulose filter and vigorously mixed. The filters 
were mounted on glass plates, covered with sheets of cling film and exposed to Kodak 
X-OMAT-S film for variable lengths of time.
2.1 IE Detection o f  radiolabelled proteins
Proteins were resolved by SDS-PAGE analysis and then the gels were vacuum dried. 
The dried gel was then exposed to Kodak X-OMAT S film.
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2.1 IF  Stripping and reprobing nitrocellulose membranes.
In order to reprobe membranes with a second antibody it was first necessary to strip the 
membranes of any previous antibodies. The filter membrane was submerged in stripping 
buffer (100 mM P-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl (pH 6.7) and 
incubated at 55°C for 1 hr with intermittent agitation. The membrane was washed 
thoroughly in PBS-T and then blocked and reprobed as previously described.
Chapter 3 -  Part I - Biochemical characterisation 
of the RING finger domains of the ICPO family of 
proteins.
3.0.0 General Introduction.
The aim of this series of experiments was to characterise the in vitro biochemical 
activity of the RING finger domains of the ICPO related proteins. The RING finger 
domain is a cysteine/histidine-rich zinc binding motif that is present in a wide variety of 
proteins expressed by many different organisms, and which frequently has been 
associated with E3 ubiquitin ligase activity (Freemont, 1993; Joazeiro & Weissman, 
2000; Pickart, 2001a). In the case of ICPO and the members of the ICPO family, the 
RING finger motif is situated towards the N-termini of the proteins (Barlow et al.,
1994). Its location is conserved throughout the family of ICPO related proteins, 
including in members not used in these studies. The presence of the RING finger is the 
main characteristic that links the ICPO family of proteins, since there is limited sequence 
homology elsewhere between the different members of the protein family. Even within 
the RING finger itself there is considerable diversity amongst the family members, with 
only the zinc-coordinating cysteine and histidine, and a limited number of others 
residues being conserved (Miyoshi et al., 2000; Parkinson & Everett, 2000, 2001). The 
RING finger domains of the ICPO related proteins were initially selected for 
investigation (rather than their full-length counterparts); previous research carried out on 
ICPO has shown this region is largely responsible for its multifunctional activities. 
Mutational studies of ICPO RING finger domain have shown that it is essential for the 
activation of HSV-1 gene expression (Cai & Schaffer, 1989; Chen et al., 1991; Everett, 
1987, 1988a), the initiation of the lytic cycle (Everett, 1989) and for the E3 ubiquitin 
ligase activity of ICPO (Boutell et al., 2002). A comprehensive review of the properties 
of the RING finger domain of ICPO can be found in part II of the Introduction.
The small size of the RING finger domains of the ICPO related proteins (the largest 
being approximately 90 a.a.) allows their expression in bacteria. Use of a bacterial 
system such as E.coli BL21 has many advantages over other protein expression systems,
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such as rapid growth of the bacteria to a high density with potentially large 
accumulations of the recombinant gene product. Furthermore, there was already an 
established method for the expression and purification of the ICPO RING finger domain 
in E.coli BL21 (Boutell et al., 2002).
Initially, the RING finger domain coding regions were separately cloned into the vector 
pGEX-2TNMCR (Everett et al., 1997; Meredith et al., 1994), enabling a GST tag to 
become fused to the N-terminus of the expressed recombinant protein. The pGEX- 
2TNMCR series of vectors containing the ICPO related RING finger domains were 
expressed in E.coli BL21, from which lysates were made. The GST-fusion proteins 
were then affinity-purified by adsorption to glutathione agarose beads (Smith & 
Johnson, 1988), washed, eluted and used in in vitro biochemical assays.
The following chapter is divided into the following sections, the first of which (Part I) 
details the methodology used to create the GST fusion proteins containing the ICPO 
related RING finger domains used to determine their E3 ligase activities. Part II assesses 
the E3 ligase activity of truncated versions of the BICPO and Eg63 RING finger 
domains. Part III analyses the auto-ubiquitination carried out by the ICPO related 
proteins in vitro. Part IV determines if the ICPO related RING finger domains form 
stable interactions with the E2-conjugating enzymes that they stimulate.
3.0.1 Construction o f the ICPO related RING finger domain expression plasmids.
The vector pGEX-2TNMCR (Everett et al., 1997; Meredith et al., 1994) (see figure
3.0.1 A) was used to introduce an N-terminal GST tag to the isolated ICPO related 
protein RING finger domains (see figure 3.0.IB). Initially the DNA fragments encoding 
the domains were isolated from the pFastBac HTa series of plasmids, which were 
originally used to express the full-length ICPO related proteins (see chapter 4). The 
restriction sites used to excise the 3’ end of the DNA fragments encoding the ICPO 
related RING domains were chosen because they were approximately 100 - 200 bp after 
the last cysteine residues of the RING finger domains. The amino acid sequence within 
each of the ICPO related protein RING finger domains is shown in section 3.0. IB and an 
overview of the cloning procedure is given below and in figure 3.0.1C.
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Figure 3.0.1A Schematic overview o f the salient features o f  
the expression vector pGEX-2TNMCR.
MCS= multiple cloning sites; Ampr= ampicillin resistance 
gene; pBR322 ori = plasmid origin of replication; Ptac = 
promoter; Lac lq = repressor gene. (Adapted from the 
pGEX-2TNMCR plasmid map, Amersham.).
BHV-1, BICPO RING finger domain and flanking sequence (109 a.a.).
Ncol *
MAPPAAAPELGSCCICLDAITGAARALPCLHAFCLACIRRWLEGRPTCPL 50
CKAPVQSLIHSVASDECFEEIPVGGGPGADGALEPDAAVIWGEDYDAGPI 100 
Aval 
DLTAADGEAS
EHV-1, Eg63 RING finger domain and flanking sequence (105 a. a.).
Ncol * *
MATVAERCPICLEDPSNYSMALPCLHAFCYVCITRWIRQNPTCPLCKVPV 50
ESWHTIESDSEFKETKVSVDFDYDSEEDEDSFEGQFLAVDSGDAPANIS 100
Ncol
AWNGPM
PRV, EPO RING finger domain and flanking sequence (265 a.a.).
Ncol A
MGCTVSRRRTTTAEASSAWGIFGFYRPRSPSPPPQRLSLPLTVMDCPICL 50
DVAATEAQTLPCMHKFCLDCIQRWTLTSTACPLCNARVTSILHHVDSDAS 100
FVETPVEGATDVDGEEDEPVGGGFAVIWGEDYTEEVRHEEAEGQGSGSGS 150
RARPRVPVFNWLYGQVSTVIESDPIREAWDNIVE11QEHGMNRQRVTEA 200
MLPMFGANTHALVDTLFDISAQWMRRMQRRAPMSHQGVNYIDTSESEAHS 250 
Xhol
D SEVS SPDEEDSGAS S
VZV, Vg61 RING finger domain and flanking sequence (229 a.a.).
Ncol *
MDTILAGGSGTSDASDNTCTICMSTVSDLGKTMPCLHDFCFVCIRAWTST 50
SVQCPLCRCPVQSILHKIVSDTSYKEYEVHPSDDDGFSEPSFEDSIDILP 100
GDVIDLLPPSPGPSRESIQQPTSRSSREPIQSPNPGPLQSSAREPTAESP 150
SDSQQDSIQPPTRDSSPGVTKTCSTASFLRKVFFKDQPAVRSATPWYGS 200
Ncol
IESAQQPRTGGQDYRDRPVSVGINQDPRTM
Figure 3.0.1 B. The amino acid sequence of the RING finger domains of the ICP0- 
related proteins.
The amino acid sequence of the RING finger domains and flanking sequences of the 
ICPO related proteins are shown. The positions of the 5’ and 3’ restriction enzyme sites 
used to excise the regions from the parental plasmids are shown on the amino acid 
sequences. The parental vectors were the pFastBac HTa series of plasmids used to 
express the full length versions of the ICPO related proteins (see chapter 4). The RING 
finger domains of the ICPO related proteins are indicated in red, with the first and last 
cysteine denoted (*). Flanking sequences that are not part of the RING finger domains 
are denoted in black.
A)
BICPO 1 -  109 a.a.
A/col Aval
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 328 b p ----------------
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Xhol
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Figure 3.0.1C Schematic representation of the construction of the pGEX plasmids expressing the 
RING finger domains of the ICPO-related proteins
A) The 328 bp DNA fragment of the RING finger domain of BHV-1 BICPO was removed by Ncol 
and Aval restriction digestion of the parental vector pFastBac HTa BICPO. The 3 ’ end of the DNA 
fragment excised by Aval restriction digestion was filled in by blunt ending reaction (see materials 
and methods for further details). B) The 315 bp DNA fragment encoding the RING finger domain of 
EHV-1 Eg63 was removed by an Ncol restriction digestion of the parental vector pFastBac HTa 
Eg63. C ) The 795 bp DNA fragment encoding the RING finger domain of PRV EPO was removed by 
separate Xhol and Ncol restriction digestion of the parental vector pFastBac HTa EPO. The 3 ’ end of 
the DNA fragment excised by Xhol restriction digestion was filled in by blunt ending reaction. D) 
The 687 bp DNA fragment encoding the RING finger domain of VZV Vg61 was removed by an Ncol 
restriction of the parental vector pFastBac HTa Vg61. To accommodate the DNA fragments A-D 
pGEX-2TNMCR was digested as follows: DNA Fragments B and D, with the restriction enzyme 
Ncol; DNA fragments A and C, with the restriction enzymes Ncol and Smal.
The vector pFastBac HTa BICPO was digested with Aval at the 3’ end of the DNA 
fragment encoding the RING finger domain and then blunt-ended (see section 2.2B). 
After ethanol precipitation to remove the reagents used in the blunt-ending reaction, 
Ncol was used to cut at the 5’ end of the DNA fragment encoding the BICPO RING 
finger domain, which was then isolated using gel electrophoresis and purified 
accordingly (see methods section).
The vector pFastBac HTa EPO was digested with Xhol at the 3’ end of the DNA 
fragment encoding the RING finger domain and then blunt-ended and purified. Ncol 
was then used to cut at the 5’ end of the DNA fragment encoding the EPO RING finger 
domain, which was then isolated and purified using gel electrophoresis.
Plasmid pFastBac HTa Eg63 was digested with Ncol, which cuts at the 5’ and 3’ ends of 
the DNA fragment encoding the Eg63 RING finger domain. The DNA fragment was 
then isolated and purified using gel electrophoresis.
The DNA fragment encoding Vg61 was isolated from pFastBac HTa Vg61. The method 
was the same as that used to isolate the DNA fragment encoding the Eg63 RING finger 
domain.
The recipient vector pGEX-2TNMCR was digested with Ncol, allowing insertion of the 
isolated DNA fragments encoding the RING finger domains of Vg61 or Eg63. For 
insertion of the DNA fragments encoding the BICPO and EPO RING finger domains, 
pGEX-2TNMCR was cut with Ncol and Smal. The DNA fragments encoding the ICPO 
related protein RING finger domains and the appropriately digested vector were then 
ligated and transformed into E.coli DH5a. The resulting colonies were screened by 
diagnostic restriction enzyme digestions of small-scale plasmid preparations. The 
identities of plasmids harbouring the desired restriction fragments were further 
confirmed by expression analysis and DNA sequencing. Expression analysis simply 
involved transfecting the pGEX vectors encoding the RING domains into E.coli BL21 
and examining the subsequent lysates by SDS-PAGE and Coomassie staining. This 
method was important for the clones containing the coding sequences of Vg61 or Eg63 
RING finger domains, as the Ncol restriction fragments could have been inserted into 
the recipient vector in either orientation. Only isolates positive for the correct
128
recombinant protein expression were further analysed by DNA sequencing. The 
individual pGEX series of plasmids expressing the ICPO related RING finger domains 
will henceforth be referred to as pGEX-BICPO, pGEX-Eg63, pGEX-EPO and pGEX- 
Vg61 and the expressed proteins collectively will be referred to as the GST-ICPO related 
proteins or individually as GST-BICPO, GST-Eg63, GST-EPO and GST-Vg61.
3.0.2 Expression and purification o f the GST-ICPO related proteins.
The pGEX series of plasmids encoding the GST-ICPO related proteins were transformed 
into E.coli BL21. Several (5 to 10) bacterial colonies were pooled and cultured in YTB 
(supplemented with ampicillin) until mid-log phase, whereupon IPTG was added to 
induce expression of the recombinant protein. Incubation was continued for a further 3- 
5 hours at 28°C. The bacteria were then pelleted and resuspended in lysis buffer and 
sonicated (see section 2.10 for further details). After initial trials, the lysis buffer EPO 
265 (100 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 0.1% NP40, 20 mM 0- 
mercaptoethanol) was found to maximise the solubility of the GST-ICPO related 
proteins. An example of a typical protein purification profile is shown in figure 3.0.2A 
(see section 2.10B for further details on the protein purification and dialysis methods). 
Figure 3.0.2B shows samples of the purified GST-ICPO related proteins that have been 
resolved by SDS-PAGE analysis. From this data it is possible to identify several 
breakdown or misread proteins in each of the samples. Furthermore, RING finger 
domain proteins frequently display aberrant gel mobilities, so from the data it is not 
possible to be certain which of the bands represents the primary translation product. 
Despite these factors, in most of the resolved purified protein samples there is a 
dominant band that has a mobility close to that of the predicted size of the intact protein 
(marked on the relevant figures).
3.0.3. Quantification o f the purified GST-ICPO related proteins.
To ensure that equal amounts of the purified GST-fusion proteins were used in repeated 
biochemical assays, densitometric analysis was used to determine the concentrations of 
each preparation. Samples of the proteins to be quantified and aliquots of BSA standards 
of known concentrations were resolved by SDS-PAGE. The gel was stained with
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F ig u re  3 .0 .2A. Purification profile o f  the BICPO RING finger  
domain.
Samples of GST-BICPO from a typical expression and purification 
experiment were resolved by SDS-PAGE and visualised by 
Coomassie staining. The arrow marks the BICPO protein band that 
corresponds with its predicted size. The abbreviations of each extract 
and the quantities resolved by SDS-PAGE are as follows: SE = 
soluble extract (5 pi); BB = bound beads (10 pi); El = elution 1 (20 
pi); E2 = elution 2 (20 pi); RB = remaining beads (10 pi).
SE BB E1 E2 RB
A)
1 2 3 4 5 6 7  8 9 10
B) Lane
Num ber
Nam e
Adjusted
Volum e
(Intensity x m m 2).
Am ount.
l BSA std. 0.1 (ig 26.22 0.1 ^g
2 BSA std. 0.3 (ig 52.41 0.3 ng
3 BSA std. 0.5 ng 124.22 0.5 ng
4 BSA std. 0.7 (ig 199.49 0.7 ng
5 BSA std. 0.9 ng 261.88 0.9 |ig
6 BSA std. 1.1 |ig 305.15 11 Pg
7 BSA std. 1.3 |*g 351.99 13  pg
8 Eg63 27.98 0.15 ng
9 BICPO 97.74 0.39 ng
10 EPO 196.65 0.72 |ig
Background 0 N/A
C)
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Figure 3.0.3A. Quantification o f the purified ICPO GST-RING finger 
domains.
A) 5 pi of purified GST-BICPO, GST-Eg63 and GST-EPO (lanes 8-10) 
were resolved by SDS-PAGE, in conjunction with BSA standards 
(lanes 1-7), that ranged in concentration from 0.1 pg to 1.3 pg. The 
resolved proteins were visualised by Coomassie staining and then 
thoroughly destained. The gel image was captured under white light 
using The Imager (Applegene). The amounts of the RING finger 
domains was determined from the captured gel image using ‘BioRad 
Quality One software v4.22\ The amount of proteins were determined 
by initially highlighting the amounts standards, lanes 1-7 (shown in 
red), then selecting the background (shown in black), finally selection 
of the unknown samples i.e. the GST-ICPO related proteins (lanes 8- 
10).
B) The volumes of the selected samples, relative to background (lanes 1- 
10) were automatically calculated, using the BioRad Quality One 
Software. Volume is the total intensity data inside a defined boundary 
(i.e. the selected area). It is calculated as follows: Volume = [The 
intensities of the pixels inside the volume boundary] x [the area of a 
single pixel]. From the volume the adjusted volume is calculated as 
follows: Adjusted Volume = [volume of the background] -  [volume of 
the sample or standard]. The adjusted volumes of the BSA standard 
and RING finger protein domains are shown in the table.
C) The adjusted volumes of the BSA standards were plotted against their 
relative amounts, with a corresponding line of best fit. The adjusted 
volumes of the RING finger domains are plotted against the line of 
best fit to determine their amounts relative to the BSA standards. The 
amounts of the ICPO related proteins in the 5 pi sample volume are 
shown in the table.
Coomassie blue, destained, and then a digital image was captured, which was then 
subjected to volume analysis using the BioRad Quantity One Software (Version 4.22). 
An example of this process is shown in figures 3.0.3A and B. The concentrations of the 
GST-fusion proteins were determined every time a new stock of protein was purified 
from bacterial lysates. When the activity of more than one of the GST-ICPO related 
proteins was to be compared, the proteins were quantified on the same SDS-PAGE gel. 
This was important as the quantification method employed would only give an 
indication of concentration relative to that of the BSA standards and furthermore 
concentration of protein samples varied slightly when re-analysed, due to experimental 
variables.
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3.1.0. Introduction to the E3 ubiquitin ligase and thiolester assays.
The ability to disrupt ND10 correlates very well with the biological activities of ICPO. It 
is thought they are targeted to release factors essential for the continued progression of 
HSV-1 infection (Negorev & Maul, 2001). However, it also been proposed that ND10 
structures play an essential role as part of a cellular repression mechanism, which 
prevents or stalls the progression of viral infection. This is supported by the fact that 
components of ND10 are interferon induced and have been implicated in the repression 
of gene expression (this is discussed in further detail in the Introduction). Additionally, 
various studies have linked ICPO with resistance to the effects of interferon (Eidson et 
al., 2002; Harle et al., 2002; Mossman et a l, 2000; Mossman & Smiley, 2002; Nicholl 
et a l, 2000; Preston et a l, 2001; Taylor et a l, 1998). Therefore, the absence of ICPO 
from the viral genome can have various deleterious affect on the progression of viral 
infection. It was recently shown that infection of HFL cells with an ICPO-null virus at 
low MOI can lead to multiple fates, including stalling of viral gene expression and the 
host cell undergoing apoptosis (Everett et a l, 2004).
ICPO has been shown to disrupt ND10 in a proteasome-dependent manner, as in the 
presence of the proteasome inhibitor MG132, it is unable to stimulate HSV-1 lytic 
infection or reactivation from quiescence. (Everett et a l, 1998c). Consistent with these 
observations it was later shown that ICPO can cause the formation of colocalising, 
conjugated ubiquitin in both transfected and infected cells, at ND10 and at centromeres 
(Everett, 2000). Furthermore, in a RING finger dependent manner ICPO can act as an 
potent E3 ligase in vitro, inducing the formation of polyubiquitin chains in the presence 
of UbcH5a and UbcH6, (Boutell et a l, 2002) and targeting p53 for ubiquitination 
(Boutell & Everett, 2003a). It was also shown that E2 enzyme UbcH5a plays a role in 
inducing the degradation of ND10 components during HSV-1 infection (Gu & Roizman, 
2003).
The ICPO related proteins have also been implicated as E3 ubiquitin ligases, as they 
have been shown to colocalise with conjugated ubiquitin and disrupt components of 
ND10 structures to varying degrees (Parkinson & Everett, 2000, 2001). However, the 
ICPO related proteins, unlike ICPO, do not affect the conjugation of SUMO-1 to PML in
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co-transfection assays (Parkinson and Everett, 2002). The differences in the biological 
properties of the ICPO related proteins to that of ICPO might be a reflection of the 
divergence of sequence within or outside of their conserved RING finger domains. 
Furthermore, the variation in sequence may have an implication on the specific E3 
ubiquitin ligase activities of the ICPO related proteins.
The GST-ICPO related proteins (described in section 3.0.2) were used in assays with a 
panel of E2 ubiquitin conjugating enzymes to identify and characterise their potential E3 
ubiquitin ligase activities. The panel of E2 enzymes included UbcH5a and UbcH6, 
which ICPO has been shown to stimulate and cause the formation of polyubiquitin 
chains in vitro (Boutell et al., 2002). Studies have also suggested there could be a third 
E2 partner of ICPO, namely cdc34, since this E2 was reported to become 
autoubiquitinated in the presence of a GST-fusion protein containing ICPO residues 543 
to 768, thus proposing a second ubiquitin E3 ligase site on ICPO (Hagglund et al., 2002; 
Van Sant et al., 2001a). Even though the residues reported to be associated with cdc34 
stimulation are located towards the C-terminus of ICPO, and appear not to be highly 
conserved or are absent from the other members of the ICPO family, cdc34 was included 
in the panel of E2 enzymes used in these studies for completeness. The initial E3 
ubiquitin ligase experiments involved screening the activities of the GST-ICPO related 
proteins against a panel of E2 enzymes that included UbcH5a, UbcH6 and cdc34, to 
determine which of these enzymes could be stimulated to form polyubiquitin chains in 
vitro.
Before assessing the E3 ubiquitin ligase activities of the ICPO related proteins, a 
thiolester assay was carried out to determine if the preparations of the E2 enzymes were 
functional. A thiolester assay is similar to the E3 ubiquitin ligase assay, except no E3 
ligase is present (see figure 3.1.0A). Initially, an ubiquitin molecule becomes activated 
by the El ubiquitin activating enzyme, which involves the formation of a thiolester 
linkage between the ubiquitin and the active site cysteine of the E l, in an ATP- 
dependent reaction. Next, in a transesterification reaction the E2 enzyme forms a 
thiolester bond between the sulphydryl group at its active site cysteine and the carboxyl 
group of the C-terminal glycine residue of the El-linked ubiquitin molecule, thus 
transferring the ubiquitin from the El to the E2. If this was an ubiquitin ligase assay and 
an E3 ubiquitin ligase was present, the E3 would then facilitate the transfer of the
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ubiquitin from the active site of the E2 to a lysine residue in the substrate protein via an 
isopeptide bond between the C-terminal carboxyl group of the ubiquitin to the amino 
group at the end of the lysine side chain. If the substrate had already been ubiquitinated, 
further ubiquitin moieties can be added to a lysine side chain on the ubiquitin molecule 
at the end of the growing polyubiquitin chain.
Unlike isopeptide bonds, thiolester linked conjugates are not stable in the presence of 
reducing agents such as p-mercaptoethanol or DTT. Therefore, following the thiolester 
assay to determine if the preparations of the E2 enzymes were functional and to preserve 
the thiolester bond, the samples were resuspended in SDS-PAGE loading buffer that did 
not contain reducing agents.
3.1.1. Thiolester assay to determine the activity o f  E2 enzyme preparations.
A thiolester assay was used to determine if preparations of purified E2 ubiquitin 
conjugating enzymes UbcH5a, UbcH6, UbcH7, UbcHIO and cdc34 were active (see 
figure 3.1.1 A) The assay was carried out according to section 2.9A. The El and E2 
components of the thiolester assay were made in-house and according to methods stated 
previously (Boutell et al., 2002) and purified ubiquitin was supplied by Sigma. Figure 
3.1.1 A shows that the E2 enzymes UbcH5a, UbcH6, UbcH7, UbcHIO and cdc34 were 
all functional, as in a non-reducing environment (-DTT) they formed a thiolester with 
ubiquitin. The mono-ubiquitinated form of each of the E2 enzymes is indicated by the 
presence of a second band of lower electrophoretic mobility in each lane. This band is 
not present in the equivalent lanes containing products from the same reactions that had 
subsequently been incubated with DTT. The results indicated the preparations of the E2 
enzymes were functional and they could be used in ubiquitin E3 ligase assays with 
GST-ICPO related proteins.
3.1.2. Optimisation o f the E3 ubiquitin ligase assay.
The protocols used to purify the GST-ICPO related proteins, and the ubiquitin E3 ligase 
assay conditions, were based on those optimised for ICPO (Boutell et a l , 2002). 
Therefore, to ensure the conditions were optimal and the ICPO related proteins were 
active, an initial ubiquitin E3 ligase assay was carried out.
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Figure 3.1.1 A In vitro thiolester assay to determine E2 
functionality.
In vitro thiolester assay was carried out using the following 
assay components: 500 nM E l, 5 pg of ubiquitin and 3-5pg 
of each E2, (UbcH5a, UbcH6 UbcH7 UbcHIO and cdc 34). 
The assay was carried out in duplicate and incubated at 
28°C for 15 min. One set o f reactions was stopped by the 
addition of boiling mix containing DTT and the second set 
with boiling mix not containing DTT. The reactions were 
resolved by SDS PAGE analysis on a 5-12% BIS-Tris gel 
(Invitrogen), according to manufacturer’s instructions and 
visualised by Coomassie staining. Below each lane, it is 
denoted which E2 was resolved.
Ub= Excess Ubiquitin.
MW
El
U bcH 5a
241
BICPO
Eg63
EPO
U b
F ig u re  3.1.2 A. Optimisation of the E3 ligase assay.
In vitro ubiquitin E3 ligase assay was carried out as described in section 2.9B. The 
components of each reaction are denoted in the table. The E3 ligase reactions were resolved 
by SDS-PAGE analysis and visualised by Western blotting. In lanes 2-6 each of the 
purified RING finger domains were assessed for potential E3 ligase assay in the presence of 
UbcH5a. MW = Molecular weight markers. 1 = Control (No E2 present). Blot A, was 
probed using anti-ubiquitin antibody P4D1 (1/1000) and blot B with FK2 (1/1000), both 
antibodies were detected by secondary hrp-conjugated anti-mouse antibody (1/1000).
The basic ubiquitin E3 ligase assay method and conditions are outlined in section 2.9B, 
using the GST-ICPO related proteins and the E2 enzyme UbcH5a (see figure 3.1.2A). 
All of the GST-ICPO related proteins stimulated UbcH5a to form high molecular weight 
polyubiquitin chains (Figure 3.1.3A panel A lanes 3 -  6). Furthermore, the activities of 
the GST-ICPO related proteins were similar to that of GST-241 of ICPO (lane 2). 
However, there are differences in the amount and molecular weight of the polyubiquitin 
formed; this will be discussed in more detail later in this chapter. The results indicated 
that all of the ICPO related RING finger fusion proteins were successfully purified and 
active in the ubiquitin E3 ligase assay, using conditions optimised previously for ICPO 
(Boutell et al., 2002).
The Western blot in figure 3.1.2A was stripped of the anti-ubiquitin (P4D1) monoclonal 
antibody and reprobed with FK2 monoclonal antibody, to determine if there was any 
difference in the results obtained. Both antibodies identify ubiquitin, however FK2 
targets the isopeptide bond that links the ubiquitin proteins and P4D1 targets the 
ubiquitin protein itself. From comparing panels A and B, it can be seen that there were 
no significant differences in the results obtained using either antibody. This was an 
important prerequisite for further experiments as the antibodies were used 
interchangeably to determine if polyubiquitin formation had occurred.
3.1.3. E2 library screen to characterise the E3 ligase activities o f the GST-ICPO 
related proteins.
It was shown in section 3.1.2. that the GST-ICPO related proteins function as ubiquitin 
E3 ligase enzymes and stimulate UbcH5a to form polyubiquitin chains in vitro. 
However, it is possible that the GST-ICPO related proteins also have other E2 partners. 
Using the same assay conditions as in section 3.1.2, the GST-fusion proteins were 
screened against a panel of E2 ubiquitin conjugating enzymes. To ensure consistency in 
the assay conditions, components that were used in all reactions were made into a 
‘master mix’, which was then aliquoted into the required number of reaction tubes and 
the individual E2 enzymes were added. The tubes were incubated at 37°C for 1 hour and 
the reactions were stopped by adding 3-times concentrated SDS-PAGE loading buffer. 
Further experimental details can be found in section 2.9B.
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Figure 3.1.3 A. E3 ligase assays to determine the E2 specificity o f the RING finger domains ofGST- 
BICPO (A) and GST-Eg63 (B).
In vitro ubiquitin ligase assay was carried out as described in section 2.9B. A panel o f E2 enzymes were 
screened for activity in the presence of the RING finger domains of GST-BICPO and GST-Eg63. The 
RING finger domains o f GST-BICPO and GST-Eg63 were assessed for potential E3 ligase in the 
presence of varying E2 enzymes. The components of each reaction (including the E2 used) are denoted 
in the table. The E3 ligase reactions were resolved by SDS-PAGE analysis and visualised by Western 
blotting. Blot A & B, Lane 1 = Control (No E2 present); Blot A, Lane 2-6 = The RING finger domain of 
BICPO only stimulated UbcH5a and UbcH6 to cause polyubiquitin formation; Blot B, Lane 2-6 = The 
RING finger domain of GST-Eg63 only stimulate UbcH5a and UbcH6 to cause polyubiquitin formation. 
Blot A & B were probed using anti-ubiquitin antibody P4D1 (1/1000) followed by secondary hrp- 
conjugated anti-mouse antibody (1/1000).
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Figure 3.1.3B. E3 ligase assays to determine the E2 specificity o f the RING finger domains of 
GST-EPO (A) and GST-Vg61 (B).
In vitro ubiquitin ligase assay was carried out as described in section 2.9B. A panel o f E2 
enzymes were screened for activity in the presence o f the RING finger domains of GST-EPO and 
GST-Vg61. The RING finger domains of BICPO and GST-Eg63 were assessed for potential E3 
ligase in the presence of varying E2s. The components of each reaction (including the E2 used) are 
denoted in the table. The E3 ligase reactions were resolved by SDS-PAGE analysis and visualised 
by Western blotting. Blot A & B, Lane 1 = Control (No E2 present); Blot A, Lane 2-6 = The RING 
finger domain of GST-EPO only stimulated UbcH5a and UbcH6 to cause polyubiquitin formation; 
Blot B, Lane 2-6 = The RING finger domain of GST-Vg61 only stimulated UbcEl5a and UbcH6 
to cause polyubiquitin formation. Blot A & B were probed using anti-ubiquitin antibody P4D1 
(1/1000) followed by secondary hrp-conjugated anti-mouse antibody (1/1000).
The results were as follows: Figure 3.1.3A, Panel A lane 1 indicates that El and GST- 
BICPO cannot form polyubiquitin chains alone. However, when E l, ubiquitin and GST- 
BICPO were incubated in the presence of UbcH5a (lane 2) and UbcH6 (lane 3), the E2 
enzymes were able to form variable length polyubiquitin chains, but the E2 enzymes 
I UbcH7, UbcHIO and cdc34 were not. Similarly, figure 3.1.3B shows that GST-Eg63
also has E3 ligase activity and could stimulate UbcH5a (lane 2) and UbcH6 (lane 3), but
[
not the other E2 enzymes. GST- EPO and GST-Vg61 also acted as ubiquitin E3 ligases 
in a similar manner, again stimulating only UbcH5a and UbcH6 (figure 3.1.3B, panels 
A and B).
| 3.1.4. Conclusions.
\
|
| The results from screening the GST-ICPO related proteins against a panel of E2 proteins
! indicate that they act as E3 ubiquitin ligases and their specificity is limited to UbcH5a
and UbcH6. Furthermore, the GST-ICPO related proteins do not contain a second E3 
ligase domain associated with cdc34 stimulation. Collectively, these results show the 
I GST-ICPO related proteins are E3 ligases and the intrinsic activity is similar to that
j previously shown for ICPO. The similar results of the ICPO related proteins to that of
ICPO are likely to be a consequence of the conserved sequence within their RING finger 
domains. Indeed, many families of cellular RING finger proteins show a similar pattern 
of E2 enzyme stimulation, so it is likely that some characteristic of RING finger 
domains in general determines their E2 specificity. A large degree of homology is also 
shared between the E2 enzymes of the UbcH5 family and UbcH6. The UbcH5 family 
members (UbcH5a, UbcH5b and UbcH5c) share over 90% sequence similarity to one 
| another, with UbcH5a sharing 75% homology to UbcH6 (Jensen et al., 1995; Nuber et
| a l, 1996). Therefore, it is probably the conserved sequence or structural similarity
I between UbcH5a and UbcH6 that enables the ICPO related proteins to stimulate both of
! the E2 enzymes. UbcH5a has also been implicated as the E2 partner of a growing
number of E3 ubiquitin ligases (Hakli et a l, 2004; Itoh et a l, 2003; Lorick et a l, 1999; 
Spencer et a l, 1999; Vandenberg et a l, 2003; Yang & Du, 2004; You & Pickart, 2001) 
as has UbcH6 (Anan et a l, 1998; Nuber et a l, 1996; Yang & Du, 2004), many of them 
members of the RING finger class.
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In contrast to the ICPO related proteins of the alphaherpesviruses that stimulate both 
UbcH5a and UbcH6, Human Papilloma Virus (HPV) E6 protein has been shown to 
utilize only members of the UbcH5 family for the ubiquitination of target substrate p53. 
However, unlike ICPO, HPV is not a RING finger protein and instead recruits the 
cellular E3 ligase HECT domain protein H6-AP to ubiquitinate p53 (Jensen et a l , 1995; 
Rolfe et a l, 1995; Scheffher et a l, 1994). In Drosophila, the Inhibitory Apoptosis 
Proteins (LAP), c-IAPl and C-IAP2, have been shown to act as ubiquitin E3 ligases and 
are able to stimulate both UbcH5a and UbcH6 to form polyubiquitin chains in vitro 
(Yang & Du, 2004). These results are remarkably similar to those in this chapter and 
those obtained previously with ICPO. The studies carried out in this chapter were 
sufficient to determine that the ICPO related proteins have the same E2 partners as ICPO 
in vitro, although it possible that other partners may exist. In the relatively small 
genome of S. cerevisiae, 13 genes exist that encode E2 enzymes (Hochstrasser, 1996), 
and more are likely to be found in higher eukaryotes. Therefore, as the number of 
defined E2 proteins increases, so may the number of potential E2 partners of ICPO and 
its related proteins.
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3.2.0. Characterisation of the ubiquitin £3 ligase activities of the ICPO related 
RING finger domains.
The following sections describe a series of experiments that characterise the in vitro 
biochemical activities of the RING finger domains of the selected members of the ICPO 
related proteins.
3.2.1. Rate o f polyubiquitin formation by GST-Eg63.
This ubiquitin E3 ligase assay was carried out to determine the rate of polyubiquitin 
formation by GST-Eg63 in the presence of the E2 enzymes UbcH5a (figure 3.2.1 A) and 
UbcH6 (figure 3.2. IB). Sixteen sets of reactions were set up (8 for UbcH5a and 8 for 
UbcH6) which were incubated (see materials and methods section for further details) 
and stopped at a series of time points. Figure 3.2.1 A lane 1 indicates that GST-Eg63 
stimulation of UbcH5a causes rapid polyubiquitin formation, within 1 minute of the 
initiation of the E3 ligase reaction. Polyubiquitin continued to accumulate during the 
first 60 minutes of the incubation (lane 1 to lane 7). In lane 7 (120 minutes), the amount 
of polyubiquitin detected was similar to that in lane 6 (60 minutes). This may be due to 
one of the components of the assay becoming inactive or the amount of free ubiquitin 
becoming limiting, or the maximum level of polyubiquitin that was possible to detect 
using Western blotting was reached. Lane 8 is the control reaction, where all assay 
components were present except UbcH5a. Figure 3.1.5B shows the rate of polyubiquitin 
formation in the presence of UbcH6 and GST-Eg63. Polyubiquitin chains were 
detectable at 15 minutes and continued to accumulate up to the final time point, 120 
minutes. Therefore the kinetics of the E3 ligase reactions with UbcH5a appear to more 
efficient than UbcH6.
3.2.2. Conclusions from the series o f  experiments to determine the rates o f  
polyubiquitin formation.
The results indicated there were differences in the kinetics of the reaction of GST-Eg63 
with UbcH5a and UbcH6. This may be down to some distinct difference in the intrinsic 
biological activity of GST-Eg63 with UbcH6, although it is more likely explained by the 
UbcH6 preparation being intrinsically less active than that of UbcH5a. When GST-Eg63
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Figure 3.2.1 A. Characterisation o f the E3 ligase activity of GST-Eg63 in the 
presence o f UbcH5a, over time.
In vitro ubiquination assay was carried out as described in section 2.9B. In lanes 
1-7 replicate E3 ligase reactions were carried out and terminated at different 
time points (see table) to assess the rate o f poly-ubiquitin formation o f GST- 
Eg63 in the presence o f UbcH5a. Lane 8 = control (no E2 present). The E3 
ligase reactions were resolved by SDS-PAGE analysis and visualised by 
Western blotting. Blot A was probed with the primary antibody a-U b (P4D1) at 
1/1000 followed by the secondary antibody hrp-conjugated anti-mouse at 
1/1000. Blot B was probed with anti-GST (1/1000), followed by the secondary 
antibody hrp-conjugated anti-rabbit (1/1000).
1 2 3 4 5 6 7 8
El + + + + + + + +
Eg63 + + + + + + + +
UbcH6 + + + + + H- + -
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Figure 3.2.IB. Characterisation o f the E3 ligase activity of GST-Eg63 in the 
presence oj'UbcH6, over time.
In lanes 1-7 replicate E3 ligase reactions were carried out and terminated at 
different time points (see table), to assess the rate of poly-ubiquitin formation of 
GST-Eg63 in the presence of UbcH6. Lane 8 = control (no E2 present). The 
ubiquitin ligase reaction was carried out according to conditions outlined in the 
previous figure.
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stimulates UbcH5a the rapid formation of polyubiquitin chains occurs, within the first 
minute of initiation of the E3 ligase reaction. As the reaction progresses the shorter
it.
polyubiquitin chains appear to accumulate, up to approximately the 60 minute. 
However, when the same assay was carried out in the presence of UbcH6, no 
polyubiquitin chains formation was detectable until 15 minutes. Thereafter, instead of 
polyubiquitin chain length being increased over time as in the case with UbcH5a, the 
chains appear to be uniform in length and increases in amount as the reaction 
progresses. This indicates an apparent difference in the biochemical activities of GST- 
Eg63/UbcH5a and GST-Eg63/UbcH6. It is likely that the variations observed are 
probably due to the biochemical differences between the E2 enzymes. Indeed, similar 
differences between the UbcH5a and UbcH6 reactions were observed with the other 
GST-ICPO related proteins.
3.2.3. Concentration dependence o f the polyubiquitination activity.
In the following series of experiments the ubiquitin E3 ligase activities of the GST-ICPO 
related proteins at different concentrations were compared. The GST-ICPO related 
proteins were quantified as described above, however a limitation that should be bome 
in mind is that some of the truncated species of the RING finger constructs that are 
present after purification (see figure 3.0.2A) may have enzymatic activity. Therefore the 
following data can provide only an approximation of the relative activities of the 
different RING fingers.
In figure 3.2.3A GST-Eg63 was titrated from 1.25 ng to 120 ng, while the other 
ubiquitin E3 ligase assay components were used at the amounts stated in materials and 
methods. The results indicate (Figure 3.2.3A, panel A) that 7.5 ng of GST-Eg63 was 
sufficient to stimulate polyubiquitin chain formation by UbcH5a. The results indicate 
that as the amount of GST-Eg63 increased the amount of polyubiquitin formation also 
increased.
In figure 3.2.3B, the E3 ubiquitin ligase assay was carried out using GST-BICPO, which 
was titrated from 7.5 ng to 120 ng, the other components were used at the 
concentrations stated in materials and methods. The results indicated (Figure 3.2.3B, 
panel A) that 30 ng of BICPO was required for detectable polyubiquitin chain formation 
in the presence of UbcH6. These results suggest the intrinsic activity of GST-BICPO is
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Figure 3.2.3A. Characterisation of the E3 ligase activity o f the titrated 
RING finger domain of GST-Eg63 in the presence o f UhcH5a.
The RING finger domain o f Eg63 was titrated, to assess its E3 ligase 
activity in the presence of UbcH5a. In lanes 2 to 9 the E3 ligase assay was 
carried out in the presence o f UbcH5a. Lanes 1 = Control (no UbcH5a was 
present). With the exception o f the E3 ligase concentration the reactions 
were carried out according to the method described in section 2.9B.
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Figure 3.2.3B. Characterisation of the E3 ligase activity o f the titrated 
RING finger domain o f BICPO in the presence o f UbcH6.
The RING finger domain of BICPO was titrated, to assess its E3 ligase 
activity in the presence of UbcH6. In lanes l to 5 the E3 ligase assay was 
carried out in the presence of UbcH5a. MW = Molecular weight markers. 
Lanes 6 = Control (no UbcH6 was present). The ubiquitin ligase reactions 
were carried out according to the method outlined in the previous figure.
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Figure 3.2.3C. Characterisation o f the E3 ligase activity of the titrated RING 
finger domain of BICPO in the presence ofUbcH5a.
The RING finger domain of BICPO was titrated, to assess its E3 ligase activity in 
the presence of UbcH5a. In lanes 2 to 6 the E3 ligase assay was carried out in the 
presence of UbcH5a. MW = Molecular weight markers. Lanes 1 -  Control (no 
UbcH5a was present). The ubiquitin E3 ligase reactions were carried out 
according to the method outlined in the previous figure.
30
21
B
220
97
1 2 3 4 5 M W 6
E l + + + + + +
UbcH6 + + + + + -
Ub + + + + + +
G ST-EPO  (ng) 7.5 15 30 60 120 60
Figure 3.2.3D. Characterisation o f the E3 ligase activity of the titrated 
RING finger domain of GST-EPO in the presence o f UbcH6.
The RING finger domain of GST-EPO was titrated, to assess its E3 ligase 
activity in the presence of UbcH6. In lanes 1 to 5 the E3 ligase assay was 
carried out in the presence of UbcH6. Lanes 6 = Control (no UbcH5a was 
present). MW = Molecular weight markers. The ubiquitin ligase reactions 
were carried out according to the method outlined in the previous figure.
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Figure 3.2.3E. Characterisation o f the E3 ligase activity of the titrated 
RING finger domain of GST-EPO in the presence of UbcH5a.
The RING finger domain of GST-EPO was titrated, to assess its E3 
ligase activity in the presence of UbcH5a. In lanes 1 to 5 the E3 
ligase assay was carried out in the presence of UbcH5a. Lanes 6 = 
Control (no UbcH6 was present). MW = Molecular weight 
markers. The ubiquitin ligase reactions were carried out 
according to the method outlined in the previous figure.
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Figure 3.2.3F. Characterisation o f the E3 ligase activity o f the titrated RING 
finger domain ofVg6I in the presence ofUbcH5a.
The RING finger domain of GST-Vg61 was titrated, to assess its E3 ligase 
activity in the presence of UbcH5a. In lanes 2 to 5 the E3 ligase assay was carried 
out in the presence of UbcH5a. Lanes 6 = Control (no UbcH5a was present). The 
ubiquitin ligase reactions were carried out according to the method outlined in the previous 
figure.
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fess than GST-Eg63; the possible reasons behind this will be discussed at the end of this 
action.
h figure 3.2.3C, GST-BICPO was titrated from 7.5 ng to 120 ng in the presence of 
UbcH5a. In this experiment, the polyubiquitin chains formed were of such high 
nolecular weight that they have remained in the upper portion of the gel. Consequently, 
i is only possible to conclude that 15 ng of GST-BICPO is sufficient to stimulate 
UbcH5a activity in the reaction conditions used.
h  figure 3.2.3D, GST-EPO was titrated from 7.5 ng to 120 ng and the remaining 
ibiquitin E3 ligase assay components were used at the concentrations stated in materials 
aid methods. The results indicated (Figure 3.1.6D, panel A) that 30 ng of GST-EPO was 
inquired for detectable polyubiquitin chain formation in the presence of UbcH6. 
However, under the same ubiquitin ligase assay conditions in figure 3.2.3E, only 7.5 ng 
cf GST-EPO was sufficient to stimulate UbcH5a activity.
h  figure 3.2.3F GST-Vg61 was titrated from 3.75 ng to 30 ng and the remaining 
ibiquitin E3 ligase assay components were used at the concentrations stated in materials 
and methods. The results indicated (Figure 3.1.6D, panel A) that 7.5 ng of GST-Vg61 
vas required for detectable polyubiquitin chain formation in the presence of UbcH5a.
3.2.4. Conclusions.
The results indicate that approximately 7.5 ng of GST-ICPO related proteins was needed 
to simulate UbcH5a and approximately 30 ng was needed to simulate UbcH6 and cause 
the formation of polyubiquitin. As mentioned previously the difference in the intrinsic 
activity of the reactions was probably a reflection of the specific activity of each E2. 
However, the data indicated, but by no means conclusively that the same approximate 
amounts of each of the ICP0 related proteins were needed to stimulate UbcH5a or 
UbcH6. From the current data, it was not possible to determine which of the GST-ICPO 
related proteins was intrinsically more active than others. It became apparent when 
carrying out these experiments that some of the GST-ICPO related proteins and E2 
enzymes were unstable, quickly losing activity after a few freeze-thaw cycles.
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Chapter 3 -  Part II - Biochemical characterisation 
of the minimal functional domains of the ICPO 
related proteins, BICPO and Eg63.
3.3.0. Introduction.
The aim of the experiments described in this section was to further characterise the in 
vitro E3 ligase activities of GST-BICPO and GST-Eg63. PCR mutagenesis was used to 
truncate the 3’ end of the DNA fragment encoding GST-BICPO. A truncation of GST- 
Eg63, previously termed ENX, was already available in-house and was originally used 
to determine the NMR structure of the RING finger domain of the ICPO related proteins 
(Barlow et al., 1994; Everett et al., 1993a). The methods used to express and purify the 
GST-BICPO and GST-Eg63 truncations were the same as those used in section 3.0.0.
3.3.1 Construction o f the minimal functional domains o f GST-BICPO.
PCR mutagenesis was used to truncate the 3’ end of the DNA fragment encoding GST- 
BICPO. Two truncated versions were constructed: BICPO 1_90 260 bp (90 a.a.) in size 
and BICPO 1 75, 225 bp (75 a.a.) in size (see figure 3.3.1A). The PCR method 
employed for the construction of BICPO 1 7 5  used the vector pGEX GST-BICPO as a 
template; BICP0/GST/FW (specific for a DNA sequence within the GST tag), 
BICP0/75/REV, (specific for a DNA sequence around the 225 bp of the BICPO RING 
finger domain) were the forward and reverse primers respectively. BICPO 1 9 0  was 
constructed using the same template vector and forward primer, while the reverse 
primer BICP0/90/REV (specific for a sequence around 270 bp of the DNA fragment 
encoding the BICPO RING finger domain) was used in place BICP0/75/REV. Each of 
the reverse primers encoded a Hindlll site at their 5’ ends, to enable the introduction of 
a Hindlll into the 3’ end of the PCR amplified DNA product. The PCR reaction 
components, cyclic conditions, the amino acid sequence of the region amplified and the 
DNA sequence of the primers, are all shown in figure 3.1.1 A.
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Construction of the BICPO RING finger domain truncations.
Nco I
MAPPAAAPELGSCCICLDAITGAARALPCLHAFCLACIRRWLEGRPTCPL 5 0
Hind\\\ Hind\ II
*  Primer B /  Primer C /
CKAPVQSLIHSVASDECFEEIPVGGGPGADGALEPDAAVIWGEDYDAGPI 100  
A val
DLTAADGEAS
Primer A = BICPO/GST/FW (5’-ATC GAC CAT GGC GCC-3’)
Primer B = BICP0/75/Rev (5’-GAT CCA AGC TTA CCC CAC AGG GAT CTC-3’)
Primer C = BICP0/90/Rev (5’-GAT CCA AGC TTA GTC CTC GCC CCA GAT-3’)
Figure 3.3.1A. Overview of the PCR procedure used to construction BICPO 
truncations.
The amino acid sequence of the BICPO RING finger domain is marked in red, 
with the first and last cysteine residues marked (*). The BICPO RING finger 
domain truncations were produced by PCR mutagenesis, using primers A, B and 
C (nucleotide sequences shown below) and the template vector pGEX GST- 
BICPO. Primer A (forward) binds upstream of the Ncol site within the template 
vector (not shown) and was used in conjunction with primer B or C in the PCR 
reactions. Primer B (reverse primer), binds to a region specific for a.a. codon 
75-80 of the template vector. Primer C (reverse primer), to a region specific for 
a.a. codon 90-95 of the template vector. Primers B & C were designed to 
introduce a a Hindlll restriction enzyme site into the 3’ of PCR product. The 
primers were used in the following combinations A + C and A + B and the PCR 
reaction components (20 ng pGEX GST-BICPO, dNTPs 10 mM, reaction buffer 
10 x, 1 unit p.f.u. turbo, 2 % DMSO, H20.) and cyclic conditions were the same 
for both reactions (1 x 94 °C for 5 min, 35 x [94 °C for 30 seconds, 57 °C for 1 
min, 72 °C for 1 min], 1 x 72 °C for 10 min).
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EHV-1 -  GST-Eg63 RING finger truncation.
Ncol * *
MATVAERCPICLEDPSNYSMALPCLHAFCYVCITRWIRQNPTCPLCKVPV 5 0
E S W H T IE S D S E F
Figure 3.3.1C. Sequence o f the GST-Eg63 RING finger truncation.
The amino acid sequence of the DNA fragment encoding the RING finger 
domain truncations of GST-Eg63 (originally 106 a. a. in length) as 
described previously (Everett et al., 1995). The RING finger domains of 
GST-Eg63 is marked in red, with the first and last cysteine residues of the 
domain marked (*).
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The PCR amplified DNA products encoding BICPO 1 7 5  and BICPO 1 9 0  were cloned 
into pGEM-T easy (Promega), according to manufacturer’s instructions (see figure 
3.3.IB). The DNA fragments encoding the GST-BICPO products and the vector were 
ligated and transformed into E.coli DH5a. Subsequently, colonies were screened by 
diagnostic restriction enzyme digestions of small-scale plasmid preparations. The 
resulting plasmids were termed pGEM-BICPO 1 7 5  and pGEM-BICPO 190.  Once the 
identities of the pGEM series of plasmids had been confirmed the DNA fragments 
encoding BICPO 1 7 5  and BICPO 1_90 were subcloned, as follows:
The vector pGEM BICPO 1 7 5  was digested with Ncol which cuts at the 5’ end and 
Hindlll which cuts at the 3’ end of the DNA fragment encoding BICPO 175 ,  which was 
then isolated by gel electrophoresis and purified accordingly. The recipient vector 
pGEX-2TNMCR was digested with Ncol and Hindlll, to allow insertion of the DNA 
fragment encoding BICPO 1_75. The DNA fragment encoding BICPO 1_90 was also 
subcloned from pGEM-l_90 into the recipient vector pGEX-2TNMCR, following the 
same procedure as before.
The DNA fragments encoding the BICPO truncations and the appropriately digested 
vector pGEX-2TNMCR were ligated and transformed into E.coli DH5a. The resultant 
colonies were screened by making small-scale plasmid preparations and diagnostic 
restriction enzyme digestions. The identities of the plasmids harbouring the desired 
restriction fragments were further confirmed by expression analysis and DNA 
sequencing. Expression analysis simply involved transfecting the pGEX vectors 
encoding either of the BICPO mutants into E.coli BL21 and examining the subsequent 
lysates by SDS-PAGE and Coomassie staining (data not shown). Only isolates positive 
for the correct recombinant protein expression were further analysed by DNA 
sequencing.
The Eg63 truncation, Eg63 1 63 had been previously cloned into pGEX-2TNMCR, and 
its expression verified (Everett et al., 1995b; Everett et a l, 1993a). The solution 
structure of this segment of Eg63 has been determined by NMR, to provide the first 
characterised structure of a RING finger domain (Barlow et al., 1994). The amino acid 
sequence of the Eg63 1_63 truncation is shown in figure 3.3.1C.
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The individual pGEX series of plasmid expressing the BICPO and Eg63 truncations will 
henceforth be referred to as pGEX BICPO 175,  pGEX BICPO 190,  pGEX Eg63 1 6 3  
and the expressed proteins as GST-BICPO 175 ,  GST-BICPO 1 9 0  and GST-Eg63 
163.
3.3.2. Expression and purification o f the truncations o f  GST-BICPO and GST-Eg63.
The pGEX series of plasmids encoding the GST-BICPO truncation proteins and GST- 
Eg63 1 63 were transformed into E.coli BL21 and subsequently purified, using the 
same method as stated in section 3.0.2. However, using this procedure, it was not 
possible to purify GST-BICPO 1_75, this may have been due to the protein folding 
incorrectly or being insoluble in the lysis buffer used. Only GST-BICPO 1 9 0  and GST- 
Eg63 1_63 were used for further experiments in this section.
Figure 3.3.2A shows SDS-PAGE analysis of purified samples of GST-BICPO 1_90,
GST-Eg63 1 63, GST-BICPO and GST-Eg63. This shows the PCR mutagenesis
procedure was successful in reducing the size of the GST-BICPO and GST-Eg63, as the 
electrophoretic mobilities of GST-BICPO 1 7 5  and GST-Eg63 1 63 were comparatively 
lower. In the resolved protein samples there are several breakdown products. However, 
there are dominant bands that have an electrophoretic mobilities close to those of the 
predicted sizes of the intact GST-ICPO related proteins; these are marked on the figure.
3.3.3. Initial E3 ubiquitin ligase assay to determine the activity o f GST-BICPO 1_90 
and GST-Eg63 1_63.
The ubiquitin E3 ligase assay was carried out to determine the activity of GST-BICPO 
1 9 0  and GST-Eg63 1_63, using the method detailed in section 2.9B. This was an 
important prerequisite to future experiments, since truncation of GST-BICPO and GST- 
Eg63 may have caused the proteins to fold incorrectly and become inactive. 
Furthermore, the established E3 ubiquitin ligase assay conditions may not have been 
optimal for these proteins. The initial ubiquitin E3 ligase assays were carried out using 
the GST-Eg63 1 63 and GST-BICPO 1 9 0  in the presence of UbcH5a (see figure 
3.1.2A) using conditions optimised for ICPO (Boutell et al., 2002).
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Figure 3.3.2A. Profile o f extracts o f the 
purified RING finger domains GST-BICPO 
and GST-Eg63 and their truncated forms.
Ten microlitres of extract containing GST- 
RING finger fusion proteins were resolved by 
SDS-PAGE and visualised by Coomassie 
staining. Below each lane, it is denoted which 
extract of purified RING finger domain was 
resolved. Due to the nature o f the purification 
method, partially degraded or truncated 
proteins were additionally purified; the arrow 
in each lane identifies the band that 
corresponds to the predicted electromobilities 
of the protein.
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Figure 3.3.3A. E3 ligase activity o f GST-BICPO I 90 and GST- 
Eg63 I 63.
The in vitro ubiquitin ligase assay was carried out as described in 
section 2.9B. The components of each reaction are denoted in the 
table. The products of the E3 ligase reactions were resolved by 
SDS-PAGE and visualised by Western blotting. GST-BICPO 1 9 0  
(Lane 2) and GST-Eg63 1 63 (Lane 4) were assessed for potential 
E3 ligase activity in the presence of UbcH5a. As GST-BICPO 
(lane 1) and GST-Eg63 (lane 3) had been previously shown to 
stimulate UbcH5a, they were used as positive controls, The blot 
was probed using anti-ubiquitin antibody P4D1 (1/1000) followed 
by the secondary hrp-conjugated anti-mouse antibody (1/1000).
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Figure 3.3.3A shows that GST-BICPO (Lane 1) and GST-BICPO 1_90 (Lane 2) both 
produced polyubiquitin chains in the presence of UbcH5a. Similar results were obtained 
with GST-Eg63 (Lane 3) and GST-Eg63 1 63 (Lane 4). The results indicated that GST- 
Eg63 1_63 and GST-BICPO 1 9 0  were successfully purified and active in the ubiquitin 
E3 ligase assay. Furthermore, it appears from the Western blots that the levels of 
polyubiquitin formation by GST-BICPO and GST-Eg63 were similar to those induced 
by their respective truncation proteins.
3.3.4. Quantification o f GST-BICPO 1_90 and GST-Eg63 1 63.
To ensure equal amounts of the purified GST-BICPO 1_90, GST-Eg63 1_63, GST- 
BICPO and GST-Eg63 were used in subsequent E3 ubiquitin ligase assays, 
densitometric analysis was used to determine the concentration of each preparation (data 
not shown). The method employed was the same as previously used in section 3.0.3.
3.3.5. Comparison o f the E3 ubiquitin ligase activities o f GST-BICPO and GST-Eg63 
and their truncated forms.
The E3 ligase assay was carried out as previously described in section 2.9B. The E3 
ligase activities of GST-BICPO 1_90, GST-BICPO, GST-Eg63 and GST-Eg63 1_63 
were compared in the presence of UbcH5a and UbcH6 (see figure 3.3.5A).
The results from these assays were as follows: Figure 3.3.5A panel A, lane 1 indicates 
that El with GST-BICPO (Lane 1) or GST-BICPO 1 9 0  (Lanes 2) does not lead to the 
formation of polyubiquitin chains alone. However, when E l, ubiquitin and GST-BICPO 
(Lanes 3) or GST-BICPO 1_90 (Lanes 4) were incubated in the presence of UbcH5a 
they facilitated the formation of variable length polyubiquitin chains in vitro. Similarly, 
incubation of E l, ubiquitin and GST-BICPO (Lanes 5) or GST-BICPO 1 9 0  (Lanes 6) in 
the presence of UbcH6, facilitated the formation of variable length polyubiquitin chains 
in vitro. The data also shows (Figure 3.3.5A, panel B) that when the assay was carried 
out using equivalent amounts of GST-BICPO (Lane 3) and GST-BICPO 1_90 (Lanes 4) 
both proteins possessed similar intrinsic E3 ligase activities in the presence of UbcH5a 
(Figure 3.3.5A, panel A). Furthermore, GST-BICPO (Lane 5) and GST-BICPO 1 9 0
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Figure 3.3.5A . Comparison o f  the E3 ligase activities o f  the GST-BICPO and GST- 
BICPO I 90 RIN G  fin g e r  domains, in the presence o f  UbcH5a and  UbcH6.
The in vitro ubiquination assay was carried out as described in section 2.9B. The 
com ponents o f  each reaction are denoted in the table. The products o f  E3 ligase 
reactions were resolved by SD S-PA G E and visualised by W estern blotting. Blot A: 
the RING finger dom ain proteins GST-BICPO and GST-BICPO 1 9 0  were added in 
equal am ounts into the E3 ligase assay, to com pare their ability to cause the form ation 
o f  polyubiquitin chains in the presence o f  U bcH 5a (lanes 3 and 4) and UbcH6 (lanes 5 
and 6). Lane 1 and 2 =  Control, no E2 was present in these reactions. Blot B : Lanes 1 
-  6, shows that com parable am ounts o f  the RING finger dom ain proteins GST-BICPO 
and GST-BICPO 1 9 0  were used in the E3 ligase reactions. Blot A was probed w ith a -  
Ub at 1/1000 followed by the secondary antibody hrp-conjugated anti-m ouse antibody 
1/1000. Blot B was probed w ith anti-GST (1/1000) followed by secondary hrp- 
conjugated anti-rabbit (1/1000) antibody.
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Figure 3.3.5B . Comparison o f  the E3 ligase activities o f  the RIN G  fin g e r  dom ain GST-Eg63  
and G ST-Eg63 I 63, in the presence o f  UbcH5a and UbcH6.
Blot A: the RING finger dom ain proteins GST-Eg63 and GST-Eg63 1 9 0  were added in 
equal am ounts into the E3 ligase assay, to com pare there ability to cause the form ation o f  
polyubiquitin chains in the presence o f  UbcH5a (lanes 3 and 4) and UbcH6 (lanes 5 and 6). 
Lane 1 and 2 = Control, no E2 was present in these reactions. Blot B : Lanes 1 -  6, show that 
com parable am ounts o f  the RING finger dom ain proteins G ST-Eg63 and GST-Eg63 1 9 0  
w ere used in the E3 ligase reactions. This set o f  experim ents was carried out using identical 
conditions to those outlined in the previous figure.
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(Lane 6) both cause the formation of polyubiquitin chains in the presence of UbcH6, but 
significantly the intrinsic activity of GST-BICPO 1_90 appears be less than that of GST- 
BICPO.
The same sets of experiments were carried out with GST-Eg63 and GST-Eg63 1_63 
(Figure 3.3.5B), the results were as follows: Figure 3.3.5B panel A, lane 1 indicates that 
incubation of El with GST-Eg63 (Lane 1) and Eg63 1 63 (Lanes 2) did not lead to the 
formation of polyubiquitin chains. However, when El ubiquitin and GST-Eg63 (Lane 3) 
and GST- Eg63 1_63 (Lane 4) were incubated in the presence of UbcH5a, formation of 
similar amounts of polyubiquitin chains in vitro occurred. When E l, ubiquitin and GST- 
Eg63 (Lane 5) were incubated in the presence of UbcH6, GST-Eg63 facilitated the 
formation of variable length polyubiquitin chains in vitro, however, under the same 
assay conditions Eg63 1 63 (Lane 6) could not. The data shows when GST-Eg63 (Lane 
3) and GST-Eg63 1_63 (Lane 4) were used at equivalent concentrations (Figure 3.3.5B 
panel B) they exhibit similar intrinsic E3 ligase activity in the presence of UbcH5a. 
However, under the same assay conditions GST-Eg63 1_63 (Lane 6), unlike GST-Eg63 
(Lane 5) has little or no ability to cause the formation of polyubiquitin chains in the 
presence of UbcH6.
The data suggests the removal of 43 residues from the C terminus of GST-Eg63 to 
create GST-Eg63 1_63 caused the near abrogation of the truncated protein’s ability to 
stimulate UbcH6 and prevented the formation of polyubiquitin chains in vitro. However, 
both proteins retained the ability to cause similar levels of polyubiquitin formation in 
the presence of UbcH5a. Similarly, the removal of 20 a.a. from the C terminus of GST- 
BICPO to create GST-BICPO 1_90 caused a significant reduction in the protein’s ability 
to facilitate the formation of polyubiquitin chains in the presence of UbcH6. 
Collectively the data suggests that residues that flank the C terminal sides of the RING 
finger domains of BICPO and Eg63 are essential for the stimulation of UbcH6, but not 
UbcH5a.
3.3.6 Inhibition assay to characterise the loss o f the E3 activity o f  GST-Eg63.
The inability of Eg63 1 63 to stimulate UbcH6 may have been due to its failure to bind 
to the E2; in other words, residues on the C-terminal side of the core RING domain may
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I 2 3 4 5 6 7 8
E l + + +
* +
+ + +
Ub + + + + + + + +
UbcH6 + + + + + + + +
Eg63 (ng) 30 30 3 0 30 3 0 30 - 60
Eg63 1_63 (ng) 15 30 60 - - - 60
E g63(n g) - - - 15 30 60
' ’
Figure 3.3.6A. Characterisation of the E3 ligase activity of the titrated RING finger 
domains of GST-Eg63 and GST-Eg63 1 63 in the presence UbcH6.
The in vitro ubiquination assay was carried out as described in section 2.9B. The 
GST-Eg63 and GST-Eg63 163 RING finger domains were titrated into each 
reaction. The table denotes the combination and amount of each protein used. In 
lanes 1-7, 30 ng of the RING finger domain of GST-Eg63 were present per reaction 
and in lanes 1-3 GST-Eg63 1_63 was present from 1 5 - 6 0  ng. In lane 4 - 6  
additional RING finger domain GST-Eg63 was present, from 1 5 - 6 0  ng. Lane 7 
and 8 = Control reactions only GST-Eg63 163 and GST-Eg63 were present. The 
E3 ligase reactions were resolved by SDS-PAGE and visualised by Western 
blotting. The blot was probed with a-Ub at 1/1000 followed by secondary hrp- 
conjugated anti-mouse antibody 1/1000.
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play an essential part in its interaction with UbcH6. Alternatively, the two proteins 
might interact but in a non-productive manner. In the latter case, Eg63 1_63 might act as 
a competitive inhibitor of the reaction in the presence of longer versions of the Eg63 
RING domain by sequestering UbcH6 protein. To address this possibility, the ubiquitin 
E3 ligase assay was performed with UbcH6 and varying amounts of GST-Eg63 and 
GST-Eg63 1_63. Thus, if GST-Eg63 1 63 sequestration of the E2 is occurring, as its 
\ concentration increases the formation of polyubiquitin induced by GST-Eg63 should
decrease. The same conditions were used as those previously outlined in the materials 
and methods, section 2.9B.
I
The results of the Eg63 1_63 inhibition assay are shown in figure 3.3.6A. In the samples 
| analysed in lanes 1-6 and 8, 30 ng of GST-Eg63 was present. In lanes 1 - 3 ,  GST-Eg63I
i 1_63 was titrated into the reaction in amounts increasing from 1 5 - 6 0  ng. The results
| indicate that increasing the amount of GST-Eg63 1_63 did not decrease the level of
|
! polyubiquitin formed; in fact the levels remain relatively uniform. In lanes 4 -  6 as a
control, additional GST-Eg63 was titrated into the reaction and caused an increase in 
polyubiquitin formation, compared to lanes 1 - 3, in the presence of UbcH5a. A slight 
‘ decrease in the levels of polyubiquitin in lanes 5 and 6 was observed, most likely due to
i
i
the presence of an inhibitory substance in this sample of purified protein. Lane 7 and 8 
| were control reactions containing only GST-Eg63 1 63 and GST-Eg63, respectively.
3.3.7. Conclusions.
The results from this section have shown that deletion of regions located on the C- 
terminal sides of the core RING finger domains of GST-BICPO and GST-Eg63 affect 
their ability to stimulate the formation of polyubiquitin chains in the presence of UbcH6, 
but not UbcH5a. In the presence of UbcH6, GST-BICPO and GST-Eg63 caused a 
greater degree of polyubiquitin formation than GST-BICPO 190 ,  which in turn had a
greater affect than GST-Eg63 1 63. This pattern of decreasing activity would suggest
that larger the C-terminal deletion, the greater the abrogation of the RING finger domain 
! proteins’ ability to stimulate UbcH6. Collectively, this data suggests that within the
I deleted 40 a.a. of GST-Eg63 and the 20 a.a. of GST-BICPO, there are regions essential
' for the formation of polyubiquitin in the presence of UbcH6 (see figure 3.3.7A).
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Furthermore, these results suggest that these same sequences of GST-Eg63 and GST- 
BICPO are not essential for the formation of polyubiquitin in the presence of UbcH5a.
The RING finger domains of E3 ubiquitin ligase enzymes have previously been shown 
to be the hub of their activity and their disruption causes reduction or abrogation of the 
proteins’ ability to function. This is discussed in detail in the Introduction and also 
reviewed in detail elsewhere (Freemont, 2000; Joazeiro & Weissman, 2000; Pickart, 
2001a). Furthermore, mutations between the boundary of the first and last cysteine 
residues of the RING finger domain of ICPO have been shown to reduce or abrogate its 
ability to facilitate the formation of polyubiquitin in the presence of UbcH5a (Boutell et 
al., 2002). Previously, it was proposed the ability of ICPO to stimulate both UbcH5a and 
UbcH6 was a result of its interaction with conserved residues or an area of structural 
homology between the two E2 proteins (Boutell et al., 2002). This hypothesis is still 
valid, but despite the structural homology of UbcH5a and UbcH6, the results presented 
here indicate that more than one region of the ICPO related proteins are required for 
stimulating UbcH5a and UbcH6.
Research carried out on other E3 ubiquitin ligase enzymes has shown that the RING 
finger domain is largely responsible for facilitating the formation of polyubiquitin in the 
presence of specific E2 partners. Therefore, it is likely that the RING finger domains of 
GST-Eg63 and GST-BICPO were responsible for specific E3 ligase activity in the 
presence of UbcH5a and UbcH6. Furthermore, the truncated RING finger domain of 
GST-Eg63 1 63 is sufficient for E3 ligase activity in the presence of UbcH5a. The 
study has also shown that regions located on the C-terminal sides of the core RING 
finger domains of GST-BICPO and GST-Eg63 are additionally required for the 
stimulation of UbcH6. However, from the available data it is not possible to conclude 
why these regions are essential. There is little sequence homology outside of the RING 
finger domain of the ICPO related proteins, therefore it is not possible to conclude if the 
loss of activity was due to deletion of a conserved motif or residues. It is most likely that 
C-terminal deletions of GST-BICPO and GST-Eg63 1 63 may have caused the proteins 
to adopt structural configurations, which prevent efficient stimulation of UbcH6, but not 
UbcH5a. In conclusion, the data from this study shows that GST-BICPO and GST-Eg63 
can facilitate the formation of polyubiquitin chains in vitro, but the mechanism used to 
stimulate UbcH5a differs in detail from that with UbcH6.
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Chapter 3 -  Part III - Autoubiquitination of the 
ICPO related proteins.
3.4.1. Introduction.
Experiments described in this section were performed in order to highlight the ability of 
| the ICPO related proteins to autoubiquitinate themselves in vitro. Autoubiquitination is a
I common occurrence amongst RING finger E3 ligases, where the RING finger or the
[ fusion partner acts as a proxy substrate. ICPO has been shown to autoubiquitinate in
| vitro (Boutell et al., 2002) and in vivo (Canning et al., 2004). In the latter case, it is
targeted for proteasome-mediated degradation, promoting its own turnover. In contrast, 
ICPO also promotes its own stability by interacting with USP7 (ubiquitin-specific
I protease 7), a member of a family of cellular enzymes that cleave ubiquitin from either
s
[ alpha or isopeptide-linked chains (Everett et al., 1997). The ICP0-USP7 interaction was
| shown to be essential in preventing autoubiquitination and the subsequent proteolysis of
ICPO in vivo (Canning et al., 2004). Mutational studies have shown that if the ICP0- 
[ USP7 interaction is prevented, the ability of ICPO to function in gene expression and
I viral growth assays is greatly reduced (Everett et al., 1999d).
| The ICPO related proteins used in this study do not contain a USP7 binding motif,
i
| despite the importance of ICPO interaction with USP7. However, the GST-ICPO related
i
| proteins do autoubiquitinate themselves or their fusion partner in vitro. The following
| section refers to figures therein and elsewhere in this chapter, highlighting examples of
i
I autoubiquitination of the GST-ICPO related proteins in the E3 ubiquitin ligase assays.i
i
3.4.2. Autoubiquitination o f the GST-ICPO related proteins.
The ubiquitin E3 ligase assay was carried out using GST-BICPO in the presence of 
| UbcH5a and UbcH6, according to the method described previously (see section 2.9B).
GST-BICPO was used here since the autoubiquitinated isoforms of BICPO were the most 
easily identifiable of the GST-ICPO related proteins.
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Figure 3.4.2A . A utoubiquitination o f  GST-BICPO I 1 10 during the E3 ligase activity.
In vitro ubiquination assay w ere carried out as described in section 2.9B. The com ponents o f  each 
reaction are denoted in the table. The products o f  the E3 ligase reactions were resolved by SD S-PAGE 
analysis and visualised by W estern blotting. The RING finger dom ain protein o f  GST-BICPO was 
titrated into the assay to assess levels o f  autoubiquitination resulting from the form ation o f  
polyubiquitin in the presence o f  UbcH5a and UbcH6. Blot A: In lanes 2 and 3, the RING finger 
dom ain o f  GST-BICPO stim ulate UbcH 5a and UbcH6, respectively. Blot B: The reprobed m em brane 
shows higher m olecular weight autoubiquitinated isoform s o f  the RING finger dom ain o f  GST-BICPO 
are present when polyubiquitin  form ation occurs in the presence o f  UbcH5a (lane 2) and UbcH6 (Lane 
3). W hen no E2 was present in the reaction mix the ubiquitinated isoform s o f  the RING finger dom ain 
o f  GST-BICPO are not present. B lot A was probed with a -U b  at 1/1000 followed by the secondary 
antibody hrp-conjugated anti-m ouse antibody 1/1000. Blot B was probed with anti-GST (1/1000) and 
secondary hrp-conjugated anti-rabbit (1/1000).
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Similar to previous findings, the results from these assays were as follows: figure 3.4.2A 
(panel A), lane 1 indicates that El and GST-BICPO cannot form polyubiquitin chains 
alone. However, when E l, ubiquitin and GST-BICPO were incubated in the presence of 
UbcH5a (lane 2) and UbcH6 (lane 3), it stimulated the E2 enzymes to form variable 
length polyubiquitin chains in vitro. In figure 3.4.2A (panel B) it is possible to see that 
GST-BICPO causes polyubiquitin chain formation in the presence of UbcH5a (lane 2) 
and UbcH6 (lane 3), where upon it becomes autoubiquitinated. It is possible to identify 
autoubiquitination due to the presence of multiple high molecular weight isoforms of 
GST-BICPO, present in lanes 2 and 3, but not in lane 1 (marked on figure 3.4.2A). 
Notably in the E3 ligase assay the pattern of autoubiquitinated GST-BICPO is markedly 
similar in presence of UbcH5a and UbcH6, despite different E2s being involved in the 
reaction.
Similar results can be seen in figure 3.3.5A (panel B) (see relevant section for specific 
experimental details). GST-BICPO and GST-BICPO 1 9 0  both undergo 
autoubiquitination in the presence of UbcH5a (Lanes 3 and 4) and UbcH6 (Lanes 5 and 
6). Figure 3.3.5B (panel B) also shows that GST-Eg63 and GST-Eg63 1_63 both 
undergo autoubiquitination in the presence of UbcH5a (Lanes 3 and 4) and UbcH6 
(Lanes 5 and 6). However, the patterns of high molecular weight autoubiquitinated 
species of GST-Eg63 1_63 are different in the presence of UbcH6 (Lane 5) and UbcH5a 
(Lane 6). The decrease in high molecular weight species of autoubiquitinated GST-Eg63 
1_63 may be a reflection of the protein’s decreased E3 ligase activity in the presence of 
UbcH6.
3.4.3. Conclusions.
The proteins GST-BICPO, GST-BICPO 1_90, GST-Eg63, GST-Eg63 1_63 all under go 
varying degrees of autoubiquitination when either UbcH5a or UbcH6 are present in the 
E3 ligase assay. Single or multiple lysine residues within the RING finger domains or 
that of the GST moiety may be targeted for ubiquitination. The results in Figure 3.3.5B 
suggest that GST-Eg63 1_63 undergoes a lower level of autoubiquitination in the 
presence of UbcH6, than that of UbcH5a; probably a consequence of the protein’s 
abrogated ability to form polyubiquitinated chains in the presence of UbcH6.
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If similar to ICPO, autoubiquitination of the ICPO related proteins has an important in 
vivo significance. These proteins would therefore make interesting targets for future 
research. Unlike ICPO, the ICPO related proteins do not contain a USP7 binding site, and 
therefore may use a different ubiquitin specific protease or mechanisms of self­
regulation to prevent their proteolysis in vivo. Furthermore, the majority of the ICPO 
related proteins contain one conserved lysine residue within their RING finger domains 
that is not shared with ICPO. It has been shown that ICPO RING finger domain contains 
two lysines near to one another and it is thought that either or both of these residues are 
targeted for autoubiquitination (Canning et al., 2004). Therefore, mutation of the 
conserved lysine residue of the RING finger domains of ICPO related proteins could 
help further elucidate the significance of autoubiquitination in the ICPO family of 
proteins.
I
!
i
i
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Chapter 3 -  Part IV - Physical interactions 
between the GST-ICPO related proteins and E2 
enzymes.
3.5.0. Introduction.
The aim of the experiments described in this section was to determine if the ICPO 
related RING finger domain proteins form stable interactions with UbcH5a and UbcH6 
in vitro. In general it is widely accepted that the interaction of the E2 ubiquitin- 
conjugating enzymes with the RING finger domain plays a central role in mediating the 
transfer of ubiquitin to substrate proteins (Freemont, 2000; Joazeiro & Weissman, 
2000). In agreement, the majority of characterised E3 ligases have been shown to form 
stable interactions via their RING finger domains with their E2 partners, for example c- 
Cbl and the E2, UbcH7 (Zheng et al., 2000); A 07 and the E2, UbcH5 (Lorick et al., 
1999); HHARI and the E2s, UbcH7 and UbcH8 (Moynihan et a l, 1999). However, 
occasionally E2-E3 complex interactions can also occur with sequences outside of the 
RING finger domain, such as in the case of the Ubc2p-Ubrlp interaction. It was shown 
that the RING domain of the E3 Ubrlp was necessary for polyubiquitination, but not for 
interaction with the E2 Ubc2p (Xie & Varshavsky, 1999). However, research carried out 
previously showed that despite clear data indicating that ICPO stimulates UbcH5a, and 
UbcH6 it was not possible identify a stable interaction between the proteins (Boutell et 
al., 2002).
It was decided to use GST-pull down assays in an attempt to identify an interaction 
between the ICPO RING finger domain proteins and UbcH5a and UbcH6. Bacterial 
extracts containing either HIS linked UbcH5a, UbcH6 or cdc34 were mixed with 
glutathione beads that had been previously charged with one of the GST-ICPO related 
proteins (see Chapter 3, section I for further details) and incubated at 37°C for a short 
period of time. The beads were then isolated and the coprecipitated proteins were eluted 
and analysed by SDS-PAGE and Western blotting (specific experimental details can be 
found in section 2.9C). The E2 enzyme cdc34 was additionally used in the assays, as it 
has been reported that it is stimulated to form autoubiquitinated products by residues
150
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within the C-terminal third of ICPO in vitro (Van Sant et al., 2001a). Furthermore, it was 
also suggested that cdc34 forms a stable interaction with the RING finger domain of 
ICPO (Van Sant et al., 2001a). However, a report published elsewhere has shown that 
neither full-length ICPO nor its isolated RING finger domain was able to induce the 
formation of polyubiquitin chains in the presence of cdc34 (Boutell et al., 2002). The 
series of experiments described in this section will also analyse if GST-ICPO (241) or 
any of the GST-ICPO related proteins form stable interactions via their RING finger 
domains with cdc34.
i 3.5.1. The GST-pull down assay.
\
I
Initially, bacterial extracts were made containing the GST-ICPO related proteins or HIS 
tagged UbcH5a, UbcH6 and cdc34, as follows:
The pGEX series of plasmids encoding the GST-ICPO related proteins and the pET24a
|
| series of plasmid encoding UbcH5a, UbcH6, or cdc34 (Boutell et al., 2002) were
transformed into E.coli BL21. Several (5 to 10) bacterial colonies were pooled and
I
I cultured in YTB (supplemented with ampicillin or kanamycin, as appropriate) until mid­
log phase, whereupon IPTG was added to induce expression of the recombinant protein. 
Incubation was then continued for a further 3-5 hours at 28°C. The bacteria were then 
pelleted and resuspended in lysis buffer and subjected to sonication. The lysis buffer 
EP0 265 (100 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% Glycerol, 0.1% NP40, and 20 
mM P-mercaptoethanol) was again used. The bacterial extract was clarified by high­
speed centrifugation and stored appropriately (see section 2.10 for further details).
|
| The soluble extracts containing bacterially expressed members of the GST-ICPO related
i
I proteins were mixed with glutathione-agarose beads, then the beads with bound fusion
i
S proteins were harvested by centrifugation and washed extensively to remove unbound
I proteins. Beads charged with GST alone were prepared to pre-clear extracts containing
the E2 enzymes and to serve as a control. Bacterial extracts containing expressed HIS- 
UbcH5a, HIS-UbcH6 or HIS-cdc34 were then pre-treated with beads linked to GST to 
deplete from the extract proteins that might bind non-specifically to the beads, then the 
supernatants from these incubations were mixed with beads charged with the GST-
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Figure 3.5.1 A. GST-pull down assay to determine i f  the RING finger domain proteins form 
stable complexes with selected E2 enzymes in vitro.
The GST-pull down assays were carried out according to the method stated in section 2.9C. Pre­
cleared extracts containing either HIS-UbcH5a, HIS-UbcH6 and HlS-cdc34, were incubated with 
glutathione beads, charged with GST, GST-ICPO (241), GST-Eg63 or GST-Eg63 1 63. The 
combination of proteins that were incubated together is shown in the table. The mixtures were 
washed and the co-precipitated proteins were eluted and then analyzed by SDS-PAGE followed 
by Western Blotting. The antibodies used to identify the proteins is stated above each of the blots 
and were used at the following concentrations: anti-HIS used at 1/750 followed by the secondary 
antibody hrp-conjugated anti-mouse 1/1000 anti-GST at 1/1000; followed by the secondary 
antibody hrp-conjugated anti-rabbit at 1/1000.
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RING finger fusion proteins. The mixtures were subsequently analyzed for co­
precipitated proteins by SDS-PAGE and Western blotting. Specific experimental details 
can be found in section 2.9C. To ensure accuracy in the results obtained the interaction 
conditions used were highly stringent, in particular, the bound proteins were eluted from 
the beads with reduced glutathione before analysis, rather than simply analysing the 
proteins present in the bead pellets. The results were as follows:
The results of GST-pull down assays to determine if GST, GST-241, GST-Eg63 and 
GST-Eg63 1 63 formed stable interactions with UbcH5a, UbcH6 or cdc34 are shown in 
figure 3.5.1 A. Lanes 1 and 2 show samples of the GST and GST-ICPO (241) bead 
preparations used in the subsequent stages of the assay. Lanes 3 - 5 are positive controls, 
showing UbcH5a, UbcH6 and cdc34, respectively in the bacterial extracts used for the 
interaction assays. Lanes 12 and 13 show samples of the GST-Eg63 and GST-Eg63 
1_63 beads. Lanes 6 - 1 1  contain eluted proteins from the interaction assays using GST 
and GST-ICPO (241) beads. The results indicate that GST does not form a stable 
interaction with UbcH5a, UbcH6 or cdc34 (lanes 6 - 8 ) .  However, from lanes 9 - 11 it is 
possible to observe that GST-ICPO (241) forms a stable interaction with UbcH6, but not 
UbcH5a or cdc34 under the conditions employed. Additionally it can be observed that 
GST-Eg63 (lanes 14-16) and GST-Eg63 1 63 (lanes 17-19) form stable interactions 
with UbcH5a and UbcH6, but not cdc34.
Figure 3.5.IB is a continuation from the previous set of results. Lanes 1, 2, 9 and 10 
show samples of the GST-BICPO 190,  GST-BICPO, GST-EPO, and GST-Vg61 beads 
used in the pull-down experiments, respectively. Lanes 3 - 5  indicate that BICPO 1_90 
forms a stable interaction with UbcH6, but not UbcH5a or cdc34. Identical results were 
also observed with GST-BICPO (Lane 7), GST-EPO (Lane 12) and GST-Vg61 (Lane 
15).
3.5.2. Conclusions from the interaction assays.
The data shows that all of the GST-ICPO related proteins form stable interactions with 
either or both of their E2 partners, UbcH5a and UbcH6. However, GST-ICPO (241) and 
none of the GST-ICPO related proteins formed stable interactions with cdc34. This
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Figure 3.5. IB. GST-pull down assay to determine i f  the RING finger domain proteins 
form stable complexes with selected E2 enzymes in vitro.
The GST-pull down assays were carried out according to the method stated in section 
2.9C. Pre-cleared extracts containing either HIS-UbcH5a, HIS-UbcH6 and HIS- 
cdc34, were incubated with glutathione beads, charged GST-BICPO 190,  GST- 
BICPO, GST-EPO or GST-Vg61. The reactions were carried out according to the 
method described in the previous figure.
V S f f C V p iW l  \j —  I X ^ O U f l O  C H I U  L / f O v U O O f v (  I .
contradicts data that what was previously published, which suggested the RING finger 
domain of ICPO forms a stable interaction with cdc34 (Van Sant et al., 2001a).
The levels of interaction with UbcH6 varied between the GST-ICPO related proteins, 
from using a basic pull down assay it is not possible to interpret if this was significant or 
not, as it may be down to minor experimental variables. Out of all of the GST-ICPO 
! related proteins only GST-Eg63 1_63 and GST-Eg63 formed strong stable interactions
with UbcH5a, this may have again been due to minor experimental variables. However, 
it is probable that all of the GST-ICPO related proteins do form stable interactions with 
UbcH5a and in future by further optimization of the assay conditions it may be possible 
to detect these.
Additionally the data showed that GST-Eg63 1_63 and BICPO 1_90 formed stable 
I interactions with UbcH6, despite their reduced ubiquitin ligase activity in its presence.
i
Furthermore, as GST-Eg63 1 63 contains only 20 a.a. from the last cysteine in its RING 
finger domain to the C-terminal end of the expressed protein fragment (see figure 
3.3.1C), this would indicate that like most other E3 ubiquitin ligase enzymes the RING 
finger domain is more than likely responsible for mediating the interaction with specifici
' E2 partners. It is probable that most of the ICPO related proteins mediate interaction
with their E2 partners via their conserved RING finger domains, due to the similar
\
intrinsic E3 ligase activity and biological properties they share. This has been shown to 
be the case for other E3 ligases, for example the LAP family of proteins all share a 
conserved RING finger domain and have all been shown to stimulate and interact with 
UbcH5a in a similar fashion (Yang & Du, 2004).
tf
[
[
r
i
[
iI
I
ii
153
I V
Chapter 3 -  Part V - Interaction assays between 
mutant versions of GST-ICPO (241) and E2 
ubiquitin conjugating enzymes.
3.6.1. Introduction.
j  The RING finger domain plays a central role in mediating interaction between E3
ubiquitin ligase enzymes with the required E2 ubiquitin-conjugating enzyme, and in 
mediating the transfer of ubiquitin to substrate proteins (Freemont, 2000; Joazeiro & 
| Weissman, 2000). As the RING finger domain is the hub of an E3 ligases activity,
mutation within this region has generally been shown to be very deleterious for the 
ability of varied E3 enzymes to interact with their E2 partners and to stimulate the 
formation of polyubiquitin chains in vitro (Pickart, 2001a). In the case of ICPO-241 it 
was shown that insertion of 4 residues at a.a. 150 and 162, deletion of the RING finger 
| domain or sequence 162-188, abrogated ICPO’s ability to act as an E3 ligase in the
I presence of UbcH5a (Boutell et al., 2002). However, point mutations within the RING
[ finger domain of ICPO-241 (K144E, W146A, Q148E and N151D) and some insertional
J  mutants (inslSS and ins 197) had little or no deleterious affect (Boutell et al., 2002).
j  Even mutation of the conserved tryptophan which is present in the majority of RING
i
| finger E3 ligase enzymes and has been shown when mutated to be exceptionally
deleterious in other related proteins (Freemont, 2000; Joazeiro & Weissman, 2000; 
Pickart, 2001a), had little affect on the E3 ligase activity of ICPO-241 (Boutell et a l, 
2002), or the in vivo activity of ICPO (O’Rourke et al., 1998). However, in contrast to 
having little affect on the E3 ligase activity of ICPO (241) the majority of the 
aforementioned mutations had an extremely deleterious affect on ICPO ability to 
simulate gene expression and disrupt ND10 in transfection assays (Everett et al., 1995a; 
I Everett, 1987). The following series of experiments were designed to determine if the
1 ICPO-241 series of mutations (see figure 3.6.1 A) were able to interact with UbcH5a or
i
| UbcH6.
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3.6.2. Interaction assays using the GST-ICPO (241) series o f mutants.
Initially soluble bacterial extracts were made containing the GST-ICPO-241 series of 
mutant proteins and HIS tagged UbcH5a and UbcH6, as follows:
The pGEX series of plasmids encoding the GST-ICPO-241 mutants and the pET24a 
series of plasmids encoding UbcH5a and UbcH6 (Boutell et a l, 2002) were transformed 
into E.coli BL21. Soluble extracts of the bacteria containing the expressed proteins was 
made according to the method stated in section 3.5.1. The GST-pull down assays were 
carried out using soluble extracts of the GST-ICPO-241 mutants, which were mixed 
separately with bacterially expressed HIS-UbcH5a and HIS-UbcH6. Again, the assay 
was carried out according to the method stated previously in section 3.5.1.
GST-pull down assays were used to determine if GST, GST-262 (FXE), GST-241 and 
GST-211 (extracts of which are shown in lanes 1-4, respectively) form stable 
interactions with UbcH5a and UbcH6, the results of which are shown in figure 3.6.2A. 
Lanes 5 and 6 are positive controls showing UbcH5a and UbcH6, respectively. Lanes 7 
and 8 are negative controls and indicate that GST does not form a stable interaction with 
UbcH5a or UbcH6. Lanes 9 and 10 indicate GST-262 FXE the RING finger deletion 
mutant, does not form a stable interaction with either UbcH5a or UbcH6. However, 
from lanes 11 and 12 it is possible to observe that GST-241 forms a stable interaction 
with UbcH6 but not UbcH5a under the conditions employed in this experiment. 
Replicate results were observed with GST-211 (lanes 13 and 14).
GST-pull down assays were carried out to determine if GST-241 ins 150, GST- 
241 ins 162, GST-241 insl88 and GST-241 ins 192 (extracts of which are shown in lanes 
1-4, respectively) form a stable interaction with UbcH5a or UbcH6, the results of which 
are shown in figure 3.6.2B. Lanes 6 and 7 are positive controls, containing UbcH5a and 
UbcH6, respectively. Lanes 8 and 9 are negative controls, indicating that GST does not 
form a stable interaction with either UbcH5a or UbcH6. Lanes 10 and 11 indicate that 
GST-241insl50 forms a stable interaction with UbcH5a and UbcH6, as does GST- 
241insl62 (lanes 12 and 13) and GST-241insl92 (lanes 16 and 17). However, the 
results indicate that under the current experimental conditions GST-241 ins 188 (lanes 14 
and 15) could only form a stable interaction with UbcH6.
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241 - + - - - - - - - + + - -
211 - - + - - - - - - - - + +
UbcH5a - - - - + - + - + - + - + -
UbcH6 - - - - + - + - + - + - +
Figure 3.6.2A GST-pull down assay to determine i f  the ICPO RING finger 
domain mutants form  stable complexes with selected E2 enzymes in vitro.
The GST-pull down assays were carried out according to the method 
stated in section 2.9C. Pre-cleared extracts containing either HIS-UbcH5a 
or HIS-UbcH6 , were incubated with glutathione beads, charged with GST, 
GST-ICPO (241), GST-211 and GST-FXE. The combination of proteins 
that were incubated together is shown in the table. The mixtures were 
washed and the co-precipitated proteins were eluted and then analyzed by 
SDS-PAGE followed by Western Blotting. The antibody used to visualise 
the proteins was as follows anti-HIS used at 1/750 followed by the 
secondary antibody hrp-conjugated anti-mouse at 1/ 1000.
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UbcH5a - + + - + - + - + - + -
UbcH6 -  - + - + - + - + - + - +
Figure 3.6.2B. GST-pull down assay to determine i f  the ICPO RING finger domain 
mutants form stable complexes with selected E2 enzymes in vitro.
Pre-cleared extracts containing either HIS-UbcH5a or HIS-UbcH6 were incubated with 
glutathione beads, charged with RING finger domain mutants of ICPO, GST-241 ins 150, 
GST-241insl62, GST-241insl88 or GST-241 ins 192. The combinations of proteins that 
were incubated together are shown in the table. The assay was carried according to the 
method out lined in the previous figure.
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Figure 3.6.2C GST-pull down assay to determine i f  the ICPO RING finger domain 
mutants form stable complexes with selected E2 enzymes in vitro.
The GST-pull down assays were carried out according to the method stated in 
section 2.9C. Pre-cleared extracts containing either HIS-UbcH5a or HIS-UbcH6 , 
were incubated with glutathione beads, charged with RING finger domain mutants 
o f ICPO, 241 W146A, 241 Q148A, 241 N 151A or 241 K144E. The combinations of 
proteins that were incubated together are shown in the table. The assay was carried 
according to the method outlined in the previous figure.
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Figure 3.6.2C is a continuation from the previous set of results. The results determine 
whether GST-241W146A, GST-241Q148A, GST-241N151A, GST-241K144E and 
GST-241 (extracts of which are shown in lanes 1-5, respectively) form stable 
interactions with UbcH5a and UbcH6. Lanes 6 and 7, indicate that GST-241 W146A is 
capable of forming a stable interaction with UbcH5a and UbcH6 respectively, as can 
GST-241Q148A (Lanes 8 and 9), GST-241N151A (Lanes 10 and 11) and GST- 
241K144E (Lanes 12 and 13). However, the results indicate under the current 
experimental conditions GST-241 (lanes 14 and 15) could only form a stable interaction 
with UbcH6.
3.6.3. Conclusions from the interaction assays.
The results showed that subtle mutation of the RING finger or its flanking sequence 
failed to abrogate ICPO ability to form a stable interaction with UbcH6. However, 
deletion of the RING finger domain of ICPO (262-FXE) managed to prevent an 
interaction with UbcH6.
Significantly, the data also indicated that most of the ICPO-241 mutants (see figure 
3.6.1A) appeared to form a stable interaction with UbcH5a unlike ICPO-241, which was 
previously shown to interact with UbcH6 alone. It is possible this is down to minor 
experimental variables and further optimization of the assay would probably enable an 
interaction between ICPO (241) and UbcH5a to be detected. However, it is equally 
possible that mutations, with exception of the RING finger deletion mutant caused a 
change in conformation of the protein, which enabled a more stable interaction between 
ICPO (241) and UbcH5a to be detected. All of the point mutants used in this study were 
within the a-helix region of ICPO (241) (see figure 3.6.1 A), which has been predicted to 
be critical for the function of the protein (Barlow et al., 1994). However, the insertional 
and point mutants used in this study had been shown not to affect the transactivation 
ability of ICPO (241), therefore they were predicted not to cause any major alterations in 
the protein fold or charge of the a-helix region (Barlow et al., 1994). In addition, later 
research showed that the same point and insertional mutants had no or only slightly 
effected ICPO (241) ability to stimulate UbcH5a and cause the formation of 
polyubiquitin chains in vitro (Boutell et al., 2002). In light of the studies described 
herein it is possible that subtle mutation of the RING finger domain and flanking
156
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sequence is insufficient to cause significant changes in the biological properties of the 
protein (Barlow et a l 1994; Boutell et al., 2002), but is sufficient to cause a change in 
conformation of the protein that allows a stable interaction between ICPO (241) and 
UbcH5a to be detected in vitro.
Chapter 4 - Characterisation of members of the 
ICPO family of proteins by expression of their full- 
length versions.
4.0. Expression of members of the ICPO family of proteins using recombinant 
baculoviruses.
4.0.1 Introduction.
The aim of this project was to create a series of recombinant baculoviruses (Autographa 
californica nuclear polyhedrosis virus [AcNPV]) for expression of full-length members 
of the ICPO family of proteins in Sf21 insect cells (see section 2.3D) and in HEp-2 cells. 
Baculoviruses have been used as vectors for the efficient expression of recombinant 
proteins in insect cells since the early 1980s, and more recently they have been adapted 
as gene delivery vectors into cultured mammalian cells, in particular hepatic cell lines 
(Hofmann et al., 1995; Kost & Condreay, 1999, 2002; Luckow et al., 1993).
Two sets of baculovirus were constructed to allow expression in mammalian and insect 
cell lines. For expression of recombinant genes encoding the ICPO related proteins in 
Sf21 insect cells, use is made of the strong polyhedron promoter of AcNPV, already 
located within the pFastBac HTa vector (see figure 4.0.1 A). However, for the 
expression of the full length proteins in mammalian cells it was necessary to insert the 
HCMV IE promoter/enhancer upstream of the recombinant gene, as the polyhedron 
promoter is unable to drive expression in mammalian cells (Kost & Condreay, 2002). 
The insertion of a mammalian active promoter allows expression only of the 
recombinant gene from the viral genome in infected mammalian cells, as it has 
previously been shown that mammalian cells are non-permissive for baculovirus 
replication, and expression of any of the insect virus proteins, even from its IE genes, is 
undetectable (R.D. Everett personal communication.).
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Figure 4.0.1 A . Schem atic overv iew  o f  the salien t fea tu res  o f  the p la sm id  pF astB ac  
HTa.
F u rth e r  d e ta ils  a re  s ta te d  in th e  tex t. p F a s tB a c  H T a  k ey  fe a tu re s  a re  as fo llo w s. 
A T G : In itia tio n  C o d o n . 6  x H IS : P o ly -h is tid in e  tag , p U C  o ri: O r ig in  o f  re p lic a tio n , 
F I  o ri: p h a g e  F I  o r ig in  o f  re p lic a tio n . A m p ic illin  an d  g e n ta m y c in : G e n e s  e n c o d in g  
a n tib io tic  re s is ta n c e . P PH: P o ly h e d ro n  p ro m o te r . S V 4 0  pA : P o ly a d e n y la tio n  s ig n a l. 
T n 7 L  a n d  T n 7 R : M in i-T ra n sp o s a b le  e le m e n ts . D ia g ra m  a d a p te d  fro m  the  
In v itro g e n  ’B a c - to -B a c  B a c u lo v iru s  E x p re s s io n  S y s te m ’ la b o ra to ry  m an u a l.
Figure 4.0. IB. Overview o f the construction of a recombinant baculovirus.
A) The foreign gene, i.e. the DNA fragment containing the ORF encoding 
one of the ICPO family of proteins, was ligated into the MCS of the pFastBac 
HTa vector, then the resultant transfer plasmid was transformed into E.coli 
DH10 Bac. B) Site specific transposition occurs between the pFastBac HTa 
containing the recombinant gene and the bacmid. Antibiotic selection and 
blue/white screening was used to identify E.coli DH10 Bac expressing 
recombinants. The white colonies were restreakcd onto the same selective 
media to produce clonally pure isolates. C) The positive colonies were 
cultured in media supplemented with the appropriate antibiotics and the high 
molecular weight bacmid DNA was isolated by alkaline lysis. D) The bacmid 
DNA was transfected into Sf21 cells. E) Low titre baculovirus was isolated 
from the cell culture after 5-7 days. F) The low titre baculovirus stock was 
used to infect further Sf21 cells. Repeated infection of Sf21 cells and 
harvesting of viral supernatant was carried out, the volume of cells in culture 
being increased at each stage of the amplification process. G) The cell pellets 
that were collected during the amplification process were analysed by 
Western blotting for recombinant protein expression. High titre stocks were 
harvested from one baculovirus positive for expressing the heterologous 
protein of the correct size. H) The recombinant protein could be easily 
analysed by immunodetection, using either an anti-HIS or anti-Myc 
antibodies. I) Plaque assays were performed to determine the titre of the 
baculovirus stocks. J) Sf21 cells were infected with recombinant 
baculoviruses. K) The expressed recombinant protein was isolated by a metal 
chelate affinity chromatography. L) Baculoviruses containing a heterologous 
gene downstream from HCMV promoter were used to infect mammalian 
cells. Protein expression was identified by immunofluorescence in cell 
culture.
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Figure 4.0.1 B. Overview o f the construction o f a recombinant baculovirus.
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The Bac-to-Bac system (Invitrogen) was employed to create the recombinant 
baculoviruses. The main features of baculovirus construction are as follows (an 
overview is shown in figure 4.01B). Initially the heterologous gene was cloned into the 
multiple cloning sites (MCS) of the vector pFastBac HTa (see figure 4.0.1 A). Insertion 
of the foreign gene into the MCS in the correct frame introduces a polyhistidine (6 x 
HIS) tag at the N-terminus of the recombinant protein, enabling purification by metal 
chelate affinity chromatography. The tag also allows immunodetection of the protein. 
The MCS are positioned within a mini-Tn7 region, a transposing element that allows 
site-specific transposition of the heterologous gene from the vector to receptor attTn7 
sites that are present within the baculovirus genome, which is contained within a 
bacmid. The bacmid is propagated in the bacteria E. coli DH10 Bac, in conjunction with 
a helper plasmid (pMON7124) which provides the Tn7 transposition function by 
encoding a transposase enzyme (Luckow et a l , 1993). After introduction of the 
pFastBac HTa recombinant plasmid into E. coli DH10 Bac (see section 2.IE), 
transposition occurs at low frequency, but clones in which transposition has occurred 
can be selected for by multiple antibiotics and blue/white screening. Transposition of 
the mini-Tn7 element to the attTn7 element of the bacmid causes the disruption of the 
LacZa peptide, so colonies expressing the recombinant gene are white in a background 
of blue colonies that contain the unaltered bacmid.
The following chapter is divided into two parts. Part I will describe the construction of 
the baculoviruses for recombinant protein expression within Sf21 cells, and the 
subsequent results. Part II will describe the construction of the baculoviruses expressing 
the HCMV driven ICPO-family members in mammalian cells and the subsequent results.
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Chapter 4 - Part I - I n  v i t r o  analysis of the ICPO 
family of proteins.
4.0.2 Clotting o f the genes encoding members o f the ICPO protein family into 
pFastBac HTa.
A schematic representation of the cloning strategy employed is shown in figure 4.0.2A. 
Initially the fragments encoding the ICPO family genes were isolated from the pCI-rtag 
series of plasmids (Parkinson & Everett, 2001), taking advantage of the Ncol sites that 
occur at the initiating ATG codon in each case, as follows:
The vector pCIrtagBICPO was initially digested with the restriction enzyme Xhol at the 
3’ end of the DNA fragment encoding BICPO. A partial restriction digestion using the 
enzyme Ncol was used to generate multiple DNA fragments of approximately 2.2 Kbp,
1.8 Kbp and 0.4 Kbp. The 2.2 Kbp fragment containing the entire BICPO coding region 
was isolated for the remaining parts of the cloning procedure.
The vector pCIrtagEg63 was initially digested with the restriction enzyme Xhol at the 3 ’ 
end o f the DNA fragment encoding Eg63. A partial restriction digestion using the 
enzyme Ncol was used to generate multiple species of DNA fragments of approximately
1.8 Kbp, 1.5 Kbp, and 300 bp. The 1.8 Kbp fragment was isolated for the remaining 
parts o f the cloning procedure.
The vector pCIrtagVg61 was initially digested with the restriction enzyme Notl at the 3’ 
end o f the DNA fragment encoding Vg61. A partial restriction digestion using the 
enzyme Ncol was used to generate multiple DNA fragments of approximately 1.8 Kbp,
1.1 Kbp, and 700 bp. The 1.8 Kbp fragment was isolated for the remaining parts of the 
cloning procedure.
The multiple restriction digestion was carried out on the vector pCIrtagEPO. The 
restriction enzymes Ncol was used to cut at the 5’ and Hindlll at the 3’ end of the DNA 
fragment encoding the EHV-1 ICPO homologue EP0. The 1.6 Kbp fragment was 
isolated for the remaining parts of the cloning procedure.
160
A)
mm
EcoR\ Myc tag A/col
M E Q K L I S E E D L N M  
AATTCATGGAGCAGAAGCTGATCTCCGAGGAGGACCTGAACATGGC
GTACCTCGTCTTCGACTAGAGGCTCCTCCTGGACTTGTACCGGTAi
- Amino acid seq 
DNA seq.
. J
B)
1)
°Op \  Ncol
BHV-1, BICPO.
2 ) bd
\  \
3) W  
4) b d
EHV-1, Eg63.
NA/col A/col
« 1 6  bp~>
PRV, EPO
A/cjbl
Xhol
<----------------------------------- 1 8 1 9 b p --------------------------- ► I
I
2.2 Kbp-
Xho\
1.8 Kbp-
Hind\\\
1.6 Kbp-
VZV, Vg61
A/col
« 687 bp
A/col 
— ►  ,
A/o/l
1.8 Kbp
mooX
J
XXX 3 O ^  3.
I t  f
pFastBac
HTa
4.9  Kbp
Figure 4 .0 .2A  Schem atic representation o f  the construction o f  the pF astB ac HTa p lasm ids expressing the ICPO- 
related proteins.
A ) The chequered box represents an oligonucleotide linker that encodes the myc epitope tag. The DNA sequence 
and the corresponding am ino acid sequence is shown. The linker contained a 3 prim e site that is com patible with 
the 5 ’ Ncol restriction site o f  the ORF encoding ICPO hom ologues (1-4). The 5 ’ restriction site o f  the oligo is 
com patible with the 5 ’ EcoR l site o f  the recipient vector pFastBacH Ta. B) 1) The 2.2 Kbp DNA fragm ent 
containing the BICPO ORF o f  BHV-1 was rem oved by an N col and Xhol restriction digestion o f  the parental 
plasmid pCIrtagBICPO. The vector pFastBac HTa was digested with EcoRl and X hol (show n in blue) to 
accom m odate the fragm ent and linker (A). 2) The 1.8 Kb DNA fragm ent encoding the Eg63 ORF o f  EHV-1 
was derived from pCIrtagEg63 rem oved by an Ncol and X hol restriction digestion. The vector pFastBac HTa was 
digested with EcoRl and Xhol (show n in blue) to accom m odate the fragm ent and linker (A). 3) The 1.6 Kbp 
DNA fragm ent encoding EPO o f  PRV was rem oved by an N col and X hol restriction digestion o f  the parental 
plasmid pCIrtagEPO. The vector pFastBac HTa was digested with N col and H in d ill  (shown in red) to 
accom m odate the fragm ent. 4) The 1.8 Kbp DNA fragm ent encoding Vg61 o f  VZV was rem oved by an N col and 
Notl restriction digestion o f  the parental plasm id pC lrtagV g61. The vector pFastBac HTa was restriction digested 
with Ncol and N otl (show n in green) to accom m odate the fragment.
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There are no efficient antibodies available for all of the ICPO related family of proteins; 
it was therefore necessary to include a method for the immunodetection of the proteins. 
As previously mentioned, insertion of the ICPO related protein coding sequence into the 
MCS of pFastBac HTa enables the fusion of a 6 x HIS tag to the N-terminus of the 
expressed protein. Furthermore, an N-terminal myc epitope tag was also used. The tag 
was introduced by ligating an oligonucleotide linker encoding the myc epitope in 
conjunction with the isolated DNA fragments encoding the ICPO related proteins into 
: suitably restriction-digested pFastBac HTa (see figure 4.0.2A). The ligated DNA
| fragments were transformed into E. coli DH5a. The resultant colonies were screened byI
making small-scale plasmid preparations and diagnostic restriction enzyme digestions. 
Clones harbouring the desired plasmids were identified and then large-scale plasmid 
preparations were made. The identities of all the constructs were confirmed by DNA 
sequencing using primers that generated sequences covering both the 5’ and 3’ cloning 
junctions.
I
4.0,3 Construction o f recombinant baculoviruses.
An overview of the procedures required in the construction of a recombinant 
baculovirus is shown in figure 4.01B. The pFastBac HTa clones expressing the 
members of the ICPO family of proteins (BICPO, Eg63, EPO and Vg61) were 
individually transformed into E.coli DH10 Bac (see section 2.IE). Colonies expressing 
the heterologous gene were identified by drug selection and blue/white screening (see 
section 4.0.1); the bacmid DNA was then isolated from purified clones. The bacmid 
DNA was transfected into Sf21 cells and a low titre recombinant baculovirus stock was 
produced after 5-7 days. The viral titre was amplified by repeated infection of 
increasingly large Sf21 cell cultures. High titre baculovirus stocks were stored at -70°C 
and used for recombinant protein expression.
ijI
iI
i
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4.0.4 Analysis o f  Sf21 insect cell extracts for the expression o f the ICPO related 
proteins after low titre baculovirus infection.
During the amplification of the recombinant baculoviruses, infected cell extracts were 
probed for recombinant protein expression by Western blot analysis. It was necessary to 
ensure that the recombinant protein expressed was of the correct size, as it was possible 
that there may have been a mutation introduced during the cloning or the amplification 
process. During the amplification process of the virus, Sf21 cells in 35 mm dishes were 
repeatedly infected (2-3 times) to increase the viral titre. Cell pellets from the final 35 
mm plate amplification stage were retained and analysed for expression of the ICPO 
related proteins (see figure 4.0.4A).
The Western blot analysis shown in figure 4.0.4A indicates that all the baculoviruses 
expressed recombinant proteins of approximately the correct size. From comparing the 
profile of lanes 1 -4 to that of lane 5 it is possible to see that the anti-myc antibody is 
highly specific for the tagged recombinant proteins as no background binding can be 
observed in the control (lane 5). In lane 1 the protein expressed by Bac BICPO is of the 
predicted size of approximately 97 KDa. In lane 2 the protein expressed by Bac Eg63 
has mobility consistent with its predicted size of 94 KDa. In lane 3 and 4 the proteins 
expressed by Bac EPO and Bac Vg61 are again consistent with their predicted sizes of 
70 KDa and 67 KDa respectively. However, in all the samples there were signs of 
degraded, cleaved or incomplete recombinant proteins; these are the bands lower than 
the predicted size of the recombinant protein that are detected by the antibody. 
Therefore, the Western blot analysis was sufficient to determine that the recombinant 
baculoviruses were expressing the desired members of the ICPO family of proteins at 
this stage of the viral titre amplification procedure.
4.0.5 Analysis o f  Sf21 cell extracts for expression o f the ICPO related proteins after 
high titre baculovirus infection.
High titre stocks of the baculoviruses expressing the ICPO related proteins were 
harvested, and a plaque assay was carried out on each to determine their titre (see 
section 2.8E for further details).
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Figure 4.0.4A Western blot analysis o f Sf21 cell pellet extracts for  
recombinant protein expression following infection with 
baculoviruses expressing the ICPO related proteins.
200 pi of supernatant containing low titre recombinant baculoviruses 
expressing either BICPO, Eg63, EPO and Vg6 l was used to infect 
Sf2l cells seeded on 35 mm dishes (see methods section for further 
details). The cell pellets were harvested 72 hours post infection and 
resuspended in 200 pi of PBS and 100 pi of 3 x boiling mix. 15 pi of 
each of the samples was resolved by SDS-PAGE and the proteins 
were transferred to a nitrocellulose membrane. The nitrocellulose 
membrane was probed with the primary antibody anti-myc (9E10) at 
a concentration of 1/1000. This was followed by anti-mouse 
secondary at a concentration of 1/1000. The Sf21 cells extracts 
analysed are those following infection with: 1= Bac BICPO, 2= Bac 
Eg63, 3= Bac EPO, 4= Bac Vg61 5= Mock extract (no infection). 
The arrows indicate the bands of the sizes expected of the full length 
ICPO-related proteins.
220 KDa
97 KDa 
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Figure 4.0.5A. Coomassie staining and i5S-methionine labelling o f baculovirus 
infected Sf2l cell extracts.
Sf21 cell extracts from high titre baculovirus infections were harvested and 
resolved by SDS-PAGE. Protein expression was detected by either Coomassie 
staining (A) or 35S-methionine labelling of cell extracts (B). The lanes contain 
extracts from the following infections, 1= Bac BICPO, 2= Bac Eg63, 3= Bac EPO, 
4= Bac Vg61, M= Marker, 5= Bac HTA, 6= Bac ICPO, 7= Mock (no infection). 
The recombinant proteins expressed by the baculoviruses are indicated by (•) 
BICPO, (•) Vg61 (•) ICPO.
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Sf21 cells were infected at an MOI of 5 p.f.u./cell with the titred recombinant 
baculoviruses Bac BICPO, Bac Eg63, Bac EPO, Bac Vg61 and the control virus Bac 
HTa that does not have a recombinant gene insert. During infection, the cells were 
radiolabelled with 35S-methionine as described in section 2.8F. The infected cells were 
harvested, lysed in SDS-gel boiling mix and the proteins were resolved by SDS-PAGE 
and analysed for radiolabelled recombinant protein expression (see section 2.8F). The 
results are shown in figure 4.0.5A.
T C - 1 0 0 - m et complete media supplemented with 35S-methionine was added 
approximately 24 hrs post infection. Consequently, any protein made within the cell 
after this time point, including those encoded by the baculoviruses, would incorporate
i f  •
the S-methionine. From the radiolabelled cell extracts (panel B), the following 
interpretations could be made: comparison of lane 7 to lanes 1-5 indicates there is a low 
abundance of radiolabelled proteins 24 hrs post infection expressed by the uninfected 
cells. To aid identification of the novel proteins encoded by the recombinant 
baculoviruses expressing the ICPO related proteins, lane 5 contains Sf21 cell extracts 
that had been infected with Bac HTa, a baculovirus that does not express a recombinant 
protein. The distinctive ladder of proteins encoded by Bac HTa is similar in lanes 1-4 
and 6. This indicates that none of the matching radiolabelled protein bands are the ICPO 
related protein’s encoded by the recombinant baculoviruses (lanes 1-4). In lane 1 a band 
can be observed running above the 97 KDa marker (indicated on figure 4.0.5A), 
indicative of the expression of BICPO from Bac BICPO, as this correlates with the 
proteins predicted size. Lane 4 indicates the VZV homologue of ICPO, Vg61 is being 
expressed by Bac Vg61, as the protein migrates at the predicted size of around 70 KDa. 
Furthermore, there appears to be multiple isoforms of the protein that could be due to 
either post-translational modification such as phosphorylation, or partial degradation of 
the protein, causing a slight smear. This characteristic of Vg61 was also observed when 
this protein was expressed from a plasmid-based system in HEp-2 cells (Parkinson & 
Everett, 2000). Lane 6 shows the extract of cells infected with Bac ICPO; the 
recombinant protein is running at its predicted size of around 110 KDa (Boutell et al., 
2002). Therefore, the baculoviruses encoding ICPO, BICPO and Vg61 are expressing the 
desired proteins. In contrast, expression of neither Eg63 nor EPO could be detected by 
either radiolabelling (panel B) or Coomassie staining (panel A) of proteins in extracts of 
cells that had been infected with Bac Eg63 and Bac EPO. The predicted sizes of the
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proteins if expressed would be approximately 97 KDa for Eg63 of EHV-1 and 70 KDa 
for EPO expressed by PRV.
The infections using Bac Eg63 and Bac EPO were repeated and the Sf21 insect cell 
extracts were analysed by Western blotting (data not shown), but it was not possible to 
detect expression of the recombinant proteins from either Bac EPO or Bac Eg63 (data 
not shown). Furthermore, the construction of Bac Eg63 and Bac EPO was repeated from 
the initial transformation of E.coli DHlOBac with pFastBac HTa containing the Eg63 or 
EPO ORFs. As before, using the final high-titre baculoviruses it was still not possible to 
detect expression of proteins Eg63 or EPO.
4.0.6 Limitations o f the use o f baculoviruses for recombinant protein expression.
From using the final high titre stocks of the recombinant baculoviruses Bac Eg63 and 
Bac EPO to infect Sf21 cells, it was not possible to attain high-level recombinant protein 
expression. This data contradicts the analysis of cell extracts from low titre viral 
infection (Figure 4.0.4A), which indicated that all of the recombinant baculoviruses 
could express heterologous proteins of the correct size. Detection of expression of the 
desired proteins during the amplification of the baculoviruses was an important 
prerequisite before moving onto the next stage of the baculovirus method. Normally cell 
extracts of 5 independent recombinant baculoviruses expressing the same protein would 
be analyzed for the expression of proteins of the correct size. Only then would one 
baculovirus positive for recombinant protein expression be selected for continued 
amplification until a high titre stock was obtained. The results indicate that the 
expression of the recombinant proteins from Bac Eg63 and Bac EPO was unstable after 
passaging of the virus. The amplification of these viruses was repeated from low titre 
stocks, positive for recombinant protein expression, and again the results indicated that 
recombinant protein expression was unstable. The instability was further confirmed 
when the whole baculovirus construction was repeated from the initial transformation of 
E.coli DH10 Bac with pFastBac HTa expressing the recombinant genes. Again 
recombinant protein expression was detected in Sf21 cell extracts previously infected 
with recombinant baculoviruses from the initial rounds of viral amplification, but not 
from the final high titre stocks.
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There are various possibilities as to why recombinant protein expression from Bac Eg63 
and Bac EPO was unstable. The instability of protein expression from the recombinant 
baculoviruses may be due to viruses that have lost the ability to express the recombinant 
transgene (non-expressing viruses) or defective interfering (DI) viruses that accumulate 
upon amplification of the viral titre; it is important to distinguish between the two types. 
It has been widely reported that defective interfering baculoviruses accumulate upon 
serial passage. This has shown to be a major obstacle in the large scale production of 
recombinant viruses and proteins in cell culture systems, this has been described as the 
passage effect (Kool et a l , 1991; Pijlman et a l, 2002; Pijlman et a l, 2001; van Lier et 
a l , 1992). However, defective interfering recombinant baculoviruses are dependent on a 
‘helper virus’ for replication as they contain major genomic deletions of up to 43%, 
including the heterologous gene (Carstens, 1982; Lee & Krell, 1992; van Lier et a l , 
1994). Consequently, as the recombinant baculoviruses are serial passaged, the viral 
titre decreases rapidly as the DI viruses have a replicative advantage over that of the 
intact recombinant baculovirus (Pijlman et al., 2001) and thus become the predominant 
strain. This feature indicates that Bac Eg63 and Bac EPO are not contaminated with DI 
viruses as they had a viral titre (approximately 1 x 109) similar to of recombinant 
baculoviruses Bac BICPO and Bac Vg61, both of which had a high level of recombinant 
protein expression.
This conclusion is further supported by 35S-methionine labelling of Bac Eg63 and Bac 
EPO. The results indicated that both baculoviruses had low recombinant protein 
expression compared to that of Bac BICPO and Bac Vg61; however other shared viral 
encoded proteins were at similar levels. This was because all of the viruses had similar 
titres (as determined by the plaque assays) and the infections were carried out at the 
same MOL Thus if the Bac Eg63 and Bac EPO stocks were contaminated with DI 
particles their titre would be much lower than that of Bac BICPO and Bac Vg61 and it 
would be necessary to use a higher MOI to attain the comparative results shown (see 
figure 4.0.5A). Consequently, it is possible to conclude that the high titre viral stocks 
were not contaminated with defective inferring virus, but as the viral titre remained 
comparable to that of other recombinant baculoviruses, they were contaminated by 
replication competent or interfering baculoviruses that fail to express the desired 
proteins.
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The results indicate that upon amplification of the baculovirus titre, the non-expressing 
viruses become predominant as recombinant protein expression decreases and viral titre 
remains high. Therefore, the non-expressing viruses must have a replicative advantage 
over the baculoviruses expressing the recombinant proteins Eg63 or EPO. The non­
expressing viruses could be generated because of baculovirus genomic instability in 
insect cells. Recently a study was carried out (Pijlman et a l, 2003), that looked at the 
stability of heterologous gene expression in baculoviruses. The technique used to make 
the virus was the Bac-to-Bac system (Invitrogen) as employed in this study. Their 
results indicated that recombinant protein expression was only just detectable by 
passage 10. By using restriction mapping to analyse the viral genome, it was determined 
that this was due to instability of the sequences expressing the transgene, as the non- 
essential expression cassette (mini F replicon, antibiotic resistance genes and the 
heterologous gene) were deleted from the viral genome upon passage in insect cells. 
Therefore, the baculovirus mutants carrying the deletion become the predominant 
species and thus cause a drop in recombinant protein production. It is likely that this is 
analogous to what happened with Bac Eg63 and Bac EPO. It may be that genetic 
rearrangement of the baculovirus genome occurs due to selective pressure from the host 
cell, perhaps caused by the toxicity of the ICPO homologues Eg63 and EPO, leading to 
the generation of a non-expressing virus that has replicative advantage, and becomes 
amplified upon serial passaging.
Another possibility for the drop in recombinant protein production was that a 
contaminating virus was introduced either due to a mixed population of bacmids being 
transfected into Sf21 insect cells during the first stage of viral amplification or a 
contaminating virus arose in the initial amplification stages. It has been shown that 
plaque purifying recombinant baculoviruses made using the Bac-to-Bac system can 
improve the level of expression of a heterologous protein that was initially expressed at 
low level from high titre virus stock, due to the presence of a contaminating virus (R.D. 
Everett, unpublished results). However, as the construction of Bac Eg63 and Bac EPO 
was repeated from a transfection with the original pFastBac HTa encoding Eg63 and 
EPO, and the same loss of recombinant protein expression at high titre occurred, it is 
therefore unlikely that the same experimental error introduced a contaminating virus a 
second time. The following question arises, why would one set of recombinant 
baculoviruses (Bac Eg63 and Bac EPO) be more susceptible to repeated loss in
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heterologous protein production, when this characteristic has not been observed with 
other recombinant baculoviruses made in the same way? However, what is clear is that 
it is not possible to conclude from the current experimental data whether the loss of 
recombinant gene expression is due to a contaminating virus or to a genetic 
rearrangement of the baculovirus genome.
In future, to increase the likelihood of heterologous protein expression from Bac Eg63 
and Bac EPO, it may be necessary to take the recombination approach to the 
construction of recombinant baculoviruses. This involves the infection of insect cells 
with a baculovirus in conjunction with transfection of a plasmid carrying the 
heterologous gene alone. Recombination occurs between homologues regions of the 
viral genome and the plasmid, followed by several rounds of plaque purification to 
isolate the virus and thus reduce the chance of interfering viruses. A possible advantage 
of the recombination approach to baculovirus construction is the reduced size of the 
expression cassette used, as it only contains a coding sequence for the heterologous gene 
and homologous flanking sequence to that of the baculovirus genome, which enables 
recombination to occur. Previously, it has been shown that baculovirus genome stability 
can be improved by reducing the amount of superfluous coding sequence of the 
expression cassette that is present in the Bac-to-Bac system, i.e. removal of antibiotic 
resistance gene, etc (Pijlman et al., 2003). Reduction in the size of the cassette is 
thought to reduce the selective pressure on the viral genome for genetic rearrangement. 
Although it has been reported that a baculovirus genome can take insertion of foreign 
sequences of up to 25 Kbp in length and remain genetically stable (Vlak et al., 1988). 
However, it could be that the selective pressure for genetic rearrangement of the bacmid 
could be due to toxicity of the encoded protein, rather than the size of the corresponding 
sequence. The traditional approach to recombinant baculovirus construction would 
obviously take longer, but if it resulted in a more stable homogeneous population of 
recombinant viruses, it would no doubt make up for the time advantages of the Bac-to- 
Bac system.
4.0.7 Purification o f baculovirus expressed recombinant proteins.
It was only possible to obtain expression of the desired proteins from the high titre viral 
stocks of Bac BICPO and Bac Vg61, as indicated in figure 4.0.5A. Consequently, only
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Figure 4.0.7A. Purification profile o f BICPO(A) and Vg61(B), 
from SJ21 insect cells.
5 fil of each extract was resolved by SDS-PAGE and visualised 
by Coomassie staining. The abbreviations are as follows CE = 
Crude extract, SE= Soluble extract, BB= Bound beads, WB= 
Washed Beads, E l=  Elution 1, E2= Elution 2, E3= Elution 3, 
RB = Remaining beads.
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these viruses were used to infect Sf21 cells for recombinant protein expression and 
purification (see section 2.8G). Sf21 cells were seeded at a cell density of 1 x 106/ml in 
300 ml of medium and infected at an MOI of 5 with Bac BICPO or Bac Vg61 and 
incubated for 3 days at 28°C. Extracts were made from the cells and subjected to metal 
chelate affinity chromatography, samples were retained at each stage of the protein 
purification. Each sample was analysed by SDS-PAGE, as shown in figure 4.0.7A. As 
BICPO and Vg61 were expected to have similar physical properties to those of ICPO, the 
buffer employed was the same as that used to purify ICPO (Boutell et a l, 2002).
The purification profile of BICPO is shown in figure 4.0.7A panel A. It was not possible 
to identify clearly the expressed recombinant protein by Coomassie staining of the 
whole cell extract. However, the 97 KDa BICPO proteins was visible in the soluble 
extract lane, indicating that at least some of the baculovirus-expressed BICPO was 
soluble. Furthermore, the expressed BICPO protein could be bound to the nickel beads 
by virtue of it’s HIS tag, and could be eluted from the beads in the first imidazole wash 
(Elution 1). For future use, the eluted sample of BICPO was dialysed against HIS 
dialysis buffer (see section 2.8G) and stored frozen at -70°C.
The purification profile of Vg61 is shown in 3.0.7A panel B. From analysis of the crude 
extract it is possible to see that Vg61 (approximately 70 KDa in size) was expressed at a 
greater level than that of BICPO. However, the protein was largely insoluble as the Vg61 
protein band was depleted in the soluble extract, although there were minor bands 
visible of mobility similar to that of Vg61 in the soluble extract (between approximately 
66 KDa and 85 KDa). However, at best there were only trace amounts of these bands 
bound to the nickel beads, and none were detectable in the imidazole elution fractions.
4.0.8 Introduction to ubiquitin ligase assay using BICPO1
The aim of this assay was to determine if BICPO had ubiquitin E3 ligase activity similar 
to that of its truncated forms GST-BICP0 and GST-BICP0 1_90 as shown Chapter 3. 
The method used was identical to the one used to assess the ubiquitin ligase activity of 
the GST tagged ICPO related proteins. The ubiquitin ligase assay was carried out in the 
presence of UbcH5a and UbcH6, as these proteins had already been shown in Chapter 3 
to be the E2 partners of the GST-ICP0 related proteins.
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4.0.9 Ubiquitin ligase assay using purified BICPO.
A sample of purified BICPO was used in an ubiquitin ligase assay to determine if it had 
E3 ligase activity. The assay was carried out as stated in section 2.9B, with the 
exception that BICPO was titrated into the reaction (1 -  4 pi of the eluted protein). The 
data indicates (figure 4.0.9 panel A) that BICPO stimulates UbcH5a (Lanes 6 - 9 )  and 
UbcH6 (Lanes 2 - 5 )  and causes the substrate-independent formation of unanchored 
| variable length high molecular weight poly-ubiquitin chains, in a fashion similar to that
I of ICPO (Boutell et a l , 2002). Lane 5 (figure 4.0.8 panel A) contains a reduced amount
i
j of poly-ubiquitin compared to that in lane 4, even though more BICPO was present
(figure 4.0.8 panel B). This effect may be due to an inhibitory agent that remained in 
sample, even after dialysis. Figure 4.0.8 Panel B shows the same blot re-probed with the 
anti-myc tag antibody.
|
The results clearly indicate that full length BICPO acts as an E3 ligase in a fashion 
similar to that of its truncated forms (see Chapter 3). The similarities between full length 
BICPO and its GST-RING finger domain proteins also extend to the molecular weight of 
the poly-ubiquitin that is formed depending on if UbcH5a or UbcH6 was in the ubiquitin 
ligase reaction mix. When UbcH5a is stimulated by full length or truncated GST- 
BICP0, mainly high molecular weight polyubiquitin is formed, and when UbcH6 is 
stimulated the polyubiquitin formed ranges from low to high molecular weight causing a 
uniform distribution down the gel. The characteristic pattern of polyubiquitin is also 
similar to that observed with the GST-ICP0 related proteins. The significance of the 
polyubiquitin chain length is discussed in further detail in Chapter 3.
I
|
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Figure 4.0.9A E3 ligase activity o f BICPO.
In vitro ubiquination assay was carried out as described in section 2.9B, with the 
exception of the concentration of the full length protein BICPO. The protein 
BICPO (20 ng/pl) was titrated into the assay to assess its potential activity as an 
E3 ligase. In lanes 2 to 5 the E3 ligase assay was carried out in the presence of 
UbcH6 , in lanes 6 to 9 in the presence of UbcH5a. Lane 1 = Control (No E2 
present.). Blot A was probed with a-Ub at 1/1000 and blot B a-myc 1/1000, 
followed by the secondary antibody hrp-conjugated anti-mouse antibody 1/1000 .
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Chapter 4 - Part II - I n  v i v o  analysis of ICPO 
related proteins.
4.1.0 Introduction to studies analysing the in vivo biological properties o f the ICPO 
related proteins.
The results presented in the previous section and in Chapter 3 indicate that full length 
BICPO and the other ICPO related proteins in vitro are able to stimulate UbcH5a and 
UbcH6 in a similar fashion to that of ICPO, as described previously (Boutell et al., 
2002). As an alternative approach to assess the biological significance of the in vitro 
ubiquitin ligase activity, the distribution of the UbcH5a, UbcH6 and cdc34 in the 
presence of the ICPO related proteins could be investigated in transfected cells. 
Previously it had been demonstrated that the E3 activity of ICPO itself was not an in 
vitro artefact and could be replicated in vivo, as colocalisation between ICPO, UbcH5a 
and UbcH6 could be observed, but not between ICPO and cdc34 (Boutell et a l, 2002). 
However, it has been reported that cdc34 and ICPO do have a relationship in vivo and in 
vitro. ICPO was reported to interact with cdc34 and mediate its relocation to ND10 
structures within the nucleus (Kawaguchi et a l, 1997b; Van Sant et a l, 2001b). 
Furthermore, a fragment of ICPO unrelated to the RING finger was reported to cause 
limited auto-ubiquitination of cdc34 (Van Sant et a l, 2001a), causing it to be degraded 
in a proteasome-dependent manner (Hagglund et a l, 2002). If cdc34 is targeted in this 
manner by ICPO, it could explain why ICPO might bring about the reported stabilization 
of both cyclin D3 and DI during HSV-1 infection (Van Sant et a l, 2001b). The 
relationship of ICPO and cdc34 is discussed in more detail in the Introduction, but as 
described there, it is likely that most or all the observations concerning ICPO and cdc34 
are artefacts. Indeed, an E3 ligase activity of ICPO with cdc34 can not be reproduced 
(Boutell et a l, 2002), and more recent analysis has proved that ICPO has no effect on 
cdc34, cyclin DI and cyclin D3 during HSV-1 infection (Everett, 2004). Nonetheless, it 
was important to examine if the ICPO related proteins’ relationships with cdc34 differ 
from that of ICPO. The homology between ICPO and the ICPO related proteins is limited 
to that of their RING finger domains, thus it is feasible that the ICPO related proteins 
may have different biological properties with cdc34 in vivo, even though they do not 
stimulate cdc34 and facilitate the formation of polyubiquitin in vitro. Therefore, the aim
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Figure 4.1.2 A Schematic representation o f  the construction o f  pFastBac HTa CMV plasmids expressing ICPO 
related proteins.
The plasm ids were constructed as follows: 1) A fragm ent encoding BICPO was rem oved from  pFastB ac HTa 
BICPO by using the restriction enzym es NcoI and Hpal. 2) A fragm ent encoding Eg63 was rem oved from  
pFastBac HTa Eg63 by using the restriction enzym es Nco\ and Hpal. 3) A fragm ent encoding EPO was 
removed from  pFastBac HTa EPO by using the restriction enzym es Ncol and Hpal. 4) A fragm ent encoding 
Vg61 was rem oved from  pFastBac HTa Vg61 by using the restriction enzym es Ncol and Hpal. The ICPO 
related proteins O RFs ( 1 - 4 )  were ligated into pFastBac HTapCI (Hindlll-Hpal) in conjunction w ith the 
DNA fragm ent HCM V + HIS (Hindlll -  Ncol). The HCM V + HIS fragm ent (show n in blue) encodes the 
HCM V IE prom oter upstream  from an in frame 6 x HIS tag. It was isolated from  pFastBac HTa CM V .H IS. 
ICPO by an in fram e Ncol -  Hindlll digestion. Insertion o f  this DNA fragm ent in to the recipient vector 
pFastBac HTapCI w ould allow from the resulting baculoviruses in frame expression o f  6 x HIS tagged ICPO 
encoding ORFs.
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promoter situated upstream from a sequence encoding a 6 x HIS tag, and was excised 
from pFastBacHta-CMV.HisICPO by digestion with Hindlll and Ncol at the 5’ and 3’ 
ends of the desired fragment, respectively. The three fragments were ligated as follows: 
The recipient vector pFastBacHTa-pCI was digested with Hindlll (5’) and Hpal (3’). 
This enabled in-frame ligation of the DNA fragment containing the HIS tag and HCMV 
IE promoter upstream of the fragment encoding the ICPO homologue (see figure
4.1.1 A.). The ligated plasmid was transformed into E.coli DH5a. The cloned DNA was 
isolated by the mini-prep method and screened by restriction analysis and sequencing to 
confirm the identity of positive clones.
Once the pFastBacHTa-pCI series of plasmids expressing the HCMV IE promoter 
driven ICPO homologues had been constructed and their identities had been confirmed 
by DNA sequencing (see section 2.4D), the method used to create the recombinant 
baculoviruses was identical to that stated previously in section 3.0.3. The resultant 
baculoviruses expressing the HCMV driven ICPO related proteins were named Bac 
CMV BICPO, Bac CMV Eg63, Bac CMV EPO and Bac CMV Vg61. Stocks of these 
viruses were generated and titrated following the same methods described previously for 
baculoviruses used for recombinant protein expression in insect cells.
4.1.3. Confirmation o f the identity o f  recombinant baculoviruses expressing HCMV 
driven ICPO related proteins.
HEp-2 cells were infected with the baculoviruses encoding the CMV driven ICPO 
related proteins to confirm that they were expressed in mammalian cells, and that the 
proteins were of the correct size. Cell extracts were analysed for recombinant protein 
expression by Western blot analysis (See figure 4.1.3A). The expressed recombinant 
proteins from Bac CMV BICPO (Lane 2) and Bac CMV Vg61 (Lane 5) were of the 
correct size, BICPO approximately 97 KDa and Vg61 66 KDa. Low-level expression 
was detected from Bac CMV EPO (Lane 4), and the expressed protein was again of the 
expected size. However, Bac CMV Eg63 expressed only low levels of an apparent 
recombinant protein, but this was not of the expected size of approximately 97 KDa. 
The generation of Bac CMV Eg63 was repeated and the same problems of low 
expression of the protein and incorrect size occurred. Expression levels from this group 
of baculoviruses as detected by Western blot analysis were variable; therefore
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Figure 4.1.3A. Analysis o f  HEp-2 cell extracts fo r  
recombinant protein expression.
Bac CMV BICPO, Bac CMV Eg63, Bac CMV EPO and Bac 
CMV Vg61 were used to infect HEp-2 cells at an MOI of 
100 and incubated at 32°C for approximately 24 hours. The 
cell pellets were analysed for recombinant protein expression 
by SDS-PAGE analysis and Western blotting. The blot was 
probed with primary anti-6 x HIS antibody at a concentration 
of 1/750 and secondary hrp-conjugated anti-mouse antibody 
at 1/1000. The lanes are extracts of HEp-2 cells infected 
with the following: 1 = Mock extract (no infection), 2 = Bac 
CMV BICPO, 3 = Bac CMV Eg63, 4 = Bac CMV EPO, Bac 
CMV Vg61. The expressed recombinant proteins are 
indicated (*) See text for analysis.
Figure 4.1.4A. Immunostaining o f  HEp-2 cells following 
infection with Bac CMV BICPO, Bac CMV Vg6l and Bac 
CMV ICPO.
All baculoviruses were used at an MOI of 200 and cells were 
fixed 24 hours post transfection. A) A typical cell infected 
with Bac CMV BICPO. B) A typical cell infected with Bac 
CMV ICPO. C) A typical cell infected with Bac CMV Vg61 
D) Negative (No infection). The negative cell was isolated 
from the same field o f view as the Bac CMV Vg61 cell. This 
was to provide an indication o f background fluorescence. 
The cells were stained with the primary mouse monoclonal 
antibody anti-HIS at a concentration 1/750. The secondary 
antibody used was FITC-conjugated goat anti-mouse IgG 
(Amersham) at 1/100.
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immunostaining was used to determine if the baculoviruses expressed detectable levels 
of the recombinant proteins in individual HEp-2 cells.
4.1.4. Immunostaining o f HEp-2 cells following baculovirus infection.
HEp-2 cells were infected with Bac CMV BICPO, Bac CMV Eg63, Bac CMV EPO and 
Bac CMV Vg61 as stated in section 2.8H. The infections were repeated and 
reproducible results were attained for Bac CMV BICPO and Bac CMV Vg61, by 
infecting HEp-2 cells at an MOI of 200 based on the titres of these viruses in Sf21 insect 
cells (see figure 4.1.4A). The expressed BICPO produced ring-like structures in the 
nucleus. The larger rings were incomplete and arcs of stained material frequently 
appeared. The foci of the expressed Vg61 tended to be quite small and uniform in size, 
but not in shape. Unlike BICPO, Vg61 was uniformly distributed around the foci. The 
morphology of the foci of BICPO and Vg61 was consistent, and very similar to that 
previously described using a plasmid transfection approach (Parkinson & Everett, 2000, 
2001), indicating that the baculovirus method was successful in expressing the 
recombinant proteins in cultured cells.
The baculovirus approach was an efficient method to observe the biological properties 
of BICPO and Vg61 in vivo. By using Bac BICPO and Bac Vg61 at an MOI of 200 the 
majority of cells seeded at 1 x 105 were consistently infected during repeated 
experiments, a higher ratio than the transfection approach. Using recombinant 
baculovirus to transduce the mammalian cells eliminated the variability in the number of 
positive cells that occurs when using the transfection approach to study the expression 
of recombinant proteins. The ability of the baculoviruses to transduce a large number of 
cells means they will be highly useful reagents to study the biological properties of 
BICPO and Vg61 in a large number of cell types.
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4.1.5. Plasmid based expression o f the full-length ICPO related proteins in cultured 
cells.
The original aim of this series of experiments was to carry out the analysis of the 
members of the ICPO family of proteins using the baculovirus expression system. 
However, as mentioned in sections 4.1.2 and 4.1.3, it was not possible to express Eg63 
or EPO using the baculovirus clones that had been isolated. Therefore, to study the 
members of the ICPO family of proteins and to maintain consistency a plasmid based 
transfection system was employed as used previously (Parkinson & Everett, 2000, 
2001). The ICPO family members were expressed using the pCIrtag plasmid system, 
which is an adaptation of the plasmid pCIneo (Promega). A schematic overview of this 
system is shown in figure 4.1.5A. The ICPO related proteins were tagged at their N- 
terminal ends with an epitope derived from the C-terminal end of HSV-1 protein UL30, 
which is referred to in the remainder of the text as ‘rtag’. The plasmids coding the ICPO 
related proteins were co-transfected with plasmid encoding FLAG tagged UbcH6 and 
cdc34. Ideally, a plasmid expressing FLAG-tagged UbcH5a would also be used for 
these cotransfection experiments, but in this series of experiments the levels of 
expression of FLAG-tagged UbcH5a were insufficient to be readily detected by 
immunofluorescence (data not shown). The sections below outline the methodology 
taken to analyse the biological properties of the ICPO related proteins with UbcH6 and 
cdc34.
4.1.6. Immunostaining o f HEp-2 cells cotransfected with plasmids expressing ICPO 
related proteins and UbcH6 or cdc34.
The pCIrtag plasmid based system was used to express the members of the ICPO family 
of proteins that are the subject of this study, while FLAG-tagged UbcH6 and cdc34 
were expressed from plasmids based on the pCMV2 vector. Plasmids expressing an 
ICPO related protein with an N-terminal rtag were co-transfected with a plasmid 
expressing FLAG-tagged UbcH6 or cdc34. One-day post transfection, the cells were 
fixed, permeabilised, then stained with rabbit serum rl 13 to detect the rtag, and 
monoclonal antibody M2 to detect the FLAG tag. The primary antibodies were detected 
using FITC or Cy5 labelled secondary antibodies, then the samples were examined by 
confocal microscopy. When expressed by themselves, the E2 ubiquitin conjugating
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Figure 4.1.5A Schematic diagram o f the pCI-rtag series o f plasmids 
expressing the ICPO related proteins.
The pCI-rtag plasmid is derived from pCIneo. The plasmid contains a HCMV 
promoter to enable expression of the ICPO-derived family of proteins in 
mammalian cells post transfection. Down stream from the HCMV promoter is 
a SV40 intron followed by the C terminal peptide of HSV-1 UL30. The UL30 
coding sequence is upstream from the ICPO-derived family coding sequence, 
consequently when expression occurs from the HCMV IE promoter it is 
introduced as a N terminal fusion tag.
Figure 4.1.6A. Immunofluorescence o f  BICPO and 
Eg63 with UbcH6 or CDC34 in vivo.
Figure 4.1.6B. Immunofluorescence o f  EPO and Vg61 with UbcH6 
or CDC34 in vivo.
HEp-2 cells were transfected with plasmids expressing tagged 
(FLAG) E2 enzymes, UbcH6 or cdc34 and the tagged (rtag) ICPO 
homologues, EPO and Vg61. The antibodies were used at the 
following concentrations, anti-FLAG tag monoclonal M2 (Sigma) 
was used at 1/300, with the secondary antibody FITC goat anti­
mouse (IgM) (Sigma 1/100); the primary antibody anti-rl 13 1/5000, 
followed by the secondary Cy5-conjugated goat anti-rabbit IgG 
(Amersham; 1/500). A) The Cy5 labelled UbcH6 control. B) The 
Cy5 labelled cdc34 control. (C to E) The single and merged 
channels for cells coexpressing EPO and UbcH6. (F to H) The 
single and merged channels for cells coexpressing EPO and cdc34. 
(I to K) The single and merged channels for cells coexpressing 
Vg61 and UbcH6. (L to N). The single and merged channels for 
cells coexpressing Vg61 and cdc34.
cdc34-Cy5
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Figure 4.1.6B. Immunofluorescence o f  EPO and Vg61 
with UbcH6 or CDC34 in vivo.
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enzymes UbcH6 and cdc34 were diffusely distributed, mostly in the nucleus of the cell 
(figure 4.1.6A, panel A and B). In the presence of a co-expressed member of the ICPO 
family, UbcH6 was partially sequestered in co-localising foci, particularly in the 
presence of BICPO (figure 4.1.6A, panel C to E), Vg61 (figure 4.1.6B, panel G to I), 
Eg63 (figure 4.1.6A, panel I to K.), and to a lesser extent with EPO (figure 4.1.6, panel 
A to C). However, it was clear that none of the ICPO related proteins, BICPO (figure 
4.1.6B, panel F to H), Eg63 (figure 4.1.6A, panel L to N), EPO (figure 4.1.6B, panel D 
to F), or Vg61 (figure 4.1.6b, panel J to L), sequestered cdc34 into colocalising foci. 
These results are very reminiscent of those obtained with ICPO itself (Boutell et al., 
2002).
4.1.7 Conclusion o f the immunofluorescence using the ICPO related proteins.
The results shown in figure 4.1.6A and 4.1.6B are typical of the immunofluorescence 
observations seen with the members of the ICPO family of proteins and the E2 enzymes 
UbcH6 and cdc34. From repeated experiments, the following interesting consistencies 
were observed: BICPO tended to form large arcs or rings (figure 4.1.6A, panel C) while 
sequestered UbcH6 (figure 4.1.6A, panel D) were localised within the BICPO ring-like 
structures. Consequently, when the channels are merged (figure 4.1.6A panel E), BICPO 
is distributed around the periphery of the foci and UbcH6 is in the middle. From 4.1.6B 
panel F and G it can be seen that formation of BICPO foci occurs in the presence of 
cdc34 although cdc34 is not recruited into the BICPO foci. EPO (figure 4.1.6B, panel A 
to C) also sequestered UbcH6 (figure 4.1.6A, panel A), although foci formation by this 
member of the ICPO related proteins was rare, normally limited to only a few cells in the 
sample and frequently the foci were located only in the nucleolus. When either Eg63 
(figure 4.1.6A, panel L to N) or EPO (figure 4.1.6B, panel D to F) proteins were 
expressed in the presence of cdc34 it was not possible to observe foci formation in cells, 
even though immunostaining was indicative of co-expression. This may be due to 
expression levels from the transfected plasmids encoding Eg63 and EPO, although this 
series of experiments was repeated with varying concentrations of plasmid to eliminate 
this possibility. Finally, Vg61 (figure 4.1.6B, panel J to L) formed foci in the presence 
of co-expressed cdc34 (although there was no co-localisation), however these foci were 
distinctly smaller than the foci observed when transfected with UbcH6 (figure 4.1.6B, 
panel G to I). From the immunofluorescence it could be seen that each of the ICPO
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homologues formed foci that were characteristic of that specific protein and these results 
replicate observations made previously using the same expression system (Parkinson & 
Everett, 2000, 2001).
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Chapter 4 - Part III -  Complementation of an ICPO 
negative virus with the ICPO related proteins.
4.2.0. Introduction to the complementation assay.
The HSV-1 strain d/1403 (Stow & Stow, 1986) is an ICPO negative vims that initiates 
lytic infection inefficiently, especially in low MOI infections of certain cell lines 
(Everett et al., 2004). This phenotype is particularly apparent in limited-passage human 
fibroblast cells and to a lesser degree in BHK and Vero cells. However, in U20S cells 
ICPO is not required for efficient HSV-1 infection and dl1403 replicates as efficiently as 
a wild type vims (Yao & Schaffer, 1995). In cells where the mutation does limit growth, 
the phenotype is multiplicity dependent and can be overcome at high MOI (Sacks & 
Schaffer, 1987). However, at a low MOI the ICPO negative vims becomes quiescent, 
although the lytic cycle can be initiated by introducing ICPO into the cells (Harris et al., 
1989; Preston, 2000; Stow & Stow, 1989). This series of experiments analyses whether 
the ICPO related proteins, like ICPO, can overcome the cellular repression mechanisms 
that prevent expression from the quiescent d/1403 genomes, thus enabling the lytic 
infection to be resumed.
4.2.1. Optimisation o f the complementation assay o f dll403 by the ICPO related 
proteins.
Initially to deduce the optimal amount of plasmid encoding the ICPO related proteins 
that was needed to complement d/1403 and to act as a basis for future experiments, Vero 
cells were seeded on 35 mm plates and cotransfected with 100 ng - 300 ng of pCIrtag 
plasmids encoding ICPO, BICP0, Eg63 or pCIrtag alone (negative control) and 2 pg of 
d/1403 DNA (section 2.7C). Following transfection, the cells were incubated for 72 
hours, where upon the plaques were counted (see table 4.2.1). The tabulated data was 
also plotted for easier comparison (see figure 4.2.1 A) of the degree of complementation 
that occurred (inferred from the number of plaques). The results show that it is possible 
to complement d/1403 with a plasmid encoding HCMV IE driven ICPO or an ICPO 
related protein using the transfection method. Furthermore, the results indicate that 
complementation was most efficient using 200 ng of plasmid encoding ICPO or the
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Figure 4.2.1A. Optimisation o f  the complementation assay o f  the ICPO 
negative virus d l l403.
The members of the ICPO are shown along the X axis and the number of 
plaques are along the Y axis. 35 mm dishes seeded with Vero cells were 
transfected with 2 pg of dl 1403 DNA and 100 -  300 ng of plasmids 
encoding ICPO or the ICPO related proteins. At 72 hours post transfection 
the plaques were counted following Giemsa staining (see methods section 
for further details). pUC9 was used as a negative control. The legend 
indicates the amount of plasmid in ng encoding ICPO or the ICPO related 
protein or the negative control.
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ICPO related protein, and 2 pg of ell 1403 DNA. Following these initial positive results 
all of the plasmid encoded ICPO related proteins were tested in this assay.
Number o f  plaques
Amount of plasmid BICPO Eg63 ICPO Negative control
100 ng 326 196 636 7
200 ng 508 445 813 12
300 ng 703 132 767 3
Table 4.2.1. Optimisation of the complementation assay of d/1403.
4.2.2. Complementation assay o f dll403 using full-length members o f the ICPO 
family o f  proteins.
The aim of this experiment was to test whether all o f the ICPO family were able to 
complement d/1403. The method used was identical to that used in section 4.2.1. The 
experimental data was variable between different experiments due to varying 
transfection efficiencies, therefore to make the data more comparable between replicate 
experiments the fold activation was calculated (see table 4.2.2). The mean fold
BICPO Eg63 EPO Vg61 ICPO Control
Plq# FdA# Plq# FdA# Plq# FdA# Plq# FdA# Plq# FdA# Plq# FdA#
1 328 109 98 33 101 34 25 8 438 146 3 -
2 172 86 80 40 50 25 10 5 210 105 2 -
3 420 140 186 62 129 43 45 15 531 177 3 -
Mean - 112 - 45 - 34 - 9 - 143
Table 4.2.2. Complementation of d/1403 with pCI-rtag plasmids expressing members 
of the ICPO family of proteins.
Plq# = Number of plaques. FdA# = Fold activation. The fold activation was calculated by number of 
plaques for each homologue per experiment divided by that of the negative control. The mean was 
taken o f the fold activation and was plotted in figure 4.2.2A.
activation and standard error of the mean are shown in figure 4.3.1 A. The 
complementation assays demonstrate how efficiently the members of the ICPO family 
complement d/1403. ICPO gave the highest fold activation and thus complements 
d/1403 most efficiently. From the results with the other members of the ICPO family it 
can be seen that BICPO has the greatest activity, whereas Eg63 and EPO are significantly
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Figure 4.2.2A. Complementation o f the ICPO negative virus dll 403.
The ICPO homologues are shown along the X-axis and fold 
activation is shown along the Y-axis. pUC9 was used as a negative 
control. 35 mm dishes seeded with Vero cells were transfected with 
1 pg of d/1403 DNA and 200 ng of plasmid encoding ICPO or the 
ICPO related proteins. At 72 hours post transfection the plaques 
were counted following Giemsa staining (see methods section for 
further details) and the fold activation was calculated. The fold 
activation is plotted in conjunction with the standard error of the 
mean, shown by the error bars.
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less efficient, with both having a similar effect. Finally, Vg61 gave the lowest level of 
complementation. The control indicates that in Vero cells without the presence of a co­
transfected plasmid expressing a member of the ICPO family, the recovery of virus from 
transfected d/1403 DNA was very low under the conditions employed. These data 
indicate that the members of the ICPO family of proteins can complement an ICPO 
negative virus and relieve cellular repression mechanisms so that the lytic cycle can 
commence.
4.2.3. The significance o f the complementation assay o f  the dll403 by the ICPO 
related proteins.
The results in section 4.2 confirm what is already known and expand upon previous 
studies of cross-complementation of the ICPO related proteins of BHV-1, EHV-1, PRV 
and VZV. It has been previously shown that the ICPO related proteins encoded by ORF 
61 of VZV and ICPO of HSV-1 can complement a PRV EPO deletion mutant in cell 
culture (Moriuchi et al., 1995) and reactivate it from latency in animal models (Smith & 
Cheung, 1998). Furthermore, cell lines expressing ORF61 partially complement the 
growth of HSV-1 ICPO negative mutants which fail to express functional ICPO 
(Moriuchi et a l, 1992). The Eg63 protein of EHV-1 was also shown to partially 
complement a HSV-1 ICPO deficient virus (Everett et al., 1995b). The results with Eg63 
and Vg61 support the previously published data (Everett et al., 1995c; Moriuchi et al., 
1992). The data in section 4.2 indicate that BICPO of BHV-1 and EPO of EHV-1 are also 
able to complement an HSV-1 ICPO deletion mutant. Significantly, the degree of 
complementation (inferred from the level of fold activation) varies amongst the ICPO 
related proteins; BICPO was the most efficient at complementing an ICPO negative 
virus, with Eg63, EPO and Vg61 only being able to carry out this to a lesser degree. 
However, when making this conclusion it is important to take in to account the relative 
transfection efficiencies of the different plasmids, and probably the degree of expression 
of the individual ICPO family members. From the immunofluorescence work carried 
using the plasmids to express the ICPO related proteins shown earlier in this chapter and 
published previously (Parkinson & Everett, 2000, 2001), it is possible to conclude that 
using the same amounts of plasmids, BICPO and Vg61 were expressed more efficiently 
than Eg63 and EPO. This is an important factor to take into account when deducing 
which ICPO related protein most efficiently complements d/1403. If Eg63 and EPO 
could be expressed at levels similar to those of the other ICPO related proteins, the
179
‘t — n c su im  aiiu  L / / o o u o o / u / / .
degree of complementation may have been higher, perhaps closer to that of BICPO. 
However, despite Vg61 being expressed well in transfected cells, it had the lowest 
activity in the complementation assay. Therefore, out of the all of the ICPO related 
proteins tested, Vg61 was the least efficient at complementing the ICPO-null virus 
d/1403.
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Chapter 5 - General Discussion.
5.0.1. The alphaherpesvirus homologues o f ICPO act as ubiquitin E3 ligases.
The role of ICPO as an ubiquitin E3 ligase is becoming increasingly well characterised, 
from initial studies that showed ICPO binds to USP7 (Everett et al., 1997) and disrupts 
constituents of ND10 (reviewed in Everett, 2001) to the most recent that have 
characterised the ICPO-mediated ubiquitination of p53 in vitro (Boutell & Everett, 
2003b, 2004). However, unlike ICPO, the functions of its homologues in other members 
of the alphaherpesvirus family were relatively unclear. It had been previously shown 
BICPO, Eg63, EPO and Vg61 to varying degrees cause the formation of colocalising 
conjugated ubiquitin and disrupt the constituents of ND10 and in some cases 
centromeres (Parkinson & Everett, 2000, 2001). Furthermore, Eg63 had been shown to 
disrupt ND10 in a proteasome-dependent manner (Parkinson & Everett, 2000). 
Collectively, this research provided strong evidence that the ICPO family of related 
protein functions via an active ubiquitin-proteasome degradation pathway. However, 
due to the variability in the result observed by Parkinson & Everett (2000 & 2001) and 
the fact the homology of the ICPO related proteins is largely limited to the structurally 
coordinating residues of their N-terminal RING finger domains, it was not conclusive 
that the ICPO related proteins all worked via the same mechanism to disrupt ND10.
This study shows that despite the difference in the intrinsic biological properties and 
their limited homology, the members of ICPO family of proteins all function as ubiquitin 
E3 ligases, in a manner similar to one another and to that of ICPO. By using the isolated 
RING finger domains, it was shown that the ICPO related proteins stimulate the same E2 
partners as ICPO. Furthermore, in the case of BICPO the E3 ligase activity of the full- 
length protein appeared to be similar to that of its isolated RING finger domain (GST- 
BICP0). Despite the fact that the E3 ligase activity of all of the full-length ICPO 
homologues was not characterised, the data suggests the isolated RING finger domain 
provides an accurate indication of E3 ligase activity and E2 specificity. This is 
supported by previous research that showed full-length ICPO has similar E3 ligase 
activity to its isolated RING finger domain (ICPO-241) (Boutell et al., 2002). 
Transfection assays further illustrated the fact that the ICPO family of proteins have E3
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ligase activity similar to that of ICPO, and they were shown to colocalise with 
exogenous UbcH6 in transfected cells.
Previous research has generally shown the ICPO homologues share similar biological 
properties. In particular, they are all strong transactivators of heterologous and 
homologous promoters in gene expression assays (see section 1.8.0. and references 
therein). Furthermore, this study has shown that to varying degrees the ICPO related 
proteins can complement an ICPO-null virus. In addition, the ICPO related proteins were 
shown to function as E3 ligases in a similar manner, in vitro. Consequently, one of the 
most significant variations in the biological properties of the ICPO family of proteins is 
their ability to disrupt constituents of ND10 (Parkinson & Everett, 2000, 2001).
It has been proposed that ND10 play an essential role in repressing viral gene expression 
and disruption of a characterised or as yet uncharacterised constituent by ICPO may be 
crucial in allowing HSV-1 replication to resume. Based on this hypothesis, the differing 
ability to disrupt ND10 may contribute to the variation in the biological properties 
amongst the alphaherpesviruses. It is possible that the alphaherpesviruses that more 
readily disrupt ND10 or its constituents will be more likely to reactivate from latency. 
For instance, VZV is associated with one or two reactivativation events throughout the 
lifetime of the infected host, and Vg61 least readily disrupts certain components of 
ND10 (see figure 1.8.6A), thus preventing the removal of a potential ND10 viral 
repression mechanism. However, it should be considered that the constituents of ND10, 
which VZV may more readily target are yet to be identified, or that this could possibly 
be a deliberate function of the virus to ensure that it remains latent. The latter has been 
shown to be the case for other herpesviruses such as EBV, which tightly controls the 
balance between lytic/latent infections via a number of proteins. One such protein is 
LMP-2A that has a role in interfering with the signalling cascade that would lead to the 
induction of the lytic cycle in infected B cells (Masucci, 2004).
An additional mechanism, which could determine frequency of viral reactivation 
amongst the alphaherpesviruses, is substrate interaction and specificity. Previously, 
ICPO has been shown to interact with p53 via residues within its C terminus (Boutell & 
Everett, 2003b). It is therefore possible as sequence homology amongst the ICPO family 
of proteins is largely limited to the RING finger domain and the divergent sequence out 
side of it may determine which cellular or ND10 components and indeed to what degree
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become degraded. The varying RING finger flanking sequence amongst the ICPO family 
of proteins may therefore be determining specificity and affinity for substrate proteins 
that could be part of a NDlO-mediated viral repression mechanism. For example, ICPO 
readily disrupts ND10 substructures unlike Vg61, consequently this may partially 
explain why VZV reactivates less frequently than HSV from latency.
5.0.2. Characterisation o f the E3 ligase activity o f Eg63.
The E3 ubiquitin ligase activity of the ICPO homologue Eg63 was extensively 
characterised within these studies. Initially, it was shown that the isolated RING finger 
domain of Eg63 (GST-Eg63) has E3 ligase activity similar to that of the other GST- 
ICPO related proteins. However, upon deletion of approximately 40 amino acids from 
the C-terminus of GST-Eg63, to create GST-Eg63 1_63, caused nearly a complete 
abrogation of the protein’s ability to stimulate UbcH6, but not UbcH5a, in the ubiquitin 
ligase assay. It was possible the inability of GST-Eg63 1 63 to stimulate UbcH6 may 
have been due to its failure to bind to the E2, suggesting that the deleted residues from 
the C-terminal side of the core RING domain may play an essential part in their 
interaction. However, it was also possible the deletion caused the two proteins to 
interact in a non-productive manner, whereby Eg63 1 63 sequesters UbcH6. The 
interaction assay showed that despite deletion of residues from the C-terminal side of 
the core RING domain, a stable interaction still occurred between GST-Eg63 1_63 and 
UbcH6. The inhibition assay using an optimised amount of GST-Eg63 showed that at 
the amount used GST-Eg63 1_63 did not sequester UbcH6. However, this possibility 
cannot be ruled out, the results observed may have been due to an insufficient amount of 
GST-Eg63 1 63 being present in the reaction to sequester UbcH6, therefore at a higher 
amount a decrease in poly-ubiquitin formation by GST-Eg63 may have been observed. 
Conversely, an excess of UbcH6 may have been present in the reaction, therefore by 
using a lower amount a decrease in the activity of GST-Eg63 may have been detected.
5.0.3. Autoubiquitination o f the ICPO homologues in vitro.
ICPO has been shown to autoubiquitinate itself in vitro (Boutell et al., 2002) and in vivo 
(Canning et al., 2004). In the latter case, it is targeted for proteasome-mediated 
degradation, promoting its own turnover. To promote its own stability ICPO interacts 
with USP7 (ubiquitin-specific protease 7), a member of a family of cellular enzymes
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that cleave ubiquitin from either alpha or isopeptide-linked chains, via residues located 
within its C-terminus (Everett et al., 1997). Research has shown that if the ICP0-USP7 
interaction is in some way inhibited, the ability of ICPO to function in gene expression 
and viral growth assays is greatly reduced (Everett et ah, 1999d), as the ICP0-USP7 
interaction has been shown to promote the stability of ICPO in vivo (Canning et a l, 
2004).
The results shown in this study indicate the ICPO homologues, like ICPO, undergo 
autoubiquitination in vitro. However, unlike ICPO, its homologues used in this study do 
not bind to USP7, nor indeed contain a USP7 binding domain. On the face of it, this 
would suggest the ICPO homologues are more susceptible to autoubiquitination and 
subsequent proteolysis than 
ICPO. However, this is on the 
assumption that the ICPO 
homologues are equally as 
susceptible to
autoubiquitination. From table
5.0.3A, it can be seen that 
BICPO, Eg63 and EPO contain 
fewer lysine residues than 
ICPO. Furthermore, as
determined by the Poisson 
distribution the number of 
lysine residues present in each 
of the ICPO related proteins is 
far less than would be 
expected. The ICPO
The table shows the actual number and expected (Exp) number of K 
homologues of HS V 1, HSV 2 r e s i d u e s  a s  determined by the Poisson distribution (calculations not
and HVB contain more lysine Shown) within each of the ICPO related proteins.
residues than BICPO, Eg63 and EPO, but additionally they contain a USP7 binding site.
Therefore, it is possible that two mechanisms have evolved to protect the stability of the
ICPO homologues in vivo. Firstly, BICPO, Eg63 and EPO do not contain a USP7 binding
site, however to compensate they only contain a few lysine residues; therefore by
reducing the number of residues, this would decrease the level of autoubiquitination and
subsequent chance of proteolysis. Furthermore, the folding of the protein may limit the
ICPO
Homologue
USP-7
binding
site.
K Length
(a.a.) K
EPO
BICPO
Eg63
(ICPO)
HSV-1
ICPO
(HVB)
ICPO
(HSV-2)
Vg61
No 1 410 21.3
No 2 676 35.2
No 3 532 27.7
Yes 8 775 40.3
Yes 6 699 36
Yes 6 825 42.9
No 24 467 24.2
Table 5.0.3 A The number o f  lysine residues within the ICPO
family o f  proteins. The workshown was carried out by D. 
Gatherer.
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number of lysine residues susceptible to autoubiquitination and the level of viral 
expression of BICPO, Eg63 or EPO may be sufficient to compensate for the level of 
proteolysis that occurs from autoubiquitination. Second, ICPO and its homologues in 
HSV-2 and HVB contain a larger number of lysine residues, which is still significantly 
lower than the number expected (see table 5.0.3). Therefore, it is equally possible these 
proteins have evolved to contain a low number of lysine residues to limit proteolysis in 
the cell. However, the USP7 binding domain may provide an additional safeguard to 
limit proteolysis due to the increased number of lysine residues compared to BICPO, 
Eg63 and EPO. This theory is supported by the fact that BICPO is most similar in size to 
ICPO, however it does not contain a USP7 binding domain, but may compensate to limit 
autoubiquitination by containing only two lysine residues to that of ICPO’s eight. The 
potential increased stability of BICPO may partially explain why it has been shown to 
have a phenotype most similar to that of ICPO, when it comes to disrupting ND10 and 
its various constituents (see Parkinson & Everett, 2000 and figure 1.8.6A) and 
complementing an ICPO-null virus. It is also important to consider that the human 
genome encodes at least 90 potential deubiquitinating enzymes (Chung & Baek, 1999) 
many of these deubiquitinating enzymes are thought act as a “proof-reader” targeting a 
specific subset of ubiquitinated proteins (Chung & Baek, 1999). However, BICPO or 
any other of the ICPO homologues that cannot bind to USP7 may maintain their stability 
in vivo by binding to a yet uncharacterised deubiquitinating enzyme. Furthermore, as the 
aforementioned homologues contain only a low number of lysine residues and 
subsequent autoubiquitination may be relatively low, the non-specific activity of certain 
deubiquitinating enzymes may be sufficient in helping to promote their stability.
Despite the majority of the ICPO homologues containing a low number of lysine 
residues, Vg61 contains 24, which is equal to a protein of its predicted size. This may 
mean Vg61 undergoes a significantly higher amount of autoubiquitination and the 
protein is intrinsically less stable than the other ICPO related proteins in vivo. 
Furthermore, this may explain why out of all of the ICPO homologues it has a phenotype 
least similar to ICPO, as assessed by its ability to complement an ICPO-null virus and 
disrupt ND10 and its various constituents. The phenotype of Vg61 is most similar to 
ICPO variants that contain mutations within their USP7 binding domain as they degrade 
PML and SplOO with reduced efficiency (Parkinson & Everett, 2000) and their activity 
in gene expression and viral growth assays was also reduced (Everett et al., 1999d). The 
phenotype of an ICP0-USP7 binding domain mutant was thought to be partially
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explained by a decrease in the stability of ICPO due to an inability to prevent 
autoubiquitination and subsequent proteolysis (Canning et al., 2004). Therefore, the 
large number of lysine residues in Vg61 and its potentially increased susceptibility to 
autoubquitination and subsequent proteolysis may explain why its phenotype is more 
similar to that of an ICP0-USP7 mutant, than wild-type ICPO. The may also contribute 
to the reduced levels of reactivation VZV undergoes compared to that of HSV-1, due to 
inability of Vg61 to relieve the potential repression mechanism of viral gene expression 
imposed by ND10, this is discussed in more detail in section 5.0.1 A.
5.0.4. The phenotype o f  the ICPO (241) RING finger domain mutants.
The RING finger mutants of ICPO (241) used in this study (see figure 3.6.1 A), were 
originally derived from full-length ICPO mutants, which have been extensively 
characterised elsewhere. It had been shown that the majority of the mutations had an 
extremely deleterious affect on full length ICPO’s ability to simulate gene expression, 
disrupt ND10 in transfection assays and colocalise with conjugated ubiquitin, in vivo 
(Everett et al., 1995a; Everett, 1987, 2000). The most notable exception was the point 
mutation W146A, as it had little affect on the biological properties of ICPO. Theses 
results were surprising as the tryptophan residue is conserved in the majority of RING 
finger E3 ligase enzymes and has generally been shown to be exceptionally deleterious 
affect to the function of a protein (Freemont, 2000; Joazeiro & Weissman, 2000; 
Pickart, 2001a).
The ICPO (241) mutants were also used to characterise the E3 ligase activity of the 
RING finger domain of ICPO in vitro (Boutell et al., 2002). It was shown that point 
mutations within the RING finger domain of ICPO (241) (K144E, W146A, Q148E and 
N151D) and the insertional mutant ms 197, had little or no deleterious affect on the E3 
ligase activity of the protein (Boutell et al., 2002). However, in vivo the mutations 
K144E or N151D were previously shown to be deleterious on full-length ICPO’s ability 
to colocalise with conjugated ubiquitin (Everett, 2000). Collectively, this suggests the 
K144E an the N15 ID mutations of the RING finger domains inhibit ICPO function as an 
E3 ligase in vivo, but have a limited affect on this activity in vitro. The insertional 
mutants of ICPO-241 (insl50, insl62 or insl88) had an exceptionally deleterious affect 
on ICPO’s ability to facilitate the formation of poly-ubiquitin chains in vitro (Boutell et 
al., 2002), and colocalise with conjugated ubiquitin in vivo (Everett, 2000). However,
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overall the in vitro data characterising the E3 ligase activity of the ICPO-241 mutants, 
correlated well with its ability to colocalise with conjugated ubiquitin.
This study shows that despite the varying affects the mutations had on the biological 
properties of ICPO, generally all of the mutants appeared to form a stable interaction 
with UbcH5a and UbcH6. In fact, compared to ICPO (241) the ability of ICPO (241) 
mutants to form stable interactions with UbcH5a and UbcH6 was enhanced, as ICPO 
(241) was unable to form a stable interaction with UbcH5a. As mentioned previously, 
the inability of ICPO-241 and certain other members of the ICPO family to form a stable 
interaction with UbcH5a may be due to assay conditions or the quality of the reaction 
components. However, it could be down to the kinetics of the E2/E3 interaction. 
Traditionally, based on the structural characterisation of various RING finger E3s and 
their E2 partners, it is thought that the two proteins form a rigid stable interaction. The 
role of the E3 ubiquitin ligase is to position the E2 and substrate for catalysis (Pickart, 
2001a; Weissman, 2001). However, what this model does not consider is that when a 
substrate becomes poly-ubiquitinated, it grows at 8 KDa per reaction cycle, therefore 
how does this rigid structure accommodate the increasing size of the ubiquitinated 
substrate? Deffenbaugh et al., (2003) used the multi-subunit RING E3 ligase SCF (see 
section 1.6.4A) and the E2 enzyme cdc34, to propose the ‘hit and run’ model of 
substrate ubiquitination. The kinetics of the reaction between the E2 and E3 was 
calculated and indicated that instead of forming a rigid structure, the E3 complex is in 
dynamic association/dissociation equilibrium with ubiquitin-charged cdc34 
(Deffenbaugh et al., 2003). The substrate only becomes ubiquitinated when it binds to 
the E3 complex whereupon the ubiquitin charged E2 is released prior to substrate 
ubiquitination. Therefore, the E3/E2 interaction under normal conditions may only 
occur in a transient manner.
It is possible using the ‘hit and run model’ that UbcH5a only forms a transient 
interaction with ICPO (241). However, when the RING finger domain of ICPO-241 is 
mutated, structural changes prevent a transient interaction occurring, thus a stable 
interaction could now be detected using the GST-pull down method, as shown. The 
following question then arises, if the ‘hit and run model’ is correct why does non­
mutated ICPO (241) form a stable interaction with UbcH6? It is possible that during the 
GST-pull down assay UbcH6 is not in a conformation that would allow a transient 
interaction to occur.
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5.0.5. Further work to characterise the ICPO family ofproteins.
Characterising the E3 ligase activity o f  the ICPO family ofproteins.
An initial area of future research would be to optimise the expression and purification of 
the full-length ICPO homologues. As mentioned previously the recombinant 
baculovimses that expressed Eg63 or EPO were unstable, therefore repeating the 
baculovims method, but introducing a plaque purification stage may lead to the 
generation of more stable recombinants. In addition, it would be necessary to develop a 
purification strategy for Vg61 as it was insoluble using the method previously optimised 
for ICPO. Once a full set of functional recombinant baculoviruses had been gained, they 
could initially be used to confirm the E3 ligase activity of the full-length ICPO 
homologues was similar to their isolated RING finger domains. Furthermore, the 
baculovims containing the CMV promoter could be used as an effective tool to 
determine if the ICPO homologues undergo novel protein-protein interactions or interact 
with UbcH5a or UbcH6 and indeed any other E2 ubiquitin conjugating enzymes in 
vitro.
Additional studies on the GST-ICPO family of proteins would include, using the ICPO 
(241) bank of mutants to determine if they have E3 ligase activity with UbcH6. This 
would be an important area for further work as deletion of C terminal residues from 
GST-Eg63 and GST-BICPO had a deleterious affect on their E3 ligase activity in the 
presence of UbcH6. Therefore, using more ‘subtle’ mutations may provide insight into 
which residues or areas within or outside of the RING finger domain are essential for 
UbcH6 stimulation. Furthermore, it would be interesting to repeat the inhibition assay, 
but use GST-Eg63 1 63 titrated to a higher concentration, to determine if UbcH6 
becomes sequestered and the E3 ligase activity of GST-Eg63 was inhibited.
Characterisation ofVg61.
As mentioned previously, Vg61 has 24 lysine residues, therefore in theory should make 
it particularly susceptible to autoubiquitination and proteasome mediated degradation. A 
recombinant baculovims or plasmid based approach could be used to determine if Vg61 
or indeed any other member of the ICPO homologues undergo autoubiquitination in
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vivo. Furthermore, if Vg61 is subjected to a larger degree of degradation in vivo 
compared to the other ICPO homologous, it would interesting to see if  larger 
concentrations of Vg61 in transfection assays caused the disruption of ND10 and other 
cellular components in a fashion more similar to ICPO. Furthermore, MG132 could be 
used to determine if inhibition of the proteasome improves the stability of Vg61 in vivo, 
furthermore it could be used to aid the identification of autoubiquitinated isoforms of 
Vg61. As Vg61 does not have a USP-7 binding domain it would be interesting to 
characterise how it protects its stability in vivo, therefore would make it a particularly 
interesting target for protein-protein interaction studies. Other areas of work could look 
at a complementation assay to determine how efficiently a Vg61-null virus is reactivated 
from latency by ICPO compared to that of Vg61.
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